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ABSTRACT
THE INTERPEDUNCULAR NUCLEUS REGULATES ANXIETY
Ian A. McLaughlin
Dr. Mariella De Biasi
This work is devoted to better understanding how a component of one of the principle anatomical
intersections of cognitive, emotional, and motivational signaling regulates anxiety and addiction. The
majority of my work focused on the interpeduncular nucleus (IPN). The IPN and its principle source of
afferent signals, the medial habenula (MHb), comprise a junction of signaling within the diencephalic
conduction system (DDC). Along with the medial forebrain bundle, the DDC is a highly conserved pathway
by which signals from the limbic forebrain reach the midbrain and hindbrain. Work in our lab and others
has implicated the MHb-IPN axis in the aversive affective and somatic withdrawal syndrome that
manifests following cessation of chronic exposure to habit-forming drugs, including alcohol, nicotine, and
opioids. Given that functional role, I sought to establish if this pathway regulates affect independently of
chronic drug exposure.
In addition to my primary work, additional experiments I performed contributed to the growing
understanding of how this pathway functions within the context of addiction. In particular, I contributed to
studies focused on how the presence of the α5 nicotinic acetylcholine receptor subunit (nAChRs) in the
IPN and its neighboring structure, the ventral tegmental area (VTA), influences predispositions to alcohol
and nicotine addictions in animal models.
Using in vivo chemogenetics, viral tracing and receptor subunit rescue, microdialysis, and behavioral
analyses, I worked to evaluate how perturbations of signaling within the IPN or VTA affected mouse
behavior.
Overall, I have found that the IPN does indeed regulate affect independently of chronic drug exposure, and
that signaling via the α5 nAChR subunit within both the IPN and VTA significantly regulates drug-taking
behavior.
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ABSTRACT
THE INTERPEDUNCULAR NUCLEUS REGULATES ANXIETY
Ian A. McLaughlin
Dr. Mariella De Biasi
This work is devoted to better understanding how a component of one of the principle anatomical
intersections of cognitive, emotional, and motivational signaling regulates anxiety and addiction.
The majority of my work focused on the interpeduncular nucleus (IPN). The IPN and its principle
source of afferent signals, the medial habenula (MHb), comprise a junction of signaling within the
diencephalic conduction system (DDC). Along with the medial forebrain bundle, the DDC is a
highly conserved pathway by which signals from the limbic forebrain reach the midbrain and
hindbrain. Work in our lab and others has implicated the MHb-IPN axis in the aversive affective
and somatic withdrawal syndrome that manifests following cessation of chronic exposure to habitforming drugs, including alcohol, nicotine, and opioids. Given that functional role, I sought to
establish if this pathway regulates affect independently of chronic drug exposure.
In addition to my primary work, additional experiments I performed contributed to the growing
understanding of how this pathway functions within the context of addiction. In particular, I
contributed to studies focused on how the presence of the α5 nicotinic acetylcholine receptor
subunit (nAChRs) in the IPN and its neighboring structure, the ventral tegmental area (VTA),
influences predispositions to alcohol and nicotine addictions in animal models.
Using in vivo chemogenetics, viral tracing and receptor subunit rescue, microdialysis, and
behavioral analyses, I worked to evaluate how perturbations of signaling within the IPN or VTA
affected mouse behavior.
Overall, I have found that the IPN does indeed regulate affect independently of chronic drug
exposure, and that signaling via the α5 nAChR subunit within both the IPN and VTA significantly
regulates drug-taking behavior.
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CHAPTER 1: GENERAL INTRODUCTION
Portions of this section are derived from a published article:
McLaughlin I, Dani JA, De Biasi M. The medial habenula and interpeduncular nucleus
circuitry is critical in addiction, anxiety, and mood regulation. J Neurochem. 2017
Aug;142 Suppl 2:130-143. doi: 10.1111/jnc.14008. Review. PubMed PMID: 28791703.

Anxiety & Addiction
In the United States, anxiety and substance use disorders (SUDs) rank among the most
commonly diagnosed psychiatric conditions, with lifetime rates of 28.8% and 14.6%,
respectively (J. P. Smith & Book, 2008). In 2017, over 70,000 individuals were lost to
drug overdoses (Hedegaard, Minino, & Warner, 2018), representing an unprecedented
number of drug related mortalities, with drug overdoses causing more injury fatalities
than both guns and traffic accidents (Abuse, 2014; Services, 2019) in the United States.
Perhaps unsurprisingly, SUDs have been identified as among the most commonly
comorbid psychiatric disorders among those diagnosed with generalized anxiety
disorder (GAD) (Wittchen, Zhao, Kessler, & Eaton, 1994). Epidemiological studies have
shown that GAD is associated with accelerated progression from first ingestion of habitforming drugs to the onset of dependence, and comorbid GAD and SUD significantly
reduces the prospects of recovery from GAD (Conway, Compton, Stinson, & Grant,
2006). Complicating successful treatment of either is the tendency of withdrawal
symptoms exhibited by individuals ceasing chronic use of habit-forming drugs to emulate
some GAD symptoms (Back & Brady, 2008). In addition to GAD, a variety of other
mental health disorders share symptomatology with withdrawal syndromes, including
depression and suicidality, borderline personality, conduct, and anti-social personality
disorders (Merikangas et al., 1998; Patriquin, Bauer, Soares, Graham, & Nielsen, 2015;
1

Trull et al., 2018). Further complications arise from the variability in the duration and
severity of withdrawal symptoms, determined by the unique pharmacologies of the habitforming drugs used by each individual (Back & Brady, 2008). Additionally, unique
pharmacogenomic effects arising between individuals and specific drugs may result in
distinct contingents of patients who warrant targeted therapeutic interventions. Currently,
medications applied in psychiatric settings fail to reduce symptoms in 30-40% of
individuals (Haile, Kosten, & Kosten, 2009; Patriquin et al., 2015). Accordingly, a basic
understanding of the neurophysiology underlying predispositions to addiction, both
generally and to specific drugs, will help to improve therapeutic approaches to this
rapidly growing challenge. Furthermore, given the high comorbidity of SUDs with
anxiety-associated conditions, a more complete understanding of the neurophysiology
underlying anxiety will likely reveal shared mechanisms, perhaps yielding novel
opportunities to target both therapeutically.
Among the constellation of CNS regions that regulate anxiety, components of the dorsal
diencephalic conduction system (DDC) have been implicated in animals and humans
(Boulos, Darcq, & Kieffer, 2017; Stamatakis & Stuber, 2012; Torrisi et al., 2017), as well
as the withdrawal syndrome from habit-forming drugs (Dani & De Biasi, 2013; Dani,
Jenson, Broussard, & De Biasi, 2011; McLaughlin, Dani, & De Biasi, 2015, 2017; E.
Perez, Quijano-Carde, & De Biasi, 2015a; Zhao-Shea et al., 2015)

The Dorsal Diencephalic Conduction System
The dorsal diencephalic conduction system (DDC) is a highly evolutionarily conserved
neural pathway, identified in species including fish, mammals, and reptiles (Epstein,
Hurley, & Taber, 2018). The majority of research has been devoted to a similar pathway,
the medial forebrain bundle, which originates in anterior olfactory areas, sending
2

posterior projections via the lateral preoptic, lateral hypothalamic, and ventral tegmental
area (VTA). Extending dorsally, the DDC consists of projections that travel along the
epithalamus, with the stria medullaris and inferior thalamic peduncle representing the
primary conduits of signaling, arriving at the epithalamic habenular complex (Sutherland,
1982). There are three central components of the DDC: the stria medullaris, the
habenular complex (Hb), and the fasciculus retroflexus (Bianco & Wilson, 2009), with the
medial habenula (MHb) representing the most dorsal component of the diencephalon
(Okamoto & Aizawa, 2013) – the anatomy of which is represented in Fig 1.
Figure 1. Afferents & efferents of the MHb-IPN axis and broader DDC.

Figure 1. The medial habenula-interpeduncular nucleus pathway unites forebrain limbic with
midbrain & hindbrain motivation & reward signaling. The medial habenula receives afferent
inputs from a wide variety of forebrain limbic structures, and the interpeduncular nucleus
sends afferent projections to a variety of midbrain & hindbrain structures implicated in the
neurophysiology underlying addiction and a variety of mood-related psychiatric conditions.
Accordingly, this pathway is a junction of signaling which regulates both addiction and moodrelated conditions.

3

Overall, the DDC represents a principal pathway by which signaling in the forebrain is
sent to, and received from, the mid- and hind-brain, and serves as a junction of
cognitive, emotional, and sensory signaling, regulating motivation and reward (Gardon et
al., 2014). Anatomically, the DDC is among the most densely populated regions with μopioid receptors in the central nervous system, with the MHb-interpeduncular nucleus
(IPN) axis hosting expression to the exclusion of the lateral habenula (LHb) (Gardon et
al., 2014). Studies of its functional properties by multiple groups have identified a role of
the MHb-IPN pathway in the manifestation of the withdrawal syndrome following
cessation of chronic intake of habit-forming drugs, including alcohol, nicotine, opioids,
and stimulants (Boulos et al., 2019; J. Carlson, Armstrong, Switzer, & Ellison, 2000; De
Biasi & Salas, 2008; Ellison, 2002; Molas, DeGroot, Zhao-Shea, & Tapper, 2017; Salas,
Sturm, Boulter, & De Biasi, 2009; Zhao-Shea et al., 2015; Zhao-Shea, Liu, Pang,
Gardner, & Tapper, 2013). While the habenular subnuclei remain prohibitively small to
resolve using neuroimaging in humans, resting state functional connectivity reveals
associations between the Hb and a variety of distal structures associated with the
regulation of anxiety, including the medial prefrontal cortex, posterior insula, bed nucleus
of the stria terminalis (BnST), hippocampus, and raphe nuclei (Torrisi et al., 2017).

The Medial Habenula
The Hb is an asymmetrical bilateral structure (Bianco & Wilson, 2009), phylogenetically
conserved (Aizawa, Amo, & Okamoto, 2011; Torrisi et al., 2017), and broadly divided
into two primary subdivisions, medial and lateral, though some studies have identified
properties of both that might indicate further sub-anatomical distinctions due largely to
the diversity of neurochemicals present within the structures (Aizawa, Kobayashi,
Tanaka, Fukai, & Okamoto, 2012). Both the LHb and MHb send efferent projections
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through the fasciculus retroflexus (FR), and some studies suggest that those originating
in the LHb travel through the sheath of the bundle, while those from the MHb comprise
the core (Bianco & Wilson, 2009). The LHb is comparatively larger, but the MHb hosts
the synthesis of, and receptivity to, a surprisingly broad array of neurotransmitters.
Those synthesized within the MHb include glutamate, acetylcholine (ACh), neurokinins,
interleukin-18 (IL-18), and substance P (SP) (Aizawa et al., 2012). Neurotransmitters
identified as likely being released within the MHb include ACh, substance P, adenosine
triphosphate (ATP), γ-aminobutyric acid (GABA), and glutamate, as well as a variety of
monoamines, including dopamine (DA), and norepinephrine (NE) from the locus
coeruleus and superior cervical ganglion (Gottesfeld, 1983; Viswanath, Carter, Baldwin,
Molfese, & Salas, 2013). Projections from the median raphe nucleus (Herkenham &
Nauta, 1977), nucleus accumbens (NAcc), and ventral tegmental area (VTA)
(Sutherland, 1982) have been identified within the MHb. The MHb also hosts among the
highest levels of expression of the GABAB receptor in the brain (Bischoff et al., 1999;
Charles et al., 2001; Durkin, Gunwaldsen, Borowsky, Jones, & Branchek, 1999; D. G.
Wang, Gong, Luo, & Xu, 2006), as well as a variety of nicotinic acetylcholine receptors
(nAChRs), with the majority of MHb neurons estimated to express nAChRs that include
the α3, α4, β2, and/or β4 nAChR subunits (Fonck et al., 2009; Paolini & De Biasi, 2011;
Sheffield, Quick, & Lester, 2000; Viswanath et al., 2013). The vast majority of efferent
projections emerging from the MHb are conveyed via the FR, arriving at the
interpeduncular nucleus (IPN) (Herkenham & Nauta, 1977).

The Interpeduncular Nucleus
While the MHb receives inputs from a broad array of forebrain nuclei, the
interpeduncular nucleus (IPN) has a more limited afferent repertoire, with the MHb
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providing the majority of inputs. However, the IPN sends efferent projections to a
broader set of targets, spanning the forebrain to the hindbrain, many of which have been
implicated in regulating affect, motivation, and reward (Lima et al., 2017; McLaughlin et
al., 2017). Much like the MHb, the IPN is a rather dense structure, receptive to a variety
of neurotransmitters. Anatomically, the IPN is oval-shaped, with only some bilateral
organization (Bianco & Wilson, 2009). Neurons within the IPN tend to be rather small,
hosting limited cytoplasmic space, and have been described as exhibiting
neurosecretory characteristics in non-human species, containing large dense granules
and beaded varicosities that were not observed to form synapses with neurons, but
rather terminate in the interpeduncular cistern (Kemali, 1977; Morley, 1986). Similarly,
other cells within the IPN appear to form connections with the pial vasculature of the IPN
in humans (Kemali & Casale, 1982).
Similar to the MHb, despite being a relatively small and dense structure, studies have
identified subdivisions of the IPN according to afferent and efferent distinctions, as well
as the neurochemicals present (Kemali, 1977; Kemali & Casale, 1982; Lenn & Bayer,
1986; Quina, Harris, Zeng, & Turner, 2017). Two elegant tracing studies conducted
recently demonstrate the topographical relationship between subnuclei within the MHb
and IPN, as well as probable distinctions in efferent targets among IPN subnuclei (Lima
et al., 2017; Quina et al., 2017). It is critical to be mindful of these anatomical nuances
when interpreting the data collected over the course of my graduate work, as the
technical limitations of methods currently available render precise functional subanatomical distinctions with behavioral relevance quite challenging. Regardless, a
modulatory role relevant to a variety of behavioral, motivational, emotional, and
endocrine activities played by the nucleus seems likely, given these anatomical features.
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While the LHb has been implicated in the dopaminergic mechanisms underlying reward
and addiction, the MHb-IPN axis has also been identified as playing a regulatory role.
Signaling within the MHb-IPN axis has been implicated in the manifestation of aversive
symptoms of withdrawal following chronic exposure to habit-forming drugs, including
alcohol (Hwang, Suzuki, Lumeng, Li, & McBride, 2004; E. Perez et al., 2015a; Roux et
al., 2015; D. G. Smith et al., 2001), nicotine (Dani & De Biasi, 2001; Dao, Perez, Teng,
Dani, & De Biasi, 2014; De Biasi & Dani, 2011; Fowler, Lu, Johnson, Marks, & Kenny,
2011; Fowler, Tuesta, & Kenny, 2013; Gorlich et al., 2013; Jackson, Muldoon, De Biasi,
& Damaj, 2015; Lotfipour et al., 2013; McLaughlin et al., 2015; Salas et al., 2009; ZhaoShea et al., 2015; Zhao-Shea et al., 2013), psychomotor stimulants (J. Carlson et al.,
2000; Ellison, 2002; Hussain, Taraschenko, & Glick, 2008; James, Charnley, Flynn,
Smith, & Dayas, 2011), and opioids (Bajic, Soiza-Reilly, Spalding, Berde, & Commons,
2015; Darcq et al., 2012; Gardon et al., 2014; Neugebauer et al., 2013). Furthermore,
infusion of 18-methoxycoronaridine, an α3β4 nAChR antagonist, into either the MHb or
IPN has been shown to influence drug-taking behavior and symptoms of withdrawal from
multiple habit-forming drugs (Glick, Maisonneuve, & Dickinson, 2000; Glick, Ramirez,
Livi, & Maisonneuve, 2006; Glick, Sell, & Maisonneuve, 2008; Panchal, Taraschenko,
Maisonneuve, & Glick, 2005; Rho & Glick, 1998; Taraschenko, Shulan, Maisonneuve, &
Glick, 2007).
In addition to addiction, the MHb-IPN axis has been identified as relevant to several
mood-related psychiatric conditions, either in humans or animal models, including
depression (Faron-Gorecka et al., 2016; Hsu et al., 2014; Mirrione et al., 2014; Padilla,
Shumake, Barrett, Sheridan, & Gonzalez-Lima, 2011; Ranft et al., 2010; Shumake,
Edwards, & Gonzalez-Lima, 2003; Svenningsen et al., 2016), anxiety- and fearassociated behaviors (Agetsuma et al., 2010; Cirulli, Pistillo, de Acetis, Alleva, & Aloe,
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1998; Facchin, Duboue, & Halpern, 2015; Jesuthasan, 2012; A. Lee et al., 2010;
Mathuru & Jesuthasan, 2013; Sugama et al., 2002; Thompson, 1960; Yamaguchi,
Danjo, Pastan, Hikida, & Nakanishi, 2013), and bipolar disorder (Savitz et al., 2011).

Role of the DDC in Addiction to Specific Drugs
Alcohol
The pharmacological activity of ethanol encompasses a broad range of targets in the
central nervous system, and studies have indicated that the MHb-IPN circuit represents
a significant component of its affective and behavioral effects. Local cerebral glucose
utilization rates in alcohol-preferring rats are significantly elevated in both divisions of the
habenular complex relative to non-preferring rats (D. G. Smith et al., 2001). Data from
our lab have identified an interaction between ethanol and nicotine withdrawal, as well
as a role played by nAChRs in the MHb or IPN in ethanol withdrawal. Specifically,
intraperitoneal injection of a non-selective nAChR antagonist, mecamylamine, is capable
of precipitating a withdrawal syndrome in mice chronically treated with ethanol.
Withdrawal symptoms are also exhibited when mecamylamine is infused into the MHb or
IPN, but not the ventral tegmental area (VTA) or hippocampus (E. Perez et al., 2015a),
indicating that nAChR blockade in the MHb-IPN circuit is sufficient to precipitate the
ethanol withdrawal syndrome. Another recent finding has identified changes in signaling
molecules associated with apoptosis, inflammation, neurodegeneration, and senescence
in the habenula, among other structures, following chronic treatment with ethanol (Roux
et al., 2015). Receptor knock-out studies have shown that neuropeptide Y (NPY) acts as
an important regulator of alcohol intake, with knock-out mice exhibiting increased alcohol
ingestion relative to wild-type mice (Thiele, Koh, & Pedrazzini, 2002). More recently, it
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was shown that alcohol-preferring rats exhibit an absence of NPY mRNA in the MHb
while non-preferring rats do have a signal of mRNA for the neuropeptide (Hwang et al.,
2004). Taken together, the literature suggests that activity in the MHb-IPN circuit likely
modulates the effects and ingestive behavior of alcohol, as well as its withdrawal
symptoms. Variations between individuals in the signaling within this circuit may underlie
predispositions to pathological intake patterns.

Opioids
One of the densest regions of opioid receptor expression is the DDC, and the MHb, FR,
and IPN are particularly rich with expression (Gackenheimer et al., 2005; Gardon et al.,
2014; Sim-Selley, Daunais, Porrino, & Childers, 1999; Zhu, Hsu, & Pintar, 1998).
Additionally, there is a diversity of neurotransmitters that the MHb-IPN circuit
synthesizes or is sensitive to, including acetylcholine, neurokinins, interleukin-18 (IL-18)
(Sugama et al., 2002; Viswanath et al., 2013), and purines (Kanjhan et al., 1999;
Pankratov, Lalo, Krishtal, & Verkhratsky, 2009; Pankratov, Lalo, Verkhratsky, & North,
2006) that may be modulated by the activities of opioids. Given the broad efferent
targets of the IPN that are known to regulate affect and substance use, including the
raphe nuclei, nucleus incertus, lateral septum, lateral dorsal tegmentum (LDTg), and
hypothalamus (Bianco & Wilson, 2009; Gardon et al., 2014; Morley, 1986; Ryan, Ma,
Olucha-Bordonau, & Gundlach, 2011; Sutherland, 1982), the MHb-IPN circuit is likely an
anatomical node, centrally involved in the signaling underlying both acute effects of, and
withdrawal from, opioids. Evidence over the past several decades has corroborated such
a role. For example, lesions of the MHb have been observed to induce hyperalgesia and
increase the analgesic efficacy of morphine (Meszaros, Gajewska, & TarchalskaKrynska, 1985), and morphine is capable of inducing analgesia when infused directly
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into the habenular complex (Cohen & Melzack, 1985). When evaluating the effects of
intracranial self-stimulation of the VTA on opioid release, a unique reduction of
endogenous opioid binding was observed in the MHb (E. A. Stein, 1993). Following
chronic morphine administration, altered acetylcholinesterase (AChE) activity is
observed in the MHb, and precipitation of withdrawal with the opioid receptor antagonist,
naloxone, resulted in altered AChE activity in the IPN (Neugebauer et al., 2013).
Additionally, chronic morphine administration induced a trend towards increased nAChR
expression in the MHb (Neugebauer et al., 2013). Acute administration of 18methoxycoronaridine (18-MC), an α3β4 nAChR antagonist, reduced signs of naltrexoneprecipitated withdrawal from morphine (Rho & Glick, 1998), an effect that appears to be
mediated by activity in the MHb and IPN (Panchal et al., 2005; Taraschenko et al.,
2007). 18-MC was also observed to reduce morphine self-administration upon
intracranial infusion into the MHb or IPN (Glick et al., 2006). In the MHb, RSK2, a
component of the ribosomal S6 kinase 90kDa family, which act as substrates of
extracellular-regulated kinases 1 & 2 to regulate cytosolic and nuclear targets, has been
identified as critical to morphine-induced analgesia (Darcq et al., 2012). Finally, the
LDTg, an efferent target of the IPN, has been shown to exhibit significant increases in
vesicular ACh transporter markers following chronic morphine administration (Bajic et
al., 2015; Gardon et al., 2014). Altogether, these data implicate the DDC, and MHb-IPN
circuit in particular, in the signaling underlying some of the acute effects of opioids, as
well as aspects of their addictive properties. Furthermore, adaptations in cholinergic
components may represent a significant facet of these changes.
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Nicotine and Psychomotor Stimulants
The role of the LHb in regulating dopaminergic activity in the VTA via the rostromedial
tegmental nucleus has been established, and represents an important mechanism by
which aversion and addiction are modulated (Barrot et al., 2012; Jean-Richard Dit
Bressel & McNally, 2014; Quina et al., 2015; Sanchez-Catalan et al., 2017). Both the
LHb and MHb send dense efferent projections through the fasciculus retroflexus, and –
as previously discussed - anatomical studies suggest that projections emerging from the
MHb course through its core and those from the LHb through its sheath (Bianco &
Wilson, 2009). Degeneration of dopaminergic fibers in the caudate following chronic
exposure to psychomotor stimulants like amphetamines was observed decades ago
(Ellison, Eison, Huberman, & Daniel, 1978). In addition to dopaminergic fibers, similar
degeneration has been observed in axons populating the sheath of the FR following
chronic exposure to cathinone, cocaine, amphetamine, methamphetamine, and MDMA
(J. Carlson et al., 2000; Ellison, 2002). In rats treated with cocaine, increased expression
of Fos-protein, a marker of neuronal activation, was observed in the MHb associated
with cue-induced reinstatement (James et al., 2011). Additionally, similar to its
interference with opioid-derived reward, 18-MC administration results in reduced
methamphetamine self-administration in rats (Glick et al., 2000). Once again, direct
infusions into the MHb and/or IPN induced similar reductions of self-administration, with
what appears to be greater efficacy when infused into the IPN, suggesting that activity in
the MHb-IPN circuit likely mediates this effect (Glick et al., 2008). Finally,
methamphetamine and cocaine have been shown to increase extracellular
concentrations of ACh in the IPN, with cocaine inducing a dose-dependent biphasic
effect (Hussain et al., 2008).
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Probably the best-characterized activity of a drug in the MHb-IPN pathway is that of
nicotine, perhaps attributable to the considerable density of a variety of nAChRs that
populate the structure (Mugnaini et al., 2002). Studies have suggested that up 90-100%
of MHb neurons express nAChRs, with the majority containing the α3, α4, α5, β2, and/or
β4 subunits (Sheffield et al., 2000; Viswanath et al., 2013). Some data suggest that
approximately 20% of nAChRs in the MHb expressed by neurons that project to the IPN
contain the α5 subunit (Grady et al., 2009; Picciotto & Kenny, 2013). In the IPN, high
levels of α2 subunit-containing nAChRs can be found (De Biasi & Salas, 2008; Grady et
al., 2009), and the distributions of nAChRs composed of specific subunit combinations
can help distinguish subnuclei within both the MHb and IPN (Shih et al., 2014).
As many reviews of the effects of nicotine in this circuit have been written over the years
(Dani & De Biasi, 2001; Dao et al., 2014; De Biasi & Dani, 2011; De Biasi et al., 2014;
Jackson et al., 2015; McLaughlin et al., 2015, 2017), this section will focus on recent
advances in characterizing the effects of chronic use and withdrawal from nicotine in the
MHb-IPN pathway. For example, it was recently shown that, during withdrawal from
nicotine, the spontaneous action potential frequencies in MHb cholinergic neurons are
doubled after mice are administered nicotine relative to mice in withdrawal treated with
saline (Gorlich et al., 2013). Further, these studies demonstrated that the pacemaking
activities of MHb cholinergic neurons are determined by the activities of
hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, and
pharmacological inhibition of these HCN channels resulted in the manifestation of
nicotine withdrawal-associated behaviors, including both somatic and anxiety-associated
symptoms. A study from our lab showed that nicotine enhances the intrinsic excitability
of MHb neurons by activating α5-containing nAChRs, which results in the facilitation of
12

neurokinin release onto NK1 and NK3 receptors (Dao et al., 2014). Notably,
pharmacological blockade of NK1 & NK3 receptors in the MHb of mice chronically
treated with nicotine resulted in the precipitation of somatic symptoms of nicotine
withdrawal. Further implicating the α5-containing nAChRs in the MHb in the physiology
of nicotine addiction and withdrawal, mice lacking the expression of the subunit have
been observed to self-administer doses of nicotine at levels that are aversive to wild-type
mice, and virus-mediated re-expression of the subunit in the MHb rescues selfadministration to levels resembling those consumed by wild-type mice (Fowler et al.,
2011). Additionally, mice lacking the α5 nAChR subunit exhibit reduced IPN activation
following exposure to nicotine relative to wild-type mice, suggesting a significant role
played by this subunit in the MHb-IPN pathway in determining the range of nicotine
doses capable of facilitating activity in brain reward circuitry (Fowler et al., 2011; Fowler
et al., 2013). Mice lacking the α2 nAChR subunit do not manifest nicotine withdrawal
signs (Salas et al., 2009). Furthermore, α2 null mice exhibit elevations of both glutamate
and GABA in the IPN, suggesting that α2-containing nAChRs may participate in the
signaling underlying the effects of nicotine (Lotfipour et al., 2013). Studies have also
demonstrated a significant role played by IPN signaling in somatic symptoms of nicotine
withdrawal, with GABAergic neuronal activation enhanced by increased glutamate
release, perhaps from the MHb (Zhao-Shea et al., 2013). This group also showed that
pharmacological inhibition of NMDA receptor activation reduced symptoms of
withdrawal, suggesting a glutamatergic signal from the MHb playing a significant role in
the nicotine withdrawal syndrome. Following chronic nicotine exposure, mecamylamine
infusion into the MHb or IPN has been observed to induce anxiety-associated behaviors
and symptoms of nicotine withdrawal (Salas et al., 2009; Zhao-Shea et al., 2015). Given
that mecamylamine infusion into nicotine-naïve mice does not result in significant
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changes in anxiety-associated behavior, the MHb-IPN axis represents a node of
neuroplastic adaptations resulting from chronic nicotine exposure that underlie the
affective and somatic symptoms of nicotine withdrawal upon cessation.
Accordingly, while not necessarily a direct pharmacological target of most psychomotor
stimulants apart from nicotine, the MHb-IPN circuit likely represents a system that
modulates the acute effects of psychomotor stimulants, and contributes to signaling
underlying withdrawal and relapse.

Role of the DDC in Emotional States
Anxiety, fear, and stress
While anxiety and fear have been associated for quite some time with anatomical
structures including the amygdala, hippocampus, hypothalamus, and periaqueductal
gray, recent research has implicated the DDC in these behaviors as well (Okamoto &
Aizawa, 2013). A genetic lesion study indicates that selective elimination of MHb
afferents arriving from two forebrain structures, the triangular septum and bed nucleus of
the anterior commissure, results in disrupted anxiety- and fear-associated behaviors
(Yamaguchi et al., 2013). In particular, lesions of the projections from the triangular
septum, which terminate in the ventral subnucleus of the MHb, disrupted anxietyassociated behavior. Conversely, lesions of projections arriving from the bed nucleus of
the anterior commissure, which terminate in the dorsal subnucleus of the MHb, disrupted
fear-associated behavior. Following both acute and chronic restraint stress in rats,
significant elevations of the pro-inflammatory cytokine, IL-18, have been observed in the
dorsal MHb (Sugama et al., 2002). Mast cells are another immune system-associated
signaling component that appears to be sensitive to environmental stressors and
aversive mood states (Frenzel & Hermine, 2013; Georgin-Lavialle et al., 2016; Nautiyal,
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Ribeiro, Pfaff, & Silver, 2008; Silver & Curley, 2013). Mice treated with a 3-week
behavioral subordination paradigm, either via exposure to an aggressor or placement in
a clean cage, exhibited increased numbers of mast cells in the habenula, thalamus, and
hypothalamus (Cirulli et al., 1998).
When characterizing fear-associated behavior in zebrafish, inhibition or lesion of the
dorsal habenula (analogous to MHb in mammals) resulted in elevated freezing behaviors
in response to a conditioned fear stimulus (Agetsuma et al., 2010; A. Lee et al., 2010).
Both control and habenula-disrupted fish froze upon first exposure to an electric shock,
but as subsequent shocks were administered, control fish exhibited reduced freezing
behavior while those with disrupted habenular function exhibited no such behavioral
adaptation. Another study identified behavioral signatures of elevated baseline anxiety in
zebrafish following dorsal habenula lesions, including responses to novel environments
and alarm substance secretion in response to overhead shadows (Mathuru &
Jesuthasan, 2013). This has led to the suggestion that reciprocal connectivity between
the IPN, raphe nuclei, and dorsal tegmental region may be critical to behavioral
responses to stressors. Furthermore, activity in the habenular complex may be an
upstream determining factor in selection of behavioral strategies to cope with stressors
(Jesuthasan, 2012; Okamoto, Agetsuma, & Aizawa, 2012). A unique characteristic of the
habenular complex is its asymmetry, with the left habenula larger than its right
counterpart (Ahumada-Galleguillos et al., 2017; Hetu et al., 2016). When this asymmetry
is lost in zebrafish, behavioral assays indicated elevated manifestations of anxiety, as
well as elevated cortisol levels in response to stressors (Facchin et al., 2015).
While the size of the habenular complex renders current neuroimaging technology
incapable of distinguishing the LHb from the MHb in human studies (Salas, Baldwin, de
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Biasi, & Montague, 2010), some studies indicate a role played by the habenular complex
in the pathophysiology of bipolar disorder (BD). In a study using high-resolution
magnetic resonance imaging (MRI), it was found that patients diagnosed with BD who
had either never been medicated, or had been un-medicated for at least two months,
exhibited smaller habenular volumes than healthy controls (Savitz et al., 2011).
Studies have also implicated the IPN in regulating anxiety and fear. Early studies of the
IPN identified a role for the structure in the retention of avoidance conditioning. Rats
were trained to perform a jumping response following a visual stimulus to avoid a shock.
After a learning period, a group of trained rats were treated with electrolytic lesions of the
IPN. Following recovery from the procedure, rats re-learned the task and retention of the
response was compared to controls. Rats with IPN lesions exhibited comparatively
inferior retention of the response, though exhibited other signatures of a fear reaction,
implying a role played by IPN signaling in specific components of fear learning
(Thompson, 1960). Following chronic nicotine administration, increased corticotropin
releasing factor (CRF) synthesis is observed in dopaminergic neurons in the VTA, which
appear to send efferents to the ventral IPN (Zhao-Shea et al., 2015). This is
accompanied by an increase in CRF1 receptor expression in a particular subnucleus of
the ventral IPN, and withdrawal induces release of CRF by the VTA onto ventral IPN
neurons. Blockade of CRF1 receptor binding in the IPN was shown to reduce anxietyassociated behavior generated during withdrawal from nicotine (Zhao-Shea et al., 2015).

Serotonin Signaling & Anxiety
Serotonin signaling has long been implicated in regulating anxiety-associated behavior,
and defensive behavior more broadly, in animals. However, pharmacological and
behavioral studies indicate that this role is complex, with serotonergic pharmacological
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agents both facilitating and inhibiting behaviors associated with anxiety and panic in
animal models (Francisco S. Guimarães, 2010; Viana, Graeff, & Loschmann, 1997).
Further, while serotonergic signaling has been implicated in a broad range of behavioral
and physiological functions, most can still operate in the absence of serotonergic
signaling (Lucki, 1998). Serotonin can bind at least 14 receptor subtypes, resulting in a
diversity of signaling both pre- and post-synaptically, rendering it among the most
complicated of neurotransmitter systems (Grandjean et al., 2019; Hoyer, Hannon, &
Martin, 2002). Evidence in humans – from discoveries of the mechanisms and efficacies
of serotonergic medications (M. S. Eison, 1990; Goldberg & Finnerty, 1979; Kahn et al.,
1986; D. F. Klein, 1964) to neuroimaging (Lanzenberger et al., 2007) - implicates
serotonin signaling in anxiety-associated psychiatric conditions, including generalized
anxiety, social phobia, and panic disorders (Lucki, 1998).

Serotonin & Anxiety in Humans
A broad set of symptoms, as well as a responsivity to pharmacological therapeutics,
characterizes anxiety-associated psychiatric disorders. Anxiety ranks among the most
common sources of psychiatric distress (Bandelow, Michaelis, & Wedekind, 2017; O. J.
Robinson, Pike, Cornwell, & Grillon, 2019). It is also central to the most common
psychiatric disorders – with generalized anxiety disorder and panic disorders the most
prevalent in the United States, and regularly among the top, internationally (Sansone &
Sansone, 2010). According to the fifth edition of the Diagnostic and Statistical Manual of
Mental Disorders (DSM-5), anxiety disorders all share features of excessive fear and
anxiety – and it is the anticipation of a future threat that distinguishes anxiety from fear
(Diagnostic and statistical manual of mental disorders : DSM-5, 2013). This distinction is
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reflected in some of the ethological frameworks proposed over time that are useful to
interpreting animal behavior in pursuit of mechanistic explanations of human psychiatric
conditions. These frameworks will be discussed in later sections, after a review of
proposed models of the role serotonin plays in anxiety.
While almost certainly oversimplifications, several heuristics have been proposed over
time to model the relationships between anxiety and serotonin signaling. One example is
the “see-saw model”, wherein increased serotonin signaling promotes anxiety while
deficient serotonin signaling produces depression. As described by Stein & Stahl (D. J.
Stein & Stahl, 2000), this model would propose that anxious states arise from elevated
serotonin release – resulting in a neuroplastic compensatory downregulation of
presynaptic 5-HT1A autoreceptors. Ultimately, treatment with selective serotonin
reuptake inhibitors (SSRIs) or 5-HT1A receptor agonists, following a period of adaptation,
results in a “normalization” of 5-HT1A receptor signaling. Conversely, in conditions of
depression, the 5-HT1A receptor exhibits upregulation due to reduced serotonin release.
Similarly, pharmacological therapeutics act to elevate serotonin signaling and
downregulates the 5-HT1A receptor.
An alternative model focuses on serotonergic modulation of specific neuroanatomical
structures implicated in anxiety. This model arises, in part, from evidence that diminished
serotonin levels over time is correlated with increased sensitivity to threatening stimuli
(Handley, 1995; D. J. Stein & Stahl, 2000). Within this framework, the efficacy of SSRI
treatments of anxiety can be explained by modulation of afferent amygdalar signaling
arriving from the raphe nuclei, modifying the output from amygdalar subnuclei to regions
that regulate defensive responses, such as the periaqueductal gray (PAG), locus
coeruleus, and hypothalamic-pituitary-adrenal (HPA) axis (D. J. Stein & Stahl, 2000).
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Among the initial recognitions of a role played by serotonergic signaling in human
anxiety were assessments of pharmacological therapeutics for the treatment of
psychiatric conditions. One example was an evaluation of the potential psychiatric utility
of the tricyclic antidepressant, imipramine, by Klein & Fink (D. F. Klein & Fink, 1962),
following an early trial conducted by Kuhn in 1957 (Brown & Rosdolsky, 2015), ultimately
followed by a publication in English in 1958 (Kuhn, 1958).
Initially developed in pursuit of antipsychotic alternatives to chlorpromazine, the efficacy
of imipramine in managing anxiety-associated distress – as opposed to depression - was
highlighted by Kahn et al. (Kahn et al., 1986). However, in addition to serotonin,
imipramine exerts reuptake inhibition upon multiple monoaminergic neurotransmitters (L.
Zhang & Barrett, 1991). Accordingly, the discovery of the efficacy of buspirone – a
serotonin 5-HT1A receptor partial agonist (Loane & Politis, 2012) - in managing anxiety,
underscored the role of monoaminergic signaling in the anxiety experienced by humans
(A. S. Eison & Temple, 1986; Goldberg & Finnerty, 1979). Additionally, early
pharmacological evaluations of fluoxetine were published, demonstrating activity as a
selective serotonin reuptake inhibitor (SSRI), in 1974 (Wong, Horng, Bymaster, Hauser,
& Molloy, 1974). While initially associated with the treatment of depression, SSRIs have
since become first-line treatments for anxiety-associated conditions like GAD due to a
side effects profile of comparatively lower severity (D. S. Baldwin & Polkinghorn, 2005;
Bandelow et al., 2017).
Further confirmation of the critical role serotonin signaling plays in the therapeutic effect
of SSRIs is derived from serotonin depletion studies performed in patients diagnosed
with panic disorder, an anxiety-associated psychiatric condition. Fourteen patients (7
male, 7 female), who had undergone treatment with the SSRI, paroxetine, for panic
disorder were evaluated in a double-blind, placebo controlled study. As the endogenous
19

synthesis of serotonin relies upon consumption of the essential amino acid, tryptophan
(Moja, Cipolla, Castoldi, & Tofanetti, 1989), its deprivation was anticipated to affect
anxiety-associated behavior when challenged with the panicogenic agent, flumazenil,
due to consequential serotonin depletion (Bell et al., 2002). To test the necessity of
serotonin availability to the therapeutic efficacy of the prescribed SSRI, the test group
were administered either a tryptophan-free drink to induce serotonin depletion, or a drink
including tryptophan. Indeed, the anxiolytic efficacy of SSRIs was shown to depend upon
serotonin signaling. Similar studies have been performed, yielding similar effects on
mood in participants with family histories of mood-associated conditions, though
suggesting that the relationship between dietary monoamine amino acid precursors may
not exert a direct effect on mood (Ruhe, Mason, & Schene, 2007).
Additional evidence derived from human studies was identified by Lesch et al., indicating
that a polymorphism in the 5’-regulatory region of the serotonin transporter (SERT) was
associated with anxiety-associated traits (Lesch et al., 1996), though subsequent studies
suggest this correlation may be less clear (Owens & Nemeroff, 1998). However, when
evaluating responsivity of children diagnosed with anxiety disorders to cognitive
behavioral therapy (CBT), Lester et al. observed epigenetic changes in regions
associated with serotonin signaling. Children diagnosed with an anxiety disorder –
exhibiting a clinical severity rating of 4 or higher, using the Anxiety Disorders Interview
Schedule for DSM-IV (ADIS-IV-C/P) - were evaluated for their DNA methylation patterns
upstream of the serotonin transporter (SERT) promoter region, both before and after
treatment with cognitive behavioral therapy (CBT). Children who exhibited a therapeutic
effect of CBT exhibited significant elevations of DNA methylation at a particular CpG site
located within the SERT promoter region, while those exhibiting no therapeutic response
exhibited reductions in DNA methylation at the same site (Roberts et al., 2014).
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Similarly, Stein et al. demonstrated that patients diagnosed with generalized social
anxiety disorder, who participated in randomized controlled trials of SSRIs and received
either paroxetine or fluvoxamine, appeared to respond favorably according to variants of
the serotonin transporter gene. Specifically, patients expressing the same allele of the
gene studied by Stein et al. - (the S, or “short” allele) - exhibited comparatively poorer
response to treatment (M. B. Stein, Seedat, & Gelernter, 2006). This allele confers
reduced efficiency of transcription (Goldman, Glei, Lin, & Weinstein, 2010), and
therefore lower production of serotonin transporters, suggesting that differences in
serotonin signaling may be involved in the differences in treatment responsivity.
Similarly, the presence of a short allele for the 5-HTT was identified in a majority of
individuals diagnosed with social anxiety disorder, and was associated with elevated trait
anxiety (Furmark et al., 2004). Interestingly, Lenze et al. found genetic variation in the
promoter region of the serotonin transporter correlated with differences in treatment
efficacy of SSRIs for the treatment of GAD in adulthood – though results of the study
suggested that the source of this variability was likely due to an effect on symptom
variability rather than a pharmacogenetic effect of treatment (Lenze et al., 2010). While
not an indication that serotonergic signaling is the sole source of pathological activity,
these data indicate that it plays an integral role in at least the clinical confrontation of
anxiety-associated conditions.
Neuroimaging studies have also implicated serotonin signaling in anxiety-associated
conditions. Using SPECT imaging with a tracer capable of visualizing the serotonin
transporter (5-HTT), I-β-CIT, van der Wee et al. identified higher 5-HTT binding in
patients diagnosed with GAD (van der Wee et al., 2008). In patients with social anxiety
disorder, Frick et al. found elevated rates of serotonin synthesis and/or transporter
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availability in a network of brain regions that includes the amygdala, raphe nuclei,
hippocampus, and insular cortex (Frick et al., 2015).
While this is not an exhaustive review of studies in humans implicating serotonergic
signaling in anxiety-associated conditions, the balance of evidence indicates that these
processes are critical to understanding their underlying neurophysiologies – and
pharmacogenomic analyses may aid in explaining why some patients respond to current
therapeutics more favorably than others. In particular, while reviews have been
conducted (D. S. Baldwin & Polkinghorn, 2005; McGowan, 2019), pharmacogenomic
studies focused on therapeutic interventions for anxiety-associated conditions may yield
greater insights regarding patient response variability. This approach has been already
applied in studies such as The Sequenced Treatment Alternatives to Relieve Depression
(STAR*D), Munich Antidepressant Response Signature (MARS), and Genome-based
Therapeutic Drugs for Depression (GEN-DEP) – all large genome-wide association
studies (GWAS) assessing anti-depressant pharmacogenomics for the treatment of
major depressive disorder.

Ethological Approaches to Anxiety
A substantial challenge to translating preclinical investigations of the neurophysiology of
anxiety is interpreting the ethological relationships between defense- and survivalassociated behavior exhibited by rodents and human anxiety. In particular, distinguishing
anxiety- and fear-driven behaviors in assays of animal behavior is critical to efforts at
mapping the governing neurophysiologies. For example, animal models of these
behaviors often derive from responses to threat, while human research generally
concentrates on analyses of psychiatric conditions (D. C. Blanchard, Hynd, Minke,
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Minemoto, & Blanchard, 2001; Davis, Walker, Miles, & Grillon, 2010). Nevertheless, a
foundation of literature suggests that the mechanisms underlying both fear and anxiety
are sufficiently analogous to justify analyses of both in animal models in pursuit of an
understanding of processes in humans (Tovote, Fadok, & Luthi, 2015).
Theoretical frameworks have been proposed over time that can aid in this effort. One
example is provided by early analyses of predator-elicited behaviors by Caroline &
Robert Blanchard (D. C. Blanchard & Blanchard, 1988; R. J. Blanchard, Griebel, Henrie,
& Blanchard, 1997), describing the concept of “defensive distance”. These models were
later updated by McNaughton & Corr who iterated upon Gray & McNaughton’s
“Neuropsychology of Anxiety” (Jeffrey A. Gray, 1982) to craft a model of animal
behavior. Particularly insightful to the work described in this dissertation is the
characterization of survival-association behaviors, articulated by the Blanchards,
associating anxiety with risk assessment of the potential presence of a predator, rather
than those directly elicited by predators, as is characteristic of fear (R. J. Blanchard et
al., 1997; McNaughton & Corr, 2004).
At the core of Gray’s original framework is a tension between two primary motivational
systems that govern behavior: a Behavioral Inhibition System (BIS) and Behavioral
Activation System or Behavioral Approach System (BAS) (Carver & White, 1994; Jeffrey
A. Gray, 1982, 2000). Briefly, catecholaminergic signaling was proposed to drive
behavioral activation, driving animals to approach or engage in behaviors in pursuit of
reward. A septo-hippocampal network, along with monoaminergic signaling from caudal
and ventral brainstem regions to the cortex and rostral structures, were proposed to
underlie the BIS (Carver & White, 1994). The BIS fundamentally operates to drive the
evaluation of risk in conflict situations. Both anxiety and fear can be contextualized within
the BIS, though – as McNaughton & Corr argue – operate in opposition with regards to
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behavioral outputs when an animal is confronted with danger. Most notably, they argue
that fear operates to motivate an animal to move away from danger, while anxiety
ultimately motivates an animal to move toward danger (McNaughton & Corr, 2004).
Another insightful framework is described by Deakin & Graeff in 1991, proposing that
distinct pathways of serotonergic neurons – originating in the midbrain raphe nuclei regulate both behavioral and physiological responses to aversive or threatening stimuli
(Deakin & Graeff, 1991). Further, they hypothesized that particular serotonergic circuits
regulate discrete components of the repertoire of behavioral and physiological
responses to negative stimuli, potentially translating to specific categories of anxietyassociated psychiatric conditions (Paul, Johnson, Shekhar, & Lowry, 2014). Principally
concerned with the neurophysiology of anxiety, fear, and panic, they enumerated a
network of anatomical structures that studies had determined to have roles in these
behavioral and physiological responses. They highlighted the amygdala, hippocampus,
medial hypothalamus, and periaqueductal grey – the dorsal subregion of which in
particular (dPAG) - as central components of this anatomical network. The network they
described comprises a system wherein serotonergic signaling from the dorsal raphe
nucleus (DRN), arriving in the dPAG, inhibits escape-associated behavior, whereas DRN
serotonin signaling arriving at the amygdala facilitates anxiety-associated responses.
Finally, they proposed, serotonin signaling in the median raphe nucleus (MRN) –
sending substantial efferent projections to the hippocampus - increases resilience to
stress and are critical to anti-depressant effects (Deakin & Graeff, 1991; Paul et al.,
2014).
While certainly abridged representations of the regulatory neurophysiology, these
frameworks facilitate more effective ethological interpretations of in vivo pharmacological
and viral perturbations of neurophysiology in behavioral assays, particularly when
24

parsing behavioral responses to aversive stimuli and environments. For example, while
behaviors associated with fear and anxiety can appear similar, nuances have been
revealed by lesion and pharmacological examinations.

Involvement of Serotonin in Anxiety
In addition to clinical observations, early indications of serotonergic regulation of anxiety
were derived from animal models. Studies had demonstrated that anxiolytic medications
used to treat anxiety-associated psychiatric conditions in the 1960s and 1970s
influenced responses to reinforcing stimuli in animal operant conditioning models
(Francisco S. Guimarães, 2010). Approach-avoidance responses, wherein appetitive
stimuli are paired with an aversive stimulus, were effectively released by the
administration of anxiolytics, such as barbiturates and benzodiazepines (Francisco S.
Guimarães, 2010). While not principally serotonergic in its pharmacological action, Wise,
Berger, and Stein identified an important effect of the benzodiazepine, oxazepam,
causing reduced serotonin turnover in the rat midbrain – as well as in releasing punished
responses in a conflict behavioral test (Francisco S. Guimarães, 2010; Wise, Berger, &
Stein, 1972). The results from studies conducted by Wise et al. indicated that part of the
anxiolytic action exerted by benzodiazepines was a reduction of serotonin release in
regions associated with behavioral responses to punishment, the periaqueductal gray
(PAG) and forebrain. The corollary interpretation of these data was a putative
enhancement of anxiety by serotonin release in these two brain regions. Indeed, the
evidence that antidepressant medications effectively confront anxiety disorders in many
patients suggests that these conditions arise from activity beyond GABAergic signaling
(D. J. Stein & Stahl, 2000). In short, several classes of anxiolytics seem to exert their
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effects either by reduction of serotonin release via GABAergic inhibition of serotonergic
neurons, as is the case with benzodiazepines, or by activation of 5-HT1A autoreceptors
presynaptically, as is the case with buspirone (Lucki, 1998).
Further, studies by Robichaud & Sledge demonstrated that selective reductions in
serotonin concentrations in the brain with para-chlorophenylalanine (PCPA) influenced
approach-avoidance conflict tests (Kathleen R. Bailey, 2009), reducing foot-shock
punishment-driven avoidance in favor of pursuing sweetened milk (Robichaud & Sledge,
1969). Subsequently, the non-selective serotonin receptor antagonists, methysergide
and bromolysergic acid, were shown to exert similar effects in a similar approachavoidance behavioral test (Graeff & Schoenfeld, 1970).
Later efforts have expanded our understanding of serotonergic regulation of anxietyassociated behaviors. Both the neural circuitry and repertoire of neurotransmitters with
regulatory roles in survival-associated behavior, and anxiety in particular, have
broadened. As mentioned earlier in this section, a consistent network of anatomical
regions has been associated with the regulation of anxiety-associated behavior in animal
models. Notable structures relevant to the thesis work described in this dissertation
within the network – all of which being serotoninoceptive - are the amygdala,
periaqueductal gray, and septo-hippocampal system.

Regulation of Anxiety by Serotoninoceptive Anatomical Structures

Periaqueductal Gray
In animal models, electrical stimulation of dorsal regions of the PAG (dPAG) have been
shown to induce defensive behaviors (Hunsperger, 1956). Attesting to the aversive
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quality of dPAG stimulation, animals readily learn to mitigate stimulation of the region
(Hunsperger, 1956). Subsequently, methysergide was shown to reduce behavioral
responses to deactivate electrical stimulation of the dPAG, while chlordiazepoxide
administration failed to result in similar behavioral reactions (Schenberg & Graeff, 1978).
Interestingly, recent studies indicate that animal diabetic models exhibit a predisposition
to panicogenesis, and this was effectively blocked by infusion of a 5-HT1A receptor
agonist, 8-OH-DPAT, into the dPAG (Gambeta et al., 2017). For additional evidence
implicating the regulation of anxiety- and panic-associated behavior by serotonin in the
PAG, see the review by Frederico Graeff (Graeff, 2004).
A fascinating experimental probe into the neuroanatomical basis of aversive emotional
experience was performed by Nashold et al. in 1969. Worth reading for its breadth of
neurophysiological functions explored, the group evaluated patients with intractable
central pain who agreed to implantation of electrodes into the dorsolateral
mesencephalic tegmentum prior to therapeutic lesioning – enabling stimulation while the
patients were awake. Severely aversive emotional reactions, including fear and panic,
were reported among the variety of subjective responses experienced (Nashold, Wilson,
& Slaughter, 1969). While principally interested in delineating the neurophysiology of
pain arising from pathologies of the central nervous system, the electrophysiological
exploration in this study implicates the dorsal periaqueductal grey in the regulation of
anxiety-associated experiences.

Amygdala
Among brain regions implicated in anxiety, the amygdala has consistently been
highlighted. Due to its role in regulating both anxiety- and fear-associated signaling,
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however, parsing its participation in each can be challenging. Further complicating these
studies is the heterogeneity of signaling contributions of different subnuclei that comprise
the structure. Some researchers even suggest that, rather than representing a unitary
anatomical structure, the amygdala may be better understood as a set of separate
structures with distinct – even divergent – contributions to anxiety and fear (McNaughton
& Corr, 2004; Swanson & Petrovich, 1998). Regardless, the amygdala has been
associated with the regulation of both anxiety and fear, evidenced in part by studies of
local anxiolytic infusions resulting in reduced anxiety-associated behavior in animal
behavioral models (Davis, 1992; Scheel-Kruger & Petersen, 1982; K. Shibata, Kataoka,
Gomita, & Ueki, 1982). Further evidence of the involvement of the amygdala in
regulating anxiety is derived from fMRI studies in humans, showing abnormal functional
connectivity between two subnuclei within the structure, the basolateral amygdala (BLA)
and central nucleus (CeA), in patients diagnosed with GAD (Etkin, Prater, Schatzberg,
Menon, & Greicius, 2009; Janak & Tye, 2015). Serotonergic signaling within the
amygdala has been shown to be involved in the physiology of panic disorder. Patients
diagnosed with social anxiety disorder were found to exhibit lower 5-HT1A receptor
binding potential in the amygdala, as well as the dorsal raphe nuclei (Lanzenberger et
al., 2007). While no direct afferent or efferent connections between the amygdala and
MHb-IPN axis have been identified, investigations of the role the MHb-IPN axis plays in
seizure physiology found that lesions of the IPN resulted in a suppression of subsequent
amygdalar kindling in rats, suggesting that kindling in the amygdala – and limbic seizure
susceptibility more broadly - may be modulated by the IPN (Chiba & Wada, 1995).
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Septo-hippocampal system
The observation of similarities between the behavioral repercussions of hippocampal
lesions and anxiolytic pharmacological agents served as a foundation for the implication
of the septo-hippocampal pathway in anxiety-associated signaling (McNaughton & Corr,
2004). Conceptually, signaling within the septo-hippocampal pathway has been
proposed to underlie the execution of behaviors pursuant of risk assessment, including
exploration to determine if approach or avoidance represents the optimal strategy. A
variety of potential mechanisms by which hippocampal activity influences these
determinations has been proposed, including the reduction of both positive and negative
associations (Ito & Lee, 2016). Recent human studies have suggested that behavioral
inhibition – measured by scores on the Sensitivity to Punishment subscale of the
Sensitivity to Punishment and Sensitivity to Reward questionnaire – is positively
associated with hippocampal volume, suggesting a role played by the structure in
regulating anxiety (Levita et al., 2014). Multiple dynamics within the hippocampus have
been implicated in anxiety-associated behavior, ranging from efferent signaling to
neurogenesis. For example, inhibition of the latter has been observed to block the
effects of serotonergic anxiolytic drugs in mice (Santarelli et al., 2003). Interestingly,
multiple antidepressant medications have been shown to enhance neurogenesis in the
dentate gyrus of the hippocampus, including the SSRI, fluoxetine (Malberg, Eisch,
Nestler, & Duman, 2000).
The septal area is a forebrain structure, located ventral to the corpus callosum, that
separates the lateral ventricles. The region has been studied from many perspectives
over the years, some of which are somewhat disquieting in retrospect (Moan & Heath,
1972). Early studies of the functional output of signaling in the septum noted that lesions
to the structure resulted in hyperirritability, a behavioral profile that came to be termed
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“septal rage”, characterized by indiscriminate defensive responses (Anthony et al., 2014;
Harrell & Balagura, 1975). Increased emotional reactivity was observed in animals
following septal lesions (J. V. Brady & Nauta, 1953). Conversely, animals will readily
self-stimulate the septal area via lever-presses through implanted electrodes, indicating
substantially rewarding responses (Olds & Milner, 1954). Studies in humans have also
indicated that stimulation of the region is similarly pleasant (Heath, 1963; Moan & Heath,
1972). Pharmacological studies have also revealed a role played by the septal region in
regulating anxiety-associated behavior. Microinfusion of the benzodiazepine, midazolam,
into the septum resulted in elevations of activity in the open arms of the elevated plus
maze (De Almeida, Giovenardi, Charchat, & Lucion, 1998), indicative of anxiolysis. In
the same study, infusion of 8-OH-DPAT, a 5-HT1A receptor agonist, yielded anxiogenesis
in the elevated plus maze at specific doses. Pharmacological studies have also revealed
septo-hippocampal – and ventral hippocampal in particular – regulation of open-arm
exploration in the elevated plus maze. Infusion of muscimol, a selective GABAA receptor
agonist derived from the Amanita muscaria mushroom, into the lateral septum and
ventral hippocampus was anxiolytic (Trent & Menard, 2010). Interestingly, however,
anxiolysis was only observed when muscimol was infused into the regions
contralaterally; ipsilateral infusion, or infusion into either structure alone, both failed to
produce this effect. Tetrodotoxin (TTX), a toxin produced by multiple animals of the order
Tetraodontiformes, most notably in the pufferfish, potently inhibits voltage-gated sodium
channels, resulting in the blocking of action potential firing (Narahashi, 2008). When
infused into the septum, TTX increased open arm exploration in the EPM, and also
reduced burying behavior in the shock-probe test, another model of anxiety-associated
behavior (Degroot & Treit, 2004; Fucich & Morilak, 2018).
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Ventral Hippocampus & Anxiety
As discussed above, the hippocampus has long been implicated in the regulation of
anxiety. The ventral subregion of the structure, and serotonergic signaling within the
structure specifically, appears to be especially involved. When infused into the ventral
hippocampus, tertatolol – a 5-HT1A receptor and β-adrendergic receptor antagonist – has
been shown to produce anxiolysis in the EPM (File & Gonzalez, 1996). Rats treated with
ventral hippocampal lesions exhibited lower anxiety-associated behavior in multiple
assays, and interestingly exhibited no signs of spatial learning impairments in the
hidden-platform water maze test (McHugh, Deacon, Rawlins, & Bannerman, 2004).
These findings corroborate prior studies of hippocampal lesions resulting in anxiolysis
(Deacon, Bannerman, & Rawlins, 2002), and the ventral hippocampus specifically
(Bannerman et al., 2002). Absence of the 5-HT1A receptor has been shown to result in
elevated anxiety associated behavior (Heisler et al., 1998). In vivo recordings of
neuronal activity in the hippocampus of 5-HT1A receptor knock-out mice revealed
elevations of theta-frequency oscillations in anxiogenic environments, while familiar
environments were associated with no such elevations (Gordon, Lacefield, Kentros, &
Hen, 2005). In the study described above, exploring TTX-induced lesions of the septum,
TTX was found to produce anxiolysis when infused into the ventral hippocampus as well
(Degroot & Treit, 2004). Interestingly, the group also found that TTX lesions of the dorsal
hippocampus failed to result in similar reductions of anxiety, indicating that septohippocampal regulation of anxiety-associated behavior may involve more granular
anatomical hippocampal sub-regions. Withdrawal from chronic administration of the
habit-forming psychomotor stimulant, amphetamine – which results in elevated anxiety
(H. Li et al., 2014) - has been shown to result in reduced extracellular serotonin
concentrations in the ventral hippocampus (Barr et al., 2013). Restraint stress has been
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shown to correlate with elevations of ventral hippocampal serotonin concentrations,
though rats undergoing amphetamine withdrawal did not exhibit this elevation – which
the researchers interpreted as potentially resulting in a vulnerability to drug relapse as a
byproduct of elevated stress sensitivity (H. Li et al., 2014).
Additional investigations of the effect of ventral hippocampal lesions found that rats
exhibited a significantly higher percentage of open arm visits compared to those with
dorsal lesions or sham-operations in the EPM (Kjelstrup et al., 2002). Among the targets
of direct ventral hippocampal efferent projections is the medial prefrontal cortex (mPFC),
the substructures of which have also been implicated in the regulation of anxiety
(Gonzalez et al., 2000). In vivo recording of neuronal activity in the mPFC, as well as
both the dorsal and ventral hippocampus, of freely-moving mice revealed increased
theta-frequency synchrony between the mPFC and ventral hippocampus in anxiogenic
environments (Adhikari, Topiwala, & Gordon, 2010). Further impressive examinations of
this circuit by this group suggest that the mPFC, influenced by signals arriving from the
ventral hippocampus, operates to construct a cognitive model of anxiogenic
environments – guiding the tension between the drive to explore and avoid potential
threats (Adhikari, Topiwala, & Gordon, 2011).
Elegant in vivo optogenetic experiments demonstrated that activation of somata within
the BLA was anxiogenic, while more selective activation of afferent terminals arriving in
the lateral CeA produced the opposite effect (Felix-Ortiz et al., 2013). Further, and
pertinently to the experiments I conducted in this dissertation, inhibition of terminals
arriving in the ventral hippocampus from the BLA proved to be anxiolytic (Felix-Ortiz et
al., 2013). Additionally, activation of the same terminals yielded anxiogenesis,
suggesting that signaling within the ventral hippocampus plays a critical role in regulating
anxiety-associated behavior. Similarly, activation of granule cells in the dentate gyrus of
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the ventral hippocampus resulted in anxiolysis in both the open field test and EPM
(Kheirbek et al., 2013). Granule cells in the dentate gyrus are notably sensitive to
elevated stress hormone levels, whereby stressful experiences can inhibit neurogenesis
(Gould, McEwen, Tanapat, Galea, & Fuchs, 1997; McEwen, 1999).
In summary, interpretations of the regulation of defensive behavior by serotonin are
complicated by contradictory effects in different anatomical structures. Behaviorally,
serotonergic signaling appears to facilitate anxiety-associated behaviors while inhibiting
those associated with panic (Francisco S. Guimarães, 2010). In the septo-hippocampal
system and amygdala, serotonin release appears to promote behaviors ethologically
associated with anxiety while, in the PAG, serotonin signaling appears to inhibit these
behaviors (Francisco S. Guimarães, 2010). Accordingly, interpretations of animal
behavior observed following circuit-specific perturbations, such as the experiments
described in this dissertation, are best served by a consideration of these potential
nuances.

Relationship of the IPN with Serotoninoceptive Structures that Regulate
Anxiety
One of the earliest reviews of the afferent and efferent connectivity of the
interpeduncular nucleus (IPN) was composed by Barbara Morley in 1986 (Morley, 1986),
referenced throughout this dissertation – most comprehensively in (McLaughlin et al.,
2017). Several anatomical structures noted by Morley, some of which have been
corroborated in subsequent studies, are implicated in both serotonergic signaling and
anxiety-associated behavior. The periaqueductal gray (PAG), locus coeruleus, and
raphe nuclei are among the relevant afferent pathways. Evidence of direct projections
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from the infralimbic region of the mPFC to dorsal regions of the IPN has been reported,
though not subsequently corroborated (Takagishi & Chiba, 1991). Among the relevant
efferent pathways are the septum, hippocampus, and lateral hypothalamus (Baisden,
Hoover, & Cowie, 1979; Groenewegen, Ahlenius, Haber, Kowall, & Nauta, 1986; Quina
et al., 2017). In addition to tracing studies, lesions of the fasciculus retroflexus – the
conduit of afferent projections from the MHb to the IPN – have been shown to reduce the
power of hippocampal theta rhythms, as well as influence rapid eye movement (REM)
sleep, in rats (Valjakka et al., 1998). As discussed above, theta rhythm oscillations within
the ventral hippocampus have been associated with anxious states, indicating one
potential mechanism by which the MHb-IPN axis might regulate anxiety arising from
hippocampal activity (Adhikari et al., 2010). Evidence of noradrenergic projections from
the locus coeruleus to the MHb-IPN axis is derived from earlier neuroanatomical studies
which have yet to be corroborated using contemporary methods (Gottesfeld, 1983).
While the MHb-IPN axis has not been shown to receive direct afferent projections from
the bed nucleus of the stria terminalis (BnST), the caudal lateral habenula (LHb) – lateral
complement to the medial subnucleus of the habenular complex - has been shown to.
Further, fMRI studies, while unable to achieve sufficient resolution to distinguish the
medial and lateral habenular subnuclei, demonstrated functional connectivity between
the habenular complex and the BnST (Torrisi et al., 2017).
Early reviews of the afferent and efferent connectivity of the IPN suggested that it sends
projections to the LHb, but only recently have they been corroborated (Morley, 1986).
Unpublished viral tracing experiments I performed identify direct projections from the IPN
to the LHb – and this has been confirmed by recent elegant tracing performed by Lely
Quina in the Turner lab (Quina et al., 2017). Additionally, the LHb may be among the
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handful of anatomical structures that receives efferent projections directly from the MHb
(Kim & Chang, 2005).
Accordingly, given the projections to the LHb from the BnST, the MHb-IPN axis
contributes to the downstream recipients of BnST signaling. The septal nuclei have been
shown to receive innervation from the IPN (Morley, 1986; Quina et al., 2017), and
additional tracing experiments I performed corroborates the existence of these
projections. A recent study by Yamaguchi et al. provided a detailed anatomy of septal
projections to the MHb, along with a parsing of the regulation of fear and anxiety by
septohabenular pathways (Yamaguchi et al., 2013).
Overall, the role of serotonin in the regulation of anxiety is complex. Defensive
behaviors, and anxiety in particular, arise from a distributed network of anatomical
structures. It is therefore prudent, when interrogating specific structures involved in the
orchestration of behaviors driven by anxiety, to consider their functional relationships
within the broader circuitry involved in anxiety-associated signaling. While this section
certainly hasn’t exhaustively reviewed all regions or signaling pathways associated with
anxiety, many prominent structures implicated in its underlying neurophysiology are
associated with the MHb-IPN axis, and therefore its functional analysis is warranted in
pursuit of a more thorough understanding of the neurophysiology of anxiety.
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Central Hypotheses
Central Hypothesis: the IPN regulates anxiety-associated behavior independently of
withdrawal from habit-forming drugs.

Secondary hypotheses: chemogenetic activation of glutamatergic IPN neurons is
anxiogenic, and broad IPN activation will correlate with altered serotonergic signaling in
the ventral hippocampus.

These hypotheses arise from two primary theoretical bases. First, the anatomy of the
dorsal diencephalic conduction system (DDC) positions the IPN as a junction of
signaling associated with cognition, mood, and motivation. As the principal recipient of
medial habenular output, and given the diversity of its efferent targets, the IPN
represents a source of signaling of multiple anatomical structures involved in affect
regulation.
The second basis is derived from pharmacological drug withdrawal experiments that
have implicated signaling within the MHb-IPN axis in the manifestation of both affective
and somatic symptoms of withdrawal from alcohol, nicotine, and opioids. I anticipated
that this signaling pathway, and the IPN in particular, participates in the regulation of
baseline affective and somatic states independently of chronic drug exposure.
Secondary hypotheses are based on the anatomical connectivity between the IPN,
raphe nuclei, and ventral hippocampus. Projections from the IPN to the raphe nuclei
have long been established, and the raphe nuclei represent a major source of
serotonergic signaling in the brain. As the raphe nuclei have been shown to send
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projections to the hippocampus, I hypothesized that general activation of the IPN would
result in changes in the concentration of serotonin in the ventral hippocampus.

37

References
Agetsuma, M., Aizawa, H., Aoki, T. et al. (2010) The habenula is crucial for experiencedependent modification of fear responses in zebrafish. Nature neuroscience, 13, 13541356.
Ahumada-Galleguillos, P., Lemus, C. G., Diaz, E., Osorio-Reich, M., Hartel, S. and
Concha, M. L. (2016) Directional asymmetry in the volume of the human habenula. Brain
structure & function.
Aizawa, H., Kobayashi, M., Tanaka, S., Fukai, T. and Okamoto, H. (2012) Molecular
characterization of the subnuclei in rat habenula. The Journal of comparative neurology,
520, 4051-4066.
Antolin-Fontes, B., Ables, J. L., Görlich, A. and Ibañez-Tallon, I. (2015) The HabenuloInterpeduncular pathway in nicotine aversion and withdrawal. Neuropharmacology, 96,
213-222.
Association, A. P. (2013) Diagnostic and statistical manual of mental disorders.
American Psychiatric Publishing, Arlington, VA.
Baisden, R. H., Hoover, D. B. and Cowie, R. J. (1979) Retrograde demonstration of
hippocampal afferents from the interpeduncular and reuniens nuclei. Neuroscience
letters, 13, 105-109.
Bajic, D., Soiza-Reilly, M., Spalding, A. L., Berde, C. B. and Commons, K. G. (2015)
Endogenous cholinergic neurotransmission contributes to behavioral sensitization to
morphine. PloS one, 10, e0117601.
Barrot, M., Sesack, S. R., Georges, F., Pistis, M., Hong, S. and Jhou, T. C. (2012)
Braking dopamine systems: a new GABA master structure for mesolimbic and
nigrostriatal functions. The Journal of neuroscience : the official journal of the Society for
Neuroscience, 32, 14094-14101.
Behzadi, G., Kalen, P., Parvopassu, F. and Wiklund, L. (1990) Afferents to the median
raphe nucleus of the rat: retrograde cholera toxin and wheat germ conjugated
horseradish peroxidase tracing, and selective D-[3H]aspartate labelling of possible
excitatory amino acid inputs. Neuroscience, 37, 77-100.
Bianco, I. H. and Wilson, S. W. (2009) The habenular nuclei: a conserved asymmetric
relay station in the vertebrate brain. Philosophical transactions of the Royal Society of
London. Series B, Biological sciences, 364, 1005-1020.
Burger, J., Capobianco, M., Lovern, R., Boche, B., Ross, E., Darracq, M. A. and McLay,
R. (2016) A Double-Blinded, Randomized, Placebo-Controlled Sub-Dissociative Dose
Ketamine Pilot Study in the Treatment of Acute Depression and Suicidality in a Military
Emergency Department Setting. Military medicine, 181, 1195-1199.
Burgunder, J. M. and Young, W. S., 3rd (1989) Neurokinin B and substance P genes are
co-expressed in a subset of neurons in the rat habenula. Neuropeptides, 13, 165-169.

38

Carlson, J., Armstrong, B., Switzer, R. C., 3rd and Ellison, G. (2000) Selective
neurotoxic effects of nicotine on axons in fasciculus retroflexus further support evidence
that this a weak link in brain across multiple drugs of abuse. Neuropharmacology, 39,
2792-2798.
Carlson, P. J., Diazgranados, N., Nugent, A. C. et al. (2013) Neural correlates of rapid
antidepressant response to ketamine in treatment-resistant unipolar depression: a
preliminary positron emission tomography study. Biological psychiatry, 73, 1213-1221.
Center, U. S. D. o. J. N. D. I. (2011) National Drug Threat Assessment. (D. o. Justice
ed.).
Cirulli, F., Pistillo, L., de Acetis, L., Alleva, E. and Aloe, L. (1998) Increased number of
mast cells in the central nervous system of adult male mice following chronic
subordination stress. Brain, behavior, and immunity, 12, 123-133.
Cohen, S. R. and Melzack, R. (1985) Morphine injected into the habenula and dorsal
posteromedial thalamus produces analgesia in the formalin test. Brain research, 359,
131-139.
Conrad, L. C., Leonard, C. M. and Pfaff, D. W. (1974) Connections of the median and
dorsal raphe nuclei in the rat: an autoradiographic and degeneration study. The Journal
of comparative neurology, 156, 179-205.
Contestabile, A. and Flumerfelt, B. A. (1981) Afferent connections of the interpeduncular
nucleus and the topographic organization of the habenulo-interpeduncular pathway: an
HRP study in the rat. The Journal of comparative neurology, 196, 253-270.
Conway, K. P., Swendsen, J., Husky, M. M., He, J. P. and Merikangas, K. R. (2016)
Association of Lifetime Mental Disorders and Subsequent Alcohol and Illicit Drug Use:
Results From the National Comorbidity Survey-Adolescent Supplement. Journal of the
American Academy of Child and Adolescent Psychiatry, 55, 280-288.
Cougle, J. R., Zvolensky, M. J., Fitch, K. E. and Sachs-Ericsson, N. (2010) The role of
comorbidity in explaining the associations between anxiety disorders and smoking.
Nicotine & tobacco research : official journal of the Society for Research on Nicotine and
Tobacco, 12, 355-364.
Cuello, A. C., Emson, P. C., Paxinos, G. and Jessell, T. (1978) Substance P containing
and cholinergic projections from the habenula. Brain research, 149, 413-429.
Dani, J. A. and De Biasi, M. (2001) Cellular mechanisms of nicotine addiction.
Pharmacology, biochemistry, and behavior, 70, 439-446.
Dao, D. Q., Perez, E. E., Teng, Y., Dani, J. A. and De Biasi, M. (2014) Nicotine
enhances excitability of medial habenular neurons via facilitation of neurokinin signaling.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 34,
4273-4284.
Darcq, E., Befort, K., Koebel, P., Pannetier, S., Mahoney, M. K., Gaveriaux-Ruff, C.,
Hanauer, A. and Kieffer, B. L. (2012) RSK2 signaling in medial habenula contributes to
39

acute morphine analgesia. Neuropsychopharmacology : official publication of the
American College of Neuropsychopharmacology, 37, 1288-1296.
Davis, L., Uezato, A., Newell, J. M. and Frazier, E. (2008) Major depression and
comorbid substance use disorders. Current opinion in psychiatry, 21, 14-18.
De Biasi, M. and Dani, J. A. (2011) Reward, addiction, withdrawal to nicotine. Annual
review of neuroscience, 34, 105-130.
De Biasi, M., McLaughlin, I. and Klima, M. L. (2016) Chapter 18 - Nicotine and
Neurokinin Signaling A2 - Preedy, Victor R. In: Neuropathology of Drug Addictions and
Substance Misuse, pp. 189-200. Academic Press, San Diego.
De Biasi, M., McLaughlin, I., Perez, E. E., Crooks, P. A., Dwoskin, L. P., Bardo, M. T.,
Pentel, P. R. and Hatsukami, D. (2014) Scientific overview: 2013 BBC plenary
symposium on tobacco addiction. Drug and alcohol dependence, 141, 107-117.
De Biasi, M. and Salas, R. (2008) Influence of neuronal nicotinic receptors over nicotine
addiction and withdrawal. Experimental biology and medicine (Maywood, N.J.), 233,
917-929.
Di Chiara, G. and Imperato, A. (1988) Drugs abused by humans preferentially increase
synaptic dopamine concentrations in the mesolimbic system of freely moving rats.
Proceedings of the National Academy of Sciences of the United States of America, 85,
5274-5278.
Edwards, F. A., Gibb, A. J. and Colquhoun, D. (1992) ATP receptor-mediated synaptic
currents in the central nervous system. Nature, 359, 144-147.
Ellison, G. (2002) Neural degeneration following chronic stimulant abuse reveals a weak
link in brain, fasciculus retroflexus, implying the loss of forebrain control circuitry.
European neuropsychopharmacology : the journal of the European College of
Neuropsychopharmacology, 12, 287-297.
Ellison, G., Eison, M. S., Huberman, H. S. and Daniel, F. (1978) Long-term changes in
dopaminergic innervation of caudate nucleus after continuous amphetamine
administration. Science (New York, N.Y.), 201, 276-278.
Facchin, L., Duboue, E. R. and Halpern, M. E. (2015) Disruption of Epithalamic LeftRight Asymmetry Increases Anxiety in Zebrafish. The Journal of neuroscience : the
official journal of the Society for Neuroscience, 35, 15847-15859.
Faron-Gorecka, A., Kusmider, M., Kolasa, M. et al. (2016) Chronic mild stress alters the
somatostatin receptors in the rat brain. Psychopharmacology, 233, 255-266.
Farris, S. G., Brown, L. A., Goodwin, R. D. and Zvolensky, M. J. (2016) Panic attack
history and smoking topography. Drug and alcohol dependence, 171, 84-90.
Feldner, M. T., Babson, K. A. and Zvolensky, M. J. (2007) Smoking, traumatic event
exposure, and post-traumatic stress: a critical review of the empirical literature. Clinical
psychology review, 27, 14-45.
40

Fowler, C. D., Lu, Q., Johnson, P. M., Marks, M. J. and Kenny, P. J. (2011a) Habenular
alpha5 nicotinic receptor subunit signalling controls nicotine intake. Nature, 471, 597601.
Fowler, C. D., Lu, Q., Johnson, P. M., Marks, M. J. and Kenny, P. J. (2011b) Habenular
α5* nicotinic receptor signaling controls nicotine intake. Nature, 471, 597-601.
Fowler, C. D., Tuesta, L. and Kenny, P. J. (2013) Role of α5* nicotinic acetylcholine
receptors in the effects of acute and chronic nicotine treatment on brain reward function
in mice. Psychopharmacology, 10.1007/s00213-00013-03235-00211.
Frenzel, L. and Hermine, O. (2013) Mast cells and inflammation. Joint, bone, spine :
revue du rhumatisme, 80, 141-145.
Gackenheimer, S. L., Suter, T. M., Pintar, J. E., Quimby, S. J., Wheeler, W. J., Mitch, C.
H., Gehlert, D. R. and Statnick, M. A. (2005) Localization of opioid receptor antagonist
[3H]-LY255582 binding sites in mouse brain: comparison with the distribution of mu,
delta and kappa binding sites. Neuropeptides, 39, 559-567.
Gardon, O., Faget, L., Chu Sin Chung, P., Matifas, A., Massotte, D. and Kieffer, B. L.
(2014) Expression of mu opioid receptor in dorsal diencephalic conduction system: new
insights for the medial habenula. Neuroscience, 277, 595-609.
Georgin-Lavialle, S., Moura, D. S., Salvador, A. et al. (2016) Mast cells' involvement in
inflammation pathways linked to depression: evidence in mastocytosis. Molecular
psychiatry, 21, 1511-1516.
Glick, S. D., Maisonneuve, I. M. and Dickinson, H. A. (2000) 18-MC reduces
methamphetamine and nicotine self-administration in rats. Neuroreport, 11, 2013-2015.
Glick, S. D., Ramirez, R. L., Livi, J. M. and Maisonneuve, I. M. (2006) 18Methoxycoronaridine acts in the medial habenula and/or interpeduncular nucleus to
decrease morphine self-administration in rats. European journal of pharmacology, 537,
94-98.
Glick, S. D., Sell, E. M. and Maisonneuve, I. M. (2008) Brain regions mediating
alpha3beta4 nicotinic antagonist effects of 18-MC on methamphetamine and sucrose
self-administration. European journal of pharmacology, 599, 91-95.
Gorlich, A., Antolin-Fontes, B., Ables, J. L., Frahm, S., Slimak, M. A., Dougherty, J. D.
and Ibanez-Tallon, I. (2013) Reexposure to nicotine during withdrawal increases the
pacemaking activity of cholinergic habenular neurons. Proceedings of the National
Academy of Sciences of the United States of America, 110, 17077-17082.
Gottesfeld, Z. (1983) Origin and distribution of noradrenergic innervation in the
habenula: a neurochemical study. Brain research, 275, 299-304.
Grady, S. R., Moretti, M., Zoli, M., Marks, M. J., Zanardi, A., Pucci, L., Clementi, F. and
Gotti, C. (2009) Rodent habenulo-interpeduncular pathway expresses a large variety of
uncommon nAChR subtypes, but only the alpha3beta4* and alpha3beta3beta4*
41

subtypes mediate acetylcholine release. The Journal of neuroscience : the official journal
of the Society for Neuroscience, 29, 2272-2282.
Groenewegen, H. J., Ahlenius, S., Haber, S. N., Kowall, N. W. and Nauta, W. J. (1986)
Cytoarchitecture, fiber connections, and some histochemical aspects of the
interpeduncular nucleus in the rat. The Journal of comparative neurology, 249, 65-102.
Guglielmotti, V. and Cristino, L. (2006) The interplay between the pineal complex and
the habenular nuclei in lower vertebrates in the context of the evolution of cerebral
asymmetry. Brain research bulletin, 69, 475-488.
Hamill, G. S. and Jacobowitz, D. M. (1984) A study of afferent projections to the rat
interpeduncular nucleus. Brain research bulletin, 13, 527-539.
Han, Y., Chen, J., Zou, D. et al. (2016) Efficacy of ketamine in the rapid treatment of
major depressive disorder: a meta-analysis of randomized, double-blind, placebocontrolled studies. Neuropsychiatric disease and treatment, 12, 2859-2867.
Hayakawa, T., Seki, M. and Zyo, K. (1981) Studies on the efferent projections of the
interpeduncular complex in cats. Okajimas folia anatomica Japonica, 58, 1-15.
Herkenham, M. and Nauta, W. J. (1977) Afferent connections of the habenular nuclei in
the rat. A horseradish peroxidase study, with a note on the fiber-of-passage problem.
The Journal of comparative neurology, 173, 123-146.
Herkenham, M. and Nauta, W. J. (1979) Efferent connections of the habenular nuclei in
the rat. The Journal of comparative neurology, 187, 19-47.
Hetu, S., Luo, Y., Saez, I., D'Ardenne, K., Lohrenz, T. and Montague, P. R. (2016)
Asymmetry in functional connectivity of the human habenula revealed by high-resolution
cardiac-gated resting state imaging. Human brain mapping, 37, 2602-2615.
Hsu, Y. W. and Wang, S. D. (2014) Role of the dorsal medial habenula in the regulation
of voluntary activity, motor function, hedonic state, and primary reinforcement. 34,
11366-11384.
Hussain, R. J., Taraschenko, O. D. and Glick, S. D. (2008) Effects of nicotine,
methamphetamine and cocaine on extracellular levels of acetylcholine in the
interpeduncular nucleus of rats. Neuroscience letters, 440, 270-274.
Hwang, B. H., Suzuki, R., Lumeng, L., Li, T. K. and McBride, W. J. (2004) Innate
differences in neuropeptide Y (NPY) mRNA expression in discrete brain regions
between alcohol-preferring (P) and -nonpreferring (NP) rats: a significantly low level of
NPY mRNA in dentate gyrus of the hippocampus and absence of NPY mRNA in the
medial habenular nucleus of P rats. Neuropeptides, 38, 359-368.
Ichijo, H. and Toyama, T. (2015) Axons from the medial habenular nucleus are
topographically sorted in the fasciculus retroflexus. Anatomical science international, 90,
229-234.

42

Jackson, K. J., Muldoon, P. P., De Biasi, M. and Damaj, M. I. (2015) New mechanisms
and perspectives in nicotine withdrawal. Neuropharmacology, 96, 223-234.
James, M. H., Charnley, J. L., Flynn, J. R., Smith, D. W. and Dayas, C. V. (2011)
Propensity to 'relapse' following exposure to cocaine cues is associated with the
recruitment of specific thalamic and epithalamic nuclei. Neuroscience, 199, 235-242.
Jean-Richard Dit Bressel, P. and McNally, G. P. (2014) The role of the lateral habenula
in punishment. PloS one, 9, e111699.
Jesuthasan, S. (2012) Fear, anxiety, and control in the zebrafish. Developmental
neurobiology, 72, 395-403.
Kanjhan, R., Housley, G. D., Burton, L. D., Christie, D. L., Kippenberger, A., Thorne, P.
R., Luo, L. and Ryan, A. F. (1999) Distribution of the P2X2 receptor subunit of the ATPgated ion channels in the rat central nervous system. The Journal of comparative
neurology, 407, 11-32.
Kassel, J. D., Stroud, L. R. and Paronis, C. A. (2003) Smoking, stress, and negative
affect: correlation, causation, and context across stages of smoking. Psychological
bulletin, 129, 270-304.
Kemali, M. and Guglielmotti, V. (1982) The connections of the frog interpeduncular
nucleus (ITP) demonstrated by horseradish peroxidase (HRP). Experimental brain
research, 45, 349-356.
Kessler, R. C., Chiu, W. T., Demler, O., Merikangas, K. R. and Walters, E. E. (2005)
Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National
Comorbidity Survey Replication. Archives of general psychiatry, 62, 617-627.
Kim, U. and Chang, S. Y. (2005) Dendritic morphology, local circuitry, and intrinsic
electrophysiology of neurons in the rat medial and lateral habenular nuclei of the
epithalamus. The Journal of comparative neurology, 483, 236-250.
Kinsey, A. M., Wainwright, A., Heavens, R., Sirinathsinghji, D. J. and Oliver, K. R. (2001)
Distribution of 5-ht(5A), 5-ht(5B), 5-ht(6) and 5-HT(7) receptor mRNAs in the rat brain.
Brain research. Molecular brain research, 88, 194-198.
Kobayashi, Y., Sano, Y., Vannoni, E. et al. (2013) Genetic dissection of medial
habenula-interpeduncular nucleus pathway function in mice. Frontiers in behavioral
neuroscience, 7, 17.
Kopp, J., Xu, Z. Q., Zhang, X., Pedrazzini, T., Herzog, H., Kresse, A., Wong, H., Walsh,
J. H. and Hokfelt, T. (2002) Expression of the neuropeptide Y Y1 receptor in the CNS of
rat and of wild-type and Y1 receptor knock-out mice. Focus on immunohistochemical
localization. Neuroscience, 111, 443-532.
Lasser, K., Boyd, J. W., Woolhandler, S., Himmelstein, D. U., McCormick, D. and Bor, D.
H. (2000) Smoking and mental illness: A population-based prevalence study. Jama, 284,
2606-2610.
43

Lecourtier, L. and Kelly, P. H. (2007) A conductor hidden in the orchestra? Role of the
habenular complex in monoamine transmission and cognition. Neuroscience and
biobehavioral reviews, 31, 658-672.
Lee, A., Mathuru, A. S., Teh, C., Kibat, C., Korzh, V., Penney, T. B. and Jesuthasan, S.
(2010) The habenula prevents helpless behavior in larval zebrafish. Current biology :
CB, 20, 2211-2216.
Lotfipour, S., Byun, J. S., Leach, P., Fowler, C. D., Murphy, N. P., Kenny, P. J., Gould, T.
J. and Boulter, J. (2013) Targeted Deletion of the Mouse α2 Nicotinic Acetylcholine
Receptor Subunit Gene (Chrna2) Potentiates Nicotine-Modulated Behaviors. The
Journal of neuroscience : the official journal of the Society for Neuroscience, 33,
10.1523/JNEUROSCI.4731-1512.2013.
Massopust, L. C., Jr. and Thompson, R. (1962) A new interpedunculodiencephalic
pathway in rats and cats. The Journal of comparative neurology, 118, 97-105.
Mathuru, A. S. and Jesuthasan, S. (2013) The medial habenula as a regulator of anxiety
in adult zebrafish. Frontiers in neural circuits, 7, 99.
McCormick, D. A. and Prince, D. A. (1987) Acetylcholine causes rapid nicotinic
excitation in the medial habenular nucleus of guinea pig, in vitro. The Journal of
neuroscience : the official journal of the Society for Neuroscience, 7, 742-752.
McLaughlin, I., Dani, J. A. and De Biasi, M. (2015) Nicotine withdrawal. Current topics in
behavioral neurosciences, 24, 99-123.
Medicine, A. S. o. A. (2016) Opioid Addiction 2016 Facts & Figures.
Meszaros, J., Gajewska, S. and Tarchalska-Krynska, B. (1985) Habenulointerpeduncular lesions: the effects on pain sensitivity, morphine analgesia and openfield behavior in rats. Polish journal of pharmacology and pharmacy, 37, 469-477.
Mirrione, M. M., Schulz, D., Lapidus, K. A., Zhang, S., Goodman, W. and Henn, F. A.
(2014) Increased metabolic activity in the septum and habenula during stress is linked to
subsequent expression of learned helplessness behavior. Frontiers in human
neuroscience, 8, 29.
Morissette, S. B., Tull, M. T., Gulliver, S. B., Kamholz, B. W. and Zimering, R. T. (2007)
Anxiety, anxiety disorders, tobacco use, and nicotine: a critical review of
interrelationships. Psychological bulletin, 133, 245-272.
Morley, B. J. (1986) The interpeduncular nucleus. International review of neurobiology,
28, 157-182.
Mugnaini, M., Tessari, M., Tarter, G., Merlo Pich, E., Chiamulera, C. and Bunnemann, B.
(2002) Upregulation of [3H]methyllycaconitine binding sites following continuous infusion
of nicotine, without changes of alpha7 or alpha6 subunit mRNA: an autoradiography and
in situ hybridization study in rat brain. The European journal of neuroscience, 16, 16331646.
44

Murrough, J. W., Iosifescu, D. V., Chang, L. C. et al. (2013) Antidepressant efficacy of
ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
The American journal of psychiatry, 170, 1134-1142.
National Center for Chronic Disease, P., Health Promotion Office on, S. and Health
(2014) Reports of the Surgeon General. In: The Health Consequences of Smoking-50
Years of Progress: A Report of the Surgeon General. Centers for Disease Control and
Prevention (US), Atlanta (GA).
Nautiyal, K. M., Ribeiro, A. C., Pfaff, D. W. and Silver, R. (2008) Brain mast cells link the
immune system to anxiety-like behavior. Proceedings of the National Academy of
Sciences of the United States of America, 105, 18053-18057.
Neugebauer, N. M., Einstein, E. B., Lopez, M. B., McClure-Begley, T. D., Mineur, Y. S.
and Picciotto, M. R. (2013) Morphine dependence and withdrawal induced changes in
cholinergic signaling. Pharmacology, biochemistry, and behavior, 109, 77-83.
Okamoto, H., Agetsuma, M. and Aizawa, H. (2012) Genetic dissection of the zebrafish
habenula, a possible switching board for selection of behavioral strategy to cope with
fear and anxiety. Developmental neurobiology, 72, 386-394.
Okamoto, H. and Aizawa, H. (2013) Fear and anxiety regulation by conserved affective
circuits. Neuron, 78, 411-413.
Padilla, E., Shumake, J., Barrett, D. W., Sheridan, E. C. and Gonzalez-Lima, F. (2011)
Mesolimbic effects of the antidepressant fluoxetine in Holtzman rats, a genetic strain
with increased vulnerability to stress. Brain research, 1387, 71-84.
Panchal, V., Taraschenko, O. D., Maisonneuve, I. M. and Glick, S. D. (2005) Attenuation
of morphine withdrawal signs by intracerebral administration of 18-methoxycoronaridine.
European journal of pharmacology, 525, 98-104.
Pankratov, Y., Lalo, U., Krishtal, O. A. and Verkhratsky, A. (2009) P2X receptors and
synaptic plasticity. Neuroscience, 158, 137-148.
Pankratov, Y., Lalo, U., Verkhratsky, A. and North, R. A. (2006) Vesicular release of ATP
at central synapses. Pflugers Archiv : European journal of physiology, 452, 589-597.
Patton, G. C., Carlin, J. B., Coffey, C., Wolfe, R., Hibbert, M. and Bowes, G. (1998)
Depression, anxiety, and smoking initiation: a prospective study over 3 years. American
journal of public health, 88, 1518-1522.
Paulozzi, J., Mack, Rudd (2014) Opioid Painkiller Prescribing, Where You Live Makes a
Difference. (C. f. D. C. a. P. National Center for Injury Prevention and Control ed.).
Atlanta, GA.
Perez, E., Quijano-Carde, N. and De Biasi, M. (2015) Nicotinic Mechanisms Modulate
Ethanol Withdrawal and Modify Time Course and Symptoms Severity of Simultaneous
Withdrawal from Alcohol and Nicotine. Neuropsychopharmacology : official publication of
the American College of Neuropsychopharmacology, 40, 2327-2336.
45

Phillipson, O. T. and Pycock, C. J. (1982) Dopamine neurones of the ventral tegmentum
project to both medial and lateral habenula. Some implications for habenular function.
Experimental brain research, 45, 89-94.
Picciotto, M. R. and Kenny, P. J. (2013) Molecular mechanisms underlying behaviors
related to nicotine addiction. Cold Spring Harbor perspectives in medicine, 3, a012112a012112.
Prevention, C. f. D. C. a. (2015) Number and Age-Adjusted Rates of Drug-poisoning
Deaths Involving Opioid Analgesics and Heroin: United States, 2000-2014. (N. C. f. H.
Statistics ed.).
Prochaska, J. J., Das, S. and Young-Wolff, K. C. (2016) Smoking, Mental Illness, and
Public Health. Annual review of public health.
Qin, C. and Luo, M. (2009) Neurochemical phenotypes of the afferent and efferent
projections of the mouse medial habenula. Neuroscience, 161, 827-837.
Quina, L. A., Tempest, L., Ng, L., Harris, J. A., Ferguson, S., Jhou, T. C. and Turner, E.
E. (2015) Efferent pathways of the mouse lateral habenula. The Journal of comparative
neurology, 523, 32-60.
Ranft, K., Dobrowolny, H., Krell, D., Bielau, H., Bogerts, B. and Bernstein, H. G. (2010)
Evidence for structural abnormalities of the human habenular complex in affective
disorders but not in schizophrenia. Psychological medicine, 40, 557-567.
Rho, B. and Glick, S. D. (1998) Effects of 18-methoxycoronaridine on acute signs of
morphine withdrawal in rats. Neuroreport, 9, 1283-1285.
Ronnekleiv, O. K. and Moller, M. (1979) Brain-pineal nervous connections in the rat: an
ultrastructure study following habenular lesion. Experimental brain research, 37, 551562.
Roux, A., Muller, L., Jackson, S. N. et al. (2015) Chronic ethanol consumption
profoundly alters regional brain ceramide and sphingomyelin content in rodents. ACS
chemical neuroscience, 6, 247-259.
Ryan, P. J., Ma, S., Olucha-Bordonau, F. E. and Gundlach, A. L. (2011) Nucleus
incertus--an emerging modulatory role in arousal, stress and memory. Neuroscience and
biobehavioral reviews, 35, 1326-1341.
Sacks, J. J., Gonzales, K. R., Bouchery, E. E., Tomedi, L. E. and Brewer, R. D. (2015)
2010 National and State Costs of Excessive Alcohol Consumption. American journal of
preventive medicine, 49, e73-79.
Salas, R., Sturm, R., Boulter, J. and De Biasi, M. (2009) Nicotinic receptors in the
habenulo-interpeduncular system are necessary for nicotine withdrawal in mice. The
Journal of neuroscience : the official journal of the Society for Neuroscience, 29, 30143018.

46

Sanchez-Catalan, M. J., Faivre, F., Yalcin, I., Muller, M. A., Massotte, D., Majchrzak, M.
and Barrot, M. (2016) Response of the Tail of the Ventral Tegmental Area to Aversive
Stimuli. Neuropsychopharmacology : official publication of the American College of
Neuropsychopharmacology.
Savitz, J. B., Nugent, A. C., Bogers, W. et al. (2011) Habenula volume in bipolar disorder
and major depressive disorder: a high-resolution magnetic resonance imaging study.
Biological psychiatry, 69, 336-343.
Sheffield, E. B., Quick, M. W. and Lester, R. A. (2000) Nicotinic acetylcholine receptor
subunit mRNA expression and channel function in medial habenula neurons.
Neuropharmacology, 39, 2591-2603.
Shibata, H. and Suzuki, T. (1984) Efferent projections of the interpeduncular complex in
the rat, with special reference to its subnuclei: a retrograde horseradish peroxidase
study. Brain research, 296, 345-349.
Shibata, H., Suzuki, T. and Matsushita, M. (1986) Afferent projections to the
interpeduncular nucleus in the rat, as studied by retrograde and anterograde transport of
wheat germ agglutinin conjugated to horseradish peroxidase. The Journal of
comparative neurology, 248, 272-284.
Shih, P. Y., Engle, S. E., Oh, G., Deshpande, P., Puskar, N. L., Lester, H. A. and
Drenan, R. M. (2014) Differential expression and function of nicotinic acetylcholine
receptors in subdivisions of medial habenula. The Journal of neuroscience : the official
journal of the Society for Neuroscience, 34, 9789-9802.
Shumake, J., Edwards, E. and Gonzalez-Lima, F. (2003) Opposite metabolic changes in
the habenula and ventral tegmental area of a genetic model of helpless behavior. Brain
research, 963, 274-281.
Silver, R. and Curley, J. P. (2013) Mast cells on the mind: new insights and
opportunities. Trends in neurosciences, 36, 513-521.
Sim-Selley, L. J., Daunais, J. B., Porrino, L. J. and Childers, S. R. (1999) Mu and kappa1
opioid-stimulated [35S]guanylyl-5'-O-(gamma-thio)-triphosphate binding in cynomolgus
monkey brain. Neuroscience, 94, 651-662.
Smaha, L. A. and Kaelber, W. W. (1973) Efferent fiber projections of the habenula and
the interpeduncular nucleus. An experimental study in the opossum and cat.
Experimental brain research, 16, 291-308.
Smith, D. G., Learn, J. E., McBride, W. J., Lumeng, L., Li, T. K. and Murphy, J. M. (2001)
Alcohol-naive alcohol-preferring (P) rats exhibit higher local cerebral glucose utilization
than alcohol-nonpreferring (NP) and Wistar rats. Alcoholism, clinical and experimental
research, 25, 1309-1316.
Smith, O. A., Astley, C. A., DeVito, J. L., Stein, J. M. and Walsh, K. E. (1980) Functional
analysis of hypothalamic control of the cardiovascular responses accompanying
emotional behavior. Federation proceedings, 39, 2487-2494.
47

Sperlagh, B., Magloczky, Z., Vizi, E. S. and Freund, T. F. (1998) The triangular septal
nucleus as the major source of ATP release in the rat habenula: a combined
neurochemical and morphological study. Neuroscience, 86, 1195-1207.
Stein, E. A. (1993) Ventral tegmental self-stimulation selectively induces opioid peptide
release in rat CNS. Synapse (New York, N.Y.), 13, 63-73.
Sugama, S., Cho, B. P., Baker, H., Joh, T. H., Lucero, J. and Conti, B. (2002) Neurons
of the superior nucleus of the medial habenula and ependymal cells express IL-18 in rat
CNS. Brain research, 958, 1-9.
Sutherland, R. J. (1982) The dorsal diencephalic conduction system: a review of the
anatomy and functions of the habenular complex. Neuroscience and biobehavioral
reviews, 6, 1-13.
Svenningsen, K., Veno, M. T., Henningsen, K., Mallien, A. S., Jensen, L., Christensen,
T., Kjems, J., Vollmayr, B. and Wiborg, O. (2016) MicroRNA Profiling in the Medial and
Lateral Habenula of Rats Exposed to the Learned Helplessness Paradigm: Candidate
Biomarkers for Susceptibility and Resilience to Inescapable Shock. PloS one, 11,
e0160318.
Takagishi, M. and Chiba, T. (1991) Efferent projections of the infralimbic (area 25) region
of the medial prefrontal cortex in the rat: an anterograde tracer PHA-L study. Brain
research, 566, 26-39.
Taraschenko, O. D., Shulan, J. M., Maisonneuve, I. M. and Glick, S. D. (2007) 18-MC
acts in the medial habenula and interpeduncular nucleus to attenuate dopamine
sensitization to morphine in the nucleus accumbens. Synapse (New York, N.Y.), 61,
547-560.
Thiele, T. E., Koh, M. T. and Pedrazzini, T. (2002) Voluntary alcohol consumption is
controlled via the neuropeptide Y Y1 receptor. The Journal of neuroscience : the official
journal of the Society for Neuroscience, 22, Rc208.
Thompson, R. (1960) Interpeduncular nucleus and avoidance conditioning in the rat.
Science (New York, N.Y.), 132, 1551-1553.
Vertes, R. P. and Fass, B. (1988) Projections between the interpeduncular nucleus and
basal forebrain in the rat as demonstrated by the anterograde and retrograde transport
of WGA-HRP. Experimental brain research, 73, 23-31.
Viswanath, H., Carter, A. Q., Baldwin, P. R., Molfese, D. L. and Salas, R. (2013) The
medial habenula: still neglected. Frontiers in human neuroscience, 7, 931.
Vorspan, F., Mehtelli, W., Dupuy, G., Bloch, V. and Lepine, J. P. (2015) Anxiety and
substance use disorders: co-occurrence and clinical issues. Current psychiatry reports,
17, 4.
Wyss, J. M., Swanson, L. W. and Cowan, W. M. (1979) A study of subcortical afferents
to the hippocampal formation in the rat. Neuroscience, 4, 463-476.
48

Yamaguchi, T., Danjo, T., Pastan, I., Hikida, T. and Nakanishi, S. (2013) Distinct roles of
segregated transmission of the septo-habenular pathway in anxiety and fear. Neuron,
78, 537-544.
Zarate, C. A., Jr., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh,
D. A., Charney, D. S. and Manji, H. K. (2006) A randomized trial of an N-methyl-Daspartate antagonist in treatment-resistant major depression. Archives of general
psychiatry, 63, 856-864.
Zhao-Shea, R., DeGroot, S. R., Liu, L. et al. (2015) Increased CRF signalling in a ventral
tegmental area-interpeduncular nucleus-medial habenula circuit induces anxiety during
nicotine withdrawal. Nature communications, 6, 6770.
Zhao-Shea, R., Liu, L., Pang, X., Gardner, P. D. and Tapper, A. R. (2013) Activation of
GABAergic neurons in the interpeduncular nucleus triggers physical nicotine withdrawal
symptoms. Current biology: CB, 23, 2327-2335.
Zhu, Y., Hsu, M. S. and Pintar, J. E. (1998) Developmental expression of the mu, kappa,
and delta opioid receptor mRNAs in mouse. The Journal of neuroscience: the official
journal of the Society for Neuroscience, 18, 2538-2549.
Zvolensky, M. J., Feldner, M. T., Leen-Feldner, E. W. and McLeish, A. C. (2005)
Smoking and panic attacks, panic disorder, and agoraphobia: a review of the empirical
literature. Clinical psychology review, 25, 761-789.

49

CHAPTER 2: THE INTERPEDUNCULAR NUCLEUS REGULATES BASELINE
ANXIETY LEVELS
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The Interpeduncular Nucleus Regulates Baseline Anxiety Levels
This chapter presents work that is under review for final publication:
Ian McLaughlin, Erika E. Perez, Kechun Yang, John A. Dani, and Mariella De Biasi
(2019). The Interpeduncular Nucleus Regulates Baseline Anxiety Levels. Progress in
Progress in Neuro-Psychopharmacology & Biological Psychiatry.

Abstract
The interpeduncular nucleus (IPN) and its principle source of afferent signals, the medial
habenula (MHb), comprise much of the dorsal diencephalic conduction system (DDC).
Along with the medial forebrain bundle, the DDC is a highly conserved pathway by which
signals from the limbic forebrain reach the midbrain and hindbrain. This circuit has been
implicated in the aversive symptoms – both affective and physical – that follow cessation
of chronic use of habit-forming drugs, including alcohol, nicotine, and opioids. In this
study, we identified a role played by IPN signaling in regulating affect independently of
chronic drug exposure and withdrawal. Using an in vivo chemogenetic approach, we
observed significant anxiolysis following chemogenetic IPN stimulation, induced by
administration of 5 mg/kg of clozapine N-oxide (CNO). We next evaluated the role
played by glutamatergic signaling in this change of behavior, infusing a virus expressing
the chemogenetic receptor, hM3Dq, in the IPN of transgenic mice expressing Cre
recombinase under the control of the vesicular glutamate transporter 3 (VGLUT3-Cre).
Stimulation of glutamatergic subpopulations within the IPN resulted in no significant
change in anxiety-associated behavior. Using a combinatorial viral approach, we also
confirmed a direct projection from the IPN to the ventral hippocampus (VH), and
microdialysis experiments revealed significant elevations of serotonin (5-HT)
concentrations in the ventral hippocampus (VH) following chemogenetic stimulation of
51

the IPN. Taken together, these data suggest that IPN signaling regulates anxiety
independently of chronic exposure to addictive drugs, and places the IPN in a broader
neuronal circuit that implicates signaling in the IPN and VH in the regulation of anxietyassociated behavior.

Introduction
Anxiety is a symptom that is consistently observed after chronic use of essentially any
recreational drug is terminated (McLaughlin et al., 2017). This proves true both in
humans undergoing withdrawal from chronic drug use, and in animal models of addiction
and withdrawal. The dorsal diencephalic conduction system (DDC) is a pathway shown
to be highly evolutionarily conserved, observed in a variety of species including
mammals, reptiles, and fish (Epstein, Hurley, & Taber, 2018). Along with the medial
forebrain bundle, the DDC is a principle means by which the forebrain conveys and
receives signals to and from the mid- and hind-brain. Given this anatomy, it is not
surprising that the pathway has been identified as an important regulator of motivation
and reward signaling in higher vertebrates, and a junction of cognitive, emotional, and
sensory signaling (Gardon et al., 2014).
Over the past two decades, our group and others have identified a substantial regulatory
role played by two primary components of the DDC, the medial habenula (MHb) and the
predominant recipient of its efferent signaling, the interpeduncular nucleus (IPN), in the
maintenance of chronic drug use and the manifestation of aversive symptoms of
withdrawal (Dani & De Biasi, 2013; De Biasi & Dani, 2011; Fowler et al., 2011; Glick et
al., 2006; McLaughlin et al., 2015, 2017; Molas et al., 2017; E. Perez et al., 2015a; Salas
et al., 2009; Taraschenko et al., 2007; Viswanath et al., 2013; Zhao-Shea et al., 2013).
In particular, chronic use of nicotine and/or ethanol results in neuroplastic adaptations
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within these structures which, upon cessation of use, leads to the manifestation of
withdrawal symptoms. Furthermore, the DDC expresses high levels of the μ-opioid
receptor, and the MHb-IPN axis in particular has been shown to be remarkably dense
with expression (Gardon et al., 2014). Consequently, the functional properties of the
DDC and MHb-IPN axis, both independent and in the context of addiction, are alluring
components of our understanding of addiction and mood-associated distress that remain
uncharacterized.
In this study, we used chemogenetics coupled with behavioral and viral tracing methods
to characterize how the IPN acutely regulates baseline anxiety-associated behaviors in
mice. Chemogenetics exploits designer receptors exclusively activated by designer
drugs (DREADDs), which are G protein-coupled receptors engineered to no longer bind
their cognate ligand, that can be expressed in neuronal populations. This enables acute
perturbations of neuronal activity using an agonist, clozapine n-Oxide (CNO), in freelybehaving mice in vivo. hM3Dq, the DREADD used in this study, is an engineered variant
of the muscarinic M3 receptor coupled to the Gq signaling cascade. Activation of the
receptor results in robust enhancements of neuronal firing that are sustained for longer
than the duration of behavioral assays we used to assess anxiety in this study, the open
field arena (OFA) and elevated plus maze (EPM). This approach enables acute and
remote activation of the IPN in a minimally invasive fashion, attenuating any unintended
anxiogenesis derived from the experiment as much as possible.
While a foundation of research has been growing that places the MHb-IPN axis within
the broader context of the neurobiology of addiction, comparatively less work has been
done that elucidates the functional properties of this pathway independently of chronic
drug exposure and resulting neuroplastic adaptations. Therefore, we set out to
understand how the IPN modulates anxiety-associated behavior, using acute activations
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of the nucleus to perturb the system, in behavioral assays that have been long
established as effective evaluations of anxiety-associated behaviors in rodents (Crawley,
1985; Crawley et al., 1997). Recent studies of the signaling contributions from the MHbIPN axis to affective distress have identified signatures of elevated neuronal signaling
within the pathway in rodent models of depression (Xu et al., 2018). Additionally, past
studies in zebrafish indicated that genetic reductions in activity within the anatomical
structure that has been proposed to be orthologous to the human MHb attenuated fearassociated behavior (Agetsuma et al., 2010), while subsequent studies showed
disproportionately severe fear-associated behavior in fish possessing the same lesion in
response to an otherwise mild stimulus (Mathuru & Jesuthasan, 2013).
Given the anatomical context of the MHb-IPN axis, we evaluated if the circuit regulates
anxiety independently of chronic drug exposure.

Materials and Methods
Animals
We studied 2- to 6-month-old C57BL/6J mice, both male and female. Weaning was
performed 21 days following birth, and same-sex littermates were housed in cages
composed of a maximum of 5 animals and a minimum of 2 with ad libitum access to food
pellets and water. All mice were maintained in a 12-h light/dark cycle, temperaturecontrolled room (24±2 °C, relative humidity 55±10%). All behavioral tests were
performed during their light cycle, and were approved by the Institutional Animal Care
and Use Committee at the University of Pennsylvania, according to the guidelines for
intramural animal research provided by the National Institutes of Health in an animal
care facility approved by the Association for Assessment and Accreditation of Laboratory
Animal Care.
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Drugs
Clozapine N-oxide (CNO) was obtained from Abcam (ab141704), and aliquoted to be
stored at -20°C until use. The stock solution was diluted in sterile saline at 1 mg/mL and
filtered through a 0.2 μm syringe filter before injection. CNO was administered via
intraperitoneal injection (i.p.) at 5 mg/kg for all in vivo experiments.

Behavioral Tests
To control for environmental confounds attributable to variations in animal husbandry
and transportation, habituation to transportation from holding room to testing room was
achieved by performing everything but injection and testing for 3 days. Prior to testing
day, mice were transported using an identical cart and allowed to rest in home cages for
a minimum of 2 hours in the testing room used for behavioral experiments. Ambient
conditions during habituation were identical to those of testing days. Following
habituation, mice were treated with either 5 mg/kg CNO or saline control injections, and
permitted to habituate in a separate cage for approximately 15 minutes before
placement in the testing apparatuses to provide sufficient time for CNO to take effect.
The open field arena (OFA) was used to measure changes in anxiety-associated
behavior. Dimensions of the maze were 40 cm x 40 cm x 40 cm, and tests were run for
30 minutes while behavior was tracked and quantified using the computer software,
ANY-maze (Stoelting). Distance traveled, and time spent, in the center region (10 cm x
10 cm) of the maze was tracked and compared between treatment groups.
The elevated plus maze (EPM) was used to further assess changes in anxietyassociated behavior following CNO administration. EPM testing was performed at least 3
days after OFA testing. The maze consisted of four black arms forming a cross shape,
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with walls surrounding the sides of two of the arms, elevated from the ground by >30 cm.
Time spent in open arms, as well as numbers of open arm entries, were tracked using
ANY-maze.
All tests were conducted at ambient light levels empirically determined to have no effect
on anxiety-associated behavior with a separate group of C57BL/6J in both mazes (8-10
lux for OFA, 7-16 lux for EPM).

Virus Use & Production
Initially, AAV8-hSyn-hM3Dq-mCherry was acquired from the UNC Vector Core. All other
viruses (pAAV-hSyn-DIO-hM3D(Gq)-mCherry; retroAAV2-CreGFP) were produced
within our lab. HEK293 cells were transfected with 3 plasmids using a Helper-Free
system. The first plasmid contains the genes of interest and promoter sequence, the
second plasmid contains most of the adenovirus gene products required for efficient
infection, and the third plasmid contains the replication and capsid genes to establish the
serotype of the virus. Following transfection, viral particles were purified and
concentrated using iodixanol gradients, spun at 80,000 RPM/1.5 hrs at 4°C, and
concentrated using Centricon columns (100,000 MWCO, Millipore UFC0910024).
Volume was reduced to 200ul HBSS, aliquoted, and stored at -80°C until use.

Stereotactic Surgery & Viral Infusions
All intracranial infusions were performed with mice approximately 2 months old under
general isoflurane (1-2%) anesthesia coupled with meloxicam (2 mg/kg). After fur
removal and disinfection, and following exposure of the skull, small holes were drilled to
enable stereotactic targeting with a 10 μL syringe with removable needle tips lacking
bevels (Hamilton; Reno, Nevada). Virus-containing fluid was infused at 0.01 μL/min with
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a microinfusion pump (kdScientific, Holliston, MA) attached to the stereotactic apparatus
(Kopf, Tujunga, CA). Total volumes infused varied by brain region, with 110-140 nL in
the IPN and 1 μL in the VH.
Stereotactic targeting of the IPN and VH used the following coordinates. IPN: A/P: -3.46 -

3.48 mm, M/L: -1.70 mm, D/V: -4.84 mm at a 20° angle. VH: A/P: -3.2 mm, M/L: 3 mm,

D/V: 3.5 mm. To allow sufficient time for viral expression, behavioral experiments were
performed following a minimum of 6 weeks.
For general IPN stimulation we used AAV2/8-hSyn-hM3D-mCherry. For stimulation of
VGLUT3+ neurons, we used AAV2/8-hSyn-DIO-hM3D-mCherry. For retrograde
expression of Cre recombinase in IPN neurons that project to the VH, retroAAV2CreGFP was infused into the VH.

Microdialysis Probe Implantation and Dialysate Collection
CMA/12 microdialysis guide cannulae were stereotactically implanted, targeting the VH
(A/P: -3.2 mm, M/L: 3 mm, D/V: 3.5 mm). Following recovery, on the day prior to
dialysate collection, CMA/12 microdialysis probes (inner diameter, 0.5 mm; length, 4
mm, membrane, polycarbonate; cutoff, 12,000 DA) were perfused with artificial cerebral
spinal fluid (147 mM NaCl, 3.99 mM KCl, 1.7 mM CaCl2, 0.90 mM MgCl2). A minimum of
14 hours prior to collection, probes were lowered slowly through the guide cannula while
mice were anesthetized with 2% isoflurane, and mice were placed in a modified cage
similar to their home cages with a counterbalance arm equipped with a swivel permitting
liquid flow. Flow rate of probe perfusion was reduced to 0.5 μL/min overnight, followed
by an increase to 2μL/min at least 1 hour prior to establishing baseline 5-HT
concentrations. Following collection of 5 baseline samples, mice were injected with 5
mg/kg of CNO IP, and samples were collected every 20 minutes for just over 3 hr while
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mice remained in modified cages. Dim ambient light levels were maintained in the
sample collection room to reflect those that mice encountered in OFA and EPM
experiments (~15 lux). Vials containing dialysates were changed manually and
immediately stored at -80°C until analyzed by high-performance liquid chromatography
(HPLC). Dummy microdialysis probes were dipped in a solution containing DiI ((2Z)-2[(E)-3-(3,3-dimethyl-1-octadecylindol-1-ium-2-yl)prop-2-enylidene]-3,3-dimethyl-1octadecylindole; perchlorate), Invitrogen, D282, Carlsbad, CA), and inserted back into
the microdialysis cannulae at the end of each experiment to verify successful targeting of
the VH. Mice were then perfused with phosphate-buffered saline (PBS) under
anesthesia, followed by 10% formalin, and brains were collected, fixed overnight in 10%
formalin followed by cryoprotection with 10%, 20%, and finally 30% sucrose solutions in
PBS over the course of 3 days. Brains were then embedded in clear Tissue-Plus
Optimal Cutting Temperature Compound (OCT; Fisher Scientific, Hampton, NH, 23-730571), and stored at -20 to -80°C. Brains were cryosectioned at 25-40 μm, and both
accurate viral targeting and probe placement were verified using epifluorescence
microscopy.

Immunohistochemistry
For verification of viral expression, 25-40 μm sectioned brain slices were collected via
cryosectioning following anesthetic overdose and the transcardial perfusion protocol
described previously. Slices were either mounted directly onto slides, or were
permeabilized in 0.1% Triton X-100, and blocked in a 5-8% combination of normal goat
and donkey serums for 2 hours in free floating wells. Next, slices were incubated with
primary antibodies against GFP and mCherry (ThermoFisher, Waltham, MA, GFP
Monoclonal Antibody, A-11120; abcam, Cambridge, United Kingdom, Anti-mCherry,
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ab167453) overnight. Slices were incubated with secondary antibodies (abcam Goat
Anti-Rabbit, ab150080; abcam Goat Anti-Mouse, ab150113) or streptavidin conjugated
to AMCA (Jackson ImmunoResearch Laboratories Inc., 016-150-084, West Grove,
Pennsylvania) for slices used in electrophysiological experiments. Stained slices were
mounted in either VECTASHIELD Antifade Mounting Medium with DAPI (Fisher
Scientific, NC9524612), or ProLong Diamond Antifade Mountant (ThermoFisher
Scientific, P36965). Slides were left to cure for a minimum of 12 hours prior to imaging
and imaging was carried out on an epifluorescence microscope (Olympus, BX63) under
4X and 20X magnifications.

Slice Preparation
Following behavioral experiments, mice infused with a virus to induce expression of the
hM3Dq variant of DREADD were deeply anesthetized with a combination of ketamine
and xylazine. Following anesthesia, transcardial perfusion was performed as described
previously (Broussard et al., 2016; Yang et al., 2017) with ice-cold N-methyl-Dglucamine (NMDG)-based artificial cerebrospinal fluid (aCSF) composed of the following
(in mM): 92 NMDG, 2.5 KCl, 1.2 NaH2PO4, 30 NaHCO3, 20 HEPES, 25 glucose, 2
thiourea, 5 Na-ascorbate, 3 Na-pyruvate, 0.5 CaCl2, and 10 MgSO4, pH 7.3-7.4 with
concentrated hydrochloric acid (Ting, Daigle, Chen, & Feng, 2014). Brains were quickly
extracted, placed in ice-cold NMDG solution saturated with 95% O2 and 5% CO2.
Horizontal slices (230 μM) that contained the IPN were collected using a vibratome
(Leica VT 1200s) in ice-cold NMDG solution. Slices were collected and placed in NMDG
solution at 32 °C for 13 minutes, then transferred to HEPES-based holding aCSF (in
mM): 92 NaCl, 2.5 KCl, 1.2 NaH2PO4, 30 NaHCO3, 20 HEPES, 25 glucose, 2 thiourea, 5
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Na-ascorbate, 3 Na-pyruvate, 2 CaCl2, and 2 MgSO4, and kept at room temperature for
a minimum of 1 hour prior to recording.

Electrophysiology
Slices containing the IPN were placed in a home-made recording chamber and were
continuously bathed in well oxygenated standard recording aCSF, containing (in mM):
124 NaCl, 2.5 KCl, 1.2 NaH2PO4, 24 NaHCO3, 24 NaHCO3, 5 HEPES, 12.5 glucose, 2
CaCl2, and 2 MgSO4. The bath solution was maintained at 32–34°C using an inline
heater system (TC-324B, Warner Instrument Corp, Hamden, CT). Responses to puff
and bath application of CNO were recorded using glass recording electrodes (~2-3 MΩ),
which were pulled using a micropipette puller (Narishige PC-10, Tokyo, Japan) from
borosilicate glass capillaries (TW 150-4, World Precision Instruments, Inc., Sarasota FL).
Electrodes were filled with a K-gluconate-based intracellular solution composed of (in
mM): 140 K-gluconate, 5 KCl, 10 HEPES, 0.2 EGTA, 2 MgCl2, 4 MgATP, 0.3 Na2GTP,
and 10 Na2-phosphocreatine, pH 7.3 with KOH. Brief, gentle suction was applied to first
achieve a tight-seal patch-clamp recording configuration, and under tight-seal patchclamp mode, baseline firing activities in fluorescently labeled, DREADD-expressing IPN
neurons were recorded. Subsequently, responses to either puff- or bath-application of
500 nM CNO, the DREADD agonist, using a Picospritzer II (Parker Instrumentation,
Fairfield, NJ) were recorded. Whole-cell recording were performed only in cells with
access resistance (Ra) of less than 10 MΩ. Ra was continuously monitored throughout
recordings. During patch-clamp recording, neurons were labeled with neurobiotin to
further ensure that recorded neurons were indeed hM3Dq+ by immunohistochemical
confirmation with streptavidin conjugated to the fluorescent dye, 7-amino-4-
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methylcoumarin-3-acetic acid (AMCA, Jackson ImmunoResearch Laboratories Inc., 016150-084) using an epifluorescence microscope (Olympus, BX63).

Data analysis
All analyses were presented as mean ± SEM. Paired/unpaired Student’s t test or SingleFactor ANOVA were used for the statistical analysis of behavioral and
electrophysiological data. Statistical significance was identified by p<0.05.
Microdialysis data were reported as percentage of baseline values that were determined
by the average of five samples collected prior to drug treatments. Repeated measure
ANOVA was used to assess treatment effects on 5-HT levels with repeated measures
over time after injection, and then compared at individual time points following drug
treatments with Tukey’s test. All assessments considered p<0.05 to be statistically
significant, and data were expressed as mean ± SEM.

Results

Stimulation of IPN neurons is anxiolytic
To identify some of the behavioral effects of stimulating IPN neurons, we stereotactically
infused a virus expressing the hM3Dq DREADD variant into the IPN of C57BL/6J mice
(Fig. 1A & 1B). Following 6-8 weeks of expression time, mice underwent behavioral
testing in the open field arena (OFA) and elevated plus maze (EPM). For the OFA, time
spent and distance travelled in the center zone were quantified and compared between
groups of mice receiving either saline or 5 mg/kg CNO (Fig. 1C & 1D) for the 30 min.
duration of the test. We observed a significant reduction of anxiety-associated behavior
in mice treated with CNO, exhibited by more time spent, and greater distance traveled,
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in the center zone, relative to saline-treated controls (n= 11, 9, 10 [F(2, 27) = 5.714, p =
0.0085]; [F(2, 27) = 4.6339, p = 0.0186]). A minimum of 3 days later, the same mice
were assessed in the EPM for 15 min in a counterbalanced treatment design (Fig. 1E &
1F). Total entries and distance traveled in open arms of the maze were quantified. CNO
administration resulted in reduced anxiety-associated behavior, exhibited by a greater
number of entries and more distance traveled in open arms relative to saline-treated
control mice (n= 12, 6, 4 [F(2, 19) = 5.276, p = 0.015]; [F(2, 19) = 25.772, p < 0.0001]).
CNO administration to wild-type mice lacking DREADD expression resulted in no
change in anxiety-associated behavior.

Stimulation of glutamatergic IPN neurons does not affect anxietyassociated behavior.
Given that general stimulation of the IPN was observed to be anxiolytic, and the IPN is a
structure that hosts the synthesis of a variety of neurotransmitters, we assessed whether
glutamatergic output from the nucleus may mediate this change in behavior following
general chemogenetic stimulation. Following 8-10 weeks of expression time, VGLUT3Cre mice infused with AAV8-DIO-hSyn-hM3Dq-mCherry (Fig. 2A & 2B) were evaluated
in the OFA for 30 min. and the EPM for 15 min. to assess any changes in anxietyassociated behavior following administration of 5 mg/kg CNO. In the OFA, there was no
significant change in anxiety-associated behavior exhibited by mice administered CNO
compared to mice receiving saline (Fig. 2C & 2D). Similarly, 5 mg/kg CNO administration
did not result in any significant change in anxiety-associated behavior observed in the
EPM (Fig. 2E & 2F).
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Behavioral responses to activation of glutamatergic IPN neurons are not
sexually dimorphic
At the suggestion of a member of my thesis committee, we evaluated whether male and
female mice might respond differently to chemogenetic activation of IPN glutamatergic
neurons. This guidance was very well received, as past studies have indicated that
modulation of anatomical structures associated with the MHb-IPN axis is indeed
associated with sexually dimorphic behavioral responses (K. Li, Nakajima, IbanezTallon, & Heintz, 2016). Further, α5-containing nAChRs – expressed at a uniquely high
density in the IPN – have been shown to mediate sex-dependent differences in anxietyassociated behavior (Gangitano, Salas, Teng, Perez, & De Biasi, 2009). However, while
interesting trends were observed, no significant dimorphism between female and male
mice was observed in the OFA (Fig. 2G – 2N) or EPM (Fig. 2O – 2V), suggesting that
glutamatergic IPN signaling in particular does not appear to mediate any differences in
anxiety-associated behavior among female or male mice.

The Interpeduncular Nucleus Sends Direct Projections to the Ventral
Hippocampus.
C57BL/6J mice at 2-4 months of age were infused with retroAAV2-hSyn-CreGFP in the
VH, and AAV2/8-hSyn-DIO-hM3Dq-mCherry in the IPN during the same stereotactic
surgery (Fig 3A & 3B). After 6-8 weeks, brains were cryosectioned, stained for both
fluorescent markers, and evaluated for the expression products of both viruses. As
expected, dense expression of CreGFP was observed at the site of injection within the
VH, as well as sparsely within the IPN. Cre-dependent expression of hM3Dq-mCherry
was observed throughout the IPN, with the densest fluorescence observed within
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specific substructures, including the intermediate (IPI) and lateral (IPL) subnuclei, and
comparatively sparser levels in the caudal and rostral subnuclei (Fig 3C).

Activation of IPN neurons results in elevated serotonin concentrations in
the VH.
Given the identification of projections arriving in the VH from the IPN, and previous
reports of the presence of serotoninergic neurons in the IPN of rats (Montone, Fass, &
Hamill, 1988), we evaluated changes in 5-HT concentrations in the VH following
chemogenetic stimulation of IPN neurons. At 2 months of age, male and female
C57BL/6J mice were infused with AAV2/8-hSyn-hM3D-mCherry into the IPN according
to the protocol described in prior experiments (Fig. 4C). Subsequent to behavioral
evaluations, mice were then implanted with microdialysis probes targeting the VH (Fig.
4A & 4B). Dialysate samples were collected in 20-minute increments. At 180 min. postinjection of 5 mg/kg CNO, we observed a significant increase in 5-HT concentrations that
initiated rapidly and remained elevated for approximately 20 minutes until returning to a
rather variable baseline approximately 40 minutes following CNO injection (Fig. 4D) (df =
7.10, F = 3.19, p = 0.004).

Discussion
The DDC, and the MHb-IPN axis in particular, has been identified as an important
regulator of midbrain motivation and reward circuitry (Bianco & Wilson, 2009; Lecourtier
& Kelly, 2007; Sutherland, 1982). In addition to evidence derived from studies with
simple model organisms, anatomical studies position the MHb-IPN axis within a broader
network of structures historically associated with the regulation of anxiety. The IPN has
been shown to send efferent signals to both the dorsal and median raphe nuclei, receive
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signaling from the locus coeruleus (Molas et al., 2017; H. Shibata, Suzuki, & Matsushita,
1986), and recent studies have demonstrated direct projections to the HPC (Lima et al.,
2017). To our knowledge, however, direct projections from the IPN to the ventral
hippocampus (VH) have yet to be confirmed using contemporary viral techniques until
this study. Past work has suggested the presence of both serotonergic and nonserotonergic efferent signaling from apical neurons in the IPN arriving in the dorsal
hippocampus (Montone et al., 1988; Wirtshafter, Asin, & Lorens, 1986).
Given that role, and that studies have implicated activity in the IPN in the manifestation
of aversive symptoms of withdrawal from alcohol and nicotine, among other drugs (E.
Perez et al., 2015a; Salas et al., 2009; Taraschenko et al., 2007; Zhao-Shea et al., 2015;
Zhao-Shea et al., 2013), we hypothesized that increased signaling within this circuit may
acutely regulate affect independently of chronic drug exposure. In particular, we
hypothesized that general activation of the nucleus would result in increased anxietyassociated behavior.
Using the same behavioral paradigms that have been used to characterize affective
symptoms of withdrawal symptoms in the past (Damaj, Kao, & Martin, 2003; De Biasi &
Salas, 2008; Irvine, Cheeta, & File, 2001), we observed that the IPN does indeed acutely
regulate affect following chemogenetic activation of IPN neurons. However, to our
surprise, activation of the IPN resulted in reduced anxiety-associated behavior in the
OFA and EPM, rather than increased anxiety as reported during drug withdrawal. Due to
the neurochemical diversity present in this dense nucleus, we further explored which
efferent signals may mediate this regulatory role. We focused on glutamatergic outputs,
given the results obtained with the expression of hSyn-hM3D-mCherry. However, upon
chemogenetic stimulation of glutamatergic IPN neurons in VGLUT3-Cre, we observed
no significant change in anxiety-associated behavior in the OFA or EPM.
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While many brain regions are involved in the regulation of affect, recent studies have
identified a role played by the VH in playing a modulatory role (Jimenez et al., 2018;
Kheirbek et al., 2013; Kheirbek & Hen, 2011). Both past and recent studies have shown
direct projections from the IPN to the HPC, and decades ago, neuroanatomical studies
proposed efferent projections from the IPN arriving in the VH, but this anatomy has yet
to be verified using contemporary methods (Montone et al., 1988; Quina et al., 2017;
Wirtshafter et al., 1986). Using a combinatorial viral approach, resulting in projectiondependent hM3Dq-mCherry expression, we have confirmed the existence of these IPNVH projections in mice. By infusing an adeno-associated virus (AAV) with efficient
retrograde functionality (Tervo et al., 2016) into the VH, along with a Cre-dependent
virus driving hM3Dq-mCherry expression, we observed robust hM3Dq-mCherry
expression within the IPN, as well as hM3Dq-mCherry positive terminals within the VH.
Interestingly, Cre-dependent hM3Dq-mCherry expression patterns within the IPN exhibit
anatomical specificity, with the densest expression observed in ventral regions of the
structure, including the intermediate and lateral subnuclei, with sparser expression in the
rostral subnucleus and along the inner periphery of the structure. This indicates that
projections from the IPN to the VH likely arise only from specific subnuclei within the
IPN, corroborating the suggestions made by Lima et al. (Lima et al., 2017).
Taken together, these data suggest that the IPN does indeed regulate anxietyassociated behavior independently of chronic drug exposure. However, the mediatory
signals of this anxiolytic effect that arise from the IPN remain to be identified. Given the
diverse repertoire of neurotransmitters that are synthesized and received by neurons
within this nucleus, there are numerous possible candidates that may convey this
anxiolytic effect. Past studies have identified both serotonergic and non-serotonergic
efferents arising from the IPN (Montone et al., 1988). An intriguing future study will be to
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inhibit serotonergic subpopulations of the median and dorsal raphe nuclei while exciting
the IPN to evaluate whether direct or indirect IPN-VH pathways mediate the anxiolysis
observed in this study, as well as elevations of 5-HT concentrations in the VH.
The limitations of interrogating IPN function warrant attention when considering behavior
arising from chemogenetic, or any virus-mediated, perturbation of the structure. Given
the complexity and density of this structure, achieving viral expression throughout its
entirety while avoiding diffusion into neighboring structures is a substantial technical
challenge. As a result, viral expression targeting the IPN necessarily excludes certain
neuronal populations due to the avoidance of this diffusion. Furthermore, studies have
shown that different AAV serotypes exhibit variable tropisms for neuronal subtypes
(Aschauer, Kreuz, & Rumpel, 2013; Hammond, Leek, Richman, & Tjalkens, 2017), and
given the variety of cell subtypes present within this nucleus, it remains possible that the
use of any one serotype may result in poor or restricted expression within components of
the structure.

Conclusions & Future Directions
The majority of research characterizing the functional properties of the MHb-IPN axis in
mammals has emerged from studies focused on the neurobiology of addiction and
withdrawal. Recent studies have revealed a regulatory role played by the pathway in
modulating affect, including conditions like depression in animal models (Xu et al.,
2018), independently of chronic drug exposure. Given that reductions of signaling within
the IPN have been shown to alleviate aversive symptoms of withdrawal, diminish fearassociated reactions, and reduce conditioned avoidance (Agetsuma et al., 2010; Salas
et al., 2009; Thompson, 1960; Vincenz, Wernecke, Fendt, & Goldschmidt, 2017), we
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anticipated that acute activation of the nucleus would amplify anxiety-associated
behaviors. However, a robust anxiolytic response was observed, indicating that the role
of neuroplastic adaptation to chronic drug administration or behavioral conditioning plays
a crucial role in determining the signaling within the nucleus and consequential
behavioral outputs. Recent studies have demonstrated shifts towards excitatory GABAA
receptor signaling within the ventral tegmental area following exposure to stressful
stimuli, influencing dopaminergic signaling associated with increased ethanol selfadministration in rodents (Aschauer et al., 2013; Thomas et al., 2018). Accordingly,
exploring how the effects of pharmacological treatment and environmental contexts,
including chronic drug administration and chronic stress exposure, influence signaling
within the IPN such that differential behavioral outputs emerge may be revealing.
Further, given the complexity and density of the nucleus, and the diversity of
neurotransmission occurring within, and emerging from, the IPN, genetic tools enabling
expression of DREADDs or opsins within specific subnuclei will enable a more precise
dissection of the functional properties that distinguish them. It is likely that activation of
distinct neuronal populations within the nucleus results in opposing modulatory activity,
promoting or inhibiting aversive affective output. Similarly, while the VH has been shown
to regulate affect in mouse models, it represents just one component of a diversity of
efferent targets emanating from the IPN, arriving at distal anatomical structures that
have been shown to regulate affect. Accordingly, projection-specific excitation/inhibition
studies will undoubtedly yield a more comprehensive understanding of how this pathway
modulates affect.
Moving forward, it will prove fruitful to investigate the behavioral effects of IPN
GABAergic activation at baseline to further elucidate the role of IPN signaling in the
regulation of anxiety-associated behavior, as well as identifying the broader circuit
68

components that contribute signaling that mediates this regulatory effect including the
raphe nuclei, lateral habenula, and septal structures.

Supplementary Methods
Depolarization of IPN neurons by the DREADD agonist clozapine N-Oxide (CNO)
To directly examine effects of DREADD on IPN neurons, we performed patch-clamp recordings in
fluorescently labeled, DREADD-expressing neurons in brain slices containing the IPN in some
animals after behavioral tests. As shown in supplementary figure 1, two types of DREADD
positive IPN neurons were recorded. Under control conditions, 62.5% of recorded neurons are
type 1 neurons (Supp Fig. 1A), which have much greater hyperpolarized rest membrane potential
(RMP) than type 2 (Supp Fig. 1B, 37.5%) neurons ( -67 ± 3.27 mV vs. -50.2 ± 3.79 mV, n= 10, 6,
p<0.005). No spontaneous action potential firings were overserved under baseline recording
conditions because of the very hyperpolarized RMP, and transient burst firings were observed
after puff application of 500 nM CNO. Bath-application of 500 nM CNO significantly depolarized
the type 1 neurons (RMP = -44.8 ± 1.65, n=5, p< 0.01 compared with baseline) and resulted in
consistent action potential firings at 9.28 ± 1.01 (Hz, n=5, Supp Fig. 1A). Spontaneous action
potential firings were recorded in type 2 neurons (Supp Fig 1B). Bath application of 500 nM CNO
dramatically depolarized the RMP from -50.2 ± 3.79 mV to -37.2 ± 1.49 mV (n=5, p< 0.05) and
partially inactivated action potential firing of the recorded neurons. As shown in Supp Fig 1C, a
brief puff application of 500 nM CNO onto a type 2 neuron only caused brief depolarization and
transient burst firings followed by inactivation of action potential firings. Our data suggest that 500
nM CNO can effectively depolarize DREADD-expressing IPN neurons in slice.
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Figures & Legends
Figure 1.
A.

IPN: AAV8-hSyn-hM3Dq-mCherry
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E.

F.
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Figure 2.
A.

IPN: AAV8-hSyn-DIO-hM3Dq-mCherry
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D.
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F.
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Figure 3.
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Figure 4.
A.
VH: Microdialysis Probe
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D.
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Supplementary Figure 1.
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Figure Legends
Figure 1. Chemogenetic stimulation of the IPN in C57BL/6J mice was evaluated for
changes in anxiety-associated behavior. Representative image of AAV2/8-hSyn-hM3DqmCherry (A) infused into the IPN at low and high magnifications (B). In the Open Field
Arena, administration of 5 mg/kg CNO resulted in increased time spent, and distance
travelled, in the center zone, indicating a reduction of anxiety-associated behavior in
C57BL/6J mice expressing the excitatory designer receptor, hM3Dq (C & D). However,
neither wild-type C57BL/6J administered 5 mg/kg CNO, nor C57BL/6J expressing
hM3Dq in the IPN administered saline, resulted in reduced anxiety-associated behavior.
Similarly, in the Elevated Plus Maze, 5 mg/kg CNO administered to C57BL/6J mice
expressing hM3Dq in the IPN exhibited reduced anxiety-associated behavior, indicated
by greater time spent, and distance traveled, in the open arms, while control groups
exhibited no change (E & F). (OFA n= 11, 9, 10 [F(2, 27) = 5.714, p = 0.0085]; [F(2, 27)
= 4.6339, p = 0.0186]; EPM n= 12, 6, 4 [F(2, 19) = 5.276, p = 0.015]; [F(2, 19) = 25.772,
p < 0.0001]).
Figure 2. Chemogenetic stimulation of vGlut3-Cre mice was evaluated for altered
anxiety-associated behavior. Representative image of AAV2/8-hSyn-DIO-hM3DqmCherry infused into the IPN (A) at low and high magnifications (B). In the Open Field
Arena, administration of 5 mg/kg CNO resulted in no significant difference in time spent,
and distance travelled, in the center zone (C & D). Upon examination of potential sexdependent dimorphism, no significant effect was detected (G-N). Similarly, 5 mg/kg CNO
administration had no significant effect on time spent, nor distance travelled, in the open
arms of the elevated plus maze (E & F). No significant sexual dimorphism was detected
in either measure (O-V) (OFA n=9, 10 p = 0.4808, p = 0.4802; EPM n=9, 10, p = 0.792,
0.687).
Figure 3. The IPN sends direct projections to the ventral hippocampus. C57BL/6J mice
were infused with retro-AAV2-hSyn-CreGFP in the ventral hippocampus, and AAV2/8hSyn-DIO-hM3Dq-mCherry in the IPN (A & B). Cre-dependent expression of hM3Dq
was observed in regionally specific ventral subnuclei of the IPN, including the IPC, IPI,
IPL, as well as sparse expression within the periphery of the structure and terminals
within the VH (C).
Figure 4. Microdialysis of serotonin in the ventral hippocampus following chemogenetic
stimulation of the IPN. C57BL/6J mice were infused with AAV2/8-hSyn-hM3Dq-mCherry
into the IPN (C), and then implanted with a microdialysis probe targeting the ventral
hippocampus (A). Probe was coated in DiI to facilitate localization of probe locations (B).
Dialysate samples were collected to establish baseline 5-HT concentrations, followed by
I.P. injection of 5 mg/kg CNO, resulting in significantly increased 5-HT concentrations
(D). (n=3, DF=14, F=3.19, p=0.004)
Supplementary Figure 1. Electrophysiological characterization of chemogenetic
stimulation of virally-infected IPN neurons. C57BL/6J mice were infused with AAV2/8hSyn-hM3Dq-mCherry into the IPN. Following behavioral evaluations, horizontal
sections containing the IPN were evaluated for responses to CNO. After obtaining stable
baseline recordings, 300 ms of 500 nM CNO was puffed onto neurons causing robust
brief increases in firing (A & C). Bath application of 500 nM led to dramatic
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depolarization, which resulted in robust increases in firing frequencies in type 1 neurons
(A), while partially inactivation of action potential firing in type 2 neurons (B).
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ABSTRACT
Substance P (SP) belongs to the family of tachykinins that also contains neurokinins A
(NKA) and B (NKB). The three neuropeptides and their respective receptors are
expressed in several of the brain regions that regulate stress, anxiety, and addictionrelated behaviors. Although there is extensive evidence for a role of the SP/NK1R
system in opiate and alcohol dependence, very little is known regarding the role that
tachykinins play in the mechanisms of nicotine dependence. This contribution provides
an overview of the molecular and circuit-based mechanisms that provide a rationale for
the effects of neurokinins on drug abuse. In particular, we provide a summary of the
evidence for the interactions with the nicotinic cholinergic system and how these
systems represent a mechanistic link between stress, anxiety, and the symptoms of
nicotine withdrawal. More studies are needed to determine whether NK receptors are
promising drug targets that might complement current smoking cessation strategies.
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INTRODUCTION
Neurokinins belong to the tachykinin family of proteins, which comprises a series of
structurally related neuropeptides found in many species, from amphibians to mammals.
Tachykinins are expressed throughout the nervous and immune systems, and participate
in a variety of physiological processes, including inflammation, nociception, smooth
muscle contractility, epithelial secretion, and proliferation. They also contribute to various
disease processes, such as acute and chronic inflammation and pain, fibrosis, bladder
and intestinal disorders, infection, and cancer. In addition, pharmacological and
biochemical evidence implicates the tachykinin signaling system in the mechanisms
underlying aversive affective states, as well as several pathological brain states. Animal
models have shown long-lasting effects on neurokinin receptor regulation by stress, and
pharmacological experiments have demonstrated an ability of neurokinin receptor
agonists and antagonists to modulate anxiety levels. Coupled with the distribution of
peptides and receptors in the CNS, pre-clinical and clinical experiments are identifying the
tachykinin system as a clear regulator of aversive affect and addiction.

Tachykinin genes and gene products. In humans, there are three tachykinin genes:
TAC1 and TAC3, which are equivalent to Tac1 and Tac2 in the mouse, respectively, and
TAC4 (Fig. 1). These genes encode precursor proteins, called pre-pro-tachykinins which
undergo post-translational proteolytic cleavage to yield the active peptides (Steinhoff, von
Mentzer, Geppetti, Pothoulakis, & Bunnett, 2014). TAC1 encodes for neurokinin A (NKA;
also known as neurokinin α and neuromedin L), neuropeptide gamma, neuropeptide K,
and substance P (SP). Three splice variants of TAC1 are known and produce different
sets of peptides. All three splice forms of TAC1 produce SP, but only the beta and gamma
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forms produce the other three peptides. TAC2 was initially assigned to the gene encoding
the NKA precursor, but was subsequently found to be identical to TAC1. TAC3 encodes
neurokinin B (NKB; also known as neurokinin β and neuromedin K). Finally, TAC4
encodes for hemokinin-1 (HK-1) and its N-terminal extended forms, endokinin A (EKA),
and EKB (Fig. 1). EKA, and EKB have biological actions similar to SP and can interact
with NKRs while EKC and EKD lack the tachykinin sequence, have minimal tachykininlike actions, and show negligible affinity for the NKRs (Steinhoff et al., 2014).

Neuropeptide distribution in the CNS. Neurokinins and their receptors are found
throughout the brain, where they have both overlapping and distinct patterns of
expression. High levels of SP-immunoreactivity are found in many forebrain, midbrain, and
brainstem areas. Those areas include the cingulate cortex, caudate putamen, nucleus
accumbens,

septum,

hippocampus,

amygdala,

various

hypothalamic

nuclei,

periaqueductal gray, dorsal raphe nucleus, locus coeruleus, various parabrachial nuclei,
and the nucleus of the tractus solitarius (Hökfelt, Kuteeva, Stanic, & Ljungdahl, 2004). In
general, the distribution of SP in the human brain is quite similar to that in the rat brain,
with particularly dense distributions of immunoreactive fibers or SP-positive neurons in
cortex, hypothalamus, hippocampus, substantia nigra, and brain stem (Hökfelt et al.,
2004).

The immunoreactivity for NKA is highly co-localized with that of SP due to the shared
precursor gene (Fig. 1 and Fig. 2). However, despite being co-localized, NKA and SP may
be expressed at different levels in a given tissue. For example, SP is more abundant than
NKA in striatum and substantia nigra, while NKA levels are higher in the hippocampus
(Arai & Emson, 1986).
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The distribution of NKB-positive neurons and fibers is, in general, distinct from that of other
neuropeptides. NKB is highly expressed in the olfactory bulb, certain hypothalamic nuclei,
the basal forebrain, and the habenulo interpeduncular tract. The bed nucleus of the stria
terminalis presents one of the highest immunoreactivities and mRNA levels for both NKB
and SP (Warden & Young, 1988). The concentration of NKB is also high in the dorsal and
ventral portions of the medial habenula (MHb) (Marksteiner, Sperk, & Krause, 1992). This
is in contrast with the distribution of SP immunoreactivity and mRNA, which are mainly
present in the dorsal part of the MHb. MHb neurons send projections to the
interpeduncular nucleus (IPN) that form an extremely dense triangular network of NKB
immunoreactive fibers, visible especially in the ventrolateral portion of the rostral IPN. At
a more caudal level, this dense immunoreactive plexus separates into the intermediate
and lateral nuclei. No NKB mRNA is observed within IPN neurons (Marksteiner et al.,
1992). The IPN also receives SP-rich projections from the MHb (Cuello & Kanazawa,
1978). The striatum and substantia nigra pars reticulata contain very few NKB-positive
neurons, in contrast with the prominent presence of SP-positive neurons (Burgunder &
Young, 1989). Conversely, the hippocampal formation expresses very low levels of SP
but contains rather high concentrations of NKB mRNA and immunoreactivity (Ribeiro-daSilva & Hokfelt, 2000).

Receptor distribution in the CNS. NK1, NK2, and NK3 are the three neurokinin receptor
subtypes found in mammals. SP binds preferentially to NK1R, NKA to NK2R, and NKB to
NK3R. Despite binding with high affinity to one receptor subtype, each tachykinin can
activate all three receptors, a feature that may contribute to pathophysiological conditions
characterized by increased tachykinin release (Ebner, Sartori, & Singewald, 2009).
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NK1Rs are widely distributed in the CNS, the PNS, and various peripheral organs. They
are highly expressed in brain areas known to regulate emotions and the response to
stress, such as the amygdala, hypothalamus, hippocampus, frontal cortex, raphe, and
locus coeruleus. In those areas, SP and NK1Rs are co-localized. However, in regions
such as the substantia nigra and the lateral interpeduncular nuclei, the intense SP staining
does not always match the signal for NK1Rs (Mantyh, 2002). In those areas, substance P
may bind to closely related NK2 or NK3 receptors (Saria, 1999).

NK2Rs have a limited distribution in the CNS and are most abundant in peripheral tissues.
In the CNS, NK2Rs are found in some cortical areas, the hippocampus, the nucleus
accumbens, parts of the thalamus, and the lateral septum (Hökfelt et al., 2004; Saffroy,
Torrens, Glowinski, & Beaujouan, 2003). As discussed for NK1Rs, the presence of NK2Rs
in several limbic structures is consistent with a role of NKA in the processing of emotions
(Hökfelt et al., 2004).

NK3Rs are mostly found in the CNS. They are expressed in the cerebral cortex, the zona
incerta, the MHb, the amygdala, the superior colliculus and the IPN, as well as the septum,
dorsal raphe, periquaductal gray, and locus coeruleus (Ebner et al., 2009). Despite
considerable anatomical overlap of NK1Rs and NK3Rs, there are marked differences of
distribution patterns in certain brain areas. For example, strong NK1R signals are found
in the medial and cortical portions of the amygdala, while NK3R expression is mainly
localized to basomedial and basolateral nuclei. Distinct patterns of expression for the two
receptors are also found in septum, hypothalamus, and prefrontal cortex (Ebner et al.,
2009; Hökfelt et al., 2004; Saffroy et al., 2003).
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Neurokinin-mediated mechanisms in the CNS. Tachykinins are found in the axons of
many neuronal populations, including those that release glutamate, GABA, serotonin, and
acetylcholine (Commons, 2010). In addition to axons, neurokinin-containing large densecore vesicles are found in somata, dendrites, and neuronal varicosities. Neuropeptides
are packaged in large dense-core vesicles that are distinct from the small synaptic vesicles
containing the co-existing neurotransmitter (Keegan, Woodruff, & Pinnock, 1992; Mantyh,
2002). The neuropeptides present in various neuronal classes are co-released with
classical neurotransmitters or neuromodulators, especially upon strong activation of the
parent cell. The mechanisms that regulate neurokinin release are different from those that
regulate fast synaptic transmission, as neurokinin-mediated responses have a slower time
course of activation compared to those triggered by ionotropic neurotransmitters. Due to
these characteristics, neurokinins provide a spatially and temporally defined refinement of
neuronal circuits.
Dopamine. SP is prominently expressed in striatal structures and has the ability to
increase extracellular DA levels (Ribeiro-da-Silva & Hokfelt, 2000). In particular, there
seems to be a positive feedback loop involving the striatum and the mesencephalon in
which the DA released from VTA projections can induce the expression of TAC1 mRNA
coding for SP in the striatum (Campbell & Walker, 2001). Conversely, the SP released
from striatal projections onto the VTA can increase DA release from midbrain neurons
(Kovács, Steinmann, Magistretti, Halfon, & Cardinaux, 2006). Given that DA release is
associated with reward and reward prediction, such a positive feedback loop is likely to
play an important role in motivation and addiction. Besides NK1Rs, the VTA and
substantia nigra pars compacta express NK3Rs, and application of the selective NK3R
agonist senktide to those two areas can also enhance the firing of DA neurons (Keegan
et al., 1992) and trigger DA release in projection sites (Marco et al., 1998).
91

Serotonin. A number of studies suggest that neurokinins may induce serotonin (5-HT) –
mediated behaviors by enhancing the release of endogenous 5-HT through the increase
of serotonin cell firing in the raphe nuclei (Gradin, Qadri, Nomikos, Hillegaart, & Svensson,
1992). Electrophysiology studies in brain slice preparations showed that both NK1 and
NK3 receptor agonists, rather than acting directly on 5-HT neurons, activate them
indirectly, by increasing excitatory postsynaptic currents (EPSCs) (R. Liu, Ding, &
Aghajanian, 2002). The EPSCs are blocked by the AMPA/kainate glutamate receptor
antagonist CNQX and can be prevented by tetrodotoxin, suggesting that neurokinins
enhance local glutamatergic neuronal afferents (R. Liu et al., 2002).
Norepinephrine. Locus coeruleus (LC) neurons are innervated by SP-containing fibers
(Baker et al., 1991), express NK1 receptors (Chen, Wei, Liu, & Rao, 2000), and are
activated by SP (Cheeseman, Pinnock, & Henderson, 1983). Acute exposure to SP
increases LC firing rates and chronic, but not acute, treatment with a SP receptor
antagonist changes firing properties from tonic to phasic burst firing (Maubach et al.,
2002). This effect resembles that of the conventional antidepressant, imipramine. Phasic
burst firing activity in the LC occurs during focused attention and orienting behavior, while
tonic firing is increased during acute stress (Aston-Jones, Rajkowski, & Cohen, 1999).
Based on this evidence, it has been hypothesized that SP might participate in the
processing of stressful experiences, and that the use of NK1R antagonists might facilitate
adaptations to stress (Maubach et al., 2002).
Acetylcholine. In addition to modulating DAergic activity, tachykinins exert a profound
influence on cholinergic activity. This effect has been documented in both the striatum and
the septum (Schable, Huston, & Silva, 2012). In the striatum, tachykinins (SP and NKA)
and GABA have opposite effects on the regulation of ACh release from cholinergic
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interneurons (Blanchet et al., 2000). While GABA has a facilitatory effect on ACh release,
tachykinins inhibit it, especially under maximal NMDA receptor activation.
In the medial septum, which sends cholinergic projections to the hippocampus and the
amygdala, tachykinins increase ACh release. The medial septum has among the highest
levels of NK2Rs (Saffroy et al., 2003), and expresses both NK1Rs and NK3Rs, which are
located on the cholinergic population of septal neurons (Schable et al., 2011). Injection of
either NK1R, NK2R, or NK3R agonists into the medial septum increases ACh levels in the
hippocampus, and NK2Rs have specifically been implicated in stress-induced
hippocampal ACh release (Schable et al., 2012). It has been proposed that these
tachykinin-mediated alterations of septal cholinergic activity might underlie the reported
effects of neurokinins on anxiety and learning processes (Schable et al., 2012). It should
also be noted that intraseptal injection of NKA and NKB increases ACh release in the
amygdala but not in the frontal cortex (Schable et al., 2012).
The medial habenula (MHb) is another brain area where tachykinins modulate cholinergic
activity. MHb neurons are glutamatergic, but the nucleus can subdivided into two principal
subnuclei based on the use of ACh as a co-transmitter in the ventral MHb (vMHb) and the
expression of SP in the dorsal MHb (dMHb) (Dao, Salas, & De Biasi, 2015). MHb neurons
respond to NK1R and NK3R stimulation with a rapid and concentration-dependent
increase in firing rates, but no effect is seen following NK2R activation (Norris, Boden, &
Woodruff, 1993).

Tachykinins and Addiction Mechanisms
Tackykinins and their receptors are expressed in areas that are prominently involved in
addictive processes such as the nucleus accumbens and the habenula (Luthi & Luscher,
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2014). Drug abuse often occurs in subjects experiencing mood and anxiety-related
symptoms, and stress is a major cause of drug seeking and relapse. Therefore, when
considering the regulation of behaviors that lie at the intersection of stress and addiction,
the ability of neurokinins to modulate neurotransmitter function is particularly relevant. For
example, norepinephrine mediates stress-induced reinstatement and escalates selfadministration of multiple addictive drugs (Erb et al., 2000; Gilpin & Koob, 2010; Leri,
Flores, Rodaros, & Stewart, 2002; Mantsch et al., 2010; Vranjkovic, Hang, Baker, &
Mantsch, 2012). NK1R ligands, by modulating the firing patterns of the LC, can affect
norepinephrine release. Dopaminergic activity, while best known for its role in rewardrelated mechanisms, is also increased during exposure to some stressors. Interestingly,
NK1R antagonists can prevent DA release in the prefrontal cortex induced by
immobilization stress (Hutson, Patel, Jay, & Barton, 2004).
Neurokinins might be directly involved in the mechanisms of drug abuse as systemic and
intracranial administration of SP (Hasenohrl et al., 2000) and the NK3R-selective agonist,
aminosenktide is sufficient to produce conditioned place preference (CPP) (Ciccocioppo
et al., 1998). The effects of SP are likely mediated by its active C-terminal fragment, which
exhibits greater affinity for NK3Rs than NK1Rs (Hasenohrl, Gerhardt, & Huston, 1992),
suggesting that NK3Rs contribute to the reinforcing effects of SP.

Neurokinins and nicotine: cellular mechanisms. Most of what is known about the
interactions between neurokinins and the nicotine contained in tobacco comes from
studies conducted on peripheral organs. Those studies established that SP and NKA,
expressed in sensory neurons and immune-system cells such as macrophages and
dendritic cells, participate in the mechanisms of bronchoconstriction and inflammation
produced by smoking (Joos, De Swert, & Pauwels, 2001). Initially, smoke activates
94

bronchopulmonary C-fiber afferents, at least in part by binding to nAChRs expressed in
nearby epithelial cells (L. Y. Lee et al., 2007). This produces a vagal reflex that leads to
the release of neurokinins (Hong, Rodger, & Lee, 1995). Neurokinins, in turn, facilitate
ACh release from postganglionic parasympathetic neurons, thereby increasing the
contractility of airway smooth muscle cells. SP and NK1Rs also promote the accumulation
of macrophages and dendritic cells in the airways following exposure to cigarette smoke.
Through this mechanism, they contribute to the development of smoking-induced
emphysema and chronic obstructive pulmonary disease (Joos et al., 2001).
In the CNS, nicotine acts through multiple, intricate mechanisms to facilitate the release
of DA and several other neurotransmitters (Li Wang et al., 2014). In the VTA and
substantia nigra, chronic nicotine treatment causes a decrease in SP immunoreactivity,
consistent with enhanced SP release and consequent tissue depletion of neuropeptide
(Alburges, Frankel, Hoonakker, & Hanson, 2009). These nicotine-mediated changes in
SP immunoreactivity can be blocked by the non-selective nAChR antagonist,
mecamylamine, as well as a dopamine D1 or D2 receptor antagonist. This observation,
considered together with the fact that SP injection into the VTA increases neuronal firing
and dopamine turnover (Kelley & Delfs, 1991), suggests that part of the effects of nicotine
on mesolimbic function could be derived from an interaction with the neurokinin system.
The MHb is another area of interaction between the cholinergic and tachykinins systems
that is involved in nicotine addiction. All MHb neurons are cholinoceptive and express high
levels of nAChRs (Dao et al., 2015). In addition, the vMHb contains neurons that
synthesize and release ACh onto the IPN and other projection sites. Our lab examined the
effects of nicotine on the cholinoceptive and cholinergic neurons located in the vMHb (Fig.
3A) and showed that activation of nAChRs by nicotine enhances the intrinsic excitability
of MHb neurons in a fashion similar to that produced by tachykinins (Fig. 3B) (Dao et al.,
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2014). We found that enhancement of excitability by nicotine does not require postsynaptic
nAChR function, nor ionotropic glutamatergic or GABAergic transmission. Rather,
nicotine's enhancement of MHb excitability is abolished by blockade of either NK1Rs or
NK3Rs. Thus, under basal conditions, SP and NKB release onto MHb neurons modulates
their intrinsic excitability, but this effect can be further amplified by local release of ACh or
by nicotine. Our work suggests that nAChRs containing the α5 subunit modulate MHb
excitability, largely by facilitating NKB release onto MHb neurons, with additional
facilitation of SP release. Because of the anatomical expression, we suspect that the
source of NKB onto the cholinoceptive/cholinergic MHb originates from local neurons, in
addition to neurons throughout the MHb. Conversely, the source of possible SP release
onto the vMHb might be from the dorsal one-third of the MHb (Dao et al., 2015).

Neurokinins and nicotine: regulation of mood and affect
Due to their expression in the limbic circuits that control stress and anxiety, tachykinins
participate in the regulation of mood and affect (Ebner et al., 2009). Most of the information
available focuses on the roles played by NK1R and its preferred ligand, SP, although more
recent animal studies have revealed that NK3R and its cognate ligand, NKB, can also
contribute to aversive emotional states. NKA and NK2Rs appear to play a modulatory role
as well.
SP/NK1R. SP infusion induces anxiety-like behavior in rodents that is NK1R-dependent
(Ebner et al., 2009). Early studies with guinea pigs, characterizing the effects of systemic
SP or NK1R agonist injections, reported behaviors associated with anxiety, such as
reduced food intake (Hasenohrl, Schwarting, Gerhardt, Privou, & Huston, 1994), grooming
behaviors (Takahasi et al., 1987), and increased vocalizations. These manifestations were
abolished by pretreatment with NK1R antagonists (Kramer et al., 1998). Acute
96

administration of an NK1R antagonist to rats is also anxiolytic when tested in the social
interaction test (File, 1997). In addition, mice with genetic deletion of the NK1R exhibit
decreased anxiety in behavioral paradigms that provoke anxious states, such as the
elevated plus maze and novelty-suppressed feeding test, and produce fewer ultrasonic
vocalizations during maternal separation (Santarelli et al., 2001). Additionally, transgenic
mice that lack Tac1, and therefore do not express SP or NKA, exhibit significantly lower
levels of anxiety relative to WT controls in several behavioral paradigms (Bilkei-Gorzo,
Racz, Michel, & Zimmer, 2002).
Although systemic injection of SP is typically anxiogenic, and NK1R antagonism is
anxiolytic, there is evidence for variable regulation of anxiety by the SP/NK1R system in
different anatomical regions. For example, selective ablation of NK1R-expressing neurons
within the amygdala generates increased anxiety-associated behavior in the EPM (Gadd,
Murtra, De Felipe, & Hunt, 2003). Immobilization stress and the EPM test elevate SP levels
in the medial sub-nucleus of the amygdala, an effect that can be blocked by microinfusion
of NK1R antagonists into the nucleus (Ebner et al., 2009). Additionally, direct infusion of
SP into the central or medial - but not basolateral sub-nuclei of the amygdala - is
anxiogenic in the EPM, suggesting distinct contributions of amygdalar sub-nuclei to the
behavior (Bassi, de Carvalho, & Brandao, 2014).
In addition to the amygdala, other studies have shown that the levels of SP in the lateral
septum increase in response to the forced swim test – with NK1R antagonists enhancing
intraseptal serotonergic transmission, which increases active stress-coping strategies
(Ebner et al., 2009). The LC, paraventricular nucleus (PVN) of the hypothalamus, and
lateral septum may also contribute to the behavioral effects of SP, as NK1R antagonists
counteract stress-induced elevations of c-Fos expression in those three brain areas
(Vendruscolo, Takahashi, Bruske, & Ramos, 2003). Further, speaking to the complex
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effects of neurokinins in the CNS, while some anxiety-provoking behavioral tests elevate
SP in anatomical structures associated with anxiety and stress, a 20 minute foot-shock
paradigm reduced SP levels in the VTA and interpeduncular nucleus (IPN) (Lisoprawski,
Blanc, & Glowinski, 1981).
Several studies in humans have validated the pre-clinical work described above. fMRI
imaging highlighted altered signaling in limbic structures following NK1R blockade in
healthy human volunteers (McCabe, Cowen, & Harmer, 2009), and the administration of
a different NK1R antagonist for 6 weeks in patients diagnosed with social phobia resulted
in significant symptom alleviation (Furmark et al., 2005). An early NK1R antagonist yielded
significant anxiolytic activity in a population of depressed patients exhibiting high levels of
anxiety (Kramer et al., 1998). Since this study, additional human studies have not yielded
consistently encouraging outcomes (McCabe et al., 2009), possibly because of
pharmacokinetic and genetic variables that were not considered in experimental designs.
NKB/NK3R. More recent efforts have revealed signaling contributions by NKB and its
preferred receptor, NK3R, in areas of the brain associated with anxiety and stress. For
example, NKB is highly expressed in the amygdala. Fear conditioning, a paradigm that
depends on intact amygdalar function, increases NKB expression significantly, and the
infusion of Osanetant, an NK3R antagonist, impairs the consolidation of fear memories
(Andero, Dias, & Ressler, 2014). Interestingly, a loss-of-function approach to establishing
the role of NKB/NK3R signaling in modulating affect revealed a nuanced story. Absence
of the NK3R impairs both the acquisition of conditioned avoidance and performance in the
Morris water maze (Siuciak et al., 2007), further suggesting a particular involvement of
NKB/NK3R in aversive emotional memory.
Other peptides might also contribute to the effects of SP on mood and affect. Restraint
stress results in altered trafficking of NK3Rs in vasopressin-expressing cells of the PVN
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(Miklos, Flynn, & Lessard, 2014). Vasopressin and the PVN are part of a signaling system
that regulates social behavior and stress, the release of ACTH, and the hypothalamicpituitary-adrenal axis (HPA) (Stevenson & Caldwell, 2012). In addition, an NK3R agonist
could inhibit gonadotropin releasing hormone (GnRH) secretion in mice (Navarro et al.,
2009), pointing to another possible mechanism for the interaction between neurokinins
and anxiety/stress via GnRH secretion (S. N. Umathe, Bhutada, Jain, Dixit, & Wanjari,
2008). Indeed, the administration of an NK3R antagonist resulted in anxiolysis (Salome,
Stemmelin, Cohen, & Griebel, 2006), performing similarly to diazepam and buspirone –
both of which are used to treat anxiety. Contrary to the lack of effect upon systemic
injection of an NK3R agonist, anxiolysis in the EPM was observed following
intracerebroventricular (ICV) infusion in the mouse. Pretreatment with naloxone enhanced
this effect, while naloxone alone did not alter behavior, suggesting a possible interaction
between NK3R and the opioid signaling systems (S. J. Ribeiro & De Lima, 1998). Taken
together, these data suggest that NKB/NK3R also participate in anxiety-associated
signaling.
NKA/NK2R. Perhaps due to the restricted expression profile of NKA/NK2 in the CNS,
relatively few studies have evaluated the role of NK2R activation in anxiety and stress.
However, the administration of NK2R antagonists has proven to be consistently anxiolytic.
Saredutant, an NK2R antagonist, was anxiolytic in gerbils undergoing the social
interaction test (Salome et al., 2006), mice tested in the light-dark box paradigm, and
primates evaluated by the human intruder response test (Walsh, Stratton, Harvey,
Beresford, & Hagan, 1995). Additionally, NK2R antagonists reduce defensive biting and
escape attempts in mice (Griebel, Perrault, & Soubrie, 2001), and reduce anxiety in the
EPM in both mice (Teixeira et al., 1996) and rats (Griebel et al., 2001). NK2R agonists are
anxiogenic in the EPM (Teixeira et al., 1996), and are capable of inhibiting the anxiolytic
99

effects of diazepam (R. L. Ribeiro & De Lima, 2002). An investigation of the long-term
consequences of footshock treatment in rats revealed significantly changed Tac1 mRNA
in a variety of anatomical structures associated with the regulation of emotional states,
and autoradiography studies revealed reduced NK2R binding in the amygdala two weeks
after treatment. While the mechanisms of this receptor down-regulation are unclear, the
authors posit that it may result from an adaptive response to limit excessive SP release
(de Lange, Wiegant, & Stam, 2008).
Neurokinins and the symptoms of nicotine withdrawal.
Although reward significantly contributes to the addictive properties of nicotine, smoking
is often motivated by the urge to alleviate the affective, cognitive, and somatic symptoms
of withdrawal (McLaughlin et al., 2015). Affective and cognitive signs of withdrawal are
produced by CNS mechanisms. Anxiety is a prominent affective symptom, and it acts as
a potent negative reinforcer that promotes smoking. Somatic signs reflect mainly
peripheral, “bodily” mechanisms such as decreased heart rate and constipation. However,
besides a peripheral nAChR component, somatic signs have a central component that is
thought to translate to a dysphoric state of heightened irritability. These withdrawal
symptoms are effectively recapitulated in animal models; upon nicotine withdrawal, both
rats and mice exhibit stereotypies, including excessive grooming, chewing, tremors, ‘wetdog shakes’, yawns, and teeth chattering – as well as behaviors that have been associated
with anxiety, anhedonia, depression, dysphoria, and hyperalgesia (McLaughlin et al.,
2015). Despite the abundance of data implicating neurokinin signaling in anxiety and
stress, to our knowledge, no studies have been conducted so far to precisely characterize
the role of neurokinins and their receptors in the anxiety-related symptoms of nicotine
withdrawal. Besides the areas in which tachykinin expression overlaps with anatomical
structures that synthesize and release serotonin, norepinephrine, and dopamine, the MHb
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and IPN are potential sites for interactions between signaling systems. This hypothesis is
derived from the high levels of SP/NK1R, NKB/NK3R and nAChRs in the MHb, and the
fact that the MHb-IPN circuit plays a prominent role in anxiety in both humans and rodents
(Dao et al., 2015). In addition, the interplay between cholinergic and neurokinin signaling
within the MHb may represent a critical anatomical region wherein neuroadaptations
occur, resulting in the signaling that causes anxiety exhibited during withdrawal from the
chronic use of nicotine and other drugs (Dao et al., 2015).
The MHb-IPN circuit has an established role in the somatic symptoms of nicotine, ethanol
and likely, morphine abstinence (Dao et al., 2015; Muldoon et al., 2014; E. Perez, QuijanoCarde, & De Biasi, 2015b). Interestingly, intraperitoneal and ICV infusions of SP in rats
elicit physiological and behavioral responses such as increased heart rates, wet-dog
shakes, and increased grooming (Tschope, Jost, Unger, & Culman, 1995). Those
symptoms are observed during stress as well as nicotine withdrawal (McLaughlin et al.,
2015). To that end, we were able to show that administration of NK1R and NK3R
antagonists in mice chronically treated with nicotine can precipitate somatic symptoms of
withdrawal (Fig. 3C) – supporting a model wherein nicotine directly modulates neurokinin
signaling in the MHb to promote intrinsic neuronal excitability (Dao et al., 2015).

Applications to Other Addictions and Substance Misuse
Several groups have examined the involvement of tachykinins in drug abuse. Most studies
addressed the role of SP and NK1Rs and have shown their involvement in the
mechanisms of dependence from opioids, cocaine, and alcohol. The following sections
describe the involvement of neurokinin signaling in addictions to other substances.
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Opiates. Substance P and NK1Rs modulate the rewarding effects of opiates (Commons,
2010). NK1R antagonism suppresses heroin self-administration in rats (Barbier et al.,
2013). In addition, NK1R null mice display morphine reward deficits in the CPP paradigm
(Gadd et al., 2003; Murtra, Sheasby, Hunt, & De Felipe, 2000) and self-administer less
morphine than their control littermates, without any change in natural reward (Ripley,
Gadd, De Felipe, Hunt, & Stephens, 2002). Morphine’s ability to potentiate reward is also
attenuated by NK1R antagonism in the intracranial self-stimulation paradigm (ICSS) (J. E.
Robinson et al., 2012). Based on lesion studies, the amygdala, rather than the nucleus
accumbens, is where the presence of NK1Rs affects morphine reward (Gadd et al., 2003).
Lack of NK1Rs also attenuates morphine-induced locomotor activation and psychomotor
sensitization (Murtra et al., 2000; Ripley et al., 2002). There are also preclinical data
indicating that NK1R blockade might attenuate the symptoms of opioid withdrawal
(Maldonado, Girdlestone, & Roques, 1993), and that administration of SP or its N-terminal
peptide can prevent the development of morphine withdrawal symptoms (Kreeger &
Larson, 1996). A small study conducted in methadone-maintained patients showed that
the FDA approved NK1R antagonist, aprepitant, might have utility for alleviating opioid
withdrawal and craving (Jones et al., 2013).
Besides the influence of SP on the brain circuits underlying morphine-related behaviors,
NK1Rs and µ-opioid receptors (MOR) may interact at the cellular level. Specifically, SP
prevents morphine-induced internalization and acute desensitization of MORs (Yu,
Arttamangkul, Evans, Williams, & von Zastrow, 2009). This phenomenon was observed in
both amygdala and LC neurons, which can co-express NK1Rs and MORs. Finally, chronic
morphine administration results in NK1R upregulation (Wan et al., 2006). Overall, these
data point to a rich interaction between the opioid and tachykinin systems and suggest
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that NK1R blockade could be one approach to reduce opiates abuse by limiting their
rewarding and reinforcing properties, as well as mitigating withdrawal symptoms.
Cocaine. The effects of SP on cocaine-induced behaviors differ from those observed for
morphine. When cocaine-induced locomotion and DA release in the dorsal striatum were
examined, it was found that NK1R blockade attenuated both responses (Loonam,
Noailles, Yu, Zhu, & Angulo, 2003). However, lack of NK1Rs did not affect locomotor
sensitization to cocaine in mice (Ripley et al., 2002), nor did it affect cocaine CPP (Murtra
et al., 2000). Furthermore, in contrast with what was found for morphine, targeted lesions
of the amygdala did not affect CPP (Gadd et al., 2003). Cocaine self-administration rates
were not affected by NK1R deletion in mice (Ripley et al., 2002) or NK1R antagonism in
rats (Schank et al., 2014). Interestingly, NK1R blockade could prevent stress-induced
reinstatement but had no effect on cocaine seeking triggered by a cocaine priming
injection (Placenza, Vaccarino, Fletcher, & Erb, 2005).
Other studies showed that NK3Rs are involved in cocaine-induced hyperlocomotion and
DA release within the nucleus accumbens, but not in cocaine-induced CPP (Jocham,
Lauber, Müller, Huston, & De Souza Silva, 2007). In summary, although neurokinins might
be involved in some aspects of cocaine dependence, there is no evidence that they
influence its rewarding properties.
Alcohol. Pre-clinical and clinical data, which are discussed in detail elsewhere in this
volume, indicate that neurokinins are involved in the mechanisms of alcohol abuse. Briefly,
similar to morphine, NK1R null mice do not display alcohol CPP (Thorsell, Schank,
Singley, Hunt, & Heilig, 2010). They also consume less alcohol in the two-bottle choice
drinking paradigm (George et al., 2008), a phenomenon also observed when using both
NK1R antagonists (Thorsell et al., 2010) and NK1R knockdown (Baek et al., 2010). In
addition, NK1R null mice do not display increased alcohol consumption after repeated
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cycles of deprivation, suggesting that SP influences the neuroadaptations that occur
during repeated withdrawal and lead to drinking escalation (Thorsell et al., 2010).
Interestingly, blockade of NK1R does not affect baseline operant alcohol selfadministration in the rat, but, similarly to what was found for cocaine, it suppresses stressinduced reinstatement of alcohol seeking (Schank et al., 2014).
Information on the effects of NK1R blockade is also available for humans. A clinical trial
of the NK1R antagonist, LY686017, in detoxified alcoholic inpatients demonstrated
suppression of spontaneous alcohol cravings and improved overall well-being (George et
al., 2008). Subsequently, a case–control association study conducted in Caucasian
subjects concluded that polymorphisms of the NK1 receptor are significantly associated
with the development of alcohol dependence (Seneviratne et al., 2009). Based on this
evidence, NK1R antagonists may be a treatment strategy for some subpopulations of
alcohol abusers, such as those with certain genetic variants of the TACR1 gene.

Conclusions
Tachykyins and their receptors are expressed in brain areas and circuits that control stress
and anxiety. These areas also participate in the mechanisms of drug abuse, and there is
evidence for the involvement of tachykinins in the abuse of opiates, cocaine, and alcohol.
For opiates, NK1Rs affect baseline reward and reinforcement, as well as escalated selfadministration rates. For cocaine and alcohol, NK1Rs mediate stress-induced
reinstatement of drug seeking and escalated drug self-administration, but do not affect
baseline self-administration. Very little is known regarding the role of tachykinins in the
manifestations of withdrawal, except for reports that link SP to some of the symptoms of
opiate abstinence.
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Surprisingly, despite a clear role of tachykinins in many peripheral effects of nicotine, there
have been no studies on their roles in nicotine reward and seeking. As for the mechanisms
of withdrawal, our lab was the first to report a link between SP and NKB and the
manifestations of physical dependence to nicotine, highlighting the MHb-IPN circuit as a
major site for those interactions. Therefore, the field is ripe for further investigations into
mechanisms and the potential application of NK1R antagonists to facilitate smoking
cessation. Even less is known about the role of NK2R and NK3R in drug addiction.
However, given the growing availability of NKR subtype–specific antagonists, genetically
engineered pre-clinical models, and many additional molecular and genetic tools, future
studies should be able to address the specific role of NKA and NKB in nicotine addiction.
As for the potential use in the clinic, NK1R antagonists are generally well tolerated,
warranting further investigation into their effectiveness for the treatment of nicotine and
other drug abuse disorders. The clinical trials examining the effect of NK1R antagonists
on alcohol abuse have yielded mixed results, possibly due, among other factors, to
relatively small sample sizes and variable drug pharmacokinetics. As pharmacogenetic
analyses become cheaper and more easily incorporated into clinical trials, investigators
will be able to determine the impact of genetic variations in neurokinin genes on both the
risk and the response to treatment in addicted subjects. The use of empirically derived
sub-phenotypes (e.g. co-morbid anxiety) will be particularly helpful in identifying the
subjects that would benefit the most from the addition of neurokinin antagonists to their
treatment strategies.
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Mini Dictionary of Terms
Cholinergic neuron: A neuron that possesses the intracellular machinery for the
synthesis and release of acetylcholine
Cholinoceptive neuron: A neuron that expresses receptors for acetylcholine
Electrophysiology: A technique that allows measurement of the electrical activity of
neurons.
Feedback loop: A mechanism through which a neuronal system can self-adjust to
optimize function and maintain equilibrium
Immunoreactivity: Measure of the signal for a particular protein that can be detected in
the brain by antibodies that bind with high specificity to that protein.
Intracranial self-stimulation: an experimental paradigm in which animals self-stimulate
certain brain regions through electrodes surgically implanted into the brain. The
stimulation activates the brain reward system.
Mecamylamine: Nicotinic receptor antagonist used to precipitate nicotine withdrawal in
mice chronically exposed to nicotine
Somatic signs of withdrawal. The physical symptoms associated with nicotine
abstinence. The nicotine abstinence syndrome comprises affective, cognitive, and
somatic signs.
Ultrasonic vocalizations: Calls of distress inaudible to humans. They are thought to
reflect negative affective states.
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Key Points
Tachykinin signaling is involved in anxiety, stress, and addiction.


Tachykinin signaling plays a modulatory role in the signaling of dopamine,
serotonin, norepinephrine, and acetylcholine – all of which are known to play
roles in the pathophysiology of mood-related disorders and addiction



Systemic injection of SP is generally anxiogenic, while antagonists targeting SP’s
cognate receptor are anxiolytic



NK2R antagonists have proven to be anxiolytic in pre-clinical models, and stress
induces long-lasting alterations of tachykinin gene product levels



Pharmacological manipulations of the NK3R result in modified anxiety-associated
behavior in animal models, depending upon the particular CNS structure into
which they are infused.



The MHb-IPN circuit, which is critically involved in anxiety and symptoms of
withdrawal from nicotine and other drugs, hosts considerable tachykinin
signaling. Pharmacological manipulations of NK1R & NK3R-dependent signaling
in this circuit are sufficient to induce withdrawal symptoms in mice chronically
treated with nicotine.



Many questions remain unanswered concerning the functional roles played by
each receptor type, as well as the roles of other tachykinin signaling peptides



Clinical applications of neurokinin receptor-targeting drugs have not consistently
proven superior to the standards of care for mood-related disorders or addiction.



More nuanced approaches to clinical trials, such as genomic screening,
combinatorial pharmacological strategies, and increased receptor specificity for
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more targeted action may yield more positive results for the treatments of moodrelated disorders and addiction
Summary Points


Substance P (SP), neurokinin A (NKA), and neurokinin B (NKB) are all members
of the tachykinin family of signaling peptides, and are expressed and released in
areas of the brain associated with anxiety, stress, and drug addiction



NK1r and NK3r are predominantly expressed in the CNS, while NK2 is most
densely expressed in the PNS



NK1 receptors (NK1R) bind SP, NK2R bind NKA, and NK3R bind NKB with the
greatest affinities – but each of the peptides is capable of binding all of the
receptors



While there is substantial overlap in anatomical distribution of expression and
release, each peptide and its receptor also occupy distinct anatomical regions



The receptors for all three receptors are G-protein coupled, and have been
shown to modulate dopamine, serotonin, and acetylcholine signaling



Tachykinin signaling has been implicated in the effects of nicotine and other
drugs, as well as the neuroadaptations that occur as a result of chronic use



Pharmacological manipulation of neurokinin receptors has been shown to alter
anxiety-, depression-, and stress-associated behavior in pre-clinical and clinical
studies
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Abstract
An aversive abstinence syndrome manifests 4 to 24 hours following cessation of chronic
use of nicotine-containing products. Symptoms peak on approximately the 3rd day and
taper off over the course of the following 3-4 weeks. While the severity of withdrawal
symptoms is largely determined by how nicotine is consumed, certain short nucleotide
polymorphisms (SNPs) have been shown to predispose individuals to consuming larger
amounts of nicotine more frequently – as well as to more severe symptoms of
withdrawal when trying to quit. Additionally, rodent behavioral models and transgenic
mouse models have revealed that specific nicotinic acetylcholine receptor (nAChR)
subunits, cellular components, and neuronal circuits are critical to the expression of
withdrawal symptoms. Consequently, by continuing to map neuronal circuits and nAChR
subpopulations that underlie the nicotine withdrawal syndrome – and by continuing to
enumerate genes that predispose carriers to nicotine addiction and exacerbated
withdrawal symptoms – it will be possible to pursue personalized therapeutics that more
effectively treat nicotine addiction.
1. Withdrawal Syndrome in Humans
1.1. Symptoms
The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) reports 7 primary
symptoms associated with nicotine withdrawal: irritability/anger/frustration, anxiety,
depressed mood, difficulty concentrating, increased appetite, insomnia, and restlessness
(Association 2013). The syndrome might also include constipation, dizziness,
nightmares, nausea, and sore throat. For practical purposes, nicotine withdrawal
symptoms are classified as affective, somatic, and cognitive. Affective symptoms include
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anxiety, anhedonia, depression, dysphoria, hyperalgesia, and irritability. Somatic
manifestations include tremors, bradycardia, gastrointestinal discomfort, and increased
appetite. Cognitive symptoms manifest as difficulty concentrating and impaired memory
(Heishman, Kleykamp et al. 2010). This constellation of symptoms reflects the brainwide influence of cholinergic transmission. Studies characterizing the participation of
specific nAChRs in signaling during particular manifestations of withdrawal are helping to
reveal their underlying mechanisms (Paolini and De Biasi 2011).
1.2. Genetic Influences.
Nicotine addiction is influenced by both genetic and environmental factors. Depending
on the parameters used to define dependence, and the population considered,
heritability contributes 50%-75% of the risk for dependence (Dokal, Pagliuca et al. 1989,
Hall, Madden et al. 2002, Lessov, Martin et al. 2004, Furberg, Kim et al. 2010, Nugent,
Million-Mrkva et al. 2014). Risk factors for nicotine dependence can be identified using
genetic methods such as linkage and candidate gene analyses, as well as genome wide
association studies (GWAS). Linkage analysis assesses the presence of a phenotype in
large, high-risk families to map the location of disease-causing loci in relation to a known
genetic marker. Candidate gene analysis assesses the association between a particular
gene allele (or alleles) potentially involved in the disease and the disease itself. GWAS,
in contrast to candidate gene approaches, do not limit analyses to relationships between
specific genes and a phenotype, and aim to identify loci for novel susceptibility genes.
An example of how such genetic approaches can be successfully utilized in nicotine
research is the gene cluster on chromosome 15q25 that encodes the α5, α3, and β4
nAChR subunits. Gene variants within the cluster have been repeatedly shown to affect
nicotine dependence and smoking quantity (Saccone, Saccone et al. 2009). A non115

synonymous nucleotide polymorphism (SNP), rs16969968, which substitutes an aspartic
acid for an asparagine (D398N) in the CHRNA5 region of the cluster, has been
associated with reduced receptivity to nAChR agonists in vitro, reduced neuronal
calcium permeability, and more extensive nAChR desensitization (Jackson, Marks et al.
2010). Individuals who are homozygous for this SNP are more likely to progress to
heavy smoking and nicotine dependence (Hartz, Short et al. 2012), and it has been
suggested that the reduction in agonist responsivity and increased desensitization may
contribute to these increased propensities (Jackson, Marks et al. 2010). Apart from the
missense rs16969968 variant, there are other SNPs within the CHRNA5-CHRNA3CHRNB4 cluster that are relevant to nicotine addiction and withdrawal, and further
biological characterizations are needed to establish the functional consequences of
those mutations. Other nAChR genes have also been shown to influence smoking
quantity and nicotine dependence, such as common variants in the chromosome 8p11
region that contains the genes encoding the α6 and β3 nAChR subunits (Thorgeirsson,
Gudbjartsson et al. 2010). Overall, linkage analyses have highlighted 13 regions on 11
chromosomes that include genes with potential influences on nicotine dependence
(Leeb and Tamse 1985, Li 2008). Genes involved in nicotine metabolism are also likely
important to the nature of nicotine withdrawal. Cytochrome P450 2A6 (CYP2A6) is the
enzyme mainly responsible for the conversion of nicotine to cotinine, which typically
accounts for 70%–80% of nicotine metabolism (Hecht, Hochalter et al. 2000). In subjects
of European descent, GWAS meta-analyses identified SNPs in the region of CYP2A6
associated with the number of cigarettes smoked per day, as well as other smoking
behavior phenotypes (Thorgeirsson, Gudbjartsson et al. 2010).
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Genetic factors may also account for 29-53% of the variance in withdrawal symptoms
and approximately 50% of the variance in quitting success (Xian, Scherrer et al. 2003,
Xian, Scherrer et al. 2005, Pergadia, Heath et al. 2006). In a linkage analysis study, a
sample of Australian and Finnish smokers was queried about withdrawal symptoms
within the context of a smoking cessation attempt that they recalled well. The study
revealed a linkage signal that meets genome-wide significance on chromosome 11p15
in the Finnish families (Pergadia, Agrawal et al. 2009). Four strong candidate genes lie
within or near the peak area on chromosome 11: dopamine receptor 4 (DRD4), TPH
tryptophan hydroxylase 1 (TPH), TH (tyrosine hydroxylase), and CHRNA10 (nAChR
subunit 10). A second region identified by linkage on chromosome 11q23 includes
HTR3A (hydroxytryptamine receptor 3A), HTR3B (hydroxytryptamine receptor 3B),
DRD2 (dopamine D2 receptor gene), ANKK1 (ankyrin repeat and kinase domain
containing 1), and GRIK4 (ionotropic kainate glutamate receptor 4 gene). An earlier
study reported that DRD2 TaqI-B polymorphisms influence abstinence and withdrawal
symptoms (Robinson, Lam et al. 2007). Smokers carrying the DRD2 TaqI-B1 risk allele
(B1/B1 or B1/B2) reported significantly more symptoms of daily smoking withdrawal
compared to smokers homozygous for the TaqI-B2 allele (B2/B2). In addition, while
withdrawal symptoms - measured 14 days pre-quit and 42 days post-quit - decreased
significantly in Taql-B2 homozygous over time, smokers with the TaqI-B1 allele reported
little improvement in self-reported withdrawal symptoms.
Several other pharmacogenetic studies, including a couple of genome wide association
study (GWAS) analyses, have examined genetic influences on smoking cessation and
response to therapy (Leeb and Tamse 1985, Uhl, Liu et al. 2007, Furberg, Kim et al.
2010, Gold and Lerman 2012, King, Paciga et al. 2012, Bloom, Martinez et al. 2013,
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Chen, Bloom et al. 2014). SNPs in CHRNB2 and the CHRNA5-CHRNA3-CHRNB4
cluster seem to influence smoking cessation, although the reported effects are not
always reproducible (Conti, Lee et al. 2008, Baker, Weiss et al. 2009, Perkins, Lerman
et al. 2009, Gold and Lerman 2012, Hartz, Short et al. 2012). The influence of CHRNA5CHRNA3-CHRNB4 haplotypes on tolerance, craving, and loss of control seems greatest
in individuals who began smoking early in life, suggesting that the risk associated with
those genes is greatest with early tobacco exposure (Baker, Weiss et al. 2009). The
rs8192475 variant in CHRNA3 was shown to predict withdrawal symptoms and craving
after quitting (Sarginson, Killen et al. 2011). The major G allele was associated with
stronger but relatively short-lived symptoms, while the minor A allele resulted in a
relatively constant level of symptoms and craving during the acute phase of withdrawal.
The rs8192475 α3 SNP leads to an R37H change in the amino acid sequence that
increases agonist sensitivity of heterologously expressed α3β4 nAChRs (Haller, Druley
et al. 2012). Rare missense variants at conserved residues in CHRNB4 (T375I and T91I)
are associated with reduced numbers of cigarettes per day and fewer signs of
withdrawal (Haller, Druley et al. 2012). Similar to the α3 SNP rs8192475, expression of
the two β4 mutations in HEK 293 cells leads to larger currents in response to ACh
stimulation, which has been suggested to increase the aversive properties of nicotine.
Similar to what was found for phenotypes related to nicotine dependence, there are also
associations of CYP2A6 enzyme activity and nicotine metabolic rates with smoking
cessation and smoking cessation strategies (Lee, Jepson et al. 2007, Chen, Bloom et al.
2014). Individual carrying the null activity allele, CYP2A6*2, are twice as likely to quit
smoking as subjects without that allele (Gu, Hinks et al. 2000). Conversely, smokers with
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high activity alleles (CYP2A6*1/*1B) experience more severe withdrawal symptoms
when trying to quit (Kubota, Nakajima-Taniguchi et al. 2006).
Currently, the literature suggests that multiple genetic loci influence the severity of
withdrawal symptoms and the ability to abstain from smoking. Such polygenic
contributions overlap, at least in part, with those associated with vulnerability to nicotine
dependence. Because the majority of published studies was conducted on relatively
small samples, examined different cessation strategies, and did not always address
withdrawal symptoms directly, additional work is needed to yield more robust and
reproducible associations between genes and withdrawal phenotypes. Once putative
genes are identified, it will be critical to assess the potential for genetic variations to alter
biological function and, consequently, nicotine-related behaviors. Pre-clinical studies that
address both behavior and molecular mechanisms can help to explain how the changes
in DNA sequence are associated with the behavioral phenotypes observed in smokers.
Rodents, and particularly mice, offer unique opportunities to explore and characterize
the relationships between gene function and nicotine withdrawal. Given the difficulty of
effectively characterizing gene products and circuits responsible for the symptomatology
of nicotine withdrawal in humans, genetic manipulations can be carried out in mice to
directly address the circuits and molecular mechanisms involved.
2. Withdrawal Syndrome in Mice.
Many symptoms of nicotine withdrawal described in humans can be recapitulated in
rodent models of addiction and withdrawal under experimental conditions. After at least
a week of chronic nicotine administration in mice, cessation of nicotine exposure or
administration of a nAChR antagonist induces affective, somatic, and cognitive signs of
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withdrawal (Malin, Lake et al. 1994, De Biasi and Salas 2008). The withdrawal syndrome
exhibited can be alleviated by nicotine administration – akin to nicotine replacement
strategies such as nicotine patches or gum – or by administration of pharmacological
agents used as cessation aids in humans, such as buproprion or varenicline (Rennard
and Daughton 2014). Because mice express neuroadaptions that result in the nicotine
withdrawal syndrome, and because nAChR-subunit knockout mouse lines are readily
available, researchers have been able to study the functional contributions of particular
nAChR subunits to specific symptoms of withdrawal.
2.1. Behavioral Manifestations and Testing Paradigms.
The nicotine withdrawal syndrome can be studied in mice by observing the frequencies
of certain stereotypies, or by evaluating changes in behavior during withdrawal, relative
to baseline behaviors exhibited by control mice naïve to nicotine. As in humans, the
behavioral manifestations of nicotine withdrawal in mice can be categorized as somatic,
affective, and cognitive.
Somatic symptoms in mice include excessive grooming, chewing, tremors, ‘wet-dog’
shakes, yawns, and teeth chattering (Paolini and De Biasi 2011). The occurrence of
these symptoms tends to increase according to the severity of withdrawal. Affective
symptoms are somewhat subtler in mice than somatic symptoms; their evaluation
requires a series of behavioral assays to reveal changes in affect that are associated
with withdrawal. Just as humans undergoing nicotine withdrawal experience anxiety,
anhedonia, depression, and hyperalgesia, behavioral paradigms applied to mice expose
analogous affective states. A challenge researchers face when evaluating rodent affect
is that no single paradigm effectively isolates any one particular affective state. Each
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measure likely evokes multiple affective states, unintentionally recruiting off-target
neuronal circuits that are outside the scope of a given study. However, several
behavioral paradigms applied as a set can help reveal relative differences in affect
following experimental treatments. The emergence of anxiety-like symptoms following
nicotine abstinence can be measured in the open field test (OFT) and the elevated plus
maze (EPM), two of the most commonly employed paradigms in studies evaluating
emotional states of rodents (Crawley, Belknap et al. 1997). The OFT is conducted by
placing a mouse or rat in a square arena and evaluating the ratio of time rodents spend
in the center of the environment to time spent along its perimeter. As rodents experience
increased anxiety, they tend to avoid the center and spend more time along the walls of
the environment, a behavior termed thigmotaxis. As rodents undergo nicotine
withdrawal, they tend to exhibit increased levels of thigmotaxis. The open field test also
enables researchers to evaluate rearing behavior, overall locomotion, freezing, and
changes in defecation during withdrawal. As a further source of experimental control,
levels of ambient illumination can be adjusted to modulate baseline levels of anxiety.
The EPM consists of two enclosed arms with walls running along their periphery, and
two open arms with no walls that present an environment resembling elevated cliffs
(Crawley, Belknap et al. 1997). The arms are arranged in the shape of a plus sign, and
anxious mice tend to make fewer entries into the open arms and spend less time in open
arms. Rodents undergoing nicotine withdrawal exhibit both of these anxiety-associated
behaviors, and anxiolytic drugs have been observed to increase open-arm entries
(Crawley, Belknap et al. 1997).
Conditioned place aversion (CPA) can be used to measure the dysphoric manifestations
associated with withdrawal. The paradigm involves repeated pairing of distinct
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environmental cues with negative stimuli (i.e. withdrawal), such that when given a
choice, mice avoid the withdrawal-paired cues relative to neutral cues. The time mice
spend avoiding environments paired with withdrawal serves as an indicator of the
severity of aversion (Kenny and Markou 2001). The emergence of depression-like
symptoms during withdrawal can be assessed with the Forced Swim Test (FST), which
assesses learned helpness by monitoring passive coping strategies such as immobility
(Cryan, Markou et al. 2002, Thanos, Delis et al. 2013). During withdrawal, immobility is
increased, indicating a depression-like state.
Intra-cranial self-stimulation (ICSS) is used to investigate the “reward” circuitry, and can
be useful to evaluate anhedonia during withdrawal. Electrodes are implanted into the
rodent brain targeted to the medial forebrain bundle, which includes the mesolimbic DA
pathway associated with hedonia or reward. The rodent is first trained to perform the
operant task of self-stimulation, and then is allowed to self-administer small electrical
stimulations to the targeted pathway. As rodents perform this operant conditioning, the
stimulus intensity is experimentally adjusted to determine the baseline stimulation
threshold at which self-stimulation is consistently achieved and retained. Following the
establishment of this threshold, researchers can explore the effects various stimuli have
on brain reward and hedonic signaling. A lowered threshold resulting from a treatment is
suggested to represent increased reward signaling along the pathway, while a
heightened threshold is interpreted as indicating a state of greater anhedonia (O'Dell and
Khroyan 2009). Animals experiencing nicotine withdrawal display elevated thresholds for
ICSS.
The effects of withdrawal on cognition, especially hippocampal-dependent learning and
memory, can be examined with contextual fear conditioning (FC). Subjects must learn
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contextual information and form an association between the context and an aversive
electric shock (Fanselow and Poulos 2005, Sigurdsson, Doyere et al. 2007). Acute
nicotine administration enhances contextual fear conditioning while nicotine withdrawal
impairs it (Davis and Gould 2008).
The five-choice serial reaction time task (5-CSRTT), also called operant signal detection,
is a behavioral test used to characterize the effects of treatments on sustained and
divided attention (Robbins 2002). The task consists of a maze that presents five holes,
each of which may be paired with a reward. A brief flash of light inside one of the holes
indicates the one that contains a reward, and rodents must poke the correct hole to
receive the reward. This task quantifies the capability of rodents to maintain spatial
attention that has been split among five locations over the course of many trials by
dividing the proportion of correct nose-pokes (pokes into the lit hole) by total nosepokes. While nicotine administration has been observed to generate cognitive
enhancements, rats withdrawing from nicotine have been observed to exhibit attention
deficits in the 5-CSRTT paradigm (Shoaib and Bizarro 2005), reflecting some of the
symptoms that human smokers report while undergoing withdrawal.
While these rodent behaviors may reflect symptoms of the human withdrawal syndrome,
the neuronal circuits recruited during experimental paradigms remain largely unknown.
Differences in the behavioral outputs of animals undergoing withdrawal, relative to
control animals, can help reveal the circuits nicotine withdrawal impinges upon, as each
behavioral test offers unique environmental stimuli to which animals must respond, and
engages specific neuronal circuits (Wahlsten 2010). The integration of mice genetically
modified to carry nAChR null (knock-out, KO) or SNP-related mutations into behavioral
research has introduced a finer level of resolution to the characterization of the neuronal
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basis of withdrawal. By examining how eliminating signaling contributions from specific
receptor subunits affects behavioral outcomes, researchers can determine which
receptor subunits are necessary for the expression of certain nicotine withdrawal
symptoms (Brown, Stanford et al. 2000). Additionally, it is important to consider the
behavioral repercussions of the genetic differences that distinguish each inbred strain of
mice, as each strain is characterized by a unique repertoire of consistent behavioral
traits (Crawley 1996, Crawley 2008, Krackow, Vannoni et al. 2010, Matsuo, Takao et al.
2010). As these differences can translate to increased or decreased detectability of
behavioral changes induced by withdrawal, it is prudent to establish which strain is most
sensitive to the hypothesized behavioral changes in question (Bailey, Rustay et al. 2006,
Crawley 2008, Lalonde and Strazielle 2008, Wahlsten 2010).
Ultimately, the development of enhanced therapeutics that effectively promote smoking
cessation with minimal side effects will result from the identification of particular receptor
subunit compositions that are necessary for the expression of withdrawal symptoms.
3. Receptors and nAChR Subunits Underlying Withdrawal Symptoms
3.1. Insight from nAChR Subunit KO mice.
In rodents, α2 mRNA levels are highest in the interpeduncular nucleus (IPN), with more
restricted expression in scattered neurons within the amygdala, hippocampus, cortex,
retina, spinal cord, and cerebellum (Lotfipour, Byun et al. 2013). Analyses of withdrawal
symptoms in α2 KO mice have shown that the physical manifestations of nicotine
abstinence are context-dependent, as α2 KO mice exhibit more somatic symptoms of
withdrawal in novel environments (Lotfipour, Byun et al. 2013), but display no somatic
signs of withdrawal in habituated environments (i.e. the home cage) (Salas, Sturm et al.
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2009). Additionally, the lack of α2 is sufficient to abolish somatic symptoms of
precipitated nicotine withdrawal (Salas, Sturm et al. 2009). In male mice, Chrna2
deletion also produces nicotine withdrawal-induced deficits of cued fear conditioning
(Lotfipour, Byun et al.). α2 KO mice also self-administer higher doses of nicotine than
WT controls (Lotfipour, Byun et al. 2013). It should be noted that in a study of European
Americans and African Americans, CHRNA2 showed a strong association with the
Fagerström Test for Nicotine Dependence (FTND) after correction for multiple testing
(Wang, A et al. 2014). The rs2472553 SNP, which seems to have the strongest
association with nicotine dependence, encodes a functional variant in the signal peptide,
which leads to a threonine-to-isoleucine amino acid substitution at residue 22. In
oocytes, the T22I mutation changes the sensitivity to nicotine of α2β4-containing
nAChRs (Dash, Lukas et al. 2014).
The α3 nAChR subunit is encoded by CHRNA3, one of the genes in the chromosome
15q25 cluster that has shown the most robust association with smoking behavior and
nicotine dependence. α3 forms functional nAChR complexes with α5 and β4, the other
two subunits encoded by CHRNA5-CHRNA3-CHRNB4. These subunits are densely
expressed in the medial habenula (MHb) and IPN (Grady, Moretti et al. 2009). Due to
developmental abnormalities - including bladder enlargement and infection, urinary
stones, and difficult urination - α3 KO mice survive birth, but exhibit severely impaired
growth and perinatal mortality (Xu, Gelber et al. 1999). This phenotype has rendered
evaluation of the subunit’s potential involvement in withdrawal symptomatology
impractical in α3 null mice. However, pharmacological data suggest that receptors
comprising the α3 and β4 nAChR subunits influence both nicotine reward and somatic
manifestations of withdrawal (Jackson, Sanjakdar et al. 2013). AuIB, an α-conotoxin
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peptide that potently blocks α3β4 nAChRs (Luo, Kulak et al. 1998), dose-dependently
inhibits nicotine elicited reward as measured in the conditioned place preference
paradigm. The α-conotoxin also reduces somatic signs of withdrawal and withdrawalinduced hyperalgesia, while it has no effect on the aversive motivational component of
withdrawal as measured in the CPA paradigm (Jackson, Sanjakdar et al. 2013).
α5-containing nAChRs are expressed in various brain areas implicated in the key effects
of nicotine, including ventral tegmental area (VTA), MHb, IPN, hippocampus and cortex
(Salas, Orr-Urtreger et al. 2003). α5 KO mice do not display physical symptoms
associated with both spontaneous and mecamylamine-precipitated nicotine withdrawal
(Salas, Sturm et al. 2009) nor withdrawal-induced hyperalgesia (Jackson, Martin et al.
2008). The MHb/IPN pathway plays a crucial role in mediating the physical
manifestations of nicotine withdrawal and is the likely location of the effects of α5containing nAChR on this phenotype (Salas, Sturm et al. 2009). Acute nicotine
application to MHb slices enhances the intrinsic excitability of MHb neurons (Dao, Perez
et al. 2014). This dynamic depends on the presence of α5-containing nAChRs within the
MHb and the release of neurokinins (Dao, Perez et al. 2014), as such enhancement of
excitability was prevented by bath application of neurokinin 1 (NK1) or NK3 receptor
antagonists. In addition, infusion of the same NK receptor antagonists into the MHb of
mice chronically treated with nicotine precipitated somatic signs of nicotine withdrawal
(Dao, Perez et al. 2014). Microinjection of neurokinin receptor antagonists into adjacent
anatomical structures, including the lateral habenula (LHb), failed to elicit behavior
resembling withdrawal. Similarly, microinjection of the NK1 and/or NK3 antagonists into
the MHb of nicotine-naïve mice failed to generate somatic symptoms of withdrawal. It
was concluded that interactions between cholinergic and neurokininergic systems
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contribute to the emergence of nicotine withdrawal symptoms (Dao, Perez et al. 2014).
The α5 null mutation does not appear to influence affective symptoms such as
withdrawal-induced CPA (Jackson, Martin et al. 2008). The same study reported that α5
KO mice do not display increased anxiety levels in the EPM during withdrawal (Jackson,
Martin et al. 2008). However, interpretation of those data is not straightforward, as
Chrna5 deletion reduces anxiety in the EPM in basal conditions independent of nicotine
treatment (Gangitano, Salas et al. 2009). It has also been shown that α5-containing
nAChRs do not regulate the reward-inhibiting effects induced by nicotine withdrawal in
the ICSS paradigm (Fowler, Tuesta et al. 2013), suggesting that the receptors do not
influence anhedonia.
The α6 subunit also appears to play a role in the nicotine withdrawal syndrome. DA
release in the NAcc following nicotine administration is regulated in part by α6-containing
(α6*) nAChRs indicating receptors containing on DAergic terminals in the dorsal and
ventral striatum (Exley, Clements et al. 2008) and DAergic somata in the VTA (Grady,
Salminen et al. 2007, Zhao-Shea, Liu et al. 2011). Intracerebral infusion of a selective
antagonist of α6β2* nAChR blocks CPA and withdrawal-precipitated anxiety-like
behavior in the EPM (Jackson, McIntosh et al. 2009). There was no influence on the
somatic symptoms of withdrawal, suggesting a selective role for α6 nAChR subunits in
the affective manifestations of withdrawal (Jackson, McIntosh et al. 2009).
Unlike most other subunits, α7 nAChR subunits are capable of forming homomeric
receptors that are broadly distributed in the brain. The hyperalgesia symptoms that
emerge during mecamylamine-precipitated withdrawal are reduced in α7 KO mice
(Grabus, Martin et al. 2005). In contrast to wild-type mice, α7 null mice failed to exhibit
elevated ICSS thresholds during nicotine withdrawal between 3 and 6 hours after their
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last nicotine exposure (Stoker, Olivier et al. 2012). When the anhedonic affective state
was evaluated between 8 and 100 h after nicotine withdrawal, ICSS thresholds were
equally elevated in α7 WT and null littermates, indicating that a lack of α7 nAChR
subunits delays, rather than abolishes, withdrawal symptoms. As for the physical signs
of abstinence, α7 null mice exhibit significantly reduced withdrawal symptoms
immediately after precipitation of withdrawal by mecamylamine injection (Salas, Main et
al. 2007). However, their physical signs are indistinguishable from those of WT mice
when measured at later times, up to 48 h after withdrawal (Jackson, Martin et al. 2008,
Stoker, Olivier et al. 2012).
β2 KO mice exhibit levels of somatic signs of withdrawal and abstinence-induced
hyperalgesia comparable to those of WT mice (Salas, Pieri et al. 2004). However, the
mutant mice do not exhibit anxiety-related behaviors normally associated with
withdrawal from chronic nicotine exposure (Jackson, Martin et al. 2008). Overall, these
results suggest participation of β2 nAChR subunits in the signaling responsible for
affective, but not somatic, symptoms of nicotine withdrawal. α6β2* nAChRs are
expressed in the VTA and ventral striatum and are associated with reward and addiction,
but they are not expressed peripherally. Therefore, the α6β2* nAChRs may represent
viable targets for the treatment of affective symptoms experienced during nicotine
withdrawal. Indeed, a non-nicotine pharmaceutical currently FDA approved for the
treatment of smoking cessation, varenicline, acts as a partial agonist at α6β2* nAChRs
(Grady, Drenan et al. 2010, Bordia, Hrachova et al. 2012).
While sequence variants associated with smoking behavior lie within the regions that
harbor the CHRNB3-CHRNA6 genes on chromomsome 8p11 (Thorgeirsson,
Gudbjartsson et al. 2010), no pre-clinical data are available on the effects of the β3 null
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mutation on nicotine-related behavior. However, it has been determined that β3 KO mice
exhibit lower baseline levels of anxiety-related behavior in three different paradigms
(Booker, Butt et al. 2007). As reported for the α5 KO mice (Gangitano, Salas et al.
2009), β3 KO mice have altered hypothalamic-pituitary-adrenal axis responses (Booker,
Butt et al. 2007). Changes were also reported for locomotor activity and prepulse
inhibition of acoustic startle, behaviors that are controlled, at least in part, by nigrostriatal
and mesolimbic dopaminergic activity (Cui, Booker et al. 2003). As β3 mRNA is detected
in the substantia nigra, ventral tegmental area, and medial habenula (Cui, Booker et al.
2003), it is tempting to attribute the anxiolytic phenotype to MHb mechanisms and the
locomotor phenotype to nigrostriatal mechanisms.
β4 KO mice exhibit no somatic signs of nicotine withdrawal or hyperalgesia following
mecamylamine-induced withdrawal (Salas, Pieri et al. 2004). Similar results were found
for β4 KO mice undergoing spontaneous withdrawal from chronic nicotine administration
(Stoker, Olivier et al. 2012). In addition, β4 KO mice do not display anhedonia-like
symptoms during withdrawal, as identified by unchanged intracranial self-stimulation
thresholds (Stoker, Olivier et al. 2012). The reported phenotypes likely reflect an
involvement of different subtypes of β4* nAChRs. α3β4* nAChRs are the most likely
contributors to physical components of withdrawal given the high levels of expression of
α3 and β4 mRNA in the MHb, and the fact that the α3β4-selective α-conotoxin AuIB
blocks the emergence of somatic signs of withdrawal (Jackson, Sanjakdar et al. 2013).
Because AuIB does not interfere with the affective symptomatology of withdrawal in the
EPM and CPA paradigms, α6β4* nAChRs might be involved. Indeed, a transgenic
mouse model that overexpresses β4 nAChR subunits exhibits altered nicotine
consumption and conditioned place aversion (Frahm, Ślimak et al. 2011), and there is a
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documented role for α6* nAChRs in withdrawal-induced CPA (Jackson, McIntosh et al.
2009).
4. Molecular mechanisms involved in the nicotine withdrawal syndrome.
4.1. nAChR Upregulation
Long term exposure to nicotine leads to an increase, or upregulation, of nicotine binding
sites in the brains of smokers (Benwell, Balfour et al. 1988) and rodents subjected to
repeated nicotine administrations (Marks, Burch et al. 1983). The increased pool of
nAChRs arising from chronic nicotine exposure may drive symptoms associated with the
nicotine withdrawal syndrome (Turner, Castellano et al. 2011, Gould, Portugal et al.
2012) and might impact the ability to maintain abstinence in the clinical population
(Staley, Krishnan-Sarin et al. 2006). Using a radioligand with specificity for β2-containing
nAChRs, which enabled the use of single-photon emission computed tomography
(SPECT) (Staley, Krishnan-Sarin et al. 2006), it was found that chronic smokers have
more cortical, striatal, and cerebellar β2* nAChRs than non-smokers (Staley, KrishnanSarin et al. 2006). Furthermore, β2* nAChRs in the anterior cingulate and frontal cortex
were significantly correlated with the number of days following cessation of smoking.
This was interpreted as a progressive increase of the number of β2* nAChRs in
proportion to the number of consecutively abstinent days. In addition, a significant
negative correlation was observed between β2* nAChR availability in the post-central
gyrus or somatosensory cortex and the urge to relieve withdrawal symptoms by smoking
(Staley, Krishnan-Sarin et al. 2006). Similarly, in rodents, nAChR upregulation in the
dorsal hippocampus was associated with withdrawal-related deficits in hippocampal
learning (Gould, Portugal et al. 2012, Portugal, Wilkinson et al. 2012).
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A variety of cellular processes influence receptor upregulation (Govind, Vezina et al.
2009, Rezvani, Teng et al. 2009, Rezvani, Teng et al. 2010, Henderson, Srinivasan et al.
2014). Receptors containing the β2 subunits are particularly sensitive to nicotine-induced
upregulation. If β4 replaces β2 subunits in either α3* or α4* nAChRs, receptor
upregulation is significantly reduced (Wang, Nelson et al. 1998, Sallette, Bohler et al.
2004). As replacement of β2 by β4 is sufficient to increase nAChR levels at the plasma
membrane in the absence of nicotine, the proposed “chaperoning” function of nicotine
might not be as effective (Srinivasan, Pantoja et al. 2011, Henderson, Srinivasan et al.
2014). The presence of an accessory nAChR subunit in the receptor complex can also
influence nicotine-induced upregulation. For example, the presence of α5 renders α4β2*
nAChRs insensitive to nicotine-induced upregulation (Mao, Perry et al. 2008).
Conversely, co-expression of β3 increases α6β2 and α6β4 receptor levels and enhances
nicotine-induced upregulation of α6β2β3 receptors compared to α6β2 receptors
(Tumkosit, Kuryatov et al. 2006). The effects of β3 on receptor trafficking and
upregulation may help explain why in the striatum α6-containing receptors without β3 are
downregulated by nicotine, while those containing β3 are unaffected (Perry, Mao et al.
2007).
4.2. Desensitization of nAChRs
While some combinations of nAChR subunits render receptor complexes more prone to
upregulation than others, desensitization is a prominent mechanism that contributes to
this upregulation (Fenster, Whitworth et al. 1999). As nicotine has a half-life in humans
of 2 hours or more, nicotine accumulates during a day of regular smoking to reach
steady-state plasma concentrations typically ranging between 10 and 50 ng/mL (Allan
W. Graham May 5, 2007). This long-lasting level of nicotine ensures that high affinity
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nAChRs recurrently bind and unbind nicotine throughout the day (Picciotto, Addy et al.
2008). Consequently, receptors undergo transitions between different conformations in
response to ligand binding and dissociation, and agonists will tend to stabilize particular
conformations. Because desensitized nAChR conformations have a higher affinity for
agonist, nAChRs will increasingly adopt desensitized conformations in response to
chronic nicotine exposure (Quick and Lester 2002, Picciotto, Addy et al. 2008). It has
been suggested that receptor desensitization may be a major contributor to the
upregulation observed in chronic users of nicotine-containing products (Benowitz 2008).
As the usage patterns of regular smokers result in persisting levels of circulating nicotine
over the course of the day, nAChR desensitization occurs in response to ongoing
occupancy of CNS nAChRs. For example, working with 11 tobacco-dependent
individuals using a radiotracer developed to image α4β2* nAChRs with positron
emission tomography (PET), it was found that regular smokers approach complete
saturation of CNS α4β2* nAChRs throughout the day (Brody, Mandelkern et al. 2006).
After 2 days of abstaining from smoking, participants’ cravings were reduced only once
nAChRs were again nearly saturated. It is important to note that rates of desensitization
are not necessarily equivalent across all nAChR subunit combinations. For example,
inclusion of the α5 subunit into α4β2* nAChRs decreases the extent of desensitization
(Bailey, De Biasi et al. 2010).
When considering the implications of receptor upregulation and desensitization for
symptoms of nicotine withdrawal, kinetics characterizing the two dynamics may present
critical processes by which withdrawal signaling occurs. In fact, nAChRs recover from
desensitization on the scale of seconds to hours (Gentry and Lukas 2002). Additionally,
studies have demonstrated that upregulation of nAChR expression can persist for
132

several days following termination of chronic nicotine (Pietila, Lahde et al. 1998, Staley,
Krishnan-Sarin et al. 2006) Accordingly, as the rates of desensitization and recovery
from receptor upregulation during nicotine withdrawal are incongruent, a physiological
landscape is established in which there are more receptors expressed than would be
present in nicotine-naïve individuals, and these receptors are less responsive to agonist
binding. When nicotine levels are low or absent, the nAChRs recover from
desensitization, leading to potentially overactive cholinergic signaling. This process
represents a major factor in the neurobiology of nicotine withdrawal (Dani and
Heinemann 1996). Considering this dynamic, Gould and colleagues (Gould, Portugal et
al. 2012) have proposed a pharmacological strategy of treating hypersensitive nAChR
systems with compounds that maintain receptor desensitization, or diminish cholinergic
signaling while avoiding upregulation and activation, to alleviate the negative impact of
withdrawal.
5. Anatomical Structures and Circuits Implicated in Nicotine Withdrawal
Given the diversity of symptoms manifested during nicotine withdrawal, a constellation of
anatomical structures is likely involved in its etiology. Different anatomical structures in
the CNS express distinct populations of nAChRs. The variety of nAChRs, combined with
the specificity determined by afferent/efferent projections, produces the distinct
neurochemistry and signaling that underlies the withdrawal syndrome. Evaluating
changes in behavior relative to WT controls upon removal of particular nAChR subunits
has been crucial to characterizing the contributions that each subunit makes to the
withdrawal syndrome. If a withdrawal symptom exhibited by wild-type mice is absent in
mice that lack functional expression of a specific nAChR subunit in a particular CNS
structure, the specific subunit is likely critical to the withdrawal symptom in question. By
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performing these kinds of experiments, neuronal circuits contributing to the withdrawal
syndrome will continue to be defined, and viable targets to enable the development of
more specific therapeutics will be identified. Thus far, several brain structures have been
already implicated in the withdrawal syndrome.
5.1. Dopaminergic System.
The mesocorticolimbic dopamine (DA) system has been identified as critical to the
development of addictive behaviors, and DA signaling is involved in reward-based
reinforcement of drug-derived behaviors. While the DAergic ventral tegmental area
(VTA) has been widely implicated in the rewarding aspects of addictive drugs, it has also
been shown to participate in the signaling of aversion and lack of expected reward
(Schultz, Tremblay et al. 1998, Ungless, Magill et al. 2004, Tobler, O'Doherty et al. 2007,
De Biasi and Dani 2011). Dopaminergic deficits in the mesolimbic pathway, particularly
in the nucleus accumbens, are among the neurochemical mechanisms underlying the
symptoms of nicotine withdrawal (Hildebrand, Nomikos et al. 1998, Carboni, Bortone et
al. 2000, Rada, Jensen et al. 2001). Such deficiencies in accumbal dopaminergic
transmission are believed to contribute to the aversive anhedonic or dysphoric state
experienced during nicotine abstinence (Koob and Le Moal 2008, Zhang, Dong et al.
2012). A reduction in basal DA levels was observed to linger for at least 5 days in mice
following 12 weeks of chronic nicotine treatment (Zhang, Dong et al. 2012). This change
in DA activity during withdrawal was correlated with a reduced modulatory influence by
β2* nAChRs over DA release in the NAcc. What causes the hypodopaminergic state
associated with withdrawal is not yet clear. However, increased inhibitory input to the
VTA is a potential mechanism, as GABA input is sufficient to suppress burst firing even
with excitatory inputs intact (Lobb, Wilson et al. 2010, Jalabert, Bourdy et al. 2011).
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GABAergic inputs arrive at the VTA from the substantia nigra pars reticulata, nucleus
accumbens, ventral pallidum/globus pallidus, laterodorsal tegmentum, pedunculopontine
nuclei, diagonal band of Broca, bed nucleus of the stria terminalis, and the caudal tip of
the VTA, termed the rostromedial tegmental nucleus (RMTg) (Geisler and Zahm 2005,
Jhou, Fields et al. 2009, Kaufling, Veinante et al. 2009). Activity in the RMTg increases
upon exposure to aversive stimuli and decreases upon exposure to reward stimuli,
representing inversely correlated signaling patterns (Hong, Jhou et al. 2011).
5.2. Habenular Complex and Interpeduncular Nucleus
The habenular complex, comprising the lateral (LHb) and medial (MHb) nuclei, is a
diencephalic, epithalamic structure located ventrally along the dorsal third ventricle (Dani
and De Biasi 2013). The habenula has been demonstrated to participate in the signaling
underlying fear, anxiety, depression, and stress (Viswanath, Carter et al. 2013). The LHb
sends excitatory glutamatergic projections to the RMTg and is a major component of the
circuit underlying negative reward (Dani and De Biasi 2013). Additionally, the
cholinoceptive cellular population within the medial habenula (MHb) has been
associated with the aversive effects of nicotine (Fowler, Lu et al. 2011). The most
prominent efferent output from the MHb is to the IPN via the fasciculus retroflexus,
forming the MHb-IPN axis. Through this projection, the MHb releases acetylcholine
(ACh), substance P (SP), and glutamate onto the IPN (Zhao-Shea, Liu et al. 2013). The
MHb also hosts the expression of norepinephrine, serotonin, ATP, and several
neuropeptides (Dao, Perez et al. 2014). The IPN is located in the ventral midbrain, with
the VTA and median raphe nucleus located dorsally.
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Mice chronically treated with nicotine exhibit symptoms of withdrawal upon
microinjection of mecamylamine into the MHb and IPN, but fail to manifest withdrawal
symptoms when mecamylamine is injected to the cortex, hippocampus, or VTA (Salas,
Sturm et al. 2009). Furthermore, lidocaine infusion into the MHb to inhibit signaling
significantly blocks the manifestations of somatic symptoms resulting from both
mecamylamine-precipitated and spontaneous induction of nicotine withdrawal (ZhaoShea, Liu et al. 2013). Following precipitated nicotine withdrawal in WT mice, there are
elevated markers of neuronal activation in GABAergic IPN cells (Zhao-Shea, Liu et al.
2013). The involvement of the IPN in the manifestation of nicotine withdrawal symptoms
was demonstrated by expression of channelrhodopsin (ChR2), a light-driven excitatory
ion channel, in the GABAergic cells of the IPN (Zhao-Shea, Liu et al. 2013). Additionally,
infusion of an α3β4* nAChR-selective antagonist into the IPN elicited somatic withdrawal
signs in nicotine-naïve mice, and an even greater number of total symptoms in mice
chronically treated with nicotine (Zhao-Shea, Liu et al. 2013). Considered together, these
data strongly implicate the MHb-IPN circuit in the nicotine withdrawal syndrome. As
previously discussed, the α5, α3, and β4 nAChR subunits participate in withdrawal
symptomatology. They are each densely expressed in the MHb and/or IPN (Salas, Pieri
et al. 2003, Salas, Pieri et al. 2004) and are potential targets for treatments of the
nicotine withdrawal syndrome (Grady, Moretti et al. 2009).
5.3. Hippocampus
The hippocampus is a crucial structure for the manifestation of cognitive deficits during
nicotine withdrawal. Contextual fear conditioning is dependent upon hippocampal
signaling (Davis, James et al. 2005), and during spontaneous withdrawal from nicotine,
mice exhibit deficient contextual fear conditioning relative to saline-treated controls
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(Davis, James et al. 2005). Administration of nicotine to mice undergoing withdrawal
ameliorates this deficit (Davis, James et al. 2005). This effect was not attributable simply
to a lowered threshold of fear responses inherent to the effects of nicotine because cued
fear conditioning was equivalent between nicotine-treated and nicotine-naïve groups.
Similar deficits of contextual fear learning were observed when a nAChR antagonist
(dihydro-β-erythroidine) was infused into the hippocampus of WT mice chronically
treated with nicotine (Davis and Gould 2009). The work also implicated β2* nAChRs in
the manifestation of memory-associated deficits during nicotine withdrawal. Furthermore,
chronic nicotine treatment upregulated a variety of nAChRs in the hippocampus, and the
duration of β2 subunit upregulation relative to other nAChR subunits most closely
corresponded to the total duration of memory-associated withdrawal symptoms (Gould,
Portugal et al. 2012).
5.4. Extended amygdala
The bed nucleus of the stria terminalis (BNST), central nucleus of the amygdala (CeA),
and shell of the nucleus accumbens (NAc-Sh) form the extended amygdala, an
anatomically and neurochemically interconnected system located in the basal forebrain
(Smith and Aston-Jones 2008). The system has been implicated in stress-related
components of drug withdrawal, and is a site of interaction between corticotropinreleasing factor (CRF) and norepinephrine (NE) transmission. Nicotine withdrawal leads
to an increase in CRF in the central nucleus of the amygdala (CeA), and blockade of
CRF1 receptors diminishes nicotine withdrawal-induced anxiety-like behavior (George,
Ghozland et al. 2007). The CRF/CRF1 receptor signaling in the CeA also mediates
nicotine withdrawal-induced increases in nociceptive sensitivity in rats that are
dependent on nicotine (Baiamonte, Valenza et al. 2014).
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Given the polygenic nature of nicotine addiction, many other mechanisms and many
other brain areas are likely to influence the manifestations of withdrawal. Preclinical
research is increasingly benefitting from the information coming from genetic studies and
pharmacogenetic trials and the speed of discovery is destined to increase in the coming
years.
6. Summary and Research Moving Forward
Individuals undergoing nicotine withdrawal experience both affective and somatic
symptoms beginning between 4 to 24 hours after ceasing intake. The syndrome is most
severe in the first week but it can persist for longer periods of time. During this time,
relapse is incentivized by the ability of nicotine to alleviate or abolish withdrawal
symptoms. In addition, there are cognitive deficits that manifest during nicotine
withdrawal, including difficulty concentrating, increased reaction times in tasks requiring
sustained attention, and impaired episodic and working memory (Myers, Taylor et al.
2008, Wesnes, Edgar et al. 2013). Knowledge of the molecular mechanisms that govern
the emergence and intensity of withdrawal symptoms, and elucidation of the genetic
variants associated with successful smoking cessation, will facilitate the development of
personalized treatments.
New techniques in neuroscience are enabling researchers to ask previously
unapproachable questions regarding which genes, circuits, and neurochemical systems
mediate and modulate different aspects of addiction and withdrawal. Using transgenic
mouse lines or viral delivery, designer receptors (DREADDs (Rogan and Roth 2011))
and light-driven ion channels (opsins (Yizhar, Fenno et al. 2011)) can be expressed in
particular anatomical structures or in particular neuronal types. These genetically
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targeted receptors and ion channels can be used to control the activities of specific
circuits and populations of neurons in freely behaving mice. When combined with
receptor KO mice, or with the delivery of nAChRs derived from specific human SNPs,
these techniques enable researchers to manipulate neuronal activity while monitoring
the dynamics of withdrawal-related behaviors.
Genetic studies of nicotine dependence and smoking cessation have identified several
risk factors using GWAS, candidate gene approaches, and pharmacogenetic analyses.
These studies provide targets that can be validated with large population samples and
across ethnicities. Once putative genes are identified, hypotheses of the functional roles
of such candidate genes can be tested in pre-clinical animal models. The functional
consequences of some SNPs can be addressed relatively easily if the SNPs are nonsynonymous coding variants. The best example is provided by rs16969968, the SNP
that leads to an aspartic acid for an asparagine substitution (D398N) in
CHRNA5(Jackson, Marks et al. 2010). The impact of the mutation that defines the risk
allele has been validated repeatedly in vitro and in animal models (Kuryatov, Berrettini et
al. 2011, Morel, Fattore et al. 2013). For many of the SNPs, however, there is no change
in protein sequence, and therefore, it is harder to formulate clear functional hypothesis.
Candidate SNPs can have a multitude of biochemical functions, such as altering DNA
methylation, histone modification, or accessibility of DNA to transcription factor binding,
that can impact when, where, and how much a gene, and its protein, is expressed.
Fortunately, analytical tools such as the Encyclopedia of DNA Elements (ENCODE), can
help the design of experiments that explore disease-related variants located within noncoding regions (Siggens and Ekwall 2014). Increasing attention is being paid to the
functional analysis of rare variants, as common variants can explain only a small
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percentage of the variance in smoking-related phenotypes. More work is necessary at
the bench and in the clinic, as a collection of genes likely operates collectively to
predispose or protect individuals to or from nicotine addiction and withdrawal. Ultimately,
this increased capability to comprehensively characterize the etiology of withdrawal
symptoms will inform more competent and efficient drug design. The future undoubtedly
holds greater development of pharmacological nicotine cessation therapeutics.
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CHAPTER 4: GENERAL CONCLUSIONS & FUTURE DIRECTIONS
The goal of my research was to identify if components of the dorsal diencephalic
conduction system (DDC) regulate anxiety-associated behavior independently of chronic
exposure to habit-forming drugs. I began with a broad perturbation of one of the primary
junctions of signaling within the pathway, the interpeduncular nucleus (IPN), using
excitatory DREADDs. Next, I determined whether glutamatergic output from the nucleus
was responsible for the modified behaviors I first observed, evaluating whether
behavioral responses were sexually dimorphic. I then identified a substantial
serotonergic response in the ventral hippocampus correlated with chemogenetic
stimulation of the IPN, and then confirmed direct projections from the IPN to the ventral
hippocampus for the first time in decades.
While our group and others have established a role played by the MHb-IPN axis in
withdrawal symptoms from multiple habit-forming drugs, only paltry evidence has
characterized the regulation of affect by this pathway independently of chronic drug
exposure. Given the substantial comorbidity between anxiety-associated psychiatric
conditions and substance use disorders (SUDs), we set out to investigate whether the
DDC might represent a point of shared neurophysiology between the two. Ultimately, we
corroborated the placement of the DDC in a broader anatomical context that regulates
anxiety, verifying direct projections from the IPN to the ventral hippocampus.
Additionally, for the first time, we identified significant increases in serotonin
concentrations in the ventral hippocampus following chemogenetic stimulation of IPN
neurons.

153

The IPN Regulates Affect
Based on prior research demonstrating the role of IPN signaling in the manifestation of
withdrawal symptoms, we hypothesized that stimulation of the IPN would result in
increased anxiety-associated behavior. To our surprise, however, we observed
anxiolysis. While some groups have identified specific signaling pathways from
subnuclei within the IPN (Zhao-Shea et al., 2015; Zhao-Shea et al., 2013), it remains
uncertain which neuronal subpopulations within the structure mediate this behavioral
output. Given the distinct efferent projections emerging from IPN subnuclei that some
groups have identified, and the limitations of viral interrogation of this structure in my
hands, I remain unable to provide more granular insights regarding this response.
However, these data demonstrate that stimulation of IPN neurons regulates anxietyassociated behavior.

IPN Stimulation Correlates with Increased Serotonin in the Ventral
Hippocampus
The IPN is a junction of signaling arriving principally from the MHb, which sends efferent
projections to a variety of structures that span the fore-, mid-, and hind-brain. There are
two pathways that may account for the increased serotonin concentrations we observed
following chemogenetic stimulation of the IPN. Projections from the IPN to the raphe
nuclei were demonstrated many years ago, though the functional characteristics have
yet to be determined. Additionally, projections from the IPN to the hippocampus were
posited several decades ago, and have been verified by recent studies. However, to
date, this work is the first to identify direct projections from the IPN to the ventral
hippocampus. Serotonergic neurons have been identified within the IPN (Montone et al.,
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1988; Wirtshafter et al., 1986), and a recent study suggests the apical subnucleus may
be where the majority can be found (Quina et al., 2017). As there is only a sparse
presence of serotonergic neurons within the IPN, future studies may exploit transgenic
mouse lines that express Cre recombinase in serotonergic neurons to achieve more
granular functional characterization. In particular, studies may explore whether elevated
serotonin in the ventral hippocampus, following chemogenetic stimulation of the IPN, is
attributable to a direct projection to the ventral hippocampus, or is rather due to an
indirect activation of structures like the raphe nuclei (Behzadi, Kalen, Parvopassu, &
Wiklund, 1990; Groenewegen et al., 1986; Quina et al., 2017).

Viral Interrogation of the MHb-IPN Axis
While interpreting behavior that results from general stimulation of brain structures, the
tropism of adeno-associated viruses (AAV) serotypes (Mason et al., 2010; Srivastava,
2016) is important to consider. This methodological limitation applies to all viral
interrogations of neurophysiology using AAVs. As a result, some neuronal populations in
the IPN may be excluded by the use of specific AAV serotypes in this series of
experiments, though hybrid serotypes may enable broader expression (Y. Mao et al.,
2016). However, the selectivity, verifiable by immunofluorescence, afforded by viral
methods helps to reveal the role the IPN plays in regulating affect at baseline. As a
result, there remains room for more comprehensive interrogation of the structure with the
application of more targeted techniques, such as the use of transgenic models
expressing transcription factor driven Cre recombinase with superior anatomical
selectivity (Bandin, Morona, Lopez, Moreno, & Gonzalez, 2014; Moreno et al., 2014).
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Optimizing Viral Tools & Methods

Lessons from Working with New Transgenic Lines & Commercially Derived
Viruses
The initial experimental design of the primary dissertation experiments described in
earlier sections included studies with the combination of a Cre recombinase-dependent
virus and a transgenic mouse line expressing Cre driven by the promoter/enhancer
regions of the vesicular inhibitory amino acid transporter (Viaat) gene. The Viaat, or
vesicular GABA transporter (VGAT) (Juge, Omote, & Moriyama, 2013), encodes a
protein that transports GABA and glycine into synaptic vesicles (Chaudhry et al., 1998).
This would enable the selective expression of viral products in neurons expressing
VIAAT, principally GABAergic neurons. The line had recently been utilized by labs
focused on developmental biology and Rett syndrome to explore GABAergic
components of the condition (Chao et al., 2010). Publicly available in situ hybridization
studies had demonstrated broad Viaat expression in the IPN (Allen Brain Atlas). In
addition, studies had identified the involvement of IPN GABAergic signaling in the
behavioral effects of nicotine (Hsu et al., 2013). We were fortunate that a lab at the
University of Pennsylvania had maintained a colony of the line, and generously
contributed founder breeders so that our lab could establish a colony.
Chemogenetics, described in Chapter 1, had become a widely-used platform to
selectively interrogate neuronal populations in vivo (Armbruster, Li, Pausch, Herlitze, &
Roth, 2007; Rogan & Roth, 2011; Roth, 2016). Accordingly, viral vectors to drive the
expression of designer receptors exclusively activated by designer drugs (DREADDs)
had become available to be purchased from academic institutions. As a result, during
the optimization of stereotactic viral infusion procedures, DREADD-expressing viruses
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were obtained commercially. I had found that commercially obtained AAV8-hM3DqmCherry successfully drove expression when surgical and infusion procedures were
successful.
At the beginning of my efforts to achieve expression in VIAAT+ IPN neurons using the
Cre-dependent virus, AAV8-DIO-hM3Dq-mCherry, I encountered additional difficulties. I
had effectively confronted the challenges of achieving expression in the IPN, but had
learned that a sufficient proportion of potential failure points were present in surgical and
infusion procedures that, essentially without exception, failure to achieve expression was
attributable to opportunities to improve tools and techniques.
Variability in the performance of syringe components was often the failure point during
infusion procedures, and a single syringe was devoted to each virus to avoid crosscontamination. Optimizing the performance of these tools will be discussed in later
sections. However, while typically successful, these maintenance procedures are
imperfect and can still produce unpredictable failures during viral infusions.
Furthermore, the IPN is a relatively dense, small, unpaired anatomical structure (Bianco
& Wilson, 2009) located in the ventral midbrain. Due to the presence of a fairly large
vascular structure – perhaps the superior sagittal sinus (Xiong et al., 2017) that runs
along the sagittal suture at the anterior/posterior coordinate of stereotactic entry approaching the structure at a 20° angle proved to result in a vastly superior survival rate
due to minimized bleeding. As a result, anatomical variability between mice relative to
stereotactic atlases, and positioning of bregma in particular, can result in missed
stereotactic targeting even under optimal circumstances. A higher rate of off-target
expression when targeting the IPN was, therefore, anticipated – even despite successful
optimization of prior viral infusion groups.
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Initial viral infusions of transgenic VIAAT-Cre mice proved unsuccessful. Following
multiple infusion attempts, and despite consistent histological verification of successful
targeting of the IPN, failure to achieve expression persisted (Fig 1).
Figure 1.

Figure 1. Representative coronal slice from VIAAT-Cre transgenic mouse infused
with AAV8-DIO-hM3D-mCherry obtained from a commercial source into the IPN with
infusion syringe tract visible in overview (left) and higher magnification image (right).
Despite multiple infusions into transgenic mice expressing Cre recombinase driven
by the VIAAT promoter, no expression was observed. Arrow indicates syringe tract.
Blue indicates A-T rich regions of DNA stained with DAPI.
As experience had instructed that failures of expression were typically attributable to
failure points in surgical procedure, the following optimizations were applied: the
frequency of syringe needle replacement increased, the stringency of the cleaning
protocol was increased to between each mouse infusion, different infusion volumes were
evaluated, and different ranges of expression times were assessed. The rationale was
the following: while the specific syringe used to infuse the Cre-independent AAV8hM3Dq-mCherry yielded successful expression, perhaps some unknown feature of
mechanical variability was resulting in different rates of blockage for the infusion of the
Cre-dependent virus. Accordingly, when a given syringe needle became blocked more
frequently than usual, checked both before and after each infusion using a test fluid, it
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was replaced. Next, while syringes were initially cleaned between each cohort of viral
infusions, more frequent cleaning might more reliably reduce unforeseeable clogging,
preventing successful expression. Then, while an optimal infusion volume and rate of
infusion had been established with Cre-independent virus, perhaps Cre-dependence
resulted in unique expression dynamics. Therefore, increased infusion volumes were
attempted. Finally, longer expression time was assessed to account for the possibility
that Cre-dependent expression simply took more time in IPN GABAergic neurons than
Cre-independent expression.
Despite these optimization measures, successful expression remained evasive. While
preparing for another round of viral infusions with further adjustments to stereotactic and
infusion protocols, I presented my ongoing progress to a group of colleagues, some of
whom were attempting experiments using Cre-dependent DREADD-expressing viruses.
Following commiseration over our shared difficulties derived from attempted Credependent DREADD expression, a colleague contacted me regarding a notification that
irregularities in virus production had been identified at the institution from which we
obtained our viral vectors. Through a personal connection, my colleague conveyed the
findings of individuals who were close to the production of the vectors, indicating
concerns regarding anomalies in expression patterns reported by other recipients of the
vectors.
While the expression products of viruses obtained remained unknown, I assumed that
the virus must be either independent or dependent upon Cre recombinase. If Credependent, then - regardless of expression products – I ought to observe some result of
infusion. However, no expression was observed.
While continuing to evaluate expression patterns in transgenic VIAAT-Cre mice infused
with the commercially obtained Cre-dependent virus, our lab began producing viral
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vectors. After obtaining plasmids from a distinct institution, which the individuals
identifying anomalies in vector production indicated were free of inconsistent quality, we
produced an equivalent, Cre-dependent, DREADD expressing virus. Following in vitro
confirmation of successful expression in Cre-expressing neurons, I proceeded to infuse
the viral constructs produced in the lab into transgenic VIAAT-Cre mice.
A small number of transgenic VIAAT-Cre mice were infused to assess the viability of
viruses produced in the lab. Successful expression was observed in the IPN, with an
expression pattern indicating sub-structure selectivity (Fig. 2).
Figure 2.

Figure 2. Representative coronal slice from VIAAT-Cre transgenic mouse infused
with AAV8-DIO-hM3D-mCherry (red), produced in the MDB lab, into the IPN with
infusion syringe tract visible in overview (left, arrow) and higher magnification image
(right). Sub-anatomical expression patterns were observed, largely excluding the
IPDM. Blue indicates A-T rich regions of DNA stained with DAPI. (IPDM=dorsomedial
subnucleus of the interpeduncular nucleus, arrows in right image)
However, members of the lab that contributed breeders of the VIAAT-Cre line indicated
that they had identified non-specific off target expression of Cre recombinase. Given the
heterogeneous neuronal composition of the IPN, and reports of the synthesis of
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monoaminergic neurotransmitters within the typical anatomical delineations of the
structure (2017 Quina, Turner 28387937) – as well as the resources and time applied to
this component of the project up to this point – I decided to abandon this particular set of
experiments to avoid the possibility of sustained unproductivity.
Recommendations for Viral Interrogation of Small Anatomical Structures: In vitro
validation & serotype evaluation
When using viral vectors to interrogate an anatomical structure that few studies have
explored previously, several considerations are warranted prior to beginning infusions. In
vitro assessments of the viability of any sample of virus is warranted. While
commercially-obtained viruses are often reliable, defective lots can result in poor
expression, the attribution of which can be laborious to identify otherwise. Ensuring the
virus to be used effectively infects target neurons prior to in vivo infusion will help to
avoid lengthy and wasteful optimization.
The tropisms of adeno-associated virus (AAV) serotypes can result in the unintentional
exclusion, or unforeseen ineffective infection, of neuronal populations within the target
structure (Mason et al., 2010; Srivastava, 2016). Furthermore, studies have identified
different propensities of viral particles to diffuse through tissue following infusion as a
function of serotype (McFarland, Lee, Hyman, & McLean, 2009). Accordingly, given
equivalent efficiency of neuronal infection, some serotypes may yield preferable diffusion
characteristics according to the desired region of infection. Some studies indicate that
serotypes confer distinct times to expression, resulting in peak expression occurring at
different intervals following infusion, and optimal waiting periods prior to behavioral
experiments as a result (McFarland et al., 2009). There is evidence that some serotypes
produce an immune response of greater severity than others. For example, when
targeting hippocampal neurons, Klein et al. found that AAV8 resulted in broader spread
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of expression compared to AAV2, though AAV5 produced the widest expression (R. L.
Klein et al., 2006). However, they also corroborated findings of greater levels of
expression within neurons initially characterized by Paterna et al. (Paterna, Feldon, &
Bueler, 2004). Further, toxicity derived from expression of viral products was mitigated
by dilution of viral doses (R. L. Klein et al., 2006).
Additionally, some serotypes are used far more widely than others, and are therefore
more thoroughly characterized. When beginning the work described in this dissertation,
there had been very few viral interrogations of the IPN in the literature, and members of
the De Biasi lab were just beginning to explore the utility of AAV-based vectors in the
MHb – as opposed to lentivirus- or rabies-based vectors - with an eye towards the IPN.
Accordingly, when beginning my work, I qualitatively evaluated the efficacies of
serotypes that were commonly used in the ventral midbrain in experiments using
optogenetics – namely, AAV2, AAV5, and AAV8. AAV8 seemed to produce an optimal
combination of reliable infection, controllable diffusion, and levels of toxicity.
Given all of the points of variation discussed, unexpected results can arise from the
infusion of an AAV packaged in the same serotype used in other brain regions.
Accordingly, early evaluation of the viabilities of multiple serotypes is warranted for
efficient viral interrogation of specific neuronal populations, followed by subsequent
characterization of resulting expression patterns, prior to initiating behavioral
experiments.
Stereotactic Targeting of Small Anatomical Structures: Fastidious maintenance of
surgical tools
When targeting small anatomical structures in the brain, several non-biological
parameters determine whether infection is successfully restricted to the intended
structure. The optimal volume of viral fluid infused will vary according to viral serotype,
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as well as the anatomical features characterizing the target. In my experience, larger
syringe needle gauges tend to develop blockages less frequently than smaller gauges,
though smaller gauges resulted in reduced disruptions of tissue when traveling ventrally
to the target structure. It seems there is, therefore, a tradeoff between the risk of
unsuccessful infusion due to blockage of a small gauge syringe needle and larger
lesions due to wider gauge needles. Additionally, I found that the rate of infusion can
influence the spread of infection, with lower infusion rates helping to limit the extent of
spreading. Once again, however, there seems to be a tradeoff between using slow rates
of infusion to minimize unintended diffusion of viral particles beyond the bounds of the
anatomical target and the risk of syringe clogging at slower rates.
The syringe system I ended up using for my experiments was a 10 μL Hamilton syringe
terminating in a removable needle. The ability to replace syringe needles ended up
being a critical capability when performing viral infusions in a sufficient number of mice
to perform behavioral experiments. Removable needles are available in a variety of point
styles, ranging from blunt to beveled at a variety of angles. Following assessment of
initial infusions into the IPN using beveled needle points, I determined that blunt points
tended to yield more consistent expression patterns, presumably due to a closer
correspondence between the direction of fluid infusion and stereotactic navigation
coordinates. While I developed the sense that beveled point styles tended to develop
blockages less frequently, I didn’t quantitatively evaluate this potential advantage of
beveled styles.
During initial cohorts of viral infusions, I cleansed infusion syringes – clearing syringe
needles in the process - both before and after groups of infusions. While optimizing my
protocol for the infusion of Cre-dependent chemogenetic viruses, I began cleansing
syringes between each viral infusion. While this change in protocol did not end up
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accounting for poor expression patterns among the Cre-dependent virus infusions in
VIAAT-Cre transgenic mice, as described previously, I found that doing so improved
rates of success in subsequent viral infusions. This cleansing protocol proceeded as
follows: before each cohort of viral infusions, flush the fully assembled syringe with
sterilized deionized water multiple times. If fluid does not flow coherently from the
syringe, use a cleaning wire dedicated to that particular syringe and virus to purge the
lumen of the syringe needle and its connection point with the syringe barrel. The
connection point between the syringe needle and barrel is particularly prone to clogging,
and so ensuring the syringe cleaning wire can pass through unobstructed is critical to
ensuring successful flow. Following flushing with purified water, flush the syringe with
sterile saline multiple times – once again ensuring fluid flows coherently upon
depression of the syringe plunger.
The syringe plunger consists of a long metal pole with a rather small plunger tip
(gasket/stopper) at the end composed of polytetrafluoroethylene. The composition of the
plunger tip is worth noting due to potential incompatibilities with solvents that might be
otherwise intuitively effective when clensing syringes. Over time, the plunger tip
deteriorates – thereby compromising the seal between the plunger and fluid loaded in
the chamber. This can be identified during tests of coherent fluid flow of small volumes
(~30 nanoliters) from the syringe. The most conspicuous indication of compromised
integrity of the plunger tip is, following depression of the syringe using the infusion pump
to deliver small volumes (~2-3 nanoliters), if the fluid appears to re-enter the syringe
after forming a droplet at the tip of the syringe needle.
Following syringe cleansing and assessment of its ability to infuse fluid, place the
syringe in the infusion apparatus such that a small volume of air fills the barrel. As some
virus-containing fluids tended to have a propensity to clog syringes after prolonged
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periods of time, I found that loading syringes immediately prior to lowering them to
stereotactic targets – following the majority of surgical procedures – minimized such
clogging. When loading syringes with viral fluid, monitoring the syringe barrel with a
stereo microscope for the inclusion of any air bubbles within the volume of loaded fluid
ensured only the intended fluid was infused. Following arrival at the anatomical target,
an interval of several minutes – 5 minutes, in the case of the IPN – prior to initiating
infusion helped to minimize diffusion of viral particles beyond the boundary of the
structure. Following completion of infusion, another waiting period of several minutes
prior to withdrawal of the syringe was similarly beneficial to limiting off-target expression.
Finally, during syringe withdrawal, very slow removal helped to minimize expression
along the tract of the syringe.
While perhaps unnecessarily laborious for the targeting of larger brain structures located
more dorsally relative to the IPN, this protocol resulted in the highest frequency of
successful expression patterns in my experience. However, while necessary for
selective targeting of the IPN in my experience, this protocol ought to improve rates of
success when targeting any brain region solely at the expense of surgical procedures of
longer duration.

Relevance to the Understanding of Anxiety
As discussed in Chapter 1, the DSM-5 describes anxiety as the anticipation of a future
threat (Crocq, 2015). This is distinct from fear, elicited in response to the perception of
an imminent threat ("Anxiety Disorders,"). While anxiety-associated and depressive
disorders are distinct diagnostic categories, elements of both are frequently comorbid.
Estimates suggest that approximately 85% of patients diagnosed with depression exhibit
anxiety-associated symptoms as well, and a comorbidity of anxiety and depression is
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frequently observed (Moller et al., 2016). The consistency of these overlapping
symptoms – when those associated with either one is not clearly dominant - has
prompted the consideration of a diagnosis of mixed anxiety and depressive disorder
(MADD) in the International Statistical Classification of Diseases and Related Health
Problems (ICD-10). Early concepts of psychiatric diagnoses framed anxiety as a
component of all psychiatric conditions, rather than a distinct category of mental illness
(Moller et al., 2016). However, upon the inception of the use of anti-depressants and
anxiolytics in psychiatry, as discussed in Chapter 1, a diagnostic distinction between
depression and anxiety was established. The merits and value of these distinctions are
beyond the purview of this dissertation, but the clinical similarities between both sets of
symptoms suggest some shared neurophysiology (Steimer, 2002).
A majority of insights regarding the functional roles of the MHb and IPN characterize the
neurobiology of addiction. In particular, as discussed previously, preclinical examinations
of the MHb-IPN axis affirm a role played by the pathway in the aversive syndrome
arising during withdrawal from a variety of habit-forming drugs – including alcohol,
opioids, nicotine, and psychomotor stimulants as well (McLaughlin et al., 2017; Molas et
al., 2017). As described in Chapter 1, the anatomy of the habenular complex renders it
prohibitively small to resolve in most human neuroimaging efforts (Batalla et al., 2017;
Salas et al., 2010; Salas et al., 2009), though some progress has been made in
distinguishing the medial from lateral habenulae (Strotmann et al., 2014). Given the
reported interaction between the habenular subnuclei (Kim & Chang, 2005), and the
reported connectivity between the LHb and IPN (Quina et al., 2017), activity in one of the
habenular subnuclei likely influences signaling in the other. Accordingly, reports of the
role that LHb activity plays in major depressive disorder (Browne, Hammack, & Lucki,
2018) suggests a further interaction of the MHb-IPN axis with affective states.
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As noted in Chapter 1, a high comorbidity between addiction and both depression and
anxiety suggest at least some overlapping neurophysiology. A more detailed
enumeration of the anatomical context of the MHb-IPN axis was included in Chapter 1,
the salience of which here being that the IPN sends efferents to a network of structures
implicated in affect regulation, psychiatric illnesses, and anxiety in particular.
The studies described in this dissertation indicate a role played by signaling within the
IPN in the regulation of anxiety-associated behavior independently of chronic drug
exposure. Until the studies described here, the role played by IPN signaling in baseline
anxiety-associated behavior had yet to be demonstrated. Alternatively stated, signaling
within the IPN is not only implicated in the pathophysiology of addiction, but perhaps
anxiety-associated conditions as well. Accordingly, the IPN may be one component of
the broader anatomical bond between addiction, anxiety, and psychiatric illnesses.
Further, efferent projections from the IPN to the raphe nuclei had been established, and
evidence of its projections to the hippocampus had been proposed several decades ago
– with one recent study confirming them (Quina et al., 2017). However, the studies
described in this dissertation confirm that – among its efferents to the hippocampus – the
IPN sends projections to the ventral hippocampus in particular. Given the role of the
ventral hippocampus in the regulation of affect - and anxiety in particular, as described in
Chapter 1 - this may be an important mechanism by which the IPN modulates anxietyassociated behavior.
Similarly, while anatomical connectivity between the IPN and raphe nuclei has been
widely appreciated, a correlation between anxiety-associated behavior, IPN signaling,
and serotonin levels had yet to be demonstrated. These studies indicate that activation
of IPN neurons is anxiolytic and correlates with significant elevations of serotonin
concentrations in the ventral hippocampus in particular. Recent tracing experiments I
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conducted suggest that at least some of these IPN efferents to the ventral hippocampus
are glutamatergic. Furthermore, the IPN sends glutamatergic efferents to other
anatomical structures associated with the regulation of affect, including the lateral
habenula and lateral hypothalamus (Fig. 1). Additional tracing studies I performed
suggest that the IPN sends efferents to components of the basal forebrain – a network
associated with the integration of arousal, behavioral inhibition, and sensory information
(Cassidy et al., 2019).
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Figure 3.

Figure 3. Slices from Vglut3-Cre transgenic mice infused with AAV8-DIO-ArchT-tdTomato
(red) into the IPN, stained with DAPI (blue). A low-magnification image of a coronal section
(A), complemented by higher magnification image of the IPN, displaying Cre-dependent
infection of glutamatergic IPN populations (B). Non-specific fluorescence induced by damage
+
along the syringe infusion tract is identified in green/yellow. tdTomato projections are
observed in the lateral habenula (C), the ventral hippocampus (D), and the lateral
hypothalamic area (E).
While other efferent signals involved in the regulation of affect very likely emerge from
the IPN, these data help to begin enumerating which among them reach anatomical
structures that participate in this activity.
More broadly, these data integrate the principal recipient of DDC signaling, the IPN –
which has been implicated in the manifestation of drug withdrawal symptoms - into a
169

broader anatomical foundation of the regulation of mood and anxiety-associated
conditions. Further, the MHb-IPN axis – a junction of signaling by which activity in the
forebrain influences the mid- and hind-brain (McLaughlin et al., 2017) – may represent a
point of feedback, such that elements of activities in caudal structures are fed back to
the forebrain.
Given the anatomy of the DDC and IPN, and evidence linking activity therein with both
addiction and psychiatric illnesses, the Hb-IPN axis is likely to continue yielding insights
regarding the pathophysiology of both conditions. Further, a pursuit of druggable targets
within this pathway in preclinical studies for the treatment of both psychiatric conditions
is likely warranted.

Future Directions
While the majority of behavioral analyses of the IPN have been performed in animal
models of chronic drug exposure and withdrawal, there are opportunities to evaluate
how activity in this pathway regulates context-dependent affective output. The behavioral
experiments in these studies were performed in environmental conditions empirically
determined to have no significant effect on baseline anxiety-associated behavior.
Ethological assays like those used in this series of studies, the open field arena and
elevated plus maze, are based upon the tension between predispositions of mice to
explore novel environments and an aversion to open and illuminated or elevated
environments (K. R. Bailey & Crawley, 2009; M. T. Bailey, Kinsey, Padgett, Sheridan, &
Leblebicioglu, 2009). Accordingly, modifying environmental stimuli during chemogenetic
perturbations of the MHb-IPN axis may reveal context-dependent regulation of anxiety,
such as illumination, aversive olfaction, or adversarial social interaction.
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An enticing set of experiments is to interrogate the functional properties of efferent IPN
projections to structures established to be associated with the regulation of affect and
manifestation of withdrawal symptoms. Principally, while initially proposed decades ago
(Groenewegen et al., 1986), discussion of efferent projections from the IPN to the LHb
has recently been revived (Quina et al., 2017; Quina et al., 2015). While few studies
have confirmed them, recent experiments I performed suggest these projections likely
do indeed exist. The behavioral relevance of such a network is likely considerable, given
the regulation of dopaminergic signaling by the LHb (Lammel, Lim, & Malenka, 2014;
Matsumoto & Hikosaka, 2007; Stamatakis et al., 2013), particularly given that the
signaling between the LHb and IPN appears to be rather complex (Beier et al., 2015).
Another projection worthy of interrogation is that between the IPN and septum. The MHb
receives projections from the medial septum that are thought to be principally
GABAergic (Qin & Luo, 2009). Recently published tracing studies suggest there are
projections from the IPN to the septal nuclei, as well as the diagonal band nucleus
(Quina et al., 2017), and pilot studies I performed comport with these findings.
Accordingly, given that these structures regulate anxiety (Henry, Vale, & Markou, 2006;
Parfitt et al., 2017), interrogation of projections from the IPN may yield insights that
broaden the anatomical regulation of anxiety by the IPN.
An experiment I attempted, that intuitively follows the findings of elevated ventral
hippocampal serotonin concentrations correlated with IPN stimulation, is to inhibit the
raphe nuclei while stimulating the IPN. In the ventral hippocampus, serotonin has been
shown to regulate anxiety-associated behavior (Adams, Kusljic, & van den Buuse, 2008;
Barr et al., 2013; Tu et al., 2014). As I am currently unable to attribute the source of this
elevation of serotonin levels in the ventral hippocampus, removal of a prime source of
serotonin may help to elucidate the functional relationships between these structures.
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Accordingly, inhibition of serotonergic neurons within the raphe nuclei while
simultaneously stimulating IPN neurons may reveal the source of ventral hippocampal
serotonin following IPN stimulation. Finally, while this series of studies used an AAV
serotype that appears to infect a significant proportion of the IPN, a systematic
comparison of the efficacies of a broader spectrum of serotypes will be very helpful in
subsequent viral interrogations of the structure.
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CHAPTER 5: SUPPLEMENTARY
ADDITIONAL SCIENTIFIC CONTRIBUTIONS

This chapter section presents two collaborative studies that are in preparation for publication
followed by additional publications during the progression of my graduate work.
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α5-dependent Modulation of nAChR Function and DA Release during
Chronic Nicotine Exposure and Nicotine Withdrawal: Effects of the
rs16969968 polymorphism.
Kechun Yang, Ian McLaughlin, John A. Dani, Mariella De Biasi
Contributions:
Electrophysiological studies conducted by Kechun Yang
Virus infusions, immunohistochemistry, and microscopy performed by Ian McLaughlin
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Abstract
A D398N (rs16969968) single-nucleotide polymorphism (SNP) in the human CHRNA5
gene has been linked to increased use of tobacco. Accumulating evidence from studies
that re-express this α5 SNP suggests that it plays an important role in regulating Ca2+
permeability and the function of nicotinic acetylcholine receptors (nAChRs), nicotine
consumption, and the treatment outcomes of some neuropsychiatric disorders (Koukouli
et al., 2017). It remains challenging, however, to directly measure functional changes in
α5-containing nAChRs, especially in adult animals exposed to nicotine treatment for
extended periods of time and following nicotine withdrawal. We studied adult α5 null
mice and their littermate controls, as well as mice expressing the rs16969968
polymorphism in dopaminergic neurons (α5 SNP). We systematically examined dynamic
changes in nAChR function by measuring ACh-induced whole-cell currents in VTA
dopamine (DA) neurons using patch-clamp recordings in mice treated with nicotine for 8
weeks, as well as up to 8 weeks after nicotine withdrawal. We also measured the
corresponding DA release in the dorsolateral striatum using fast-scan cyclic
voltammetry. We demonstrated that deletion of the α5 nAChR subunit leads to a
dramatic decrease in nAChR function and single-pulse evoked DA release. Expression
of the rs16969968 CHRNA5 polymorphism in dopaminergic neurons of α5 null mice only
partially restored nAChR function. Chronic nicotine exposure produced the most
profound enhancement of both nAChR function and DA release at single-pulse evoked
basal levels, and 20 Hz evoked maximal levels in SNP-expressing mice. Our results
provide new insights into the roles of this α5 SNP in chronic smoking and smoking
cessation, and reveals new potential treatment strategies for aiding smoking cessation.
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Introduction
Tobacco smoking is a major public health concern that leads to millions of preventable
deaths every year worldwide. The majority (80%) of smokers have attempted to quit, but
only 3% quit successfully (Benowitz, 2010). Nicotine is the principal addictive component
of tobacco, which exerts complicated effects on nicotinic acetylcholine receptors
(nAChRs) and further modulates the release of a variety of neurotransmitters, including
dopamine (DA), in the brain (Dani & De Biasi, 2013). Most functional nAChRs in the
brain consist of a combination of five α and/or β subunits (Dani, 2015). The α5 subunit is
distinguished by its role as an obligate accessory subunit, and functional α5 containing
nAChRs can be formed by different α and β subunits (Berrettini et al., 2008; RamirezLatorre et al., 1996; Sciaccaluga et al., 2015). Different lines of evidence from patchclamp studies show that genetic deletions of the α5 subunit reduces the functionality of
nAChRs, reflected by smaller peak amplitudes of whole-cell currents (Chatterjee et al.,
2013; Morel et al., 2014; Sciaccaluga et al., 2015).
Genome-wide association studies have found that the α5 subunit containing a
nonsynonymous variant, rs16969968 - a single-nucleotide polymorphism (SNP) in which
aspartic acid [D] 398 is replaced by asparagine [N] (D398N) - is highly associated with
heavy smoking (Berrettini et al., 2008; Bierut et al., 2008; Lips et al., 2010; Sarginson et
al., 2011). We and others have shown that mice expressing the α5 SNP, in either
dopaminergic cells or the entire brain, self-administer larger doses of nicotine relative to
control mice (Morel et al., 2014; O'Neill et al., 2018). However, the neurobiological
mechanisms underlying this increased nicotine intake caused by the SNP remain
unclear. With the development of SNP re-expression in cell lines, and targeted reexpression of the SNP in ventral midbrain neurons, it has been shown that the
176

polymorphism results in significant changes in Ca2+ permeability and function of both
α3β4-nAChRs and α4β2-nAChRs (Sciaccaluga et al., 2015; Tammimaki et al., 2012).
Acutely applied nicotine produced significant differences in DA release in striatal
synaptosomes from the offspring of nicotine-treated, SNP-expressing mice compared to
untreated SNP-expressing mice. It was also shown that chronic nicotine could
significantly influence the central nervous system and reverse both neurocognitive and
behavioral deficits observed in mice expressing the human SNP (Koukouli et al., 2017).
However, the neurobiological mechanisms underlying changes resulting from chronic
nicotine exposure remain largely unknown. In this study, we directly examined the
dynamic changes in both nAChR function, and the corresponding DA release, induced
by chronic nicotine exposure followed by extended nicotine withdrawal. We found that
chronic nicotine treatment resulted in altered functionality of nAChRs and DA release
probability, and these changes depended upon the α5 subunit. These findings shed light
on the pivotal roles played by this α5 SNP in both smoking and smoking cessation.
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Materials and Methods
Animals
We studied 4- to 8-month-old mice of both sexes, including α5 null mice and their
littermate controls, and α5 nulls crossed with mice expressing Cre recombinase driven
by the dopamine transporter (DAT-Cre). We worked with α5 null x DAT-Cre mice to
study the effects of α5 WT vs. α5 SNP re-expression in dopaminergic neurons. All mice
were maintained in a 12-h light/dark cycle, temperature-controlled room. All behavioral
tests were performed during their light cycle, and were approved by the Institutional
Animal Care and Use Committee at the University of Pennsylvania, according to the
guidelines for intramural animal research provided by the National Institutes of Health in
an animal care facility approved by the Association for Assessment and Accreditation of
Laboratory Animal Care (AAALAC).
Nicotine treatment
Mice received either 2% saccharine (SAC) as control or 200 mg/l nicotine + 2%
saccharine in their drinking water for 8 weeks after weaning. After the 8 weeks of
nicotine treatment, mice were withdrawn from nicotine to study nAChR responses after
short term (1-4 days), intermediate (2 weeks) or long-term (2 months) nicotine
withdrawal.
Viral injections
Intracranial viral infusions were performed with mice approximately 2 months old under
general isoflurane (1-2%) anesthesia coupled with meloxicam (2 mg/kg). Following fur
removal, disinfection, and exposure of the skull, small holes were drilled to enable
stereotactic targeting with a 10 μL syringe with removable needle tips (Hamilton, Reno,
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Nevada). Virus-containing fluid (AAVDJ-DIO-α5-copGFP or AAVDJ-DIO-α5SNPcopGFP) was infused at 0.01 μL/min with a microinfusion pump (kdScientific, Hollistoin,
MA), attached to the stereotactic apparatus (Kopf, Tujunga, CA). 1.70 – 2.0 μL of viral
fluid was infused into the VTA (A/P: -3.2 mm - -3.25 mm, M/L: ± 0.05 mm - 0.12 mm, D/V:
-4.20 mm - -4.35 mm).
Slice preparation
Mice were deeply anesthetized with an intraperitoneal injection of a mixture of
ketamine/xylazine, and transcardial perfusion was performed as previously described
(Broussard et al., 2016; Yang et al., 2017) with an ice-cold, N-methyl-D-glucamine
(NMDG) based artificial cerebrospinal fluid (ACSF, in mM): 92 NMDG, 2.5 KCl, 1.2
NaH2PO4, 30 NaHCO3, 20 HEPES, 25 glucose, 2 thiourea, 5 Na-ascorbate, 3 Napyruvate, 0.5 CaCl2, and 10 MgSO4, pH 7.3-7.4 with concentrated hydrochloric acid
(Ting et al., 2014). After decapitation, the brain was quickly removed from the skull and
placed in ice-cold NMDG solution, saturated with 95% O2 and 5% CO2. Horizontal slices,
containing either the ventral tegmental area (VTA, 230 µm) for patch-clamp recordings
or the dorsal striatum (300 µm) for fast scan cyclic voltammetric studies, were cut using
a vibratome (Leica VT 1200s) in ice-cold NMDG solution. The slices were recovered in
the NMDG solution at 32oC for 13 min, and then transferred to HEPEs-based holding
ACSF (in mM): 92 NaCl, 2.5 KCl, 1.2 NaH2PO4, 30 NaHCO3, 20 HEPES, 25 glucose, 2
thiourea, 5 Na-ascorbate, 3 Na-pyruvate, 2 CaCl2, and 2 MgSO4 at room temperature for
at least 1 hour until recording. All procedures were approved by the Institutional Animal
Care and Use Committee at the University of Pennsylvania.
Electrophysiological Recordings
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Slices containing the VTA were placed in a home-made recording chamber, and were
continuously bathed in well-oxygenated standard recording ACSF (in mM): 124 NaCl,
2.5 KCl, 1.2 NaH2PO4, 24 NaHCO3, 5 HEPES, 12.5 glucose, 2 CaCl2, and 2 MgSO4,
maintained at 32–34°C using an inline heater system (TC-324B, Warner Instrument
Corp, Hamden, CT). Responses were recorded using glass recording electrodes (~2-3
MΩ), which were pulled from borosilicate glass capillaries (TW 150-4, World Precision
Instruments, Inc, Sarasota, FL) using a micropipette puller (Narishige PC-10, Tokyo,
Japan), and were filled with a K-gluconate-based intracellular solution (in mM): 140 Kgluconate, 5 KCl, 10 HEPES, 0.2 EGTA, 2 MgCl2, 4 MgATP, 0.3 Na2GTP, and 10 Na2phosphocreatine, pH 7.3 with KOH. Tight-seal patch-clamp recording configuration was
first achieved by applying a brief gentle suction. Under tight-seal patch-clamp mode,
spontaneous action potential firing could be observed in most recorded neurons, and the
identification of DA neurons was first confirmed by sensitivity to puff-applied quinpirole (2
µM), a selective D2-receptor agonist (Fig 1D). Then, whole-cell mode configuration was
achieved by briefly applying strong suction. Only access resistance (Ra) < 10 MΩ was
accepted, and the Ra was monitored throughout the experiment. Putative DA neurons
were then identified by the presence of hyperpolarization-activated potassium currents
(H-current, Fig 1C), a typical electrophysiological property of DA neurons. Some
recorded putative DA neurons were labeled with neurobiotin during patch-clamp
recording, and were further confirmed as DA neurons with positive tyrosine hydroxylase
(TH) immunohistochemistry (Fig 1B). To fully activate nAChRs in the recorded neurons,
1 mM ACh was puff-applied by Picospritzer II (Parker Instrumentation, Fairfield, NJ)
every 2 min via a puff electrode (marked as P in Fig 1A), an electrode identical to those
used for recording, while the recorded neurons were clamped at -60 mV (VH = -60 mV)
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under voltage-clamp mode (sFig 1). Atropine (1 µM) (Yang et al., 2011; Yang et al.,
2009a) was added to recording ACSF to block muscarinic receptors.
Fast-scan cyclic voltammetry
Slices containing the dorsal striatum were transferred to the same recording chamber as
above and were continuously perfused with the same well oxygenated standard
recording ACSF (32-34 °C). Fast-scan cyclic voltammetry was performed using
homemade carbon fiber (10 µm diameter, Amoco Polymers, Greenville, SC) electrodes
(~ 100 µm of exposed fiber) within the dorsal striatum (Le, Zhang, Xie, Li, & Dani, 2015).
The carbon-fiber electrode potential was linearly scanned at a rate of 300 mV/ms every
100 ms from 0 to −400 to 1000 to −400 to 0 mV against a silver chloride reference
electrode. DA transients were evoked by electric stimulations via a bipolar tungsten
electrode (Stereotrode Tungsten; WPI) with two poles spaced about 150 μm apart,
placed within the dorsal striatum. The tip of the carbon-fiber recording electrode was
about 150 μm away from each of the two poles of the stimulating electrode. Different
stimulating protocols were designed with the aid of the Master-8 (A.M.P. Instruments
LTD. Jerusalem, Israel) to mimic physiological DA release, induced by either single
pulse stimulation or by tonic or phasic bursting stimulations. Each stimulus pulse (about
0.15 mA) was 1 ms in duration, produced with an A365 Stimulus Isolator (World
Precision Instruments, Inc. Sarasota, FL). Single pulses were applied every 120 seconds
to allow recovery of the DA release. To measure phasic/tonic ratios ([DA]5p/([DA]1p or
[DA]20p/[DA1p), single stimulations and the phasic burst stimuli, at an intraburst frequency
of 20 Hz, were separated by 120 seconds. Peak DA signals were converted into DA
concentrations based on a post-experimental calibration of the carbon-fiber electrode
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against fresh DA solutions (from 0.5 to 10 μM). All data were collected using Clampex 10
software via an Axopatch 200B amplifier and a digitizer 1550 (Molecular Devices).
Chemicals
Dihydro-β-erythroidine hydrobromide (DHβE) and quinpirole were purchased from
Tocris. Nicotine hydrogen tartrate salt was purchased from Glentham Life Sciences.
NEUROBIOTIN™ tracer was purchased from Vector Laboratories. All other chemicals
were from Sigma-Aldrich (St. Louis, MO, USA).
Statistical analyses
All values were expressed as mean ± SEM, and the number of experiments was
indicated by n. Statistical analyses were conducted using either paired/unpaired
Student’s t test, or one-way ANOVA with post hoc Tukey’s test, and p<0.05 was
considered to be statistically significant.

Results
The α5-nAChR subunit is critical to nAChR function in VTA DA neurons
Our previous work (Gangitano et al., 2009; Morel et al., 2014), and studies from other
groups, found that knock-out of the α5 nAChR subunit influences behavior (Fowler et al.,
2011; Koukouli et al., 2017; X. A. Liu & Kenny, 2017). Moreover, the CHRNA5
polymorphism significantly influences nicotine intake, anxiety-associated behavior,
DAergic responses to nicotine, and hypofrontality observed in patients with
schizophrenia (Koukouli et al., 2017).
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To better understand the role of the α5 subunit in the dynamics of nicotine exposure and
withdrawal, we first compared nAChR function in DAergic neurons from age-matched
drug-naïve (SAC-treated), wild-type (WT), α5 null mice, their littermate controls, and α5
SNP mice. Only neurons with clear H-currents (Fig 1C) were considered to be DAergic.
Under voltage-clamp mode, 1 mM ACh was puff-applied every 120 seconds onto
recorded putative VTA DA neurons held at -60 mV (VH= -60 mV). ACh-induced inward
currents were able to be stably recorded for at least 20-30 minutes (Fig 2), with some
lasting up to 1 hour (sFig1). The greatest peak amplitude of the inward currents (99.34 ±
11.59 pA, n=17) induced by 1 mM ACh was recorded in VTA DA neurons of WT mice
(Fig 2A, D). In null mice, nAChRs without the α5 subunit showed very limited function, as
evidenced by the small peak amplitude of inward-currents (9.66 ± 1.17 pA, n=20)
induced by 1 mM ACh in VTA DAergic neurons (Fig 2B, D). These results corroborate
those of previous works, showing that the α5 subunit enhances baseline nAChR currents
in VTA DA neurons from both young (Chatterjee et al., 2013; Sciaccaluga et al., 2015)
and adult mice (Morel et al., 2014). The function of nAChRs was partially recovered by
expression of the rs16969968 polymorphism in DAergic neurons (α5 SNP), resulting in
larger ACh-induced inward currents (22.51 ± 2.76 pA, n=10, p<0.001, SNP vs. null, Fig
2C, D), that were, however, still smaller than those measured from WT neurons
(p<0.001, SNP vs. WT, Fig 2D). One-way ANOVA showed significant differences in the
peak amplitudes of ACh-induced currents among WT, α5 null, and α5 SNP mice (F(2,44) =
40.5, p< 0.0001, Fig 2D), suggesting that the α5-nAChR subunit plays key roles in
modulating nAChR function in VTA DA neurons.
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α5-containing nAChRs play an important role in the modulation of DA release in
the dorsolateral striatum
At physiologically relevant levels, nicotine can modulate striatal DA release, either via
nAChRs expressed in DA neurons/axons, or via nAChRs locally expressed in cholinergic
interneurons (L. Wang et al., 2014; T. Zhang et al., 2009; Zhou, Liang, & Dani, 2001).
Frequency-dependent modulation of DA release by nicotine has been observed in both
the ventral and dorsolateral striatum (H. Zhang & Sulzer, 2004; L. Zhang, Doyon, Clark,
Phillips, & Dani, 2009).
To date, the α5 nAChR subunit has proven to be particularly critical to the regulation of
DA release in the dorsal striatum, but not the nucleus accumbens (Exley, McIntosh,
Marks, Maskos, & Cragg, 2012). In addition, compared with DA terminals in the ventral
striatum, those in the dorsal striatum are able to gain a significantly higher proportion of
DA release from presynaptic nAChR activation. A single action potential arriving at DA
terminals in the dorsolateral striatum is more likely to trigger DA release than one
arriving at DA terminals in the NAcc shell (T. Zhang et al., 2009). To better understand
the role played by α5-containing (α5*) nAChRs in the regulation of DA release in the
dorsal striatum, and the effects of the rs16969968 SNP, we first compared basal DA
release in the dorsolateral striatum with a single-pulse stimulus (1p), delivered every 120
seconds, in drug naïve mice. The biggest peak amplitude of DA signals (1.63 ± 0.16 µM,
n=29) was recorded in WT mice (Fig 3 A, D), suggesting that WT mice have the greatest
DA release probability. The smallest DA signals (0.40 ± 0.04 µM, n=13) were recorded in
α5 null mice (Fig 3B, D), indicating that a lack of α5 is associated with the lowest DA
release probability. Interestingly, the peak amplitude of DA signals (0.98 ± 0.07 µM, n=
22) is partially recovered in α5 SNP mice, which is greater than that of null mice
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(p<0.001, SNP vs. null, Fig 3C, D), but remains smaller than that of WT mice (p<0.001,
SNP vs. WT, Fig 3D). One-way ANOVA detected significant differences in the peak
amplitudes of single pulse-evoked DA signals among WT, null, and SNP mice (F(2,61) =
7.27, p< 0.001, Fig 3D). These results imply that the probability of DA release in the
dorsolateral striatum greatly depends on the functional levels of nAChRs, is determined
by the nAChR α5 subunit, and is affected by the presence of the CHRNA5
polymorphism.
To further confirm that striatal DA release is mainly regulated by nAChRs, we examined
the effects of 0.1 µM DHβE by applying the β2-nAChR antagonist via 20-minute bath
application. As shown in Fig. 4 A&B, inhibition of β2-nAChRs dramatically decreased
single-pulse induced DA release to 0.23 ± 0.02 (n=5, p< 0.001 vs. baseline, Fig 4A, E)
and 0.25 ± 0.03 (n=7, p< 0.001 vs. baseline Fig 4B, E) of baseline in WT and α5 null
mice, respectively. 60 minutes after DHβE washout, the DA signal was partially
recovered to 0.64 ± 0.05 (n=5, p<0.001, washout vs. DHβE, Fig 4A,E) and 0.78 ± 0.06
(n=7 p<0.001, washout vs. DHβE, Fig 4 B,E) of the baseline in WT and α5 null mice,
respectively. Reversible inhibition of DA release by DHβE is consistent with our previous
findings (L. Zhang et al., 2009; Zhou et al., 2001), and corroborates studies from other
groups (Threlfell et al., 2012), indicating that dorsolateral striatal DA release largely
depends on nAChR function.
We further tested the effects of nicotine (Nic) on striatal DA release, as it is well-known
that nicotine desensitizes nAChRs (Dani, 2015; McLaughlin et al., 2015) and inhibits DA
signals (L. Wang et al., 2014; T. Zhang et al., 2009; Zhou et al., 2001). Single-pulse
evoked DA release was suppressed to 0.22 ± 0.03 (n=5, p<0.001 vs. baseline, Fig 4C,
F) and 0.22 ± 0.03 (n=7, p<0.001 vs. baseline, Fig 4D, F) of baseline levels in WT and
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α5 null mice, respectively, by 20 min of bath-application of 0.5 µM nicotine. The
suppression of DA signals resulting from nicotine-induced desensitization partially
recovered to 0.83 ± 0.07 (n=5, p<0.001, washout vs. Nic, Fig 4C, F) of baseline in WT
mice, and to 0.49 ± 0.10 (n=6, p<0.05, wash out vs. Nic, Fig 4D, F) of baseline in α5 null
mice, 60 min after nicotine wash-out. Neither DHβE nor nicotine completely abolished
single-pulse evoked DA release in the dorsolateral striatum, indicating that nAChRs,
although major contributing factors (L. Wang et al., 2014), work in concert with a variety
of other neurotransmitters and receptors in the regulation of local DA release. The
reversible suppression of DA signaling by DHβE and nicotine, however, strongly
supports the important roles played by α5* nAChRs in modulating the probability of
dorsolateral striatal DA release.
Dramatic and long-lasting changes in nAChR function after chronic nicotine
treatment
Chronic nicotine exposure may lead to long-term homeostatic regulation of nAChR
function that contributes to the addiction process. Several lines of evidence from studies
measuring nAChR binding (Nguyen, Rasmussen, & Perry, 2003; Perry, Davila-Garcia,
Stockmeier, & Kellar, 1999) and using electron microscopy (Pakkanen, Jokitalo, &
Tuominen, 2005) suggest that long‐term exposure to nicotine results in upregulation of
nAChRs in WT rodent brains. A recent study, using quantitative ligand-binding
autoradiography, reported that chronic nicotine treatment down-regulates α6β2-nAChRs
and up-regulates α4β2-nAChRs in DAergic and optic-tract nuclei. Conflicting lines of
evidence from the above studies indicate that chronic nicotine, depending on subunit
composition, can upregulate, down regulate, or have no effect on nAChR function. Most
electrophysiological studies that directly examined nAChR function in VTA DA neurons
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were carried out in young animals (Chatterjee et al., 2013; Wooltorton, Pidoplichko,
Broide, & Dani, 2003; Wu et al., 2004; Yang et al., 2009b). Given the challenges
associated with patch-clamp recording in VTA DA neurons of adult animals chronically
treated with, and withdrawn from, nicotine, our understanding of the dynamic changes in
the function of VTA DA neurons with nAChRs is limited. No information is available on
the effects of chronic nicotine treatment and withdrawal on the function of α5* nAChRs.
In this study, we directly measured nAChR-mediated whole-cell currents in VTA DA
neurons of adult WT, α5 null, and α5 SNP mice undergoing either chronic nicotine
treatment or nicotine withdrawal. In WT animals, ACh-induced whole-cell currents were
comparable between SAC- treated controls (99.34 ± 11.59 pA, n=17) and animals
treated for 8 weeks with nicotine (89.47 ± 10.15 pA, n=16, p>0.05 vs. SAC) (Fig. 5A, E).
This result is consistent with previous findings indicating that chronic nicotine does not
change nAChR function in midbrain DA neurons, including both the VTA and the
substantia nigra pars compacta (Nashmi et al., 2007; Xiao et al., 2009). ACh-induced
whole-cell currents, however, became significantly smaller after nicotine withdrawal (WD
1-4d: 54.40 ± 4.96 pA, n=10, p<0.05 vs. SAC/Nic, Fig. 5A), indicating down-regulation of
nAChR function resulting from nicotine withdrawal. Under our experimental conditions,
the suppressed ACh-mediated currents did not recover after 2-4 weeks of withdrawal
(WD 2-4 wk: 50.14 ± 4.06 pA, n=7, p<0.05 vs. SAC/Nic), and, surprisingly, remained
suppressed even after 8 weeks of withdrawal (WD 8 wk: 48.40 ± 4.97 pA, n=10, p<0.005
vs. SAC/Nic). One-way ANOVA revealed significant differences in the peak amplitudes
of ACh-induced currents during withdrawal (F(4, 55) = 5.08, p<0.005;Fig. 5E) in WT mice.
The results from WT mice clearly suggest that chronic nicotine did not change nAChR
function, but nicotine withdrawal resulted in long-lasting down-regulation of nAChRs. We
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next tested the effects of chronic nicotine treatment and nicotine withdrawal on the
function of nAChRs in α5 null mice. VTA DA neurons from null mice that were chronically
treated with nicotine were more responsive to ACh (26.34 ± 3.39 pA, n=15 p<0.005 vs.
SAC, Fig. 5B, E) compared to SAC-treated controls. This indicates that chronic nicotine
treatment leads to upregulation of nAChR function in the absence of α5. In contrast to
the downregulation observed during nicotine withdrawal in WT mice, the upregulation of
nAChR function in null mice persisted, even after 8 weeks of withdrawal from chronic
nicotine. As shown in Fig. 5B & E, the peak amplitudes of ACh-induced currents
remained larger 1-4 days (42.65 ± 7.88 pA, n=13, p<0.005 vs. SAC), 2-4 weeks (36.91 ±
6.67 pA, n=13, p<0.005 vs. SAC), and 8 weeks (37.08 ± 7.33 pA n=12, p<0.005 vs.
SAC) after nicotine withdrawal. One-way ANOVA showed significantly increased
amplitudes of ACh-induced currents (F(4,68)=7.39, p<0.001) in null mice that underwent
chronic nicotine treatment and nicotine withdrawal compared to WT.
Chronic treatment of α5 SNP mice with nicotine for 8 weeks further improved nAChR
function, demonstrated by bigger ACh-induced currents (60.03 ± 10.22 pA, n=11,
p<0.005 vs SAC, Fig. 5C, E). This indicates that chronic nicotine exposure enhances
nAChR function in mice expressing the rs16969968 SNP. Enhancement of nAChR
function persisted in the days immediately following cessation of nicotine treatment
(days 1-4 of nicotine withdrawal; 72.59 ± 12.22 pA, n= 12, p<0.005 vs. SAC, Fig. 5C, E).
However, the peak amplitudes of ACh-induced currents returned to baseline levels
beginning at 2 weeks following withdrawal (35.19 ± 9.65 pA, n= 8, p>0.05 vs. SAC, Fig.
5C, E). Normalization of the currents was also confirmed at 8 weeks after nicotine
withdrawal (28.15 ± 3.24 pA, n= 14, p>0.05 vs. SAC). Dramatic changes in nAChR
function were further revealed by one-way ANOVA (F (4,50) = 6.85, p<0.001). We further
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compared the differences in nAChR function across the three different animal groups
tested in response to the same treatment (Fig. 5D). As shown in Figs. 2D & 5D,
significant differences (F(2,44) = 40.5, p< 0.001) in the peaks of ACh-induced currents
were detected across nicotine naïve WT, α5 null, and α5 SNP mice. After 8 weeks of
chronic nicotine treatment, significant differences among the three groups were detected
(F(2,39) = 15.58, p<0.001, Fig. 5D). There was no difference among nAChR currents in
WT, null, and SNP mice after 1-4 days (F(2,32) = 2.86, p=0.07, Fig. 5D), up to 2-4 weeks
(F(2, 25) = 0.99, p= 0.38, Fig. 5D) of nicotine withdrawal. After 8 weeks of withdrawal, ACh
induced smaller currents in SNP mice compared to WT and SNP mice (t test: WT vs.
SNP, p< 0.01; one-way ANOVA: F(2,33) = 3.52, p=0.04, Fig. 5D). Accordingly, the results
from WT, null, and SNP mice suggest that chronic nicotine and nicotine withdrawal can
result in increased, decreased, or unchanged function, and the α5 subunit - and its
rs16969968 polymorphism - play a key role in determining nAChR function during
different states induced by nicotine.
Dramatic changes in single-pulse evoked DA release in the dorsolateral striatum
after chronic nicotine treatment
We next examined whether chronic nicotine and nicotine withdrawal may have the same
profound effects observed for nAChR function on single-pulse evoked DA release in the
dorsolateral striatum in WT, α5 null, and α5 SNP mice. In WT mice, the peak amplitude
of single-pulse-evoked DA release was dramatically suppressed after 8 weeks of
nicotine treatment, (p<0.001, Fig. 6 A, E) from 1.63 ± 0.16 µM (n=29) to 0.53 ± 0.06 µM
(n=16). The DA signal was partially recovered to 0.72 ± 0.05 µM (p<0.05 vs. Nic, n=26,
Fig. 6A, E) after 1-4 days of nicotine withdrawal and remained slightly suppressed (0.74
± 0.03 µM, p<0.05 vs. Nic, n=16, Fig. 6A, E) after 8 weeks of nicotine withdrawal. The
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suppression of DA signals by chronic nicotine was a long-lasting effect, and did not
recover to control levels (F(3, 80) =20.91, p<0.001, one-way ANOVA) up to 8 weeks after
nicotine withdrawal in WT mice. In α5 null mice, however, the same chronic nicotine
treatment significantly increased the amplitudes of DA signals (p<0.05, Fig. 6B, E) from
0.40 ± 0.04 µM (n=13) to 0.57 ± 0.06 µM (n=16). DA signals remained elevated after
short-term withdrawal (WD 1-4: 0.63 ± 0.17 µM, n=14, p<0.001 vs. SAC, Fig. 6B, E), and
this potentiation was sustained 8 weeks after nicotine withdrawal (0.61 ± 0.05 µM, n=23,
p<0.001 vs. SAC, Fig. 6B, E) compared to those in SAC-treated controls. Thus, under
our experimental conditions, chronic nicotine and nicotine withdrawal resulted in longlasting potentiation of DA signals in α5 null mice (F(3,62)= 3.79, p<0.05, one-way ANOVA).
Similar to the results observed in α5 null mice, chronic nicotine produced significant
changes in DA release in α5 SNP mice (F(3,57)=3.10, p<0.05). Peak amplitudes of
single-pulse evoked DA release were greatly increased from 0.98 ± 0.07 µM (n=22) to
1.42 ± 0.11 µM (n=14) in α5 SNP mice chronically treated with nicotine (p<0.005, Fig.
6C, E). The potentiated DA signals remained high after short-term withdrawal (1.24 ±
0.10 µM, n=17, p<0.05, WD 1-3d vs. SAC), but DA signals were no longer significantly
elevated after 8 weeks of withdrawal compared to control levels (1.13 ± 0.26 µM, n=8,
p>0.05, WD 8 wk vs. SAC) (Fig. 6C, E).
When we examined the differences in DA release in response to the same treatments
across WT, α5 null, and α5 SNP mice, we confirmed significant differences in singlepulse evoked DA release (Fig. 6D). As shown in Figs. 3 and 6, WT mice showed the
greatest levels of DA release, while null mice exhibited the lowest levels of DA release.
After 8 weeks of treatment with nicotine, followed by withdrawal, probability of DA
release was dramatically suppressed in WT mice while probability of DA release was
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greatly potentiated in both α5 null and SNP mice. Nicotine-treated WT and α5 null mice
were comparable (Fig. 6D), while α5 SNP mice showed increased DA release (F(2,43) =
39.47, p<0.001) during chronic nicotine treatment and during short-term nicotine
withdrawal (F(2,54) = 20.13, p<0.001) up to 8 weeks (F(2,41) = 6.46, p<0.005). Therefore,
chronic treatment with nicotine, and subsequent nicotine withdrawal, can lead to either
suppression or potentiation of single-pulse evoked striatal DA release. This effect is
influenced by nAChR function and is regulated by α5* nAChRs.
Modulation of DA release evoked by 20 Hz phasic stimuli in the dorsolateral
striatum during chronic nicotine exposure and nicotine withdrawal
Reward-related signaling is associated with changes in DA levels in the brain in
response to transitions between tonic and phasic firing. As shown in Fig. 4 and previous
studies (Rice & Cragg, 2004; L. Wang et al., 2014; T. Zhang et al., 2009; Zhou et al.,
2001), acute application of smoking-related concentrations of nicotine not only
suppresses single-pulse evoked DA release, but also modulates DA release elicited by
tonic and phasic stimulation in the striatum. The reinforcing properties of nicotine,
however, are at least partially related to nicotinic modulation of peak DA release during
phasic, but not tonic, firing (Rice & Cragg, 2004). By comparing DA release evoked by
bursts of variable lengths, previous studies (L. Zhang, Dong, Doyon, & Dani, 2012; L.
Zhang et al., 2009), and studies from other groups (H. Zhang & Sulzer, 2004),
demonstrated that maximal DA signals can be reliably generated by 20 Hz phasic
stimuli. Furthermore, longer burst firing evokes the greatest DA release in the NAcc of
WT mice, during either acute nicotine application or after one day of withdrawal from
chronic nicotine.
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Here, we explored the role of α5* nAChRs in regulating potential reserve pools of DA
reward. This was evaluated by comparing stimulated DA release, elicited by a 20 Hz
phasic stimulus, with longer (20 pulses, 20p) to shorter (5 pulses, 5p) trains in the
dorsolateral striatum, of WT, α5 null, and α5 SNP mice during long-term nicotine
exposure and after short-term (1-3 days) and long-term (8 weeks) withdrawal. Because
baseline DA signals evoked by a single pulse were variable, all values were normalized
to baseline as ratios to reveal relative changes in DA peak amplitudes evoked by 5p
([DA]5p/[DA]1p) and 20p ([DA]20p/[DA]1p). We first examined the dynamic alterations in DA
release caused by chronic nicotine and by nicotine withdrawal. As shown in Fig. 7A & E,
no significant differences between 5p and 20p were detected in WT mice treated with
SAC (20p: 1.32 ± 0.08, n=13; 5p: 1.19 ± 0.05, n=14, p>0.05) or nicotine (20p: 1.48 ±
0.11, n=14; 5p: 1.37 ± 0.08, n= 13, p>0.05), indicating that only limited reserve pools of
DA can be accessed by longer phasic firing under control conditions. In addition, more
DA was produced by 20p than by 5p in WT mice undergoing both short-term (20p: 2.13
±0.17, n=20; 5p: 1.55 ± 0.09, n=21, p<0.01) and long-term (20p: 2.19 ± 0.22, n=10; 5p:
1.63 ± 0.16, n=10, p<0.05) withdrawal from chronic nicotine. These results suggest that
the reserve pools of DA are amplified by longer phasic firing in WT mice undergoing
nicotine withdrawal. Conversely, in α5 null mice, 20p stimulation always evoked more
DA release than shorter, 5p stimulation (Fig. 7B, E) independently of whether mice were
treated with SAC (20p: 4.41 ± 0.58, n=13; 5p: 2.24 ± 0.31, n=11, p<0.01), nicotine (20p:
1.93 ± 0.28, n=12; 5p: 1.36 ± 0.05, n=13, p<0.05) - or whether they were undergoing
short-term (20p: 2.02 ± 0.31, n=12; 5p: 1.45 ± 0.09, n=12, p<0.05) or long-term nicotine
withdrawal (20p: 2.79 ± 0.16, n=22; 5p: 2.02 ± 0.13, n=22). These findings show that, in
the absence of α5, longer phasic firing produces greater enhancement of evoked DA
release, suggesting that the reserve pools of DA release may not be altered by chronic
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nicotine and subsequent nicotine withdrawal. In α5 SNP mice, longer 20p evoked more
DA release than shorter 5p did, in groups receiving SAC (20p: 2.18 ± 0.25, n=12; 5p:
1.47 ± 0.08, n=12, p<0.05) and those receiving chronic nicotine (20p: 2.07 ± 0.20, n=13;
5p: 1.43 ± 0.06, n=13, p<0.01) (Fig. 7C, E). However, the differences in DA release
evoked by 20p vs. 5p became undetectable after SNP mice were withdrawn from
nicotine measured in the days immediately following withdrawal (WD 1-3 days; 20p: 1.37
± 0.39, n=9; 5p: 1.33 ± 0.28, n=9, p>0.05), up to 8 weeks post nicotine cessation (20p:
1.40 ± 0.23, n=7; 5p: 1.34 ± 0.13, n=7, p>0.05). These observations suggest that, in the
presence of the rs16969968 polymorphism, mice withdrawn from chronic nicotine may
have reduced DA responses to longer phasic firing.
Figure 7D compares the ratios of DA signals evoked by 5p vs. 20p in WT, α5 null, and
α5 SNP mice across various experimental conditions. In drug naïve, SAC-treated
controls, 20 Hz phasic stimulation with both 5p and 20p produced the greatest increases
in DA release in α5 null mice and the lowest increases in DA release in WT mice (5p:
F(2,34)= 9.81, p<0.001; 20p: F(2,35)=18.50, p<0.001 one way ANOVA). The degree of
increase in DA release elicited by phasic stimulation was inversely correlated with the
levels of initial baseline DA release probability. The lowest DA release probability by
single-pulse observed in α5 null mice (Fig. 3B, D) was associated with greater facilitation
of DA release by phasic stimulation with either 5 or 20 pulses (Fig. 7D). The higher DA
release probability at baseline observed in WT mice suggests reduced reserve pools
available for DA release after phasic stimulation with either 5 or 20 pulses. Such
differences were attenuated by chronic nicotine treatment (F(2,36)=2.38, p>0.05), and
persisted during early nicotine withdrawal (F(2,38)=2.91, p=0.06), although statistically
significant differences were apparent after 8 weeks of withdrawal when the effects of 20p
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were considered (F(2,36)=10.52, p<0.001). Overall these results suggest that nicotine
exposure and nicotine withdrawal may affect DA reserve pools, and that α5* nAChRs
are important mediators of these effects.
Modulation of tonic vs. phasic DA release during chronic nicotine exposure and
withdrawal
The differential DA release observed when switching between tonic and phasic
frequencies is directly related to reward prediction and reinforcement learning. Acute
interruption of nicotinic signaling using newly developed, light-controllable nAChRs has
shown that nAChRs greatly influence the firing patterns of VTA DA neurons (Durand-de
Cuttoli et al., 2018). Previous work from our group and others has shown that both acute
nicotine, and withdrawal from chronic nicotine, regulate DA signals evoked by tonic and
phasic activities (Rice & Cragg, 2004; L. Zhang et al., 2012). Here, we focused on the
effects of chronic nicotine, and subsequent nicotine withdrawal, on tonic vs. phasic DA
release in WT, α5 null, and α5 SNP mice to explore the specific role played by the α5
subunit in the alterations of DA signals that promote nicotine addiction. Given that tonic
pulses at 3-4 Hz produced significantly smaller DA signals than single pulses did (Le et
al., 2015; L. Zhang et al., 2012; L. Zhang et al., 2009), DA release evoked by 3-4 Hz
tonic pulses was difficult to distinguish from background noise in α5 null mice under our
experimental conditions due to the low DA release probability shown in Fig. 3B. Thus,
we applied very slow, 0.2 Hz tonic pluses to let each single stimulus produce bigger,
detectable DA signals (Fig. 8B). As shown in Fig. 8A-C, greater DA release was
produced by a 20 Hz phasic stimulus with 5 pulses, which was observed 5 seconds after
relatively small DA signals were evoked by 4 0.2-Hz tonic stimuli which reached a
pseudo steady state. To examine differences in DA release, we compared the ratios of
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phasic-to-slow-tonic DA signals ([DA]5p/[DA]1p). In WT mice (Fig.8 A, E), chronic nicotine
treatment dramatically decreased the ratios, from 2.44 ± 0.24 (n=18, SAC controls) to
1.67 ± 0.09 (n=14, NIC; F(3,60) = 3.80, p<0.05). The ratios returned to control levels after
short-term (1-3 days;2.16 ± 0.13, n=11) and 8 weeks-long (2.38 ± 0.15, n=21) nicotine
withdrawal. In α5 null mice, however, chronic nicotine did not significantly increase the
ratios that went from 1.89 ± 0.09 (n=14) at baseline to 2.11 ± 0.12 (n=16) during nicotine
treatment. Ratios remained unchanged (2.05 ± 0.10, n=12) shortly after nicotine
withdrawal, but were significantly increased to 2.63 ± 0.28 (n=16) after 8 weeks of
withdrawal (F(3,54) = 3.32, p<0.05, ANOVA, Fig. 8B, E). Similar to the results obtained in
α5 null mice, the ratios of phasic-to-slow-tonic DA signals were not altered by chronic
nicotine or during short-term withdrawal compared to baseline in α5 SNP mice (control:
1.76 ± 0.06, n=13; chronic nicotine1.66 ± 0.10, n=14; WD 1-3 days: 1.54 ± 0.07, n=17).
However, contrary to what was seen in the null mice, ratios were significantly decreased
to 1.30 ± 0.07 (n=7) after 8 weeks of nicotine withdrawal (F(3,47) = 4.48, p<0.01,Fig. 8C,
E).
Fig. 8D compares ratios of phasic-to-slow-tonic DA signals in WT, α5 null, and α5 SNP
mice across the experimental conditions. In the SAC-treated, drug naïve condition, WT
mice had significantly greater ratios (F(2,42) = 4.39, p<0.05,) relative to α5 null and α5
SNP mice, suggesting that both null and SNP mice may experience lower reward
signals, generated by a contrast between phasic and tonic DA signals, compared to WT
controls. Following chronic nicotine exposure, however, α5 null mice exhibited higher
ratios (F(2,41) = 6.01, p<0.01) compared to WT and SNP mice, indicating that nicotine
exposure might enhance reward signals produced by phasic firing. In α5 SNP mice,
ratios were unaffected by chronic nicotine exposure, but decreased significantly during
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both short-term withdrawal (F(2,37) = 12.74, p<0.001) and up to 8 weeks of withdrawal
(F(2,41) = 6.59, p<0.005). These results imply that mice carrying the rs16969968
polymorphism may experience lower levels of reward for an extended period of time
following cessation of nicotine exposure. Overall, these results confirm that both chronic
nicotine exposure and withdrawal may differently influence an animal’s experience of
rewarding signals by modulating the function of nAChRs that contain the α5 subunit via
distinct mechanisms.
Discussion
In this study, we systematically examined the roles of the α5 subunit in the regulation of
dynamic alterations in the function of nAChRs in VTA DA neurons. Further, we found
that the α5 subunit plays pivotal roles in modulating DA release evoked either by singlepulse stimulation or by tonic/phasic stimulus trains in the dorsolateral striatum of WT,
null, and SNP mice treated with chronic nicotine and following nicotine withdrawal.
Significant regulatory roles of the α5 subunit in controlling nAChR function and
DA release in drug naïve controls
It is well-known that the α5 nAChR subunit is an obligate accessory subunit that cannot
form functional receptors by itself and requires additional α and β subunits (Berrettini et
al., 2008; Ramirez-Latorre et al., 1996; Sciaccaluga et al., 2015). Studies using α5 null
mice found that the absence of α5 subunits caused a dramatic loss of nAChR
functionality, identified by smaller peak currents recorded in VTA DA neurons
(Chatterjee et al., 2013; Morel et al., 2014; Sciaccaluga et al., 2015). Corroborating
previous observations, the data from SAC treated naïve controls, presented in Fig. 2,
demonstrate that WT mice exhibited the greatest nAChR functionality, evidenced by the
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biggest peak currents, while null mice had very limited nAChR functionality with the
smallest currents (Fig. 2). Recent developments in genome-wide association studies for
nicotine dependence susceptibility genes revealed a strong association of increased risk
of nicotine dependence with a single-nucleotide polymorphism (SNP) in which an
aspartic acid residue at position of 398 was replaced with asparagine in the α5 subunit
(Bierut et al., 2008; Saccone et al., 2007). We re-expressed the SNP in VTA DA neurons
of α5 null DAT-Cre mice (Fig. 9), which resulted in a partial recovery of the nicotinic
responses. This corroborates very similar observations from previous studies in VTA DA
neurons, HEK cell lines, and GH4C1 cells (Morel et al., 2014; Sciaccaluga et al., 2015;
Tammimaki et al., 2012). Thus, these data indicate that the responses of nAChRs to
nicotine are directly determined by the characteristics of α5 subunit variants, and null
mice require much higher concentrations of nicotine to achieve the same dopaminergic
responses relative to WT controls (Fowler et al., 2011; Morel et al., 2014). Our results
may partially explain why heavy smoking is highly associated with SNPs in CHRNA5
(Lips et al., 2010; Sarginson et al., 2011). The precise mechanisms underlying how the
α5 subunit controls nAChR function in the VTA remain unclear. However, it is reported
that α4β2-nAChRs are the most commonly expressed nAChRs in VTA DA neurons
(Klink, de Kerchove d'Exaerde, Zoli, & Changeux, 2001; D. Mao, Gallagher, & McGehee,
2011; Yang et al., 2009b), and the α5 subunit plays critical roles in controlling the
expression and function of α4* nAChRs in the VTA (Chatterjee et al., 2013). Recent
evidence from studies using immunoprecipitation and ligand-binding techniques suggest
that α4β2-nAChRs are also highly expressed on both striatal dopaminergic and
nondopaminergic terminals (Gotti et al., 2005; Zoli et al., 2002). Indeed, we confirmed
that striatal DA signals are predominantly suppressed in brain slices containing the
dorsolateral striatum by blockade of β2* nAChRs in WT mice, and in the same brain
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slices, in nAChR β2-subunit null mice (L. Zhang et al., 2009). Interestingly, a recent
study using mice with deletions of α4, α5, α6, or β3 subunits showed that the α5 nAChR
subunit plays an important role in the modulation of DA release by nAChRs containing
α4β2 subunits in the dorsal striatum (Exley et al., 2012). However, these roles played by
α5 subunit in controlling DA release, especially under the influences of chronic nicotine
and nicotine withdrawal, remain poorly understood. In the present study, for the first
time, we further demonstrated that the α5 subunit and α5 SNP also proved to play
important roles in regulating baseline DA release evoked by single pulse stimuli applied
every 120 s with the aid of voltammetry recordings in brain slices containing the
dorsolateral striatum of WT, null, and SNP mice. Under the same recording conditions,
WT mice exhibited the greatest DA signals, followed by SNP mice, while null mice
exhibited the lowest DA signals (Fig. 3). The following 2 mechanisms may underlie the
greatly diminished DA release in null and SNP mice: (1) significantly decreased
cholinergic signals, identified by much smaller ACh-induced currents (Fig. 2), and (2) a
dramatic reduction of nAChR-mediated Ca2+ signals (Sciaccaluga et al., 2015;
Tammimaki et al., 2012). Confirmation that the activation of nAChRs participates in the
modulation of DA release is shown in Fig. 3. DHβE was bath-applied first to block β2*
nAChRs. DA signals were dramatically and reversibly suppressed by 20 min application
of DHβE (Fig. 4A, B). Furthermore, desensitization of nAChRs by bath-application of 0.5
µM nicotine resulted in similar inhibition of striatal DA release (Fig. 4C, D). The finding
that there is overwhelming inhibition of evoked DA release by both DHβE and nicotine
corroborates previous studies (Exley et al., 2012; Threlfell et al., 2012; L. Wang et al.,
2014; L. Zhang et al., 2009; Zhou et al., 2001), and suggests that nAChRs govern levels
of DA release in the dorsolateral striatum. Thus, we conclude that baseline DA release
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probability is mainly determined by nAChR function, with the α5 subunit playing a critical
regulatory role.
α5 subunit dependent modulation of nAChR function and DA release by chronic
nicotine treatment
Chronic nicotine exposure through tobacco smoking may lead to long-term homeostatic
regulation of nAChR function, which is the cellular mechanism underlying nicotine
addiction. There is considerable evidence that long‐term exposure to nicotine results in
upregulation of nAChRs in WT rodent brains, indicated by measurements of nAChR
binding (Nguyen et al., 2003; Perry et al., 1999), and by studies using electron
microscopy (Pakkanen et al., 2005). However, behavioral and in vivo
electrophysiological studies by Besson et al. showed that upregulation of nAChR
function can only be detected in chronic nicotine-treated β2-/-, but not WT, mice (Besson
et al., 2007). A recent study reported that chronic nicotine treatment down-regulates
α6β2-nAChRs and up-regulates α4β2-nAChRs in DAergic and optic-tract nuclei using
quantitative ligand-binding autoradiography (Marks et al., 2014). The different lines of
conflicting evidence from the above studies suggest that chronic nicotine exposure,
subunit-dependently, either up-regulates, down-regulates, or does not significantly
change nAChR function. In the cortex, however, all the changes in β2/α4 subunit ratios,
(α4)2(β3)3 vs. (α4)3(β3)2, elicited by 2-weeks of chronic nicotine returned to basal levels
with an average half-life of 2.8 days after nicotine withdrawal (Fasoli et al., 2016). In VTA
DA neurons, increased AMPA/NMDA ratios can last at least 3 days after a single
injection of nicotine and can last up to 8 days after a treatment of once-daily nicotine
injections for 7 days. (Gao et al., 2010). The potential functional alterations of α5*
nAChRs caused by long-term chronic nicotine treatment and withdrawal remain largely
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unknown. In this study, we extended both chronic nicotine treatment and subsequent
nicotine withdrawal up to 8 weeks, and then investigated the influences of chronic
nicotine upon nAChR function in VTA DA neurons. We detected significant increases in
the amplitude of ACh-induced whole cell currents in null and SNP mice (Fig. 5).
Increased functionality of nAChRs in SNP mice mirrored findings in oral keratinocytes
that found nicotine stimulates expression of α5* nAChRs (Arredondo, Chernyavsky,
Jolkovsky, Pinkerton, & Grando, 2008). Different from both null and SNP mice, chronic
nicotine did not show significant effects on ACh-induced whole-cell currents in WT mice,
which corroborates previous findings in 2-3 month-old α4YFP mice after 10 days of
treatment with nicotine by measuring levels of α4YFP fluorescence (Nashmi et al.,
2007). Thus, chronic nicotine results in an α5 subunit-dependent modulation of the
function of nAChRs expressed in VTA DA neurons. Normal ACh-induced responses
were only partially recovered in null mice, but were almost completely restored in SNP
mice to levels comparable to WT mice after chronic nicotine exposure (Fig. 5). The
restoration of nAChR function observed in this study could be a key underlying
mechanism that contributes to the altered firing of pyramidal neurons in the
hypofrontality of α5 SNP schizophrenia models after 14 days of nicotine exposure via
mini-pump implantation (Koukouli et al., 2017). Accordingly, restoring normal cholinergic
function may be an internal motivation for carriers of the SNP to smoke cigarettes.
Chronic nicotine exposure also significantly influences DA release in the dorsolateral
striatum in an α5 subunit-dependent manner. Substantially suppressed single-pulse
evoked striatal DA signals were recorded in WT mice after 8 weeks of chronic nicotine
treatment (Fig. 6A), which reflects the findings of previous reports (X. A. Perez, Khroyan,
McIntosh, & Quik, 2015; X. A. Perez, Ly, McIntosh, & Quik, 2012), indicating that
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decreased DA release was detected in the NAcc of both rats and monkeys treated with
nicotine in drinking water for 2-6 months. However, the same chronic nicotine treatment
resulted in much bigger single-pulse stimulated DA signals in the dorsolateral striatum of
null (Fig. 6B) and SNP (Fig. 6C) mice. In particular, SNP mice had the greatest singlepulse evoked basal DA release compared to WT and null mice (Fig. 6D), suggesting that
chronic smoking may be more pleasurable for SNP mice. The increases in DA signals
may result from both restored nAChR function, shown in Fig. 5, and the corresponding
improvement in Ca2+ permeability via α5* nAChRs after nicotine exposure (Arredondo et
al., 2008). The data from SNP mice further extended our findings from mice to humans,
which may explain reported associations between the polymorphism in CHRNA5 and
enhanced pleasurable responses to early smoking experiences among current regular
smokers (Sherva et al., 2008). Thus, chronic smoking not only restores deficits in
cholinergic function, but can also increase DA release, rendering the effects of nicotine
even more rewarding for null and SNP mice, and particularly for SNP mice.
Long lasting impact of chronic nicotine upon nAChR function and phasic DA
release during extended nicotine withdrawal
Withdrawal from chronic nicotine is believed to trigger powerful negative reinforcement
that drives relapse and compulsive tobacco use. Smokers may continue to consume
nicotine primarily to alleviate the aversive symptoms of nicotine withdrawal and craving
(Tan, Bishop, Lauzon, Sun, & Laviolette, 2009). Therefore, a better understanding of the
effects of long-term nicotine withdrawal on nAChR function, and corresponding changes
in DA release, is a critical step towards developing more effective therapeutics for
smoking cessation. Smoking cessation is a long-term process that has been
characterized by 6 stages of progressive changes (Prochaska & Velicer, 1997).
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However, most previous studies (Grieder et al., 2012; Natividad, Tejeda, Torres, &
O'Dell, 2010; X. Y. Zhang et al., 2012) have only characterized animals that have
undergone nicotine withdrawal for hours to days. In the present study, we extended
nicotine withdrawal to 8 weeks and systematically investigated the dynamic changes that
arose in both the functionality of nAChRs in VTA DA neurons, as well as DA release in
dorsolateral striatum. Significantly smaller ACh-induced whole-cell currents were
recorded in VTA DA neurons of WT mice undergoing nicotine withdrawal for 1-4 days, 24 weeks, or 8 weeks (Fig. 5A), suggesting a long-lasting depression of nAChR function
after cessation of long-term nicotine exposure. Nicotine withdrawal also resulted in the
same long-lasting reduction of single-pulse stimulated DA signals in WT mice (Fig. 6A).
These findings confirm previous observations from our lab and others that nicotine
withdrawal substantially lowers baseline DA release in both mice and rats undergoing
nicotine withdrawal for 1-10 days (Grieder et al., 2012; L. Zhang et al., 2012).
Interestingly, nicotine withdrawal showed distinct effects on nAChR function and DA
release in null and SNP mice. The up-regulated nAChR function was sustained during 8
weeks of nicotine withdrawal in null mice (Fig. 5B), but only 1-4 days - then returning to
baseline levels - during the same 8 weeks of nicotine withdrawal in SNP mice (Fig. 5C).
Corroborating an alteration in nAChR function, under the same nicotine withdrawal
conditions, we found that enhanced single-pulse evoked DA signals were maintained at
the same significantly higher levels in null mice (Fig. 6B). Meanwhile, DA signals only
remained elevated for 1-3 days, returning to baseline levels in null mice (Fig. 6C). SNP
mice have the greatest single-pulse induced DA release relative to both WT and null
mice during 1-3 days of withdrawal, while no significant difference was detected
afterwards between SNP and WT mice (Fig. 6D).
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To fully understand the impact of nicotine withdrawal on DA release, we further
investigated maximal DA release by applying 20 Hz phasic stimuli, measuring changes
in ratios of phasic vs. tonic DA release. SNP mice exhibited greater maximal DA release
compared to WT mice after chronic nicotine treatment. Surprisingly, SNP mice exhibited
the lowest maximal DA release throughout nicotine withdrawal compared to both WT
and null mice (Fig. 7D). In addition, SNP mice had the lowest phasic vs. tonic ratios
relative to both WT and null mice (Fig. 8D), which suggests that phasic stimulation
produced the lowest efficiency to boost DA release, and failed to generate comparable
reward signaling in SNP mice undergoing nicotine withdrawal. Previous studies using in
vivo microdialysis demonstrated that acute nicotine dramatically increases peak, but not
basal, DA release in mice undergoing nicotine withdrawal (L. Zhang et al., 2012).
Indeed, nicotine exerts dual effects on striatal DA release, increasing phasic DA release
while decreasing tonic DA release (Rice & Cragg, 2004). Therefore, during nicotine
withdrawal, it is possible that animals may consume nicotine to temporarily enhance DA
release via phasic firing (Grieder et al., 2012). It is reasonable to speculate that SNP
mice undergoing nicotine withdrawal may experience the strongest motivation to seek
nicotine in order to restore suppressed reward from phasic DA activation that they
previously experienced from chronic nicotine exposure.
Summary
We systematically examined the dynamic functional alterations of nAChRs in VTA DA
neurons, and the corresponding DA release in the dorsolateral striatum, induced by 8
weeks of chronic nicotine, as well as 8 weeks of nicotine withdrawal. Overcoming the
challenges of performing patch-clamp recordings in 5-7 month-old mice, and employing
fast-scan cyclic voltammetry, we worked with α5 null mice, finding that the α5 nAChR
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subunit plays important roles in regulating VTA nAChR functionality, as well as striatal
DA release. Relative to WT controls, null mice not only displayed limited nAChR
function, but exhibited much smaller single-pulse evoked DA release as well. Expression
of the human α5 SNP in mice resulted in only a partial recovery of VTA nAChR function
and striatal DA release. These data translate our findings from mice to human smokers
carrying the α5 SNP, yielding insights regarding the neurobiological mechanisms by
which the α5 subunit contributes to both chronic nicotine use and smoking cessation. We
further demonstrated that 8 weeks of chronic nicotine exposure significantly enhanced
nAChR function and, in turn, dramatically increased single-pulse stimulated DA release
in both null and SNP mice. It should be noted that, following chronic nicotine treatment,
SNP mice exhibited the greatest single-pulse evoked DA signals compared to both WT
and null mice, as well as significantly greater maximal DA release elicited by 20 pulses
of 20 Hz phasic stimuli compared to WT controls. However, the same chronic nicotine
treatment didn’t significantly change nAChR functionality, but substantially suppressed
single-pulse induced DA release in WT mice. Accordingly, chronic nicotine can improve
nAChR function, enabling carriers of the SNP to experience significantly greater rewardrelated DAergic responses. These findings suggest that SNP mice respond the most to
chronic nicotine exposure, which might elucidate the underlying neurobiological
mechanisms that promote heavy smoking in human carriers of the α5 nAChR SNP.
Withdrawal from nicotine, following 8 weeks of chronic nicotine treatment, produced
persistent down-regulation of nAChR function in WT mice or up-regulation of nAChR
function in null mice. Up-regulated nAChR function in SNP mice persisted for only 1-4
days following withdrawal, however, and returned to basal levels afterwards. Nicotine
withdrawal also produced profound effects on DA release. SNP mice exhibited the
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greatest levels of single-pulse evoked DA release for only 1-3 days of nicotine
withdrawal, returning to levels comparable to those exhibited by WT. Notably, SNP mice
exhibited the lowest maximal DA release, evoked by 20 pulses at 20 Hz, as well as the
smallest ratios of phasic/tonic DA signals, during the entire period of 8 weeks of nicotine
withdrawal. These results suggest that SNP mice may lose a majority of DA reward
signals, and therefore experience withdrawal symptoms of greater severity. These
findings elucidate why heavy smokers carrying the SNP may derive greater pleasure
from tobacco, and also why they experience stronger cravings during withdrawal.
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A-C: DA signals were evoked by 1p (left), 5p (middle), and 20p (right) @ 20 Hz
recorded in the dorsolateral striatum in WT (A), null (B), and SNP (C) mice chronically
treated with SAC, Nic, nicotine withdrawal 1-3 d (WD 1-3 d), or 8 weeks (WD 8 wk)
D-E: All values were normalized to the corresponding control levels ([DA]1p) as 100%
indicated by the dashed line
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A-C: DA signals were evoked by a slow tonic stimulus (4 pluses @ 0.2 Hz after
achieving pseudo steady state) followed by a phasic stimulation (5 pulses @ 20 Hz)
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Fig 9. Expression of α5(SNP) nAChR subunit in catecholaminergic neurons of the
ventral tegmental area in transgenic mice lacking endogenous expression of the
subunit.
Figure
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Figure 9. Expression of α5(SNP) nAChR subunit in catecholaminergic neurons of the
ventral tegmental area in transgenic mice lacking endogenous expression of the
subunit. Transgenic mice lacking expression of the α5 nAChR subunit, expressing
Cre recombinase in catecholaminergic neurons (TH-Cre), were infused with a virus
(AAVDJ-DIO-α5SNP-copGFP) driving expression of a short nucleotide polymorphism
of the receptor subunit into the VTA. Successful expression was observed with some
sub-anatomical selectivity.
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α5-containing nAChRs Within the Interpeduncular Nucleus Influence the
Affective and Physical Symptoms of Alcohol Withdrawal
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Introduction
Alcohol abuse and dependence can be defined as a chronic relapsing disorder (Heilig &
Egli, 2006; McLellan, Lewis, O'Brien, & Kleber, 2000). Individuals proceed through
repetitive rounds of intoxication followed by cessation, and the resulting emergence of
withdrawal symptoms produces cravings and promotes relapse (Heilig & Egli, 2006;
McLellan et al., 2000). Understanding the mechanisms responsible for the affective and
physical symptoms that emerge after alcohol withdrawal may guide the development of
new therapeutics for the treatment of alcoholism. Given the high rate of heavy smoking
and nicotine dependence among alcoholics, modulation of the cholinergic system is a
possible target for cessation therapies.
Currently, varenicline, a partial nAChR agonist approved by the FDA as a smoking
cessation agent, is being evaluated as possible therapeutic for alcohol cessation.
Varenicline was initially identified as a possible alcohol cessation aid in laboratory
settings by observing smokers who were also heavy drinkers (McKee et al., 2009).
Subjects treated with varenicline reported significant reductions in the pleasant
subjective effects of alcohol accompanied by decreased cravings and alcohol intake. A
more recent study also reported that varenicline can improve smoking abstinence in
those with alcohol abuse or dependence while also reducing the number of alcoholic
drinks per drinking day in this population of smokers (Hurt et al., 2018). Additional
studies focused on alcohol dependent individuals undergoing cessation treatment also
observed reduced drinking behavior after varenicline (Fucito et al., 2011; Litten et al.,
2013; Mitchell, Teague, Kayser, Bartlett, & Fields, 2012; Plebani et al., 2013). Overall,
these studies support the conclusion that varenicline treatment significantly reduces both
alcohol cravings and heavy alcohol consumption independently of smoking behavior.
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Interestingly, varenicline seemed to have no effect on the total number of alcohol
abstinent days. Polymorphisms in CHRNA5, which encodes the α5 nAChR subunit have
also been associated with the intensity of alcohol response, age of initiation, and risk of
alcohol dependence in humans (Berrettini et al., 2008; Breitling et al., 2009; Choquet et
al., 2013; Grucza et al., 2010; Hallfors et al., 2013; Joslyn et al., 2008; J. C. Wang et al.,
2009).
We recently reported that deletion of the α5 nAChR subunit in mice enhances ethanolinduced hypothermia, hypnosis, and an anxiolytic-like response in comparison to wildtype controls (Dawson et al., 2018). The α5 KO mice showed reduced conditioned place
preference for ethanol, suggesting that the rewarding properties of ethanol are
decreased in the mutant mice. Interestingly, Chrna5 gene deletion had no effect on
basal ethanol drinking behavior, or ethanol metabolism, but did decrease ethanol intake
in the drinking in the dark (DID) paradigm following restraint stress. Another study also
showed that rats expressing the non-synonymous CHRNA5 variant rs16969968, which
has important consequences on smoking behavior in humans, consume more alcohol,
and exhibit increased relapse to alcohol seeking after abstinence (Besson, Forget,
Correia, Blanco, & Maskos, 2019).
Several symptoms of alcohol cessation are similar to those reported for nicotine,
suggesting shared neurocircuitry (Hughes, Higgins, & Bickel, 1994). Our lab has
demonstrated that continued use of nicotine attenuates physical symptoms in mice
experiencing alcohol withdrawal after receiving chronic alcohol and nicotine cotreatment, mimicking pharmacological activity in alcoholics who also smoke (E. Perez et
al., 2015a). In addition, we were able to precipitate somatic signs of withdrawal by
antagonism of nicotinic acetylcholine receptors (nAChRs) in mice treated with either
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ethanol or co-treated with both ethanol and nicotine. Pre-clinical research using various
nAChR subunit knockout mice has enabled the identification of specific roles for several
receptor subunits. For example, β2, α4, and α6 nAChR subunit knockout mice appear
insensitive to the rewarding properties of nicotine (Brunzell et al., 2006; Picciotto et al.,
1998; Pons et al., 2008). In contrast, β4 and α5 knockout mice exhibit attenuated
physical symptoms of nicotine withdrawal and are tolerant to the aversive effects of
nicotine (Salas, Cook, Bassetto, & De Biasi, 2004; Salas, Orr-Urtreger, et al., 2003;
Salas, Pieri, & De Biasi, 2004; Salas et al., 2009).
Our previous studies have established a role for the cholinergic system in the physical
symptoms of alcohol abstinence after either alcohol or alcohol co-administered with
nicotine. However, the alcohol withdrawal syndrome is associated with a variety of
affective symptoms that are longer-lived and are thought to be critical factors that
promote relapse, such as anxiety and depression (K. T. Brady & Lydiard, 1993; R. W.
Carlson et al., 2012; Hall & Zador, 1997; Heilig, Egli, Crabbe, & Becker, 2010; Hershon,
1977; McKeon, Frye, & Delanty, 2008; Saitz, 1998). The first objective of this study was
to investigate the role of the cholinergic system in the affective manifestations of alcohol
withdrawal. Given the potential influence of CHRNA5 polymorphisms on alcohol abuse,
a second goal of our experiments was to determine whether and how α5* nAChRs
modulate affective and physical symptoms of alcohol withdrawal.
Methods
Animals.
Experiments were conducted with four-month-old, male and female, C57BL/6J mice or
α5 null mice and their wild-type littermates. α5 mice were backcrossed into a C57BL/6J
background for a minimum of 10 generations (N10). Mice were weaned at postnatal day
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21, separated into same sex littermates, and housed in cages containing a maximum of
five animals. Genotyping was performed as previously described (Salas, Orr-Urtreger, et
al., 2003). Mice had ad libitum access to water and food pellets (Labdiet 5001, PMI®,
Brentwood, MO). Rooms were maintained on a 12-h light/dark cycle. Investigators were
blind to the genotype of each animal until the end of the experiment. All procedures were
approved by the Baylor College of Medicine and The University of Pennsylvania Animal
Care and Use Committees, and followed the guidelines for animal intramural research
from the National Institutes of Health.
Chronic alcohol treatment.
Mice were treated with either daily ethanol injections or a liquid ethanol diet. Both
methods have been used to induce withdrawal-associated symptoms 24 hours after
ethanol cessation. For the injection delivery method, mice received a daily injection of
saline or 2 g/kg ethanol for a minimum of 9 days. 9 mg/kg of 4-methylpyrazole (4MP,
Sigma-Aldrich, St. Luis, MO), an alcohol dehydrogenase inhibitor, was added to both the
control and ethanol solutions. All testing was performed during the light phase of the
cycle, 24 hours after the last injection. Mice treated with the liquid ethanol diet were
single housed with a nestlet to mitigate the effects of the stress associated with single
housing. During the first week of treatment, mice received the control liquid diet, which is
composed of the chocolate flavored, high protein nutritional drink, Boost® (Nestlé Health
Science, Lausanne, Switzerland), supplemented with 3 g/L vitamin mixture (MP
Biomedicals, LLC, Solon, OH) and 5 g/L mineral mix (ICN Biomedicals, Inc., Aurora, OH)
(Gilpin, Misra, & Koob, 2008; Verleye, Heulard, & Gillardin, 2009). Afterwards, mice were
randomly assigned to receive a 4% (vol/vol) ethanol liquid diet or control diets containing
an isocaloric equivalent amount of sucrose. Diets were prepared and changed daily, two
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hours into the dark phase of the light cycle. All testing was performed during the dark
phase of the light cycle. Spontaneous withdrawal was triggered by replacing the ethanol
diet with control diet 24 hours before testing. To analyze multiple behaviors, the ethanol
diet was replaced immediately after testing and mice had free access to the diet for a
minimum of 48 hours before a subsequent withdrawal session was induced. Precipitated
withdrawal was induced by giving mice a 1 mg/kg intraperitoneal (IP) injection of
mecamylamine 3 hours after a fresh ethanol diet was provided.
Open field arena (OFA).
Anxiety-associated behavior was measured during spontaneous and precipitated
ethanol withdrawal. Briefly, mice were placed in a clear Plexiglas arena (40 x 40 x 40
cm), and locomotor activity was measured for 30 min. The computer-operated system,
ANY-maze (Stoelting, Wood Dale Il) was used to monitor the total distance travelled
within the apparatus. The center ratio, i.e. the distance travelled in the center of the
arena/total distance traveled, was used as a measure for anxiety (Bouwknecht & Paylor,
2008; Gangitano et al., 2009; Salas, Pieri, Fung, Dani, & De Biasi, 2003).
Marble burying test (MBT).
Ethanol withdrawal-induced compulsive-like behavior was measured using the MBT.
Mice were placed in a cage containing a depth of 5 cm of bedding and 20 marbles
evenly spaced throughout the cage for 30 min. To be counted as buried, a minimum of
2/3 of each marble was covered in bedding (S. Umathe, Bhutada, Dixit, & Shende,
2008). The total number of marbles buried was used as a measure of compulsive-like
behavior.
Physical signs of ethanol withdrawal.
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After chronic alcohol treatment, physical signs of withdrawal were measured during
either precipitated or spontaneous ethanol withdrawal. Mice were placed into a home
cage and observed for 20 minutes. The following signs were recorded and their sums
used for comparisons: shaking, scratching, grooming, paw tremors, chewing, ptosis,
vocalizations, tail rattling, cage scratching, and writhing behaviors (Salas, Pieri, et al.,
2004; Salas et al., 2009).
Ethanol dose-response for locomotor activity.
Mice were tested for changes in locomotor behavior after an acute administration of
ethanol in the OFA. On the first day, mice received an IP injection of saline and were
placed in the OFA for 30 min. Over the course of five more days, mice received a single
injection of ethanol (0.1, 0.5, 1, 2, 3 mg/kg) or saline before being placed into the OFA.
Ethanol was administered at increasing doses with a minimum of 24 hours between
testing. All injections, including controls, contained 9 mg/kg of the alcohol
dehydrogenase inhibitor 4MP. Locomotor behavior was normalized to PBS (day 1) for
each dose.
Construction of mouse α5 over-expression plasmids for lentiviral & adeno-associated
viral vectors and synthesis of lentiviral particles.
The full-length mouse α5 cDNA (NM_176844.3) was amplified using primers to
incorporate the NotI restriction site on either side of the coding region. The cDNA was
then inserted into pLL3.7 plasmid (also prepared with NotI digestion) such that it is
expressed by the elongation factor 1 alpha (EF-1) AAV-DJ (Grimm et al., 2008)
promoter. An internal ribosomal entry site (IRES) is located after the α5 stop codon
followed by eGFP/copGFP as a reporter gene. The production of recombinant lentiviral
particles was done using the methods of Dr. Kazuhiro Oka (Associate Professor,
Department of Molecular and Cellular Biology, Baylor College of Medicine), and AAV
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particles by Marion Scott (Department of Psychiatry, University of Pennsylvania). The
particles are created through a triple transfection of psPAX2 (a packaging plasmid),
pMD2.G (an envelope plasmid, which has the vesiculo-stomatitis virus G-protein), a gift
of Dr. Didier Trono (École Polytechnique Fédérale de Lausanne, Switzerland), and α5
over-expression plasmid (or empty vector plasmid consisting of only eGFP/copGFP) into
293T cells using the calcium phosphate method as described previously (Lai et al.,
2012). The culture medium was exchanged after an initial 6-hour incubation. Culture
medium containing lentiviral particles was collected after 48 h incubation, and was
filtered through a 0.45 μm pore size cellulose acetate filter. Lentiviral vectors were
concentrated using sucrose gradient ultracentrifugation. Briefly, viral particle containing
media is transferred to Polyclear centrifuge tubes and underlaid with 20%
sucrose/DMEM. The tubes are then spun at 25000 RPM at 4°C for 2 hours in a
Beckman SW 40Ti Rotor. The supernatant is aspirated and the pellet is dissolved into
DMEM. Aliquots of 10 – 25 μL are transferred to cryotubes to be stored at -80°C until
use. Genomic integration and infectious unit titer of the lentiviral particles was
determined. HEK 293T cells were split at a density of1X105 cells per well with LV
particles diluted 1:10. After 48 hours, genomic DNA is harvested (Qiagen DNA Easy Kit)
and analyzed with Q-PCR targeting the viral WPRE component
Surgical Procedures.
Mice were anesthetized using isoflurane, then treated with bupivacaine, before being
stereotactically injected with lentiviral or AAV vectors expressing the α5 nAChR subunit
or GFP controls. The following coordinates (Paxinos & Franklin, 2004) relative to bregma
were used for cannula placement: MHb, anterior/posterior (AP) −1.70 mm, medial/lateral
(ML) ± 0.25 mm, dorsal/ventral (DV) −2.5 mm; IPN, 20° angle, AP −3.48 mm, ML + 0.17
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mm, DV −4.84 mm. A Nanoject or KD Scientific Syringe Pump was used to deliver 0.20 0.5 µL of virus at a rate of 0.01 μL - 0.15 µL/min. 2-5 minutes after infusion, the glass
pipette or syringe was removed, the hole in the skull was sealed with bone wax, and
sutures were placed to seal the incision. Mice recovered for a minimum of 2 weeks
before starting ethanol treatment.
Data analysis and statistics.
Data were examined by ANOVA or ANOVA with repeated measures, when appropriate.
The Newman-Keuls post-hoc test was used for specific comparisons.
Results
Mecamylamine precipitates ethanol withdrawal-related behaviors.
Our lab has previously shown that nAChRs play a role in the somatic manifestations of
withdrawal from ethanol treatment. In that study, wild-type, C57Bl/6J mice were treated
with chronic ethanol injections for 9 days before ethanol withdrawal was precipitated
using the non-selective nAChR antagonist, mecamylamine. Physical symptoms are one
of many behavioral manifestations that occur after ethanol cessation (Kurokawa,
Mizuno, & Ohkuma, 2013; Majchrowicz, 1975). Therefore, to test whether mechanisms
mediated by nAChRs influence the affective manifestations of withdrawal, we examined
withdrawal behaviors in mice exposed to a liquid ethanol diet.
Mice were placed on a 4% ethanol or control liquid diet for 6 weeks. On testing days, 3
hours after the liquid diet was refreshed, mice received an IP injection of 1 mg/kg
mecamylamine, and 10 min later mice were monitored for changes in behavior. We
previously determined that this mecamylamine dose is sufficient to precipitate withdrawal
symptoms and higher mecamylamine doses produce sedation in ethanol-treated mice.
Mice were tested in the open field arena (OFA, Fig 6.1A, B), marble burying test (MBT,
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Fig 6.1C) or for changes in somatic signs (Fig 6.1D). The total distance traveled in the
OFA arena was used as a measure of locomotion and it was unaffected by
mecamylamine injections (Fig 6.1A, Finjection[1,23]=0.465, p=0.502; Fdiet x
injection[1,23]=0.110,

p=0.743). However, there was a significant decrease in the total

distance traveled by ethanol treated animals, regardless of acute injection. This is
highlighted by a significant main effect of the liquid diet on locomotion
(FDiet[1,23]=10.418, p=0.004). Since the center ratio (measure of anxiety-associated
behavior; distance traveled in the center/total distance) is dependent on overall
locomotion, we chose to analyze control and ethanol treated groups separately. In
control-treated mice, mecamylamine had no effect on the center ratio (Fig 6.1B; Student
t test, p=0.451). In contrast, mecamylamine produced a decrease in the center ratio of
ethanol-treated mice, which did not meet statistical significance (Student t test, 0.058).
Data from our lab and others (S. Umathe et al., 2008) show that ethanol withdrawal
induces an increase in compulsive-like behavior when measured in the MBT during
spontaneous ethanol withdrawal. Mecamylamine injections in control diet-treated
animals had no effect on marble burying behavior. However, in ethanol treated mice,
mecamylamine injections led to a significant increase in the number of marbles buried,
suggesting that a nAChR mechanism influences the manifestation of compulsive-like
behavior during ethanol withdrawal. Statistical analysis revealed a significant interaction
between ethanol treatment and mecamylmine injections (FDiet x injection[1,24]=12.765,
p=0.002).
In our previous study, we were able to precipitate somatic signs in mice treated with
ethanol injections. However, we wanted to replicate this result using a more chronic
ethanol treatment. Similar to what was previously observed, a 1mg/kg
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Figure 6.1: Mecamylamine can precipitate affective and physical signs of ethanol
withdrawal. C57BL/6J mice were treated with either control or ethanol-containing liquid
diet for six weeks. Mice had access to diet until testing. A. Mecamylamine injection
(white bars) did not have any effect on the total distance traveled within the open field
arena. B. nAChR antagonism did produce a trend towards increased anxiety-like
behavior in mice consuming the ethanol diet. C. When tested in the marble burying test,
mecamylamine-treated mice buried more marbles than control-injected (black bars) and
control diet fed mice. D. Increases in the total number of somatic signs were only
observed in ethanol-fed mice receiving mecamylamine injections. Ns for all figures are 86 mice for each experimental group. **p<0.01 compared to control-diet and controlinjected mice.
mecamylamine injection is sufficient to precipitate somatic signs during withdrawal in
mice treated with ethanol liquid diet (Fig 6.1D, FDiet x Injection[1,23]=60.202, p<0.001). The
number of precipitated signs in liquid ethanol diet-treated mice was similar to what is
induced by mecamlyamine in mice treated with ethanol injections or chronic nicotine
(Salas, Pieri, et al., 2004; Salas et al., 2009)). Given that nAChR antagonism can
precipitate somatic signs in ethanol treated mice, regardless of the type of treatment,
these data suggest that nAChRs modulate the physical signs of ethanol withdrawal.
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α5 null mice show a normal dose-response to acute ethanol injections.
Since α5 null mice and their wild-type littermates were chronically treated with ethanol
injections containing the alcohol dehydrogenase inhibitor, 4MP, it was important to
establish that α5 null mice did not differ from their wild-type littermates in their responses
to the acute effects of ethanol. A dose response curve was measured by injecting mice
with increasing concentrations of ethanol (0, 0.1, 0.5, 1, 2, or 3 mg/kg) + 9 mg/kg 4MP
before being placed in the OFA over the course of six days. Low doses of ethanol
produced small changes in locomotor behavior in both α5 null and wild-type mice. Larger
doses (2, 3 mg/kg) of ethanol significantly reduced locomotor behavior in all mice.
Overall, there was no significant interaction between genotype and ethanol dose (Fig
6.2, Fgeno x ethanol[5,55]=0.470, p=0.797) or main effect of genotype (Fgeno[1,11]=0.017,
P=0.900) on locomotor behavior after acute ethanol injections.
A short-term ethanol treatment suggests a role for α5 nAChRs in ethanol withdrawal.

Normalized Distance

30
20

Wild Type
a5 null

10
0
-10
-20
-30
-40
-50
-60
0

0.1

0.5

1

2

3

Dose of ETOH (g/Kg)

225

Figure 6.2: α5 null mice do not differ from wild-type littermate in acute effects of ethanol.
α5 null mice and their wild-type littermates were treated with various doses of ethanol (0,
0.1, 0.5, 1, 2 and 3 g/kg) + 9mg/kg 4MP before being placed in the open field arena.
Distance traveled for each mouse was normalized to the distance traveled after saline
control injection. Although ethanol affected locomotor activity, there was no difference
overall between the two genotypes. n = 6 for wild-type, 7 for α5 null mice.
Alcohol withdrawal produces a wide range of affective and physical symptoms. Since
mecamylamine administration can precipitate various symptoms of ethanol withdrawal,
we tested the hypothesis that α5* nAChRs influence the manifestations of ethanol
withdrawal-induced behaviors. α5 null mice have previously been shown to be resistant
to the physical symptoms of nicotine withdrawal (Salas et al., 2009). We also showed
that neuronal structures that express the α5 nAChR subunit (the MHb-IPN axis) are
important modulators of somatic signs during nicotine and ethanol cessation (Salas et
al., 2009). Therefore, α5 null mice and their wild-type littermates were treated with
ethanol injections to evaluate the role of this nAChR subunit in ethanol withdrawal.
Since anxiety-associated behavior is cited as a common symptom of ethanol withdrawal,
and mecamylamine injections produced a strong trend towards increased anxietyassociated behavior (Fig 6.1B), mice were tested in the OFA for spontaneous withdrawal
24 hours after the last ethanol injection. No significant differences in the total distance
traveled by mice treated with either control or ethanol solutions - of either genotype was observed, suggesting that locomotor behavior was not affected by ethanol
withdrawal (Fig 6.3A; Fwithdrawal x genotype[1,35]= 1.21, p=0.65). Unlike the total distance
traveled, the center ratio (distance traveled in the center/total distance traveled) for
ethanol withdrawal was significantly different relative to control-treated mice in a
genotype-dependent manner (Fig 6.3B; Fwithdrawal x genotype[1,35]= 4.24, p=0.047). Ethanol
withdrawal induced a significant increase in anxiety-associated behavior in wild-type
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mice only, suggesting that α5* nAChRs play a role in regulating the manifestation of
anxiety during ethanol withdrawal.
In addition to the OFA, mice were assessed with the MBT for changes in compulsive-like
behavior during ethanol withdrawal. Ethanol-treated wild-type mice buried significantly
more marbles than control-treated mice. Unlike their wild-type littermates during ethanol
withdrawal, α5 null mice did not bury more marbles (Fig 6.3C, Fwithdrawal x
genotype[1,26]=9.688,

p=0.004), suggesting that α5*nAChRs are important for compulsive-

like behavior after ethanol cessation.
α5* nAChRs have been shown to play a role in somatic signs during nicotine withdrawal.
Therefore, we tested the hypothesis that they are also important for physical signs of
ethanol withdrawal. Significant increases in somatic signs during ethanol withdrawal
were only observed in wild-type mice (Fig 6.3D; Fwithdrawal x genotype[1,38]=38.367, p<0.001).
Since there was no effect of ethanol withdrawal in α5 null mice, α5* nAChRs also likely
play a role in the manifestation of physical signs during ethanol cessation.
α5 null mice treated with an ethanol liquid diet do not exhibit affective or somatic signs
during ethanol withdrawal.
Testing with daily ethanol injections suggests that expression of the α5 nAChR subunit is
important for ethanol withdrawal-associated behaviors. However, it was important to
show that this relationship remains valid when mice are administered a longer course of
ethanol treatment, such as a liquid ethanol diet. Mice were provided with control or a 4%
ethanol liquid diet for six weeks. Behavioral testing was conducted 24 hours after the
replacement of the ethanol-containing diet with control diet. In the OFA, similar to what
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Figure 6.3: α5 null mice treated with ethanol injections do not display affective or
physical signs of withdrawal. α5 and their wild-type littermates were treated daily with 2
g/kg ethanol + 9mg/kg 4MP or control IP injections. All testing took place 24 hours after
the last ethanol injection. A. Neither ethanol withdrawal nor genotype had an effect on
the locomotor behavior in the open field arena. B. The center ratio, a measure for
anxiety-like behavior, was significantly decreased in wild-type mice undergoing ethanol
withdrawal. No effect on the center ratio was observed in α5 null mice during withdrawal.
C. In the marble burying test, upon ethanol withdrawal, wild-type mice undergoing
ethanol withdrawal buried significantly more marbles, suggesting that α5* nAChRs play a
role in compulsive-like behavior after alcohol cessation. D. Increases in physical signs of
withdrawal were only observed in wild-type, ethanol-treated mice. N’s are 6-14 mice per
experimental group. **p<0.01 compared to control-treated mice and wild-type mice.
was observed with the short-term ethanol treatment, locomotor behavior was not
affected by either genotype or ethanol withdrawal. (Fig 6.4A; Fwithdrawal x genotype[1,41]=
0.08, p=0.78). The center ratio decreased significantly in wild-type mice undergoing
ethanol withdrawal, suggesting an increase in anxiety-associated behavior (Fig. 6.4B).
Interestingly, α5 null mice did not exhibit significant changes in the center ratio compared
to control treated null mice. Statistical analysis confirmed a significant interaction
between withdrawal behavior and genotype (Fwithdrawal x genotype[1,41] =6.14, p= 0.017).

228

Mice were also tested in the MBT during spontaneous withdrawal occurring 24 hours
after the removal of ethanol diet. During withdrawal, wild-type mice buried significantly
more marbles than their control-treated littermates, suggesting that ethanol withdrawal
leads to increased compulsive-like behavior (Fig 6.4C; Fwithdrawal x genotype[1,44]=24.644,
p<0.001). Similar to the previous result obtained in α5 null mice treated with ethanol
injections, withdrawal did not increase the total number of marbles buried.
Lastly, we measured somatic signs during ethanol withdrawal. Consistent with our
previous result, somatic signs were significantly elevated in wild-type mice undergoing
ethanol withdrawal while α5 null mice did not manifest physical symptoms and behaved
like control-treated mice (Fig 6.4D). Statistical analysis revealed a significant interaction
between withdrawal and genotype, F[1,47]=29.022, p<0.001. Overall, we observed that
α5* nAChRs affect the manifestations of ethanol withdrawal following both short- and
long-term ethanol treatment.
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Figure 6.4: α5 null mice treated with a liquid ethanol diet do not manifest ethanol
withdrawal symptoms. α5 and their wild-type littermates were provided with either a
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control or ethanol-containing liquid diet for six weeks. All testing took place 24 hours
after ethanol-diet was replaced with control-diet. A. Total distance traveled was not
affected by either ethanol withdrawal or genotype in the open field arena. B. Similar to
what was observed in ethanol-injected mice, the center ratio was significantly decreased
in wild-type animals only during withdrawal, but anxiety levels did not change in α5 null
mice. C. In the marble burying test, only wild-type mice undergoing ethanol withdrawal
buried significantly more marbles, suggesting that α5* nAChRs play a role in
compulsive-like behavior after cessation of alcohol administration. D. Increases in
physical signs of withdrawal were only observed in wild-type, ethanol-treated mice. n =
6-10 mice per experimental group. **p<0.01 compared to control-treated mice and wildtype mice.

Re-expression of the α5 nAChR subunit in the IPN of null mice rescues compulsive-like
behavior and somatic signs associated with ethanol cessation.
We have previously shown that the MHb and IPN play roles in the emergence of
physical signs associated with nicotine, ethanol, or concurrent nicotine and ethanol
cessation (Salas et al., 2009). In situ hybridization studies done by our lab and others
(Salas, Orr-Urtreger, et al., 2003; Wada, McKinnon, Heinemann, Patrick, & Swanson,
1990) have shown that α5* nAChRs are expressed at low densities within the MHb and
at high densities in the IPN. Given that our current results using mecamylamine and α5
null mice suggest that the nicotinic system plays a role in both affective and physical
signs of ethanol withdrawal, we hypothesized that α5* nAChRs expressed within the IPN
modulate these behaviors. Although the MHb also expresses the α5 subunit, we chose
to focus on the IPN due to it being the primary recipient of MHb output.
Viral vectors were produced and packaged by the Baylor College of Medicine Viral
Vector Core Facility and in our lab at the University of Pennsylvania. α5 null mice were
infused into the IPN with viral particles expressing either a control vector encoding
copGFP or a vector encoding α5 subunit and copGFP. Mice recovered from the surgery
for one week before being single housed. Control or alcohol-containing liquid diet was
introduced two weeks after surgery and was provided daily for a total of 6 weeks before
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testing sessions began. Mice infused with viruses expressing only copGFP exhibited no
differences in total ethanol consumption compared to those infused with viruses
expressing the α5 subunit. All mice were tested in either the OFA, MBT, or for changes
in somatic signs 24 hours after ethanol cessation.
In the OFA, viral expression of α5 did not affect the total distance traveled in the maze
(Fig 6.5A; Fvirus[1,39]=0.217, p=0.644). Similar to our previous results, ethanol withdrawal
did not produce changes in locomotion and there was no significant interaction of
ethanol treatment with viral treatment (Fwithdrawal[1,39]=0.695, p=0.410; Fvirus x
withdrawal[1,39]=0.366,

p=0.549). In addition, we compared the locomotor behavior of virus-

injected mice fed the control liquid diet to what was previously observed in α5 null mice
not treated with viral infusions (Fig 6.5A, red line). Overall, mice infused with viral vectors
did not differ from non-injected α5 null mice (Fvirus[2,31]=0.473, p=0.628). When anxietyassociated behavior was analyzed, we found that there was no significant difference
between α5 null mice expressing copGFP or the α5 nAChR subunit in the IPN (Fig
6.5B). Interestingly, ethanol withdrawal did not have a significant effect on the center
ratio (Fvirus x withdrawal[1,39]=0.592, p=0.446), suggesting that re-expression of α5* nAChRs
within the IPN is not sufficient to restore anxiety-associated behavior during ethanol
withdrawal. However, when we plotted the center ratio baseline behavior of α5 null mice
that were not infused with virus, we found that all virus-treated animals exhibited
significantly lower center ratios regardless of treatment (Fig 6.5B, redline;
Fvirus[2,31]=3.711, p=0.036), making it harder to confidently conclude that α5* nAChRs
within the IPN are having no effect on anxiety-associated behavior during ethanol
withdrawal. These experiments are currently being repeated.
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Compulsive-like behavior during withdrawal was measured by testing mice in the MBT
24 hours after alcohol removal. The total number of marbles buried by α5 null mice
expressing the control vector did not decrease upon ethanol withdrawal (Fig 6.5C). In
mice expressing the α5 nAChR subunit, there was a significant increase in the total
number of
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Figure 6.5: Re-expression of the α5 nAChR subunit in the IPN rescues compulsive and
physical signs of ethanol withdrawal in α5 null mice. α5 null mice were injected with viral
particles expressing either the α5 nAChR subunit + copGFP or solely copGFP. Two
weeks after viral infusions, mice were provided with either a control or ethanol-containing
liquid diet for six weeks. All testing took place 24 hours after the ethanol-diet was
replaced with a control diet. A. Total distance traveled was not affected by either ethanol
withdrawal or viral expression in the open field arena. B. No significant difference was
observed in the center ratio of mice injected with the α5 viral vector or treated with
ethanol. Compared to the baseline behavior of α5 null mice not infused with any viral
particles (red line), all control-fed mice displayed a significant decrease in the center
ratio. C. In the marble burying test, mice expressing the α5 nAChR subunit undergoing
ethanol withdrawal buried significantly more marbles, suggesting that α5* nAChRs within
the IPN play a role in compulsive-like behavior after alcohol cessation. D. Increases in
physical signs of withdrawal were only observed in ethanol-treated mice expressing the
α5 nAChR subunit in the IPN. n = 9-12 mice per experimental group. *p<0.05 and
**p<0.01 compared to control-treated mice and cop-GFP injected mice.

marbles buried during ethanol withdrawal, suggesting that α5* nAChR expression within
the IPN is important for the manifestation of compulsive-like behavior during ethanol
withdrawal. Statistical analysis also reflected a significant interaction between α5 viral
expression and ethanol withdrawal (F[1,39]=11.778, p=0.001). When we compared the
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baseline behavior of α5 null mice that were not infused with viral vectors to control-fed
viral-treated mice (Fig 6.5C, red line), we found that there was no significant shift in
baseline behaviors (Fvirus[2,33]=0.092, p=0.912). Overall, we can confidently conclude
that α5* nAChRs within the IPN play a role in the compulsive-like behaviors induced by
ethanol withdrawal.
Our lab has previously highlighted the role of nAChRs within the IPN in the modulation of
somatic signs of withdrawal after ethanol and nicotine cessation (Salas et al., 2009). In
addition, we have explored the role of the IPN in mice co-treated with nicotine and
ethanol. Since the α5 nAChR subunit is highly expressed within the IPN, we tested the
hypothesis that the nAChRs involved in the physical manifestations of ethanol
withdrawal contain the α5 nAChR subunit. Somatic signs were not affected by ethanol
withdrawal in α5 null mice expressing solely copGFP, while re-expression of the α5
subunit in the IPN led to the emergence of physical signs of ethanol withdrawal (Fig
6.5D). Statistical analysis confirmed a significant interaction between α5 expression and
ethanol withdrawal (F[1,39]=4.392, p=0.043). Interestingly, when control-virus injected
mice were compared to non-virus treated α5 null mice (Fig 6.5D, red line), there was a
significant increase in baseline somatic sings in virus-infused animals (Fvirus[2,33]=6.702,
p=.004). Despite this shift in baseline, it remained evident that re-expression of α5*
nAChRs within the IPN is sufficient to reinstate physical signs of ethanol withdrawal.
Discussion
The symptomology of alcohol and nicotine withdrawal is similar, suggesting a common
regulatory neuronal circuit (Hughes et al., 1994). Using techniques previously utilized to
understand the mechanisms underlying nicotine withdrawal, we showed that similar
nicotinic cholinergic mechanisms and brain areas were implicated in ethanol withdrawal
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(Salas et al., 2009). The non-selective nAChR antagonist, mecamylamine, has been
shown to precipitate somatic signs of withdrawal in mice treated with chronic nicotine
and ethanol injections (Salas, Pieri, et al., 2004; Salas et al., 2009), and we used the
same approach to precipitate an array of withdrawal behaviors in mice chronically
treated with a liquid ethanol diet. Mecamylamine led to a significant increase in
compulsive-like behavior and physical signs in ethanol-treated mice and produced a
strong trend towards increased anxiety-associated behavior without affecting total
locomotion.
Pre-clinical studies with mice that overexpress the human
CHRNA5/CHRNAα3/CHRNBβ4 gene cluster of α5, α3 and β4 nAChR subunits found
that global overexpression results in a significant decrease in alcohol consumption
(Gallego et al., 2012). Interestingly, the α5 nAChR subunit has also been shown to
influence nicotine self-administration (Fowler et al., 2011; Morel et al., 2013). It has also
been established to play a role in the physical manifestations of nicotine withdrawal
(Salas et al., 2009). Results from ethanol injections, and a longer treatment using a
liquid ethanol diet, suggest that α5* nAChRs influence anxiety-associated behavior,
compulsive-like behavior, and physical symptoms during ethanol abstinence. We tested
a small group of α5 null mice in the elevated plus maze (EPM), which is considered a
behavioral measure of anxiety-like behavior. In the EPM, α5 null mice did not exhibit a
reduced entry ratio or time spent in the open arms that were exhibited by their wild-type
littermates during ethanol withdrawal (data not shown). It should be noted the α5 null
mice display an anxiolytic phenotype in the EPM in basal conditions (Gangitano et al.,
2009). We therefore chose to focus on the OFA as a measure of anxiety-like behavior.
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Given the number of brain structures in which the α5 nAChR subunit is expressed, and
the high density of expression found in the IPN (Salas, Orr-Urtreger, et al., 2003), we
decided to re-express the α5 subunit in the IPN. Previous studies using mecamylamine
had shown that the MHb and IPN are involved in nicotine and ethanol withdrawal (Salas
et al., 2009). We used hippocampus and the ventral tegmental area as control sites,
neither of which influenced the modulation of physical signs during withdrawal from
either nicotine or ethanol. In the experiments presented here, re-expression of α5*
nAChRs in the IPN of α5 null mice resulted in significant increases in compulsive-like
behavior and physical signs during withdrawal. Interestingly, re-expression in the IPN did
not have an effect on anxiety-associated behavior during withdrawal. However, baseline
anxiety-associated behaviors exhibited by control-diet fed mice, infused with either α5or copGFP-expressing viruses, were altered. Furthermore, the animals appeared more
anxious than α5 null mice that did not receive viral infusions. Given that the absence of
α5* nAChRs is protective against the manifestations of anxiety-associated behavior
induced by ethanol withdrawal, it is possible that the expression of α5* nAChRs in the
IPN alone is insufficient to modulate anxiety-associated behavior induced by ethanol
withdrawal. The MHb, which also expresses the α5 subunit, is another potential region
that has been shown to play a role in drug withdrawal and affective behaviors (P. R.
Baldwin, Alanis, & Salas, 2011; Gorlich et al., 2013; Lecourtier & Kelly, 2007; Mathuru &
Jesuthasan, 2013; Mirrione et al., 2014; Neugebauer et al., 2013; Panchal et al., 2005;
Salas et al., 2009; Viswanath et al., 2013; Yamaguchi et al., 2013).
In conclusion, our study has highlighted α5* nAChRs as important modulators of the
behavioral manifestations of alcohol withdrawal, suggesting that this receptor subtype
could be targeted to assist alcohol cessation treatments. Given that an absence of α5
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nAChR subunit expression reduces withdrawal-induced behaviors, drugs targeting
receptors including this subunit may prove to be superior to varenicline, which seems to
affect how much a person drinks during a drinking session without affecting overall
cessation rates (Litten et al., 2013; McKee et al., 2009; Muller, Geisel, Banas, & Heinz,
2014; Plebani et al., 2013). We also found that α5* nAChRs within the IPN influence the
emergence of compulsive behavior and physical signs of alcohol withdrawal.
Accordingly, therapeutics that modify the activity of the MHb-IPN axis may be worth
evaluation as candidates for the treatment of alcoholism.
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Figure 5.6

α5-/- Mice

Figure 6.6. Viral rescue of α5 nAChR subunit expression in α5 null mice. Mice lacking
expression of the α5 nAChR subunit were infused with a virus (AAVDJ-α5-copGFP)
driving expression of the receptor subunit into the IPN. Successful expression was
observed with some sub-anatomical selectivity.
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The medial habenula & interpeduncular nucleus is critical in addiction,
anxiety, and mood regulation
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Abstract
Abstinence from chronic use of addictive drugs triggers an aversive withdrawal
syndrome that compels relapse and deters abstinence. Many features of this syndrome
are common across multiple drugs, involving both affective and physical symptoms.
Some of the network signaling underlying withdrawal symptoms overlaps with activity
that is associated with aversive mood states, including anxiety and depression. Given
these shared features, it is not surprising that a particular circuit, the dorsal diencephalic
conduction system, and the medial habenula and interpeduncular nucleus (MHb-IPN) in
particular, have been identified as critical to the emergence of aversive states that arise
both as a result, and independently, of drug addiction. As the features of this circuit
continue to be characterized, the MHb-IPN axis is emerging as a viable target for
therapeutics to aid in the treatment of addiction to multiple drugs of abuse as well as
mood-associated disorders.
Introduction
Drug addiction is a substantial public health and societal burden, causing over $700
billion in annual costs associated with crime, lost work productivity, and healthcare
(National Center for Chronic Disease et al. 2014, Sacks et al. 2015, Center 2011).
Although they have unique pharmacological effects, all addictive drugs share actions on
the dopaminergic system that contribute to their rewarding effects (Di Chiara & Imperato
1988). The withdrawal syndrome that follows cessation of chronic use has also been
identified as having common substrates. Additionally, epidemiological data have
identified Aanxiety and mood disorders, as the first and second most common
psychiatric disorders in the United States (Kessler et al. 2005), may also reflect
alterations in overlapping circuits. Interestingly, Rresearch characterizing the
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mechanisms underlying addiction, withdrawal, and aversive moods states has implicated
a common pathway. The medial habenula (MHb) and interpeduncular nucleus (IPN) are
two components of the dorsal diencephalic conduction system (DDC), a highly
evolutionarily conserved pathway which, along with the medial forebrain bundle, conveys
signals from the limbic forebrain to the midbrain and hindbrain (Bianco & Wilson 2009,
Okamoto et al. 2012). In higher vertebrates, the DDC has evolved to be a significant
pathway by which the forebrain regulates midbrain motivation and reward circuitry
(Sutherland 1982). The epithalamic MHb receives inputs from a very variety of
structures, including the triangular septal nucleus, septofimbral nucleus, ventral
tegmental area, and raphe nuclei (Herkenham & Nauta 1977, Lecourtier & Kelly 2007,
Phillipson & Pycock 1982). Studies also indicate that the MHb receives inputs from the
nucleus accumbens (Sutherland 1982), locus coeruleus and superior cervical ganglion
(Gottesfeld 1983), diagonal band nucleus and medial septum (Qin & Luo 2009), as well
as the median raphe nucleus (Sutherland 1982, Conrad et al. 1974). Some studies
suggest that the MHb may project to the pineal body (Ronnekleiv & Moller 1979,
Guglielmotti & Cristino 2006), as and it may also send sparse efferents to the VTA
(Cuello et al. 1978), as well as extend boutons en passant to the LHb (Kim & Chang
2005). However, the MHb It then sends its most dense efferent projections to the
mesencephalic IPN through the core of the fasciculus retroflexus (FR) (Herkenham &
Nauta 1979), which, in turn, sends efferents to a wide variety of mid- and hindbrain
structures implicated in regulating affective states. Those structures, includeing the
dorsal tegmental nucleus (Shibata & Suzuki 1984), hippocampus (Shibata & Suzuki
1984, Baisden et al. 1979, Wyss et al. 1979), lateral hypothalamus (Massopust &
Thompson 1962, Morley 1986, Kemali & Guglielmotti 1982, Smith et al. 1980), ventral
tegmental area (Hayakawa et al. 1981, Smaha & Kaelber 1973), septum, preoptic area,
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and nucleus of the diagonal band (Smaha & Kaelber 1973, Morley 1986). Additionally,
there are data indicating projections from the IPN to the dorsal and median raphe nuclei
(Groenewegen et al. 1986, Behzadi et al. 1990), as well as the lateral habenula
(Massopust & Thompson 1962, Morley 1986). Though the major source of innervation in
the IPN arrives from the MHb, there is evidence of afferents arriving from structures
including the horizontal limbs of the diagonal band nucleus (Contestabile & Flumerfelt
1981), substantia innominata (Vertes & Fass 1988), infralimbic region of the medial
prefrontal cortex (Takagishi & Chiba 1991), preoptic nucleus (Shibata et al. 1986),
hypothalamic nuclei (Contestabile & Flumerfelt 1981, Hamill & Jacobowitz 1984),
supramammillary nucleus (Contestabile & Flumerfelt 1981, Hamill & Jacobowitz 1984),
raphe nuclei (Conrad et al. 1974), nucleus incertus (Hamill & Jacobowitz 1984) and
dorsal tegmental nucleus (Hamill & Jacobowitz 1984). While some of these anatomical
studies were conducted recently, some were conducted many years ago, so
corroborative reproducibility experiments are likely warranted, given the availability of
more targeted tracer techniques. A summary of these afferent and efferent projections
for the MHb and IPN are available in figure 1 and tables 1 and 2.
While both are fairly small anatomical structures, the MHb and IPN host the synthesis
and release of a wide variety of neurotransmitters. Studies have identified acetylcholine
(McCormick & Prince 1987), substance P (SP) (Burgunder & Young 1989, De Biasi et al.
2016, Jackson et al. 2015), glutamate and GABA (Qin & Luo 2009), norepinephrine
(Gottesfeld 1983), serotonin (Kinsey et al. 2001), ATP (Edwards et al. 1992, Sperlagh et
al. 1998), interleukin-18 (Sugama et al. 2002), and a host of neuropeptides in the MHbIPN pathway (McLaughlin et al. 2015, Kopp et al. 2002). Additionally, the MHb-IPN
circuit has been implicated in mechanisms that mediate some of the acute and aversive
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features of withdrawal from multiple drugs, including alcohol, opiates, nicotine, opiates,
and other stimulants. This review will focus on studies that specifically implicate the
DDC, and the MHb-IPN pathway in particular, in the neurophysiology associated with
both addiction and mood-related psychiatric conditions, with an eye towards the
possibility of identifying druggable targets within the pathway that may yield therapeutic
benefits for the treatment of both sets of conditions.
Alcohol
The pharmacological activity of ethanol encompasses a broad range of targets in the
central nervous system, and studies have indicated that the MHb-IPN circuit represents
a significant component of its affective and behavioral effects. Local cerebral glucose
utilization rates in alcohol-preferring rats are significantly elevated in both divisions of the
habenular complex relative to non-preferring rats (Smith et al. 2001). Data from our lab
have identified an interaction between ethanol and nicotine withdrawal, as well as a role
played by nAChRs in the MHb or IPN in ethanol withdrawal. Specifically, intraperitoneal
injection of a non-selective nAChR antagonist, mecamylamine, is capable of
precipitating a withdrawal syndrome in mice chronically treated with ethanol. Withdrawal
symptoms are also exhibited when mecamylamine is infused into the MHb or IPN, but
not the ventral tegmental area (VTA) or hippocampus (Perez et al. 2015), indicating that
nAChR blockade in the MHb-IPN circuit is sufficient to precipitate the ethanol withdrawal
syndrome. Another recent finding has identified changes in signaling molecules
associated with apoptosis, inflammation, neurodegeneration, and senescence in the
habenula, among other structures, following chronic treatment with ethanol (Roux et al.
2015). Receptor knock-out studies have shown that neuropeptide Y (NPY) acts as an
important regulator of alcohol intake, with knock-out mice exhibiting increased alcohol
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ingestion relative to wild-type mice (Thiele et al. 2002). More recently, it was shown that
alcohol-preferring rats exhibit an absence of NPY mRNA in the MHb while non-preferring
rats do have a signal of mRNA for the neuropeptide (Hwang et al. 2004). Taken
together, the literature suggests that activity in the MHb-IPN circuit likely modulates the
effects and ingestive behavior of alcohol, as well as its withdrawal symptoms. Variations
between individuals in the signaling within this circuit may underlie predispositions to
pathological intake patterns.
Opioids
Drug overdose represents the leading cause of accidental death in the United States
(Medicine 2016), and addiction to opioids, including both illicit substances, such as
heroin, and prescription analgesics, such as oxycodone and fentanyl, drive this epidemic
(Prevention 2015). Interestingly, overdose fatalities, sales, and substance use disorder
treatment admissions have increased in parallel from 1999 to 2008 (Paulozzi 2014),
indicating a significant need for improved treatments for substance abuse disorder and
opioid addiction in particular.
One of the densest regions of opioid receptor expression is the DDC, and the MHb, FR,
and IPN are particularly rich with expression (Gackenheimer et al. 2005, Gardon et al.
2014, Zhu et al. 1998, Sim-Selley et al. 1999). Additionally, there is a plethoradiversity of
neurotransmitters that the MHb-IPN circuit synthesizes or is sensitive to, including
acetylcholine, neurokinins, interleukin-18 (IL-18) (Viswanath et al. 2013, Sugama et al.
2002), and purines (Pankratov et al. 2009, Pankratov et al. 2006, Kanjhan et al. 1999)
that may be modulated by the activities of opioids. Given the broad efferent targets of
the IPN that are known to regulate affect and substance use, including thethe raphe
nuclei, nucleus incertus, lateral septum, lateral dorsal tegmentum (LDTg), and
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hypothalamus (Sutherland 1982, Ryan et al. 2011, Bianco & Wilson 2009, Morley 1986,
Gardon et al. 2014), the MHb-IPN circuit is likely an anatomical node, centrally involved
in the signaling underlying both acute effects of, and withdrawal from, opioids. Evidence
over the past several decades has corroborated such a role. For example, lesions of the
MHb have been observed to induce hyperalgesia and increase the analgesic efficacy of
morphine (Meszaros et al. 1985), and morphine is capable of inducing analgesia when
infused directly into the habenular complex (Cohen & Melzack 1985). When evaluating
the effects of intracranial self-stimulation of the VTA on opioid release, a unique
reduction of endogenous opioid binding was observed in the MHb (Stein 1993).
Following chronic morphine administration, altered acetylcholinesterase (AChE) activity
is observed in the MHb following chronic morphine administration, and precipitation of
withdrawal with the opioid receptor antagonist, naloxone, resulted in altered AChE
activity in the IPN (Neugebauer et al. 2013). Additionally, chronic morphine
administration induced a trend towards increased nAChR expression in the MHb
(Neugebauer et al. 2013). Acute administration of 18-methoxycoronaridine (18-MC), an
α3β4 nAChR antagonist, reduced signs of naltrexone-precipitated withdrawal from
morphine (Rho & Glick 1998), an effect that appears to be mediated by activity in the
MHb and IPN (Panchal et al. 2005, Taraschenko et al. 2007). 18-MC was also observed
to reduce morphine self-administration upon intracranial infusion into the MHb or IPN
(Glick et al. 2006). In the MHb, RSK2, a component of the ribosomal S6 kinase 90kDa
family, which act as substrates of extracellular-regulated kinases 1 & 2 to regulate
cytosolic and nuclear targets, has been identified as critical to morphine-induced
analgesia (Darcq et al. 2012). Finally, the LDTg, an efferent target of the IPN, has been
shown to exhibit significant increases in vesicular ACh transporter markers following
chronic morphine administration (Bajic et al. 2015, Gardon et al. 2014). Altogether, these
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data implicate the DDC, and MHb-IPN circuit in particular, in the signaling underlying
some of the acute effects of opioids, as well as aspects of their addictive properties.
Furthermore, adaptations in cholinergic components may represent a significant facet of
these changes.
Nicotine and Psychomotor Stimulants
The role of the lateral division of the habenular complex (LHb) in regulating
dopaminergic activity in the VTA via the rostromedial tegmental nucleus has been
established, and represents an important mechanism by which aversion and addiction
are modulated (Barrot et al. 2012, Sanchez-Catalan et al. 2016, Jean-Richard Dit
Bressel & McNally 2014, Quina et al. 2015). Both the LHb and MHb send dense efferent
projections through the fasciculus retroflexus, and anatomical studies suggest that
projections emerging from the MHb course through the core and those from the LHb
through the sheath of thise dense fiber bundle (Bianco & Wilson 2009). Degeneration of
dopaminergic fibers in the caudate Following chronic exposure to psychomotor
stimulants like amphetamines, degeneration of dopaminergic fibers in the caudate
washad been observed decades ago (Ellison et al. 1978). In addition to dopaminergic
fibers, similar degeneration has been observed in axons populating the sheath of the FR
following chronic exposure to cathinone, cocaine, amphetamine, methamphetamine, and
MDMA (Ellison 2002, Carlson et al. 2000). In rats treated with cocaine, increased
expression of Fos-protein, a marker of neuronal activation, was observed in the MHb
associated with cue-induced reinstatement (James et al. 2011). Additionally, similar to its
interference with opioid-derived reward, 18-MC administration results in reduced
methamphetamine self-administration in rats (Glick et al. 2000). Once again, direct
infusions directly into the MHb and/or IPN induced similar reductions of self246

administration, with what appears to be greater efficacy when infused into the IPN,
suggesting that activity in the MHb-IPN circuit likely mediates this effect (Glick et al.
2008). Finally, methamphetamine and cocaine have been shown to increase
extracellular concentrations of ACh in the IPN, with cocaine inducing a dose-dependent
biphasic effect (Hussain et al. 2008).
Probably the best-characterized activity of a drug in the MHb-IPN pathway is that of
nicotine, perhaps attributable to the considerable density of a variety of nAChRs that
populate the structure (Mugnaini et al. 2002). Studies have suggested that up 90-100%
of MHb neurons express nAChRs, with the majority containing the αα3, αα4, αα5, ββ2,
and/or ββ4 subunits (Viswanath et al. 2013, Sheffield et al. 2000). Some data suggest
that approximately 20% of nAChRs in the MHb expressed by neurons that project to the
IPN contain the αα5 subunit (Picciotto & Kenny 2013, Grady et al. 2009). In the IPN,
high levels of α2 subunit- containing nAChRs can be found (De Biasi & Salas 2008,
Grady et al. 2009), and the distributions of nAChRs composed of specific subunit
combinations can help distinguish subnuclei within both the MHb and IPN (Shih et al.
2014).
As many reviews of the effects of nicotine in this circuit have been written over the years
(McLaughlin et al. 2015, De Biasi et al. 2014, De Biasi & Dani 2011, Dani & De Biasi
2001, Jackson et al. 2015), this section will focus on recent advances in characterizing
the effects of chronic use and withdrawal from nicotine in the MHb-IPN pathway. For
example, it was recently shown that, during withdrawal from nicotine, the spontaneous
action potential frequencies in MHb cholinergic neurons are doubled after mice are
administered nicotine relative to mice in withdrawal treated with saline (Gorlich et al.
2013). Further, these studies demonstrated that the pacemaking activities of MHb
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cholinergic neurons are determined by the activities of hyperpolarization-activated cyclic
nucleotide-gated (HCN) channels, and pharmacological inhibition of these HCN
channels resulted in the manifestation of nicotine withdrawal-associated behaviors,
including both somatic and anxiety-associated symptoms. A study from our lab showed
that nicotine enhances the intrinsic excitability of MHb neurons by activating αα5containing nAChRs, which results in the facilitation of neurokinin release onto NK1 and
NK3 receptors (Dao et al. 2014). Notably, pharmacological blockade of NK1 & NK3
receptors in the MHb of mice chronically treated with nicotine resulted in the precipitation
of somatic symptoms of nicotine withdrawal. Further implicating the αα5- containing
nAChRs in the MHb in the physiology of nicotine addiction and withdrawal, mice lacking
the expression of the subunit have been observed to self-administer doses of nicotine at
levels that are aversive to wild-type mice, and virus-mediated re-expression of the
subunit in the MHb rescues self-administration to levels resembling those consumed by
wild-type mice (Fowler et al. 2011a). Additionally, mice lacking the αα5 nAChR subunit
exhibit reduced IPN activation following exposure to nicotine relative to wild-type mice,
suggesting a significant role played by this subunit in the MHb-IPN pathway in
determining the range of nicotine doses capable of facilitating activity in brain reward
circuitry (Fowler et al. 2011b, Fowler et al. 2013). Mice lacking the αα2 nAChR subunit
exhibit elevations of both glutamate and GABA in the IPN, suggesting that αα2containing nAChRs may participate in the signaling underlying the effects of nicotine
(Lotfipour et al. 2013). Studies have also demonstrated a significant role played by IPN
signaling in somatic symptoms of nicotine withdrawal by the IPN, with GABAergic
neuronal activation enhanced by increased glutamate release, perhaps from the MHb
(Zhao-Shea et al. 2013). This group also showed that pharmacological inhibition of
NMDA receptor activation reduced symptoms of withdrawal, suggesting a glutamatergic
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signal from the MHb playing a significant role in the nicotine withdrawal syndrome.
Following chronic nicotine exposure, mecamylamine infusion into the MHb or IPN has
been observed to induce anxiety-associated behaviors and symptoms of nicotine
withdrawal (Zhao-Shea et al. 2015, Salas et al. 2009). Given that mecamylamine
infusion into nicotine-naïve mice does not result in significant changes in anxietyassociated behavior, the MHb-IPN axis represents a node of neuroplastic adaptations
resulting from chronic nicotine exposure that underlie the affective and somatic
symptoms of nicotine withdrawal upon cessation.
Accordingly, while not necessarily a direct pharmacological target of most psychomotor
stimulants apart from nicotine, the MHb-IPN circuit likely represents a system that
modulates the acute effects of psychomotor stimulants, and contributes to signaling
underlying withdrawal and relapse.
Depression-like behavior
In addition to playing a role in the acute effects of multiple drugs and the manifestation of
their withdrawal from multiple drugs, as well as their acute effects, the MHb-IPN circuit
has been implicated in mood-associated conditions. For example, one group worked to
identify brain regions exhibiting activation during uncontrollable stress that then
correlated with a subsequent manifestation of helplessness behaviors (Mirrione et al.
2014). Using positron emission tomography (PET) with rats, the habenula and lateral
septum emerged as central in a network of brain regions, corroborating a role played by
these structures in vulnerability to uncontrollable stress (Mirrione et al. 2014). An
evaluation of the effects of chronic mild stress in rats on somatostatin (SST) receptor
expression and SST release revealed that this signaling system significantly changes in
the MHb (Faron-Gorecka et al. 2016). In fact, SST2 receptor expression in the MHb, and
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peripheral SST concentration in plasma, were identified as particularly sensitive
biochemical indicators of whether an animal would be stress responsive or nonresponsive. Following an effort to characterize changes in the expression of microRNA
(miRNA) species in the MHb and LHb of rats that underwent learned helplessness
identified, six miRNAs were shown to be significantly altered (Svenningsen et al. 2016).
The miRNA species identified are associated with MAPK, neutrophin, and ErbB
signaling pathways.
Though the MHb is a relatively small structure, it can be segregated into subnuclei
based upon localization of neurotransmitter and transporter protein expression in
specific regions. The MHb is glutamatergic, and is often sub-divided into a dorsal subregion, which expresses SP, and a ventral sub-region, which expresses ACh (Kobayashi
et al. 2013). Some studies suggest that it can be further divided based on transporter
protein and receptor densities (Aizawa et al. 2012). Moreover, efferent projections from
the MHb target the IPN topographically, with efferents from the dorsal MHb targeting the
lateral IPN, those from medial regions of the MHb terminating in the ventral IPN, and
those from the lateral MHb terminating in the dorsal IPN (Bianco & Wilson 2009). Given
the neurochemical differences in these topographic projections, it is not unsurprising that
studies suggest these anatomical distinctions correspond to different functional roles
(Ichijo & Toyama 2015). As altered physical activity and anhedonia are diagnostic
indicators of major depressive disorder according to the Diagnostic and Statistical
Manual of Mental Disorders (Association 2013), the MHb has been evaluated as a
regulator of analogous behaviors like wheel running activity (WRA) in rodents (Hsu &
Wang 2014). Working with a genetic ablation model of the dorsal subnucleus of the
MHb, reduced WRA and sucrose preference was observed, both of which are
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indicativeons of depressive-like behaviors. Interestingly, despite no known direct
synaptic connection with dopaminergic populations, mice exhibited a significant
preference for optogenetic intracranial self-stimulation of the dorsal MHb (Hsu & Wang
2014). Conversely, inhibition of the terminals arriving in the IPN from the dorsal MHb
yielded place aversion. This corroborates studies that characterized metabolic
differences in brain regions of rats bred for susceptibility to helplessness, which
exhibited significantly increased markers of metabolic activity in both the lateral and
medial habenula (Shumake et al. 2003). Using the same metabolic profiling method in
Holtzman rats, a strain that exhibits susceptibility to stress-evoked helplessness, Padilla
and colleagues characterized the effects of a two-week treatment with fluoxetine
following a learned helplessness paradigm were characterized (Padilla et al. 2011). The
group identified a protective effect of fluoxetine against depression-like behaviors in the
forced swim test relative to rats treated with vehicle. This protective effect correlated with
changes in regional metabolic activity in a variety of brain networks, including the
habenular complex, IPN, and dorsal raphe nucleus (Padilla et al. 2011). In particular,
fluoxetine treatment was associated with comparatively stronger positive correlations
with prefrontal regions, including the dorsal, orbital, and prelimbic cortices. The IPN was
positively correlated with the lateral orbital cortex in rats treated with fluoxetine, and this
correlation was not present in vehicle-treated rats. Finally, metabolic markers in the
dorsal raphe become somewhat positively correlated with the habenula in fluoxetinetreated rats, while strongly negatively correlated among the vehicle-treated group.
Due to challenges derived from the small size and sub-cortical location of the MHb-IPN
circuit, the majority of studies characterizing its function have been performed in animal
models. However, a few studies with humans have corroborated a role played by the
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circuit in depression. Accumulating literature over the past decade indicates that
ketamine may represent a novel pharmacological treatment strategy for major
depressive disorder (Han et al. 2016, Burger et al. 2016, Zarate et al. 2006, Murrough et
al. 2013). When evaluating changes in cerebral glucose metabolism using PET, 20
unmedicated patients with treatment-resistant major depressive disorder were scanned
before and after a ketamine infusion. The habenular complex, among several other brain
regions, exhibited reduced metabolism in association with a rapid antidepressant effect
of ketamine (Carlson et al. 2013). Finally, a post-mortem study of sections from the
brains of patients diagnosed with various mood disorders identified significant reductions
in the volumes, cell numbers, and mean cell areas in the MHb of depressive patients
(Ranft et al. 2010).
Anxiety, fear, and stress
While anxiety and fear have been associated for quite some time with anatomical
structures including the amygdala, hippocampus, hypothalamus, and periaqueductal
grayfor quite some time, recent research has implicated the DDC in these behaviors as
well (Okamoto & Aizawa 2013). A genetic lesion study indicates that selective
elimination of MHb afferents arriving from two forebrain structures, the triangular septum
and bed nucleus of the anterior commissure, results in disrupted anxiety- and fearassociated behaviors (Yamaguchi et al. 2013). In particular, lesions of the projections
from the triangular septum, which terminate in the ventral subnucleus of the MHb,
disrupted anxiety-associated behavior. Conversely, lesions of projections arriving from
the bed nucleus of the anterior commissure, which terminate in the dorsal subnucleus of
the MHb, disrupted fear-associated behavior. Following both acute and chronic restraint
stress in rats, significant elevations of the pro-inflammatory cytokine, IL-18, have been
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observed in the dorsal MHb (Sugama et al. 2002). Mast cells are another immune
system-associated signaling component that appears to be sensitive to environmental
stressors and aversive mood states (Georgin-Lavialle et al. 2016, Nautiyal et al. 2008,
Silver & Curley 2013, Frenzel & Hermine 2013). Mice treated with a 3-week behavioral
subordination paradigm, either via exposure to an aggressor or placement in a clean
cage, exhibited increased numbers of mast cells in the habenula, thalamus, and
hypothalamus (Cirulli et al. 1998).
When characterizing fear-associated behavior in zebrafish, inhibition or lesion of the
dorsal habenula (analogous to MHb in mammals) resulted in elevated freezing behaviors
in response to a conditioned fear stimulus (Agetsuma et al. 2010, Lee et al. 2010). Both
control and habenula-disrupted fish froze upon first exposure to an electric shock, but as
subsequent shocks were administered, control fish exhibited reduced freezing behavior
while those with disrupted habenular function exhibited no such behavioral adaptation.
Another study identified behavioral signatures of elevated baseline anxiety in zebrafish
following dorsal habenula lesions, including responses to novel environments and alarm
substance secretion in response to overhead shadows (Mathuru & Jesuthasan 2013).
This has led to the suggestion that reciprocal connectivity between thethe IPN, raphe
nuclei, and dorsal tegmental region may be critical to behavioral responses to stressors.
Furthermore, activity in the habenular complex may be an upstream determining factor
in selection of behavioral strategies to cope with stressors (Okamoto et al. 2012,
Jesuthasan 2012). A unique characteristic of the habenular complex is its asymmetry,
with the left habenula larger than its right counterpart (Ahumada-Galleguillos et al. 2016,
Hetu et al. 2016). When this asymmetry is lost in zebrafish, behavioral assays indicated
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elevated manifestations of anxiety, as well as elevated cortisol levels in response to
stressors (Facchin et al. 2015).
While the size of the habenular complex renders current neuroimaging technology
incapable of distinguishing the LHb from the MHb in human studies, some studies
indicate a role played by the habenular complex in the pathophysiology of bipolar
disorder (BD). In a study using high-resolution magnetic resonance imaging (MRI), it
was found that patients diagnosed with BD who had either never been medicated, or
had been un-medicated for at least two months, exhibited smaller habenular volumes
than healthy controls (Savitz et al. 2011).
Studies have also implicated the IPN in regulating anxiety and fear. Early studies of the
IPN identified a role for the structure in the retention of avoidance conditioning. Rats
were trained to perform a jumping response following a visual stimulus to avoid a shock.
After a learning period, a group of trained rats were treated with electrolytic lesions of the
IPN. Following recovery from the procedure, rats re-learned the task and retention of the
response was compared to controls. Rats with IPN lesions exhibited comparatively
inferior retention of the response, though exhibited other signatures of a fear reaction,
implying a role played by IPN signaling in specific components of fear learning
(Thompson 1960). Following chronic nicotine administration, increased corticotropin
releasing factor (CRF) synthesis is observed in dopaminergic neurons in the VTA, which
appear to send efferents to the ventral IPN (Zhao-Shea et al. 2015). This is
accompanied by an increase in CRF1 receptor expression in a particular subnucleus of
the ventral IPN, and withdrawal induces release of CRF by the VTA onto ventral IPN
neurons. Blockade of CRF1 receptor binding in the IPN was shown to reduce anxietyassociated behavior generated during withdrawal from nicotine.
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Conclusion
The dorsal diencephalic conduction system is emerging as an important node in the
pathophysiology of addiction to multiple drugs, including alcohol, opioids, and
nicotinealcohol. In addition to this involvement in substance abuse and addiction, the
DDC also appears to regulate affect and mood-associated psychiatric conditions. Given
the high comorbidity of substance use disorders and psychiatric illnesses, it makes
sense that both conditions engage some overlapping pathways. For example,
approximately one-third of individuals diagnosed with major depressive disorder also
have a substance use disorder (excluding nicotine dependency), with almost half of all
patients with depression having a family history of substance use disorders (Davis et al.
2008). Individuals with both disorders tend to experience earlier onsets of depression,
greater persistence of the disorders, and exhibit more suicide attempts. When
considering another addictive drug, nicotine, individuals diagnosed with mental illnesses
are approximately twice as likely to smoke tobacco (Lasser et al. 2000), and studies
have shown that 81.8% of individuals diagnosed with bipolar disorder, and 76.8%
diagnosed with generalized anxiety disorder have smoked daily for at least a month
(Lasser et al. 2000). Anxiety disorders have been implicated in alcohol, opioid, and
stimulant abuse (Vorspan et al. 2015). Among adolescents, the majority of substance
use disorders occur among youth with prior psychiatric disorders, with alcohol abuse
observed in 17.3% and drug abuse observed in 20% of those diagnosed with prior
anxiety disorders (Conway et al. 2016). A relationship between anxiety, stress,
depression, and other psychiatric conditions and increased nicotine consumption has
been established for many years (Lasser et al. 2000, Feldner et al. 2007, Morissette et
al. 2007, Patton et al. 1998, Zvolensky et al. 2005, Kassel et al. 2003, Cougle et al.
2010), and a recent study has indicated that this dynamic has not changed, despite
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declining overall usage over the past 6 decades (Prochaska et al. 2016). This
relationship even translates to a unique puff volume among those with psychiatric
conditions, with smokers who have a history of panic attacks exhibiting increased puff
volumes relative to those without histories of panic attacks (Farris et al. 2016).
Accordingly, mounting data indicates an involvement of the DDC, and the MHb-IPN
pathway in particular, in both addiction to multiple drugs of abuse and mood-associated
conditions, and the MHb-IPN circuit may represent a junction at which signaling
underlying both sets of conditions occurs. Given the presence of nAChRs composed of
unique subunit compositions in the MHb-IPN pathway (Antolin-Fontes et al. 2015), this
circuit may yield strategic targets for pharmacological therapeutics to improve treatment
outcomes of both sets of conditions.
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Table 1.

MHb Afferent & Efferent
Connections
Afferent

Efferent

Structure

Reference

Structure

Reference

Triangular
Septum

Herkenham &
Nauta, 1977

Interpeduncular
Nucleus

Morley, 1986;
Herkenham &
Nauta, 1979

Medial Septal
Nucleus

Qin & Luo,
2009

Pineal body

Ronnekleiv &
Moller, 1979;
Guglielmotti &
Cristino, 2006

Diagonal Band
Nucleus

Qin & Luo,
2009

Lateral
Habenula

Kim & Chang,
2005

Septofimbral
Nucleus

Herkenham &
Nauta, 1977

VTA

Cuello, 1978

VTA

Herkenham &
Nauta, 1977

Interfascicular
nucleus of the
VTA

Phillipson &
Pycock, 1982

Locus
coeruleus

Gottesfeld,
1983

Superior
cervical
ganglion

Gottesfeld,
1983

Preoptic area

Groenewegen,
1986;
Herkenham &
Nauta, 1977

Median Raphe
Nucleus

Conrad, 1974;
Sutherland,
1982

Nucleus
basalis

Herkenham &
Nauta, 1977

Nucleus
accumbens

Sutherland,
1982
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Table 2.

IPN Afferent & Efferent
Connections
Afferent

Efferent

Structure

Reference

Structure

Reference

Medial Habenula

Morley, 1986

Hippocampus

Shibata &
Suzuki, 1984;
Baisden, 1979;
Wyss, 1979

Contestabile &
Flumerfelt,
1981

Lateral
Hypothalamus

Massopust,
Thompson,
1962; Kemali,
Gugliemotti,
1982; Smith,
1980

Vertes, 1988

Ventral
Tegmental
Area

Morley, 1986;
Hayakawa,
1981; Smaha,
1973

Septum

Morley, 1986;
Hayakawa,
1981

Preoptic Area

Morley, 1986;
Hayakawa,
1981

Nucleus of the
Diagonal
Band

Morley, 1986;
Hayakawa,
1981

Diagonal band
nucleus

Substantia
innominata

Hypothalamic
nuclei

Supramammillary
nucleus

Dorsal tegmental
nucleus

Contestabile &
Flumerfelt,
1981; Hamill &
Jacobowitz,
1984
Contestabile &
Flumerfelt,
1981; Hamill &
Jacobowitz,
1984
Hamill &
Jacobowitz,
1984

Preoptic nucleus

Shibata, 1986

Dorsal Raphe
Nucleus

Groenewegen,
1986

Infralimbic region
of medial
prefrontal cortex

Takagishi &
Chiba, 1991

Median
Raphe
Nucleus

Groenewegen,
1986; Behzadi,
Wiklund, 1990

Raphe nuclei

Conrad, 1974

Lateral
Habenula

Morley, 1986;
Massopust,
Thompson,
1962

Nucleus Incertus

Hamill &
Jacobowitz,
1984

Dorsal
Tegmental
Nucleus

Hamill &
Jacobowitz,
1984;
Groenewegen,
1986
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Table 3.
Roles in the actions of drugs
MHb
Technique

Finding

Local cerebral Higher in MHb of
glucose
EtOH-preferring
utilization
rats
IP nAChR
antagonist
injection

IPN
Reference

Technique

Naloxoneprecipitated
9
opioid
withdrawal

Precipitates EtOH
withdrawal
syndrome

10

18-MC IPN
infusion

NPY Receptor Knock-out mice
knock-out
ingest more EtOH

11

18-MC IPN
infusion

EtOH-preferring
mice lack NPY
mRNA in MHb

MHb lesion

Hyperalgesia,
increase analgesic
efficacy of morphine

28

Intracranial
infusion to
MHb

Analgesia

29

VTA ICSS

Reduced
endogenous opioid
binding in MHb

30

Altered AChE
activity in the MHb

31

18-MC MHb
infusion

Trend to increased
MHb nAChR
expression
Reduced morphine
self-administration
Reduced morphine
analgesia

Altered AChE
activity in the
IPN
Reduced
morphine selfadministration
Reduced
methamphetami
ne selfadministration

Methampheta
Increased
mine &
12, 13
extracellular
cocaine
[ACh]
administration

In situ
hybridization

Chronic
morphine
administration
Chronic
morphine
administration
18-MC MHb
infusion
RSK2 knockout in MHb
Cocaine cueinduced
reinstatement

Finding

31
35
36

Increased Fosprotein in MHb

45

Reduced
methamphetamine
self-administration

46
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Reference

31

35

46

48

Table 4.

Roles in Mood Disorders
MHb

Technique

Finding

Hb identified as
PET in stresscentral in network of
treated rats
brain regions

Chronic mild
stress in rats

Learned
helplessness
in rats
Genetic
ablation of
dorsal MHb

Altered SST release
and SST2 receptor
expression in MHb
distinguish stressresponsive from
non-responsive
Altered miRNA
associated with
MAPK, neutrophin,
and ErbB in MHb &
LHb

IPN
Reference

Technique

Finding

Reference

Inhibition of
afferent
49
terminals in
IPN

Place aversion

56

Stress-evoked
helplessness
50 treated with
fluoxetine in
rats

Fluoxetine was
protective,
correlated with
altered
metabolic
activity in IPN

58

Electrolytic
lesion of IPN

Inferior retention
of conditioned
avoidance
response

80

51

Chronic
Increased CRF
56 nicotine
release to
administration ventral IPN

81

Optogenetic
Preference for
self-stimulation
stimulation
of dorsal MHb

Increased CRF1
Chronic
receptor
56 nicotine
expression in
administration
ventral IPN

81

Rats bred for
susceptibility
to
helplessness

Increased markers
of metabolic activity
in MHb & LHb

Reduced
anxietyBlockade of
associated
57 CRF1 receptor
behaviors during
in IPN
nicotine
withdrawal

81

Fluoxetine was
protective,
correlated with
altered metabolic
activity in Hb

58

Reduced
metabolism in the
Hb

63

Reduced volume,
cell number, and
mean cell areas in
MHb

64

Disrupted anxietyassociated
behaviors

66

Elevated IL-18 in
dorsal MHb

22

Stress-evoked
helplessness
treated with
fluoxetine in
rats
PET in
depressed
patients
treated with
ketamine
Post-morten
study of brain
sections of
patients with
depression
Elimination of
MHb afferents
from TS &
BAC
Acute &
chronic
restraint stress
Subordination
paradigm

Reduced wheel
running activity

Elevated mast cell
numbers in the Hb
Elevated freezing
Inhibition or
behavior, elevated
lesion of dMHb anxiety, elevated
in zebrafish
alarm substance
secretion
MRI of
unmedicated
Reduced Hb
patients with
volumes
bipolar
disorder

71

72, 73, 74

79
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Abstract
Nicotine dependence plays a critical role in addiction to tobacco products, and thus
contributes to a variety of devastating tobacco-related diseases (SGR 2014). Annual
costs associated with smoking in the US are estimated to be between $289 and $333
billion. Effective interventions for nicotine dependence, especially in smokers, are a
critical barrier to the eradication of tobacco-related diseases. This overview highlights
research presented at the Plenary Symposium of Behavior, Biology and Chemistry:
Translational Research in Addiction Conference (BBC), hosted by the UT Health
Science Center San Antonio, on March 9-10, 2013. The Plenary Symposium focused on
tobacco addiction, and covered topics ranging from basic science to national policy. As
in previous years, the meeting brought globally-renowned scientists, graduate student
recruits, and young scientists from underrepresented populations in Texas and other
states together with the goal of fostering interest in drug addiction research in young
generations.
General Introduction
Nicotine, the alkaloid primarily responsible for the addictive properties of tobacco
products, acts at nicotinic acetylcholine receptors (nAChRs). Found throughout the
nervous system, nAChRs comprise numerous combinations of α (α2-9) and β (β2-4)
subunits in the form of homo- and heteromeric ion channels (Gotti et al., 2009). nAChRs
can mediate either fast synaptic transmission - as they primarily do in the periphery - or
modulate the function of other neurotransmitter systems, as is common in the central
nervous system (Dani and Bertrand, 2007; De Biasi, 2002).
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The majority of smokers desire to quit, but only a small fraction of attempts are ultimately
successful (Benowitz, 2010). According to the Center for Disease Control (CDC),
approximately 69% of smokers want to quit, and 52% of smokers attempted to quit in
2010 – but only 6.2% were successful (CDCP, 2011).
There are several issues to confront when considering smoking cessation. First,
nicotine’s ability to interfere with the dopaminergic (DA) reward system is an important
factor contributing to both the initiation and maintenance of nicotine use (Picciotto and
Corrigall, 2002). Second, smoking is also motivated by the urge to alleviate affective,
cognitive, and physical symptoms of withdrawal that emerge during periods of
abstinence (De Biasi and Dani, 2011). Therefore, to be successful, smoking cessation
strategies must reduce both the motivation to smoke and the symptoms of withdrawal
during quit attempts. Nicotine replacement therapy (NRT), bupropion, and varenicline
are the most commonly applied pharmacological aids for smoking cessation. Although
all three work better than placebo, long-term success rates remain low among smokers
attempting to quit (Paolini and De Biasi 2011). The following summarizes progress that
contributing authors’ labs are making toward understanding the molecular mechanisms
of nicotine addiction, as well as the design of pharmacological and non-pharmacological
strategies aimed at improving smoking cessation outcomes.
1.
Nicotinic Receptor Subunits and Their Influence on Nicotine Addiction and
Withdrawal (Mariella De Biasi, Ian McLaughlin, Erika E. Perez)
1.1 Symptoms of nicotine withdrawal. The unpleasant symptoms associated with
nicotine withdrawal act as negative reinforcers that promote nicotine dependence (Koob
and Volkow, 2010; Piper et al., 2011; Allen et al., 2008). These negative reinforcers
include both affective (anxiety, depression, and irritability) and somatic (decreased heart
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rate, constipation, general restlessness) symptoms (Malin and Goyarzu, 2009; Salas et
al., 2009). Mice chronically exposed to nicotine display withdrawal symptoms that
develop spontaneously, peak 24hr following cessation of administration, and can last for
several days. Withdrawal can also be precipitated by systemic injection of non-selective
nAChR antagonists such as mecamylamine (Paolini and De Biasi, 2011). Several
behavioral tests are available to explore both somatic and affective symptoms in
rodents. Affective signs of withdrawal can be examined in rodents using behavioral
paradigms that test for anhedonia, conditioned place aversion, anxiety, and conditioned
fear (De Biasi and Salas, 2008; Damaj et al., 2003; Epping-Jordan et al., 1998; Davis et
al., 2005). Physical signs of withdrawal include chewing, teeth-chattering, shakes,
tremors, writhing, palpebral ptosis, gasps, and yawns (De Biasi and Salas, 2008; Malin
and Goyarzu, 2009).
1.2. A gene cluster on chromosome 15q25 influences nicotine addiction. Ample studies
have demonstrated that genetic factors predispose individuals to younger smoking
initiation, increased quantities of cigarettes smoked, nicotine dependence, and smoking
persistence (Li et al., 2003; Rhee et al., 2003; Schnoll et al., 2007). A cluster of nicotinic
receptor genes (CHRNA5/CHRNA3/CHRNB4) located on chromosome 15q25 has been
repeatedly associated with nicotine dependence, smoking behaviors, and lung cancer
(Amos et al., 2008; Berrettini et al., 2008; Furberg et al., 2010; Greenbaum and Lerer,
2009; Hung et al., 2008; Liu et al., 2010; Rose, 2007; Saccone et al., 2010, 2007;
Thorgeirsson et al., 2008). SNPSs rs16969968, rs578776, and rs588765 represent three
statistically distinct nicotine dependence loci associated with the CHRNA5/A3/B4 gene
cluster (Saccone et al., 2010; Saccone et al., 2009). The α5 risk variant, rs16969968
G/A, causes an Asp398Asn amino acid substitution, and the risk allele (Asn398)
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produces hypofunctional α5-containing nAChRs with reduced Ca 2+ permeability and
faster desensitization rates than non-risk alleles (Bierut et al, 2008; Kuryatow et al,
2011). Other polymorphisms are associated with different levels of α5 or α3 mRNA
(Wang, 2009), and the functional significance of several other gene variants in the
CHRNA5/A3/B4 gene cluster is currently being investigated (Flora et al., 2013).
1.3 nAChR mutant mice help reveal mechanisms of nicotine withdrawal symptoms. Preclinical rodent models can be used to elucidate the functions of genes and brain
pathways involved in nicotine addiction. Our lab took advantage of genetically
engineered mice carrying null mutations in nAChR subunit genes to examine the roles of
various subunits in the mechanisms of withdrawal. We focused on physical symptoms of
nicotine withdrawal - studied either 24 hr after nicotine deprivation, or upon systemic
injection of mecamylamine in mice with free access to nicotine in drinking water. We
found that mice lacking functional β4 nAChR subunits exhibited reduced somatic signs
relative to wild-type mice undergoing nicotine withdrawal (Salas et al., 2004). Further
experiments with additional mice lacking nAChR subunits revealed that physical
symptoms of withdrawal also depend on α5, α2, and partially on α7 nAChR subunits
(Salas et al., 2007; Salas et al., 2009). Interestingly, mice lacking the β2 nAChR subunit
displayed symptoms of withdrawal resembling those of wild-type mice (Fig. 1). Mice
carrying a null mutation for the α3 nAChR subunit were not studied due to perinatal
mortality (Xu et al., 1999).
1.4 Medial Habenula (MHb) and Interpeduncular nucleus (IPN) are key brain areas for
physical manifestations of nicotine withdrawal. We focused on the MHb-IPN pathway which is among the brain areas with the highest co-expression of α5, α3, α2, and β4 – to
pursue neuronal circuits associated with physical symptoms of withdrawal (De Biasi and
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Dani, 2011). The MHb, together with the lateral habenula (LHb), forms the habenular
complex (Hb). The IPN is the main projection target of the MHb, while the LHb sends
projections to the rostromedial tengmental nucleus (RMTg) in the midbrain. These brain
areas play significant roles in aversion, negative reinforcement, negative prediction
errors, and negative motivation (De Biasi and Dani, 2011; Fowler and Kenny, 2014). In
mice chronically treated with nicotine, mecamylamine administration was sufficient to
induce nicotine withdrawal behaviors only when microinjected into the MHb or the IPN,
but not when microinjected into other brain areas, including the ventral tegmental area
(VTA) (Salas et al., 2009).
Future studies. One unanswered question is whether the MHb-IPN pathway and the
nAChRs contained therein, are important for the affective manifestations of nicotine
withdrawal. This is a key question, given the emerging role of the Hb in anxiety-related
disorders, and the fact that both β4 and α5 null mice exhibit reduced anxiety-related
behavior in the elevated plus maze (Mathuru and Jesuthasan, 2013; Yamaguchi et al.,
2013; Gill et al., 2013). In addition, given the role of the MHb-IPN pathway in nicotine
aversion and withdrawal, it would be interesting to determine whether the same nAChR
subtypes and the MHb-IPN pathway influence withdrawal from other drugs of abuse.
Withdrawal from ethanol is a candidate, given similarities between certain manifestations
of alcohol and nicotine withdrawal (Hughes et al.,1994). This hypothesis is corroborated
by the observation that, although different from those influencing tobacco addiction,
polymorphisms in the CHRNA5/A3/B4 gene region are independently associated with
alcohol dependence (Wang et al., 2009; Sherva et al., 2010) - some of which are
associated with altered levels of α5 mRNA (Wang et al., 2009). Furthermore, the
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rs16969968 α5 SNP has been linked to increased risk not only for nicotine, but also for
alcohol dependence (Schlaepfer et al., 2008).
1.5 Conclusions. nAChRs, especially those in the CHRNA5/A3/B4 gene cluster,
influence aversive manifestations of nicotine withdrawal - and thereby represent novel
molecular targets for medications aimed at smoking cessation.
2.

Discovery of Nicotinic Receptor Antagonists as Agents for Treating Nicotine

Addiction (Peter A. Crooks, Linda P. Dwoskin, Michael T. Bardo)
2.1 Introduction and Rationale. Activation of neuronal nicotinic acetylcholine receptors
(nAChRs) evokes dopamine (DA) release within neuronal circuitry associated with
reward (Picciotto and Corrigall, 2002). DA release is well known to underlie reinforcing
properties of nicotine (Wise and Rompre, 1989). Therefore, tobacco smoking is
reinforced and maintained, at least in part, by nicotine activation of nAChRs within DA
reward circuitry. Results from a comprehensive molecular genetics study, in which an
individual nAChR subunit gene (α4, α5, α6, α7, β2, β3, and β4) was deleted, suggest
that nicotine-evoked DA release is mediated by 6 nAChR subtypes (Salminen et al.,
2004; Gotti et al., 2005). These include α-conotoxin MII (α-CtxMII)-sensitive (α6β2β3*,
α4α6β2β3*, α6β2*, and α4α6β2*) and α-CtxMII-insensitive (α4β2* and α4α5β2*)
subtypes, while deletion of α7 and β4 subunits had no effect. Thus, multiple nAChR
subtypes likely mediate nicotine-evoked DA release. Based on these data, we set out to
develop smoking cessation therapies to identify subtype-selective nAChR antagonists
that inhibit nAChRs mediating nicotine-evoked DA release (α6β2-containing nAChRs).
We hypothesized that such subtype-selective nAChR antagonists would: i) be
efficacious tobacco use cessation agents, ii) have limited side-effects due to their
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receptor selectivity, and iii) offer smokers who do not respond well to existing smoking
cessation therapies alternative treatment options.
2.2 Target and Drug Discovery. Kulak and colleagues (Kulak et al., 1997) previously
reported that the neuropeptide α-CtxMII potently blocks nicotine-stimulated DA release
in rat striatal synaptosomes. While relevant to the development of smoking cessation
therapies, neurotoxin peptides acting as subtype-selective nAChR antagonists are
unlikely to be developed into treatments for tobacco addiction because they are highmolecular weight compounds, and are unlikely to cross the blood–brain barrier (BBB).
Thus, our strategy was to develop small, drug-like molecules that are selective
antagonists at α6- and β2-containing, α-CtxMII-sensitive nAChR subtypes (i.e., α6β2*,
α6β2β3*, α6α4β2β3*, and α4α6β2*). Importantly, since these α-CtxMII-sensitive
nAChRs are located on DA neurons that mediate nicotine-evoked DA release (Wickham
et al., 2013; Gotti et al., 2010), they represent viable targets for the development of
tobacco cessation agents.
We initially focused on a series of N-n-alkylnicotinium analogs and related compounds
for their ability to inhibit nicotine-evoked DA release from rat striatal slices and to
displace [3H]-nicotine binding to rat striatal membranes (α4β2* nAChRs) (Dwoskin et al.,
1992; Crooks et al., 1995). The most potent compound that emerged was S-(-)-N-noctylnicotinium iodide (NONI, Fig. 2). Though lacking selectivity, NONI exhibited good
antagonist potency at α6β2* nAChRs (IC50 = 0.62 mM) (Crooks et al., 2004). NONI was
also found to have good affinity for the BBB choline transporter (Crooks et al., 2004;
Dwoskin et al., 2004; Lockman et al., 2008), suggesting good brain bioavailability due to
its cationic quaternary ammonium structure.
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Second generation libraries incorporated a second quaternary ammonium moiety into
the scaffold of the N-alkylnicotinium analogs, generating bis-quaternary ammonium
analogs containing diverse headgroups separated by variable alkane, alkene, or alkyne
linker units. The most potent among them was bPiDDB (N,N’-dodecane-1,12-diyl-bis-3picolinium dibromide; Fig. 3) (IC50 = 2 nM; Imax = 60% at α6β2*-containing nAChRs) which had little or no affinity for either α4β2* or α7* nAChRs (Crooks et al., 2004;
Dwoskin et al., 2004), and was an excellent substrate for the BBB choline transporter
(Lockman et al., 2008). Pharmacokinetic studies carried out in rats treated with 14CbPiDDB confirmed its brain bioavailability (Albayati et al., 2008). bPiDDB dosedependently decreased nicotine self-administration in Sprague-Dawley rats with no
effect on sucrose-maintained responding (Neugebauer et al., 2006), and attenuated
hyperactivity produced by acute and repeated nicotine dosing. Interestingly, in rats
repeatedly administered nicotine, the in vitro inhibitory potency of bPiDDB at α6β2*
nAChRs increases significantly compared to that exhibited in similar in vitro assays in
naïve rats (i.e., IC50 = 5 pM vs. 6 nM, respectively; Smith et al., 2010), demonstrating
that repeated nicotine treatment may differentially regulate the stoichiometry and/or
conformation of α6β2* nAChRs.
2.3 Exploring Analogs of bPiDDB. As part of an iterative SAR study, the effect of
introducing an additional picolinium or other headgroups into the bPiDDB scaffold on
inhibition of nicotine-evoked DA release was evaluated. Initially, three lead trisquaternary ammonium molecules, TRIS-1, TRIS-2, and TRIS-3, emerged that were
potent and selective inhibitiors of α6β2* nAChRs (IC50 = 0.2–4 nM; e.g. TRIS-1, Fig. 2;
Zheng et al., 2007). However, further development of these molecules was abandoned
due to toxicity at higher doses in nicotine self-administration studies in rats, and poor
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affinity for the BBB choline transporter. The introduction of two additional picolinium
headgroups into the bPiDDB scaffold resulted in tetrakis-analogs (e.g. TETRAKIS-1, Fig.
2) (Zhang et al., 2008), which were selective, lower potency antagonists at α6β2*
nAChRs, but were not substrates for the BBB choline transporter, and were thus
ineffective in decreasing nicotine self-administration in rats (unpublished results).
Replacement of the above quaternary ammonium head groups in the bis-, tris- and
tetrakis-analogs with tertiary amine head groups is predicted to improve oral
bioavailability and drug-likeness of such compounds. The resulting analogs should have
good water-solubility, and cross the BBB independently of choline transporters due to
passive diffusion through lipid membranes. Evaluation of a small library of these tertiary
amine analogs as antagonists at α6β2* nAChRs identified several bis-analogs with IC50
values in the low nM or sub-nM range (Zhang et al., 2011).
Two of these bis molecules: r-b3,5L/3PiDDB and r-bPiDDB (Fig. 2) are chemically
reduced analogs of bPiDDB, and both compounds potently and selectively inhibit
nicotine-evoked [3H]-DA release (IC50 = 0.009–0.058 nM; Imax = 60–74%) at α-CtxMIIsensitive α6β2* nAChRs (Dwoskin et al., 2009; Smith et al., 2010). These analogs were
more potent antagonists at α6β2* nAChRs compared to their corresponding quaternary
ammonium counterparts (Zhang et al., 2011). Importantly, inhibition produced by a
maximally effective concentration of r-b3,5L/3PiDDB and r-bPiDDB was not additive with
a maximally effective concentration of α-CtxMII (Smith et al., 2010; Crooks et al., 2014),
demonstrating interaction with the same nAChR subtypes with which α-CtxMII interacts.
Also, r-b3,5L/3PiDDB and r-bPiDDB both decreased responding for i.v. nicotine in rats at
doses that did not produce lethargy, weight loss, or other signs of toxicity, and that had
no effect on food responding (Crooks et al., 2014).
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r-bPiDI (Fig. 2), a structurally related analog of r-bPiDDB containing a C10 rather than a
C12 n-alkane linker, exhibited decreased inhibitory potency (IC50 = 37.4 nM, Imax =
65%) compared to the above two C12 analogs, and did not inhibit [3H]nicotine or
[3H]methyllycaconitine binding (Beckmann et al., 2013). Also, r-bPiDI inhibition of
nicotine-evoked DA release was not different in the absence or presence of α-conotoxin
MII, characterizing it as a potent and selective α6β2* nAChR antagonist. Acute systemic
administration of r-bPiDI decreased nicotine self-administration with no effect on foodmaintained behavior (Beckmann et al., 2013), indicating that r-bPiDI specifically
decreases nicotine reinforcement. Thus, r-bPiDI, is another selective antagonist at α6β2*
nAChRs.
The most recent drug-like antagonist identified in this series is r-b3EPDDB (Fig. 2) (pKa
= 9.5; Log P = 5.2), a close structural analog of r-bPiDDB in which the two tetrahydro-3picolino headgroups are chemically reduced to afford a tetrahydro-3-ethylpyridino
headgroup. r-b3EPDDB exhibited a remarkable IC50 value of 2 pM in the nicotineevoked [3H]-DA release assay (Imax = 80%) (Fig. 3). Data in Fig. 3 compare the IC50
and Imax values of r-b3EPDDB and b3EPDDB (the parent quaternary ammonium
compound) in the nicotine-evoked [3H]-DA release assay, and demonstrate that
chemical reduction of the bis-quaternary ammonium compound, b3EPDDB , affords an
analog, r-b3EPDDB, that exhibits 60 times greater inhibitory potency at α6β2* nAChRs
with no change in Imax. This highly potent inhibitor is being evaluated in nicotine selfadministration studies in rats.
2.4 Summary. Striatal rat brain slices have been used to screen novel analogs that
inhibit nicotine-evoked DA release in the search for potential smoking cessation agents.
Several libraries of compounds were constructed and SAR generated. Evolution of the
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initial series of quaternary ammonium compounds into tertiary amino analogs provided
lead candidates with IC50 values in the pM range. r-bPiDDB, r-bPiDB, r-b3,5L/3PiDDB
and r-b3EPDDB have been identified as four promising new analogs with drug-like
physicochemical properties. These molecules are potent antagonists at α6β2-containing
nAChRs. r-bPiDDB, r-bPiDB and r-b3,5L/3PiDDB specifically decrease nicotine selfadministration in a rat behavioral model with no effect on food-maintained responding,
and are potential preclinical leads for development as smoking cessation agents.
Our future aim is to enhance the drug-likeness of our lead compounds by improving
water-solubility through introduction of hydrogen-bond acceptor moieties in the linker,
and by decreasing conformational flexibility. We intend to identify orally bioavailable,
drug-like preclinical leads for development as smoking cessation and/or relapse
prevention pharmacotherapies. Current experiments are focused on determining if these
analogues block cue-induced reinstatement of nicotine seeking.
3.

Vaccines for the treatment of tobacco addiction (Paul Pentel)

3.1 Rationale. Existing medications used for the treatment of tobacco addiction (nicotine
replacement products, buproprion, varenicline) are valuable, but their efficacy is modest.
The neuronal pathways they target - which include those mediating reward, cognition
and affect - are diverse and essential to many normal functions. Interrupting their
function in order to treat tobacco addiction can interfere with normal functions and cause
side effects, which limit the usable dose of medication and its efficacy.
3.2 Nicotine vaccines. Vaccination against nicotine provides an alternative medication
strategy, targeting the drug rather than the brain (Bevins et al., 2008; LeSage et al.,
2006b; Raupach et al., 2012; Shen et al., 2012). The nicotine vaccines most thoroughly
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studied consist of nicotine conjugated (covalently attached) through a short linker to a
foreign carrier protein. The nicotine binds and stimulates B lymphocytes, which will
mature into antibody producing cells, and the carrier protein serves to activate T
lymphocytes to provide signals required for B cell maturation (McHeyzer-Williams and
McHeyzer-Williams, 2005). This construct is administered with an adjuvant, such as
alum, which creates an immune-competent environment at the injection site (Awate et
al., 2013).
Nicotine vaccines elicit production of nicotine-specific antibodies that can bind nicotine in
serum or extracellular fluid, and reduce or slow its distribution to brain (Maurer et al.,
2005; Pentel et al., 2006; Satoskar et al., 2003). The antibodies themselves are
excluded from the brain because they are too large to cross the blood-brain barrier. In
animals, vaccination blocks or attenuates a wide range of nicotine-related behaviors
including the acquisition, maintenance, and reinstatement of nicotine self-administration
at clinically relevant nicotine doses (LeSage et al., 2006a; Lindblom et al., 2002).
Nicotine-specific antibodies bind nicotine and its minor but active metabolite nornicotine,
but essentially nothing else, including acetylcholine (the natural ligand of nicotinic
cholinergic receptors), other neurotransmitters, or medications with similar structures.
This specificity, and the exclusion of antibodies from the brain, explains the absence of
side effects (other than transient minor discomfort at the injection site) of this approach
in both animals and humans.
3.3 Vaccine efficacy. As the goal of vaccination is to bind as much drug as possible,
efficacy is highly dependent upon the concentration (often estimated as titer) of antibody
in serum. High antibody levels can be produced in rodents, but this often requires large
vaccine doses, or routes of administration and adjuvants that are unacceptable for
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humans. Antibody levels achieved in clinical trials of nicotine vaccines have been
considerably lower than in rodents (Keyler et al., 2008; Maurer et al., 2005). In addition,
antibody levels in both animals and humans show high individual variability (Cornuz et
al., 2008; Hatsukami et al., 2011). Reliably achieving high antibody concentrations has
emerged as the principal challenge for translating vaccines into clinical use.
Clinical trials of nicotine vaccines have not shown the efficacy seen in animal studies. A
phase II clinical trial of one nicotine vaccine (NicVax) showed a doubling of smoking
cessation rates (Hatsukami et al., 2011), but follow-up Phase III trials of the same
vaccine showed no treatment effect (Fahim et al., 2013). However, subgroup analysis of
the phase II study showed efficacy in the 30% of subjects with the highest serum
antibody levels, and a similar subgroup finding emerged from a phase II study of an
unrelated nicotine vaccine (NicQb) (Cornuz et al., 2008). These analyses suggest that
nicotine vaccines may be effective if sufficient antibody levels can be consistently
achieved. Current efforts to improve vaccines involve modifications of conjugate vaccine
design, development of nanoparticle vaccines, use of newer adjuvants, combining
vaccines with each other or with other types of medications, and passive immunization
through gene transfer.
3.4 Improving conjugate vaccines. Nicotine that is modified to allow placement of a linker
is referred to as a hapten. Many nicotine haptens, with different linker positions, have
proven useful, and none is clearly superior under all conditions (Isomura et al., 2001;
Pravetoni et al., 2012). A conformationally constrained hapten that prevents rotation of
the pyridine and pyrrolidine rings improved immunogenicity of one nicotine vaccine
(Moreno et al., 2012). Fluorination, widely used in medicinal chemistry to improve ligand
binding to receptors, also improved a model nicotine immunogen (Cai et al., 2013).
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Overall, however, modifications in hapten design have provided only modest benefit.
Similarly, many linker lengths and structures have proven effective with particular
haptens but no one structure emerges as consistently best.
A variety of carrier proteins have been used in nicotine vaccines, generally selected from
proteins known to elicit strong immune responses on their own. Tetanus toxoid,
recombinant diphtheria toxin (CRM197), and keyhole limpet hemocyanin are most
commonly used, but others are also effective. Intact or disrupted viral capsid can serve
the same purpose (Cornuz et al., 2008; De et al., 2013). The choice of carrier protein for
a particular hapten remains highly empirical. T cell activation is provided by peptide
sequences with the carrier proteins, and these peptides can serve in place of the full
protein. To date, this approach has worked but has not been more effective than using
the whole protein.
3.5 Nanoparticle vaccines. Nanoparticle vaccines are being developed based on
liposomes, synthetic polymers, or novel materials such as DNA (Matyas et al., 2013;
Peek et al., 2008). Several are effective in animals and have entered clinical trials, but
results are not yet available (Kishimoto et al., 2012). Nanoparticles function as a scaffold
to which essential vaccine components can be attached or incorporated with a high
degree of control. Liposomes or polymer spheres can have their surfaces modified to
allow attachment of nicotine or other vaccine components, enabling their display to
immune cell surface receptors. Other components, such as T-cell help peptides, can be
encapsulated for delivery to cytoplasmic receptors. Nanoparticles allow greater control of
hapten, T cell help peptide, and adjuvant density and spacing than conjugate vaccines.
Some, such as those based on DNA, can also achieve precise control of size and shape
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that may prove useful to optimize vaccine uptake by phagocytic cells or transport to
regional lymph nodes (Liu et al., 2012).
3.5 Multivalent vaccines. It is well established that different vaccines can be combined
and administered in the same injection with little or no loss of their individual activities,
as is routinely done with common infectious disease vaccines such as MMR (measles,
mumps, rubella). Some nicotine vaccines can be combined to address problems of low
and variable antibody levels (Keyler et al., 2008). Nicotine haptens that have linkers at
different positions can act as distinct immunogens, stimulating different populations of B
cells, and eliciting antibodies that do not cross-react (Pravetoni et al., 2012). Each
hapten elicits antibodies against nicotine, but these antibodies recognize different
features of the nicotine molecule.
In rats, combining 3 nicotine immunogens based on haptens with linkers at the 1’ or 3’
position of the pyrrolidine ring, or 6 position of the pyridine ring, produced additive
antibody titers and greater ability to prevent nicotine distribution to brain than a
monovalent vaccine (de Villiers et al., 2013). In addition, some rats with poor responses
to one immunogen had brisk responses to one of the others. This independence of
response reduced the number of low- or non-responders that had ineffectual antibody
titers. An appealing feature of this strategy is that it is quite general, and could be
applied to other nicotine vaccines - even those based on very different designs such as
nanoparticles, provided that the haptens used incorporate appropriate linker positions.
3.6 Passive immunization and gene transfer. Immunization can be accomplished actively
by vaccination or passively through the transfer of pre-formed nicotine-specific
monoclonal antibody. Passive immunization can achieve the same effects in animals as
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vaccination (Carrera et al., 2004; Keyler et al., 2005), but offers some advantages. The
dose of monoclonal antibody, and resulting serum antibody levels, can be controlled to
avoid the problem of non-responders, and the amount administered can be increased to
provide a higher serum antibody concentration than that achievable with even the best
vaccines. Passive immunization also has an immediate onset of effect, whereas
vaccination takes weeks to months. The main limitation of passive immunization is the
cost of monoclonal antibodies, and the doses needed for this application are high (Roiko
et al., 2008). No clinical trials of passive immunization for nicotine have been reported,
but if costs are reduced, it will merit further study.
An alternative means of delivering monoclonal antibody is administration of viral vectors
containing genes for antibody expression. Vectors based on adeno-associated virus
(AAV) have been used to produce very high levels of nicotine-specific antibody
expression in mice, resulting in reduced nicotine distribution to brain and attenuated
physiologic and behavioral effects (Hicks et al., 2012). These vectors have shown no
important toxicity in clinical trials for the transfer of other types of genes (Mingozzi and
High, 2011). If safety is confirmed with more extensive use, and high levels of
expression can be achieved in humans, gene therapy could prove an effective means of
providing therapeutic antibodies for tobacco or other addictions.
3.7 Combining immunotherapy with medications. There are compelling reasons to
consider combining vaccines or passive immunization with medications that act via
different mechanisms to assist with treating tobacco dependence. Even if very high
nicotine-specific antibody levels can be reliably achieved through one or more of the
strategies described above, immunotherapy is likely to have limits on both its magnitude
and spectrum of therapeutic effects. Reasons include: 1) Immunotherapies reduce, but
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do not completely prevent, nicotine distribution to brain, and even low brain
concentrations of nicotine can produce substantial nicotinic receptor occupancy (Brody
et al., 2009); 2) Immunotherapies can act only when nicotine is present for antibodies to
bind. Effects that may occur when nicotine is no longer present, such as withdrawal and
craving, cannot be directly blocked using vaccines; 3) Minor alkaloids and other
components of tobacco may contribute to tobacco addiction, and are not bound or
blocked by nicotine-specific antibodies (Hoffman and Evans, 2013).
As proof-of principle, a combination of the nicotinic receptor antagonist mecamylamine
and passive immunization with a nicotine-specific monoclonal antibody (Nic311) was
studied and these were found to have strong synergistic effects in rats (LeSage et al.,
2012). Mecamylamine can block nicotine actions, but use in humans for this purpose is
not feasible because it has side effects due to blocking the actions of endogenous
acetylcholine. However, combining a low dose of mecamylamine with a low dose of
antibody produced complete blockade of nicotine discrimination even though the
individual therapies at these doses were essentially without any effect (Figure 4). These
preliminary data support further study of immunotherapy/medication combinations to
enhance treatment efficacy.
3.8 Summary. Nicotine vaccines appear quite effective in animals, but have been
disappointing in clinical trials for smoking cessation. Many options are under
development for improving vaccine efficacy or providing antibody through alternative
strategies. These advances are likely to provide the higher serum nicotine-specific
antibody levels needed to test the therapeutic potential of immunotherapy.
4.

Reducing levels of nicotine in cigarettes (Dorothy Hatsukami)
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4.1 Introduction. Rather than targeting the smoker, another area of tobacco addiction
intervention is altering the tobacco product itself. Reducing the addictiveness or appeal
of cigarettes as a national regulatory measure can potentially lead to significant public
health benefits by reducing the prevalence of smoking. Prior reports have stated that
prevention of tobacco use, cessation of its use, and reduction of tobacco-caused
mortality are greatly impeded by the addictive nature of cigarettes (WHO Study Group
on Tobacco Product Regulation, 2012; USDHHS, 1988). As a result, Benowitz and
Henningfield (1994) proposed a gradual reduction of nicotine levels in all marketed
cigarettes over 10-15 years, with the goal of preventing nicotine addiction in youth. This
proposal can also facilitate abstinence among those who are already addicted to
cigarettes. For many years, this concept was not fully embraced by the public health
community because no governmental agency had regulatory authority to require the
reduction of nicotine levels in tobacco products. However, since 2009, when the Family
Smoking Prevention and Tobacco Control Act (FSPTCA) was enacted, the U.S. Food
and Drug Administration now has jurisdiction over some tobacco products, and the law
allows a reduction in levels of nicotine in these products to the point that they are
rendered non-addictive, but not to zero.
4.2 Reducing nicotine content. Research in animals (e.g., Donny et al., 2012) and
humans (e.g., Hatsukami et al., 2010a) have been conducted that supports the viability
of reducing nicotine to non-addictive levels in cigarettes. Most animal studies have
shown an inverted U-shaped dose-response curve for nicotine self-administration and
t

-administered more than saline,
(Donny et al.,

2012; Smith et al., 2013; Grebenstein et al., 2014). In humans, four clinical trials
291

examined the effects of reducing nicotine in cigarettes either gradually (Benowitz et al.,
2007, 2012) or immediately to very low levels (Hatsukami et al., 2010b, 2012). In
general, these studies have shown that cigarette consumption and carbon monoxide
(CO) exposure were significantly reduced with very low nicotine content (VLNC)
cigarettes (< 0.1 mg nicotine yield), with some compensatory smoking occurring with
cigarettes containing > 0.2 mg nicotine yield. There was no evidence of increased
exposure to toxicants, nor evidence of adverse effects on cardiovascular biomarkers,
even at higher doses of reduced nicotine content (RNC) cigarettes (Benowitz 2007,
2012). Decreased exposure was seen at the lowest nicotine content cigarettes (< 0.05
mg; Hatsukami et al., 2010; 2013). It is important to note that these cigarettes are unlike
the “light” and “ultralight” cigarettes, marketed as generating reduced tar and nicotine
yield, but resulted in levels of nicotine and toxicant exposure that were similar to
“regular” cigarettes (NCI monograph 13). The “light” and “ultralight” cigarettes had the
same amount of nicotine content as regular cigarettes, but were reduced in machinedetermined nicotine yields, primarily through filter ventilation holes. The RNC cigarettes
have reduced nicotine in the tobacco itself, making compensation at very low doses
difficult.
These clinical trials also demonstrated no substantial withdrawal symptoms with the
switch to RNC cigarettes, and minimal withdrawal when smokers quit using VLNC
cigarettes (Benotwitz 2012; Hatsukami et al., 2010b; 2013). Similarly, smokers reported
reduced dependence scores with VLNC cigarettes. Although the primary outcome of
these studies was not cessation, in the Hatsukami et al. studies, in which participants
were motivated to quit smoking, the 7-day point prevalence biochemically verified
(cotinine and CO) quit rates with the VLNC was 36% at 6 weeks post-treatment in one
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study (Hatsukami et al., 2010b), and 24% at 6 weeks post-product assignment in
another study (Hatsukami et al., 2013). For the Benowtiz studies, in which smokers were
not motivated to quit, rates ranged from 4% at the end of taper, when nicotine content
was changed on a monthly basis (Benowtiz et al., 2012), to 25% when nicotine content
was reduced on a weekly basis in a separate study (Benowitz et al., 2007).
4.3 Gradual reduction vs. immediate reduction. To date, minimal studies have examined
the best approach to reducing levels of nicotine in cigarettes - that is, gradual reduction
over time, or an immediate reduction to non-addictive levels on a specified date. In one
study, Smith et al., (2013) showed that whether nicotine doses were reduced

nicotine self-administration with no significant compensation (increased infusions in
response to lowered nicotine dose).
limited and temporary compensation. Although, no human clinical trials have been
conducted to directly compare these two approaches. Nevertheless, similar to the
findings in the animal study, in the Benowitz et al. studies (2007, 2012), with gradual
reduction, modest increases in numbers of RNC cigarettes smoked and CO exposure
were observed, with no significant change in exposure to toxicants in the initial phases of
reduction. No substantial decrease would be seen until nicotine content is reduced
significantly. However, no major withdrawal or discomfort may be experienced during the
reduction period. On the other hand, with the abrupt reduction to VLNC cigarettes, a
more immediate effect is observed in the reduction in numbers of VLNC cigarettes
smoked, and consequently more immediate reduction in exposure to toxicants
(Hatsukami et al., 2010b, 2013). This approach has the advantage of benefiting public
health sooner. Furthermore, the number of individuals likely to engage in significant
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compensatory smoking is likely to be limited because the dose of nicotine is so low,
whereas with higher RNC cigarettes, greater variability in compensatory smoking is likely
to be experienced. However, an immediate reduction in nicotine to very low levels may
generate greater discomfort in smokers, particularly in heavily dependent smokers.
4.4 Moderating responses to VLNC cigarettes. Several factors may moderate or mitigate
discomfort experienced when switching to a VLNC cigarette, including use of medicinal
nicotine products, other medications to reduce withdrawal, or alternative less harmful
non-combusted tobacco products (e.g., electronic cigarettes). Few studies have
examined this area. One study compared the effects of VLNC (0.05-0.9 mg nicotine
yield) cigarettes alone, nicotine patch (NP) alone, and a combination of NP and VLNC
cigarettes over the course of 6 weeks (Hatsukami et al., 2013). The combination
approach led to fewer VLNC cigarettes smoked and lower CO exposure, than VLNC
cigarettes alone, and fewer usual brand cigarettes smoked than the other two conditions.
In addition, significantly less severe withdrawal was experienced when smokers were
switched from usual brand cigarettes to combination compared to NP condition, and
near significant differences when compared to VLNC cigarettes alone. Another study
also observed that the combination approach leads to lower consumption of usual brand
cigarettes and total number of cigarettes smoked than VLNC alone (Rose et al., 2006).
In another short-term 10-day study (Donny and Jones, 2009), smokers were assigned to
one of four conditions: 1) placebo patch (PP) plus 0.6 mg nicotine yield cigarette; 2) 7
mg NP plus 0.05 mg nicotine yield (VLNC) cigarette; 3) 21 mg NP plus VLNC cigarette.
This study also found that subjects assigned to NP (21 mg and 7 mg) plus VLNC
cigarettes, compared to PP plus VLNC cigarettes, showed greater reductions in the
numbers of VLNC cigarettes smoked, in total volume of inhaled cigarette smoke, and
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fewer withdrawal symptoms. These studies show beneficial effects when combining
VLNC with medicinal nicotine, demonstrating less discomfort and need to smoke either
usual or experimental cigarettes.
Relatively few studies have examined the effects of a combination approach relative to
VLNC cigarettes to facilitate cessation. In the study conducted by Hatsukami (2013), an
exploratory analysis of the data showed no differences in cessation rates between the
combination vs. VLNC or NP alone. A large clinical trial had been conducted, in smokers
who called a telephone-based cessation support system. Abstinence rates were
compared in smokers who were randomly assigned to usual care involving both
medicinal nicotine products and behavioral treatment plus VLNC (0.05 mg nicotine yield)
cigarettes versus usual care alone. The usual care plus VLNC cigarettes had higher 7day point prevalence abstinence rate at the 6-month follow-up compared to usual care
(33% vs. 28%, RR=1.18, 95% CI 1.01, 1.39), and higher continuous abstinence rates
(23% vs. 15%, RR=1.50, 95% CI 1.20, 1.87).
4.5 Reducing nicotine in vulnerable populations. One concern is the effect of reducing
nicotine content cigarettes in vulnerable populations, such as smokers who have serious
mental illnesses. While no clinical trials have been conducted, a laboratory study
showed no adverse effects of these cigarettes in smokers with schizophrenia (Tidey et
al., 2013). In this study, smokers with schizophrenia and a control group of smokers
without psychiatric diagnoses underwent 5 laboratory sessions, during which products
were used under controlled conditions for 5 hours: 1) usual brand cigarettes; 2) VLNC
cigarettes with 42 mg NP; 3) VLNC cigarettes with PP; 4) no cigarettes with 42 mg NP;
and 5) no cigarettes with PP. After the session of product use, participants were allowed
to smoke cigarettes ad libitum during a 90-minute period. The results showed that
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smoking VLNC cigarettes reduced usual-brand smoking and withdrawal symptoms, did
not worsen psychiatric or performance measures, and were reported to be acceptable
among smokers with schizophrenia. The addition of an active patch had no effect in this
population, which may be a function of the short duration of this study or the fact for
smokers with schizophrenia, the act of smoking has greater valence.
4.6 Remaining questions and future: Although studies thus far support a reduction of
nicotine content in cigarettes, many issues remain. These include:
•

Determining the dose of nicotine that will facilitate cessation and/or minimize the

development of addiction among those who experiment with cigarettes.
•

Directly comparing a gradual reduction in nicotine content of cigarettes with an

immediate reduction to a non-addictive level of nicotine content.
•

Determining the effects of RNC cigarettes in vulnerable populations of smokers

(e.g., those with co-morbid disorders) in clinical trials.
•

Examining other factors that might moderate responses to RNC cigarettes and

determining the variability in response.
•

Identifying and examining ways to mitigate negative consequences resulting from

reducing nicotine levels in cigarettes.
Some of these gaps are already being addressed by NIH grants oriented towards
developing tobacco regulatory science. It is important to recognize that reducing level of
nicotine in cigarettes alone may not be sufficient. Levels of nicotine in all combustible
tobacco products will be required to dramatically reduce death and disease associated
with smoking .Should a policy to reduce nicotine to non-addictive levels in all
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combustible tobacco products marketed in the U.S. be enacted, it would be critical to
establish a surveillance system able to track its impact.
4.7 Summary: The future for tobacco control is bright. We not only have effective
existing methods of reducing the prevalence of smoking (e.g., comprehensive smoking
bans, increased taxes on cigarettes, anti-smoking media campaigns), we can now
regulate the contents of cigarettes under the FSPTCA and Article 9 of the World Health
Organization Framework Convention on Tobacco Control. Regulation of nicotine content
can reduce or eliminate the use of the deadliest tobacco products sold to consumers
(i.e., combusted tobacco products), which would lead to a substantial reduction in
tobacco-caused death and disease.
5.

Overall Conclusion

The neurophysiological etiology of tobacco addiction is complex, involving both genetic
predispositions and environmental influence. Therefore, a broad-based set of
interventions ranging from specific neurobiological targets for medications to policies
must be considered. The wide range of signaling pathways and circuits that undergo
neuroplastic adaptation during prolonged use render quitting very difficult. Effective
treatments will need to confront the spectrum of systems involved in dependence and
withdrawal. Accordingly, studies of approaches to treating different components of
addiction will be critical to revealing comprehensive therapies. Through work with
genetically modified mice, we have learned that particular nAChR subunits appear to
mediate specific symptoms of nicotine withdrawal, representing potentially druggable
targets for more effective pharmacological intervention. The development of highly
specific drugs, capable of attenuating or abolishing downstream dopaminergic signaling
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in response to nicotine intake, may present the ability to prevent the appeal of cigarettes
by blocking their rewarding effects. Innovative approaches to preventing the effects of
nicotine by taking advantage of immune system-mediated elimination of the drug may
represent another method by which tobacco might be rendered ineffective – and,
therefore, unappealing to individuals attempting to quit. As research continues to find
new ways to effectively treat smokers, the prospect of reducing nicotine levels in tobacco
products through federal regulation may reduce consumption of combusted tobacco
products – and, ultimately, reduce the prevalence of tobacco-associated disease.
As this research begins to yield a wider variety of options for smokers attempting to quit,
clinicians will be capable of providing treatments with fewer side-effects that are better
tailored to the unique characteristics of patients. Additionally, the ability to combine
therapies will assist in the treatment of cravings – as well as physical, emotional, and
cognitive withdrawal symptoms. Such targeted therapies, or combination of targeted
therapies, represent opportunities to more effectively ameliorate the burden of tobaccoassociated disease on public health.
Figure legends.
Fig.1 Lack of β4, α5 or α2 nAChR subunits protects against increases in nicotine
withdrawal-induced somatic signs. Various nAChR null mice and their wild-type
littermates were treated chronically with nicotine (24mg/kg/day free base) or saline,
using a mini-osmotic pump, for two weeks. On day 14, each mouse received a 3 mg/kg
injection of the nonselective nicotinic antagonist, mecamylamine. Somatic signs were
measured for 20 min. Mecamylamine treatment precipitated increases in somatic signs
in wild-type, β2 null, and α7 null mice chronically treated with nicotine. Such increases
were not observed in β4, α5, or α2 null mice - suggesting that nAChRs containing these
subunits participate in the modulation of nicotine withdrawal symptoms. *p<0.05. The
numbers within the bars indicate the number of animals tested for each strain.
Fig. 2 Chemical structure and pharmacological characteristics of potential smoking
cessation agents. IC50 values of for the inhibition of NIC-evoked [3H]DA release from rat
striatal slices for NONI, bis-, tris, and tetrakis quaternary ammonium compounds, and
the bis-tertiary amino analogues (r-series compounds).
298

Fig. 3 b3EPDDB derivatives inhibit dopamine release in vitro. b3EPDDB (left) and rb3EPDDB (right) both inhibit NIC-evoked [3H]DA release from rat striatum in vitro in a
concentration-dependent manner. n = 5-8/analog. Data are mean ± SEM total [3H]
overflow.
Fig. 4 Synergistic effect of mecamylamine and the nicotine-specific monoclonal antibody
Nic311 for blocking the subjective effects of nicotine. Rats were trained in a two-lever
nicotine discrimination assay. Data are the mean ± SE % responding on the nicotine
lever during consecutive daily sessions with the 0.4 mg/kg s.c. nicotine training dose.
Nic311 or control antibody was administered i.v. one day prior to session 1, and
mecamylamine or saline was administered s.c. 15 minutes prior to each session.
Dashed lines indicate criterion levels of performance for discrimination of the 0.4 mg/kg
nicotine training dose. Significantly different from Control antibody+Saline, *p<0.05,
***p<0.001. Significantly different from Nic311+Saline, ##p<0.01, ###p<0.001.
Reproduced from (LeSage et al., 2012).
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